Unnamed: 0,datetime,title,source,link
0.0,1/13/2005 7:27:00 PM,Sod-Turning Ceremony Marks Start of Construction of First Pediatric HI,PR Newswire,/news/stocks/sod-turning-ceremony-marks-start-of-construction-of-first-pediatric-hi-1009438132
1.0,12/13/2005 8:32:00 PM,PLAVIX(R) (clopidogrel bisulfate) Recommended as Effective Cardiovascular Risk Reduction Treatment for Patients With Established Peripheral Arterial Disease (P.A.D.),PR Newswire,/news/stocks/plavixr-clopidogrel-bisulfate-recommended-as-effective-cardiovascular-risk-reduction-treatment-for-patients-with-established-peripheral-arterial-disease-p-a-d--1000053026
2.0,1/18/2006 2:42:00 PM,FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) Supplemental New Drug Application (sNDA) for Additional Type of Heart Attack,PR Newswire,/news/stocks/fda-grants-priority-review-to-plavix-r-clopidogrel-bisulfate-supplemental-new-drug-application-snda-for-additional-type-of-heart-attack-1028241630
3.0,1/23/2006 3:12:00 PM,Crohn's Patient Robert Hill Reaches Peak of Antarctica's Tallest Mountain,PR Newswire,/news/stocks/crohns-patient-robert-hill-reaches-peak-of-antarcticas-tallest-mountain-866939
4.0,1/25/2006 1:02:00 PM,Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2005 and Announces EPS Guidance for 2006,PR Newswire,/news/stocks/bristol-myers-squibb-company-reports-financial-results-for-the-fourth-quarter-and-twelve-months-of-2005-and-announces-eps-guidance-for-2006-1012388763
5.0,9/28/2006 2:12:00 PM,Crohn's & Colitis Foundation of America and ConvaTec Announce 2006 Great Comebacks Regional Awards Recipients,PR Newswire,/news/stocks/crohns-&-colitis-foundation-of-america-and-convatec-announce-2006-great-comebacks-regional-awards-recipients-1000124648
6.0,11/13/2006 9:32:00 PM,ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria,PR Newswire,/news/stocks/orencia-r-abatacept-data-demonstrated-improvement-in-children-and-adolescents-with-juvenile-idiopathic-arthritis-as-measured-by-the-validated-acr-pediatric-criteria-1005290630
7.0,11/20/2006 6:27:00 PM,Crohn's and Colitis Foundation of America and ConvaTec Recognize Young Patients With Inflammatory Bowel Disease,PR Newswire,/news/stocks/crohn-s-and-colitis-foundation-of-america-and-convatec-recognize-young-patients-with-inflammatory-bowel-disease-1027845523
8.0,4/13/2007 12:10:00 PM,BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment,PR Newswire,/news/stocks/baraclude-r-entecavir-therapy-resulted-in-undetectable-levels-of-hepatitis-b-virus-in-cohort-of-patients-who-re-started-treatment-1012353856
9.0,11/12/2007 5:55:00 PM,"Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)",PR Newswire,/news/stocks/post-hoc-data-show-daily-activity-participation-independence-and-sleep-quality-improved-in-adults-with-moderate-to-severe-rheumatoid-arthritis-after-treatment-with-orencia-r-abatacept-1027498817
10.0,9/27/2016 3:40:24 PM,"BRIEF-Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration (BMY, NKTR)",Reuters,/news/stocks/brief-bristol-myers-squibb-and-nektar-therapeutics-announce-oncology-clinical-collaboration-bmy-nktr-1001420874
11.0,9/27/2016 4:20:23 PM,"Bristol-Myers to test Opdivo with Nektar drug for several cancers (BMY, NKTR)",Reuters,/news/stocks/bristol-myers-to-test-opdivo-with-nektar-drug-for-several-cancers-bmy-nktr-1001420897
12.0,10/5/2016 11:30:22 AM,"BRIEF-U.S. FDA warns about the risk of Hepatitis B (BMY, GILD, JNJ, MRK)",Reuters,/news/stocks/brief-u-s-fda-warns-about-the-risk-of-hepatitis-b-bmy-gild-jnj-mrk-1001436685
13.0,10/10/2016 11:20:20 AM,"Roche lung cancer drug success adds to pressure on Bristol (MRK, BMY)",Reuters,/news/stocks/roche-lung-cancer-drug-success-adds-to-pressure-on-bristol-mrk-bmy-1001445153
14.0,10/10/2016 11:30:24 AM,"Merck drug shines in lung cancer and also works with chemo (MRK, BMY, AZN)",Reuters,/news/stocks/merck-drug-shines-in-lung-cancer-and-also-works-with-chemo-mrk-bmy-azn-1001445152
15.0,10/10/2016 12:10:24 PM,"UPDATE 1-'New day' in lung cancer as Merck drug shines, works with chemo (MRK, BMY, AZN)",Reuters,/news/stocks/update-1-new-day-in-lung-cancer-as-merck-drug-shines-works-with-chemo-mrk-bmy-azn-1001445165
16.0,10/10/2016 1:10:24 PM,"No silver lining in failed Bristol cancer drug trial (BMY, MRK)",Reuters,/news/stocks/no-silver-lining-in-failed-bristol-cancer-drug-trial-bmy-mrk-1001445520
17.0,10/10/2016 2:40:22 PM,"UK Stocks-Factors to watch on Oct. 10 (RDSA, WMH, BA., BLT, BHP, RRS, BMY, AZN, SVI, WTM, VED)",Reuters,/news/stocks/uk-stocks-factors-to-watch-on-oct-10-rdsa-wmh-ba-blt-bhp-rrs-bmy-azn-svi-wtm-ved-1001445819
18.0,10/10/2016 2:50:22 PM,"BRIEF-Innate Pharma announced data for two Phase I studies for lirilumab and nivolumab (IPH, BMY)",Reuters,/news/stocks/brief-innate-pharma-announced-data-for-two-phase-i-studies-for-lirilumab-and-nivolumab-iph-bmy-1001446002
19.0,10/10/2016 3:10:22 PM,"UPDATE 1-UK Stocks-Factors to watch on Oct. 10 (RDSA, WMH, BA., BLT, BHP, RRS, BMY, AZN, SVI, VED, MTO)",Reuters,/news/stocks/update-1-uk-stocks-factors-to-watch-on-oct-10-rdsa-wmh-ba-blt-bhp-rrs-bmy-azn-svi-ved-mto-1001446131
20.0,10/10/2016 11:30:20 PM,"INSIGHT-Doctors grapple with best use of potent new cancer drugs (MRK, BMY, AZN)",Reuters,/news/stocks/insight-doctors-grapple-with-best-use-of-potent-new-cancer-drugs-mrk-bmy-azn-1001447119
21.0,10/12/2016 7:40:53 PM,"A new kind of drug is working better than chemotherapy in some lung cancer patients (BMY, MRK)",Business Insider,/news/stocks/a-new-kind-of-drug-is-working-better-than-chemotherapy-in-some-lung-cancer-patients-bmy-mrk
22.0,10/14/2016 3:40:22 PM,BRIEF-Bristol-Myers receives positive CHMP opinion for Opdivo (BMY),Reuters,/news/stocks/brief-bristol-myers-receives-positive-chmp-opinion-for-opdivo-bmy-1001456913
23.0,10/19/2016 12:20:24 PM,"Roche's lung cancer drug wins U.S. approval (MRK, BMY)",Reuters,/news/stocks/roches-lung-cancer-drug-wins-u-s-approval-mrk-bmy-1001463837
24.0,10/21/2016 3:46:22 PM,"Merck's immunotherapy drug succeeds in key bladder cancer trial (MRK, BMY)",Reuters,http://www.businessinsider.com/r-mercks-immunotherapy-drug-succeeds-in-key-bladder-cancer-trial-2016-10
25.0,10/21/2016 4:32:24 PM,"UPDATE 1-Merck's Keytruda succeeds in key bladder cancer trial (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-mercks-keytruda-succeeds-in-key-bladder-cancer-trial-2016-10
26.0,10/21/2016 11:30:20 PM,BRIEF-Bristol-Myers Squibb says U.S. FDA accepts for priority review the sBLA for Opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-us-fda-accepts-for-priority-review-the-sbla-for-opdivo-2016-10
27.0,10/25/2016 1:10:19 PM,"UPDATE 1-Merck wins early U.S. approval for Keytruda in untreated lung cancer (MRK, BMY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-merck-wins-early-us-approval-for-keytruda-in-untreated-lung-cancer-2016-10
28.0,10/25/2016 2:18:21 PM,BRIEF-Bristol-Myers presents new results for opdivo (nivolumab) (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-presents-new-results-for-opdivo-nivolumab-2016-10
29.0,10/27/2016 1:28:20 PM,Bristol hikes 2016 forecast after top drugs deliver (BMY),Reuters,http://www.businessinsider.com/r-bristol-hikes-2016-forecast-after-top-drugs-deliver-2016-10
30.0,10/27/2016 2:44:18 PM,"UPDATE 1-Bristol hikes 2016 profit forecast after top drugs deliver (PFE, BMY)",Reuters,http://www.businessinsider.com/r-update-1-bristol-hikes-2016-profit-forecast-after-top-drugs-deliver-2016-10
31.0,10/27/2016 10:10:18 PM,BRIEF-Bristol says expects Opdivo to face pressure from Roche lung cancer drug (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-says-expects-opdivo-to-face-pressure-from-roche-lung-cancer-drug-2016-10
32.0,10/27/2016 11:06:30 PM,"Biotech's election-year political cloud threatens to linger (VRX, LLY, BMY, ARIA, VRX)",Reuters,http://www.businessinsider.com/r-biotechs-election-year-political-cloud-threatens-to-linger-2016-10
33.0,11/3/2016 4:36:18 PM,BRIEF-Blackline announces pricing of IPO of 8.60 mln shares at $17/shr (BLN),Reuters,http://www.businessinsider.com/r-brief-blackline-announces-pricing-of-ipo-of-860-mln-shares-at-17/shr-2016-10
34.0,11/9/2016 3:20:18 PM,"BRIEF-Bristol-Myers, Infinity Pharma to evaluate Opdivo with IPI-549 in advanced solid tumors (BMY, INFI)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-infinity-pharma-to-evaluate-opdivo-with-ipi-549-in-advanced-solid-tumors-2016-11
35.0,11/10/2016 12:46:18 PM,"AstraZeneca drops early head and neck cancer drug plans (AZN, MRK, BMY)",Reuters,http://www.businessinsider.com/r-astrazeneca-drops-early-head-and-neck-cancer-drug-plans-2016-11
36.0,11/10/2016 1:44:18 PM,"Bristol-Myers' deepens focus on fibrosis with Nitto deal (6988, BMY)",Reuters,http://www.businessinsider.com/r-bristol-myers-deepens-focus-on-fibrosis-with-nitto-deal-2016-11
37.0,11/10/2016 1:48:20 PM,"Bristol-Myers' Opdivo immunotherapy succeeds in key stomach cancer study (4528, BMY)",Reuters,http://www.businessinsider.com/r-bristol-myers-opdivo-immunotherapy-succeeds-in-key-stomach-cancer-study-2016-11
38.0,11/10/2016 2:36:18 PM,"UPDATE 1-Bristol-Myers' Opdivo succeeds in key stomach cancer study (4528, BMY)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-opdivo-succeeds-in-key-stomach-cancer-study-2016-11
39.0,11/10/2016 3:40:18 PM,"BRIEF-Bristol-Myers Squibb and Pfizer to deliver 12 new Eliquis (apixaban) presentations at American Heart Association (AHA) scientific sessions 2016 (BMY, PFE)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-pfizer-to-deliver-12-new-eliquis-apixaban-presentations-at-american-heart-association-aha-scientific-sessions-2016-2016-11
40.0,11/10/2016 3:40:18 PM,"BRIEF-Opdivo (nivolumab) demonstrates overall survival benefit in patients with unresectable advanced or recurrent gastric cancer in phase 3 study (BMY, 4528)",Reuters,http://www.businessinsider.com/r-brief-opdivo-nivolumab-demonstrates-overall-survival-benefit-in-patients-with-unresectable-advanced-or-recurrent-gastric-cancer-in-phase-3-study-2016-11
41.0,11/10/2016 5:16:12 PM,A pharma giant just made a $100 million move into a disease that's been called 'one of the next epidemic-level chronic diseases' (BMY),Business Insider,http://www.businessinsider.com/bristol-myers-squibb-picks-up-nash-drug-for-100-million-2016-11
42.0,11/16/2016 1:12:18 PM,"BRIEF-Bristol-Myers Squibb and Enterome announce immuno-oncology collaboration (BMY, ETRM)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-enterome-announce-immuno-oncology-collaboration-2016-11
43.0,11/17/2016 8:34:20 AM,"Roche, Bristol-Myers cut cancer drug prices to win UK approval (PFE, BMY)",Reuters,http://www.businessinsider.com/r-roche-bristol-myers-cut-cancer-drug-prices-to-win-uk-approval-2016-11
44.0,11/17/2016 10:54:20 AM,"Japan sets 50 pct price cut for Opdivo cancer drug: Ono Pharma (4528, BMY)",Reuters,http://www.businessinsider.com/r-japan-sets-50-pct-price-cut-for-opdivo-cancer-drug-ono-pharma-2016-11
45.0,11/17/2016 11:42:18 AM,"UPDATE 1-Japan sets 50 pct price cut for Bristol Myers' Opdivo cancer drug (4528, BMY)",Reuters,http://www.businessinsider.com/r-update-1-japan-sets-50-pct-price-cut-for-bristol-myers-opdivo-cancer-drug-2016-11
46.0,11/21/2016 12:18:19 PM,"Swiss stocks - Factors to watch on Nov. 21 (BMY, MRK, LECN, 300068, ODHN)",Reuters,http://www.businessinsider.com/r-swiss-stocks---factors-to-watch-on-nov-21-2016-11
47.0,11/22/2016 12:48:20 PM,"UPDATE 1-AstraZeneca cleared to resume enrolment in cancer drug trials (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-astrazeneca-cleared-to-resume-enrolment-in-cancer-drug-trials-2016-11
48.0,11/22/2016 10:54:21 PM,BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-opdivo-gets-european-commission-approval-for-relapsed-or-refractory-chl-treatment-2016-11
49.0,11/25/2016 11:28:18 AM,"Costly leukaemia pill wins UK green light after price cut (JNJ, PFE, BMY, 4523)",Reuters,http://www.businessinsider.com/r-costly-leukaemia-pill-wins-uk-green-light-after-price-cut-2016-11
50.0,12/2/2016 6:26:05 PM,"BRIEF-EMA says patients treated with direct-acting antivirals for hepatitis C may be at risk of hepatitis B re-activation (BMY, GILD)",Reuters,http://www.businessinsider.com/r-brief-ema-says-patients-treated-with-direct-acting-antivirals-for-hepatitis-c-may-be-at-risk-of-hepatitis-b-re-activation-2016-12
51.0,12/2/2016 6:34:06 PM,EU health regulator warns some hep C drugs could reactivate hep B,Reuters,http://www.businessinsider.com/r-eu-health-regulator-warns-some-hep-c-drugs-could-reactivate-hep-b-2016-12
52.0,12/2/2016 7:16:03 PM,"UPDATE 1-EU health regulator warns some hep C drugs could reactivate hep B (JNJ, BMY, GILD)",Reuters,http://www.businessinsider.com/r-update-1-eu-health-regulator-warns-some-hep-c-drugs-could-reactivate-hep-b-2016-12
53.0,12/5/2016 3:24:03 PM,BRIEF-CytomX says Bristol-Myers will pay company $15 mln (BMY),Reuters,http://www.businessinsider.com/r-brief-cytomx-says-bristol-myers-will-pay-company-15-mln-2016-12
54.0,12/6/2016 12:00:07 PM,"DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12
55.0,12/6/2016 2:02:03 PM,"RPT-DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-rpt-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12
56.0,12/6/2016 3:28:05 PM,BRIEF-Heat Biologics presents topline results from lung cancer drug study (BMY),Reuters,http://www.businessinsider.com/r-brief-heat-biologics-presents-topline-results-from-lung-cancer-drug-study-2016-12
57.0,12/6/2016 4:56:03 PM,BRIEF-Bristol-Myers provides positive results from Phase 1/2 study Checkmate-032 (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-provides-positive-results-from-phase-1/2-study-checkmate-032-2016-12
58.0,12/7/2016 8:02:03 AM,EU clears Bristol-Myers immunotherapy drug for blood cancer (BMY),Reuters,http://www.businessinsider.com/r-eu-clears-bristol-myers-immunotherapy-drug-for-blood-cancer-2016-12
59.0,12/7/2016 2:00:08 PM,Japan PM's advisers urge annual review of drug prices,Reuters,http://www.businessinsider.com/r-japan-pms-advisers-urge-annual-review-of-drug-prices-2016-12
60.0,12/7/2016 8:24:03 PM,"BRIEF-Transgene says UC Davis to conduct phase 2 trial of the combination of TG4010 with Opdivo (BMY, TNG)",Reuters,http://www.businessinsider.com/r-brief-transgene-says-uc-davis-to-conduct-phase-2-trial-of-the-combination-of-tg4010-with-opdivo-2016-12
61.0,12/7/2016 8:50:03 PM,"BRIEF-Transgene announces phase 2 trial with Bristol-Myers Squibb for 2nd line treatment of metastatic non-small cell lung cancer (TNG, BMY)",Reuters,http://www.businessinsider.com/r-brief-transgene-announces-phase-2-trial-with-bristol-myers-squibb-for-2nd-line-treatment-of-metastatic-non-small-cell-lung-cancer-2016-12
62.0,12/8/2016 8:50:07 PM,Bristol-Meyers Squibb to pay $19.5 mln to settle off-label promotion case (BMY),Reuters,http://www.businessinsider.com/r-bristol-meyers-squibb-to-pay-195-mln-to-settle-off-label-promotion-case-2016-12
63.0,12/8/2016 9:50:04 PM,REFILE-Bristol-Myers Squibb to pay $19.5 mln to settle off-label promotion case (BMY),Reuters,http://www.businessinsider.com/r-refile-bristol-myers-squibb-to-pay-195-mln-to-settle-off-label-promotion-case-2016-12
64.0,12/8/2016 11:22:03 PM,BRIEF-Bristol-Myers Squibb reports dividend increase (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-reports-dividend-increase-2016-12
65.0,12/13/2016 3:36:05 PM,BRIEF-CytomX says clinical candidate probody from Bristol-Myers Squibb collaboration selected (BMY),Reuters,http://www.businessinsider.com/r-brief-cytomx-says-clinical-candidate-probody-from-bristol-myers-squibb-collaboration-selected-2016-12
66.0,12/19/2016 4:16:05 PM,"UPDATE 1-Japan to review drug prices annually rather than every two years -sources (4528, BMY, GILD)",Reuters,http://www.businessinsider.com/r-update-1-japan-to-review-drug-prices-annually-rather-than-every-two-years--sources-2016-12
67.0,12/29/2016 1:18:03 PM,"BRIEF-Bavarian Nordic starts trial of CV301 in combination with Nivolumab (BAVA, BMY)",Reuters,http://www.businessinsider.com/r-brief-bavarian-nordic-starts-trial-of-cv301-in-combination-with-nivolumab-2016-12
68.0,1/6/2017 1:28:03 PM,BRIEF-Bristol-Myers Squibb and genecentric diagnostics announces exploratory biomarker research collaboration (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-genecentric-diagnostics-announces-exploratory-biomarker-research-collaboration-2017-1
69.0,1/6/2017 5:00:06 PM,"BRIEF-Bristol-Myers' Nivolumab study reaches limit, suspends recruitment - Clinicaltrials.gov (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-nivolumab-study-reaches-limit-suspends-recruitment---clinicaltrialsgov-2017-1
70.0,1/10/2017 7:20:06 PM,BRIEF-Bristol-Myers sees operating expenses flat through 2020 (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-sees-operating-expenses-flat-through-2020-2017-1
71.0,1/19/2017 3:46:07 PM,BRIEF-Opdivo demonstrated efficacy in patients gastric cancer in a Phase 3 study (BMY),Reuters,http://www.businessinsider.com/r-brief-opdivo-demonstrated-efficacy-in-patients-gastric-cancer-in-a-phase-3-study-2017-1
72.0,1/19/2017 9:30:04 PM,U.S. top court to hear Bristol-Myers out-of-state injury appeal (BMY),Reuters,http://www.businessinsider.com/r-us-top-court-to-hear-bristol-myers-out-of-state-injury-appeal-2017-1
73.0,1/20/2017 12:56:09 AM,BRIEF-Bristol-Myers decides not to pursue accelerated regulatory pathway for combination of Opdivo plus Yervoy (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-decides-not-to-pursue-accelerated-regulatory-pathway-for-combination-of-opdivo-plus-yervoy-2017-1
74.0,1/20/2017 1:26:04 AM,"Bristol-Myers won't seek accelerated Opdivo lung cancer approval (MRK, BMY)",Reuters,http://www.businessinsider.com/r-bristol-myers-wont-seek-accelerated-opdivo-lung-cancer-approval-2017-1
75.0,1/20/2017 5:06:54 PM,"Bristol-Myers shares are sliding after some bad news on its lung cancer drug (BMY, MRK)",Reuters,http://www.businessinsider.com/bristol-opdivo-yervoy-lung-cancer-no-fast-approval-2017-1
76.0,1/20/2017 10:16:07 PM,"BRIEF-Merck announces license agreement resolving Keytruda patent litigation (MRK, BMY)",Reuters,http://www.businessinsider.com/r-brief-merck-announces-license-agreement-resolving-keytruda-patent-litigation-2017-1
77.0,1/20/2017 10:24:06 PM,"BRIEF-Bristol-Myers squibb and Ono pharmaceutical enters license agreement with Merck (BMY, MRK)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-ono-pharmaceutical-enters-license-agreement-with-merck-2017-1
78.0,1/21/2017 12:06:09 AM,"UPDATE 1-Merck, Bristol-Myers agree to settle Keytruda patent suit (4528, MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-merck-bristol-myers-agree-to-settle-keytruda-patent-suit-2017-1
79.0,1/21/2017 12:14:12 AM,"Merck, Bristol-Myers agree to settle Keytruda patent suit",Reuters,http://www.businessinsider.com/r-merck-bristol-myers-agree-to-settle-keytruda-patent-suit-2017-1
80.0,1/26/2017 5:56:05 PM,"BRIEF-Bristol-Myers cites forex, oncology competition for outlook cut (MRK, BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-cites-forex-oncology-competition-for-outlook-cut-2017-1
81.0,1/26/2017 7:10:05 PM,"UPDATE 1-Bristol-Myers cuts 2017 outlook amid Opdivo competition (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-cuts-2017-outlook-amid-opdivo-competition-2017-1
82.0,1/27/2017 12:30:06 PM,"Roche cancer drug taking bite out of Bristol's Opdivo (MRK, BMY)",Reuters,http://www.businessinsider.com/r-roche-cancer-drug-taking-bite-out-of-bristols-opdivo-2017-1
83.0,2/1/2017 6:54:08 PM,BRIEF-Bristol-Myers squibb announces European Patent Office decision on Sprycel (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-european-patent-office-decision-on-sprycel-2017-2
84.0,2/2/2017 9:02:07 PM,"BRIEF-FDA grants accelerated approval to Bristol-Myers Squibb's nivolumab (BMY, MRK)",Reuters,http://www.businessinsider.com/r-brief-fda-grants-accelerated-approval-to-bristol-myers-squibbs-nivolumab-2017-2
85.0,2/2/2017 9:34:07 PM,U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer,Reuters,http://www.businessinsider.com/r-us-fda-approves-bristol-myers-opdivo-for-bladder-cancer-2017-2
86.0,2/3/2017 1:02:08 AM,BRIEF-Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab) (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-receives-fda-approval-for-opdivo-nivolumab-2017-2
87.0,2/10/2017 2:34:10 PM,BRIEF-Bristol-Myers Squibb Canada reached an agreement with Pan-Canadian Pharmaceutical Alliance (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-canada-reached-an-agreement-with-pan-canadian-pharmaceutical-alliance-2017-2
88.0,2/14/2017 10:16:13 PM,"BRIEF-Jana Partners takes sole share stake in Bristol-Myers, Cognizant (BMY, CTSH, CRM, GPK)",Reuters,http://www.businessinsider.com/r-brief-jana-partners-takes-sole-share-stake-in-bristol-myers-cognizant-2017-2
89.0,2/21/2017 1:13:42 PM,Bristol-Myers Plans $2 Bln Accelerated Share Buyback; Names 3 New Directors ,RTTNews,/news/stocks/bristol-myers-plans-2-bln-accelerated-share-buyback-names-3-new-directors-1001767464
90.0,2/21/2017 2:06:14 PM,Bristol-Myers adds three directors in deal with Jana Partners (BMY),Reuters,http://www.businessinsider.com/r-bristol-myers-adds-three-directors-in-deal-with-jana-partners-2017-2
91.0,2/21/2017 5:30:11 PM,"UPDATE 1-Bristol-Myers adds 3 directors in agreement with JANA Partners (BMY, MRK, VRTX, SHP)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-adds-3-directors-in-agreement-with-jana-partners-2017-2
92.0,2/21/2017 6:36:14 PM,BRIEF-Bristol-Myers sees restructuring charges between $1.5-$2.0 bln through 2020 (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-sees-restructuring-charges-between-15-20-bln-through-2020-2017-2
93.0,2/22/2017 3:43:04 AM,Icahn Takes Stake In Bristol-Myers ,RTTNews,/news/stocks/icahn-takes-stake-in-bristol-myers-1001770437
94.0,2/22/2017 10:10:52 AM,Carl Icahn has reportedly taken a stake in Bristol-Myers and its shares are jumping (BMY),Business Insider,http://www.businessinsider.com/carl-icahn-stake-bristol-myers-2017-2
95.0,2/22/2017 4:10:12 PM,"US STOCKS-Wall St slips on weak oil prices; Fed minutes in focus (XOM, GRMN, BMY, UPS, TSLA, HPQ)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-slips-on-weak-oil-prices-fed-minutes-in-focus-2017-2
96.0,2/22/2017 6:22:12 PM,"US STOCKS-Wall St slightly lower ahead of Fed minutes (DD, DOW, GRMN, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-slightly-lower-ahead-of-fed-minutes-2017-2
97.0,2/22/2017 6:29:15 PM,"Carl Icahn just jumped into a $90 billion drug maker, and people are betting it'll be a takeover target (BMY)",Business Insider,http://www.businessinsider.com/carl-icahn-invests-in-bristol-myers-squibb-heres-why-2017-2
98.0,2/22/2017 7:36:13 PM,"US STOCKS-S&P, Nasdaq dip ahead of Fed minutes; Dow hits record high (DD, DOW, GRMN, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-nasdaq-dip-ahead-of-fed-minutes-dow-hits-record-high-2017-2
99.0,2/23/2017 12:20:12 AM,BRIEF-Bristol-Myers squibb files pricing term sheet (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-files-pricing-term-sheet-2017-2
100.0,2/23/2017 12:58:12 AM,BRIEF-Bristol-Myers Squibb prices $1.5 billion of senior notes (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-prices-15-billion-of-senior-notes-2017-2
101.0,2/27/2017 1:28:13 PM,BRIEF-Bristol-Myers Squibb expands international immuno-oncology network (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-expands-international-immuno-oncology-network-2017-2
102.0,2/28/2017 11:58:14 AM,"Deals of the day-Mergers and acquisitions (ISP, 9437, FRO, DHT, BLND, WOR)",Reuters,http://www.businessinsider.com/r-deals-of-the-day-mergers-and-acquisitions-2017-2
103.0,3/1/2017 2:26:19 PM,BRIEF-Bristol-Myers announces equity investment in GRAIL Inc (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-announces-equity-investment-in-grail-inc-2017-3
104.0,3/2/2017 11:16:19 PM,BRIEF-Bristol-Myers Squibb declared a qtrly div of $0.39 per share (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-declared-a-qtrly-div-of-039-per-share-2017-3
105.0,3/8/2017 7:00:22 PM,BRIEF-Bristol-Myers Squibb appoints Thomas Lynch as Chief Scientific Officer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-appoints-thomas-lynch-as-chief-scientific-officer-2017-3
106.0,3/9/2017 6:56:22 AM,"PRESS DIGEST - Wall Street Journal - March 9 (AMZN, MSFT, 005930, BMY, S)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---march-9-2017-3
107.0,3/13/2017 4:10:24 PM,BRIEF-Heat Biologics Meets Efficacy Endpoint in Phase 1B Lung Cancer Trial (BMY),Reuters,http://www.businessinsider.com/r-brief-heat-biologics-meets-efficacy-endpoint-in-phase-1b-lung-cancer-trial-2017-3
108.0,3/13/2017 6:52:26 PM,"US STOCKS-Wall St dips as drug stocks drag; Fed meeting in focus (MRK, BMY, INTC, NVDA, WYNN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-dips-as-drug-stocks-drag-fed-meeting-in-focus-2017-3
109.0,3/13/2017 7:46:23 PM,"BRIEF-Transgene SA says first results from Phase 2 trial could be expected from end of 2017 (TNG, BMY)",Reuters,http://www.businessinsider.com/r-brief-transgene-sa-says-first-results-from-phase-2-trial-could-be-expected-from-end-of-2017-2017-3
110.0,3/17/2017 12:10:00 PM,"Technical Reports on Drug Makers Stocks -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Immune Pharma",PR Newswire,/news/stocks/technical-reports-on-drug-makers-stocks-bristol-myers-squibb-astrazeneca-eli-lilly-and-immune-pharma-1001845502
111.0,3/20/2017 12:20:22 PM,"Bristol-Myers, CytomX Extend Deal To Find Probody Therapeutics To Treat Cancer ",RTTNews,/news/stocks/bristol-myers-cytomx-extend-deal-to-find-probody-therapeutics-to-treat-cancer-1001849534
112.0,3/20/2017 12:24:44 PM,"BRIEF-Bristol-Myers Squibb, Cytomx Therapeutics extend worldwide collaboration (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-cytomx-therapeutics-extend-worldwide-collaboration-2017-3
113.0,3/20/2017 4:28:56 PM,"A small drug company that's trying to make cancer treatments safer just received a $3.8 billion endorsement (CTMX, BMY)",Business Insider,http://www.businessinsider.com/cytomx-partners-with-bristol-myers-squibb-for-200-million-2017-3
114.0,3/21/2017 12:30:45 PM,BRIEF-Heat Biologics reports positive results from mid-stage lung cancer trial (BMY),Reuters,http://www.businessinsider.com/r-brief-heat-biologics-reports-positive-results-from-mid-stage-lung-cancer-trial-2017-3
115.0,3/23/2017 8:26:45 PM,"FDA approves Pfizer, German Merck immunotherapy for skin cancer",Reuters,http://www.businessinsider.com/r-fda-approves-pfizer-german-merck-immunotherapy-for-skin-cancer-2017-3
116.0,3/23/2017 10:40:47 PM,BRIEF-Bristol-Myers' CEO Caforio's 2016 total compensation $16.9 mln (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-ceo-caforios-2016-total-compensation-169-mln-2017-3
117.0,3/24/2017 2:34:49 PM,BRIEF-Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-receives-positive-chmp-opinion-recommending-opdivo-2017-3
118.0,3/24/2017 4:42:45 PM,"LPC: Top US firms raise loans on tax reform hopes (LLY, BMY, CSCO)",Reuters,http://www.businessinsider.com/r-lpc-top-us-firms-raise-loans-on-tax-reform-hopes-2017-3
119.0,3/27/2017 5:03:34 AM,"XENE Loses Face As Acne Trial Flops, NBRV Awaits LEAP Data, Opdivo Scores A Nod ",RTTNews,/news/stocks/xene-loses-face-as-acne-trial-flops-nbrv-awaits-leap-data-opdivo-scores-a-nod-1001868165
120.0,3/27/2017 10:00:47 PM,"Senators press Icahn on White House influence, business conflicts (CVI, HLF, BMY, BWSA)",Reuters,http://www.businessinsider.com/r-senators-press-icahn-on-white-house-influence-business-conflicts-2017-3
121.0,3/28/2017 1:30:20 PM,"PICI, Bristol-Myers, CRI Collaborate To Accelerate Immuno-Oncology Research ",RTTNews,/news/stocks/pici-bristol-myers-cri-collaborate-to-accelerate-immuno-oncology-research-1001873382
122.0,3/29/2017 6:34:47 PM,U.S. FDA nominee moves to untangle potential conflicts of interest,Reuters,http://www.businessinsider.com/r-us-fda-nominee-moves-to-untangle-potential-conflicts-of-interest-2017-3
123.0,3/29/2017 11:14:50 PM,"UPDATE 1-U.S. FDA nominee moves to untangle potential conflicts of interest (GSK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-nominee-moves-to-untangle-potential-conflicts-of-interest-2017-3
124.0,3/30/2017 1:24:48 PM,"BRIEF-Bristol-Myers enters collaboration to identify predictive biomarkers across multiple tumor types, immunotherapy agents (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-enters-collaboration-to-identify-predictive-biomarkers-across-multiple-tumor-types-immunotherapy-agents-2017-3
125.0,4/3/2017 6:05:53 AM,"Setback For ACOR In Ampyra Suit, EARS Put On Notice, STDY On Steady Rise ",RTTNews,/news/stocks/setback-for-acor-in-ampyra-suit-ears-put-on-notice-stdy-on-steady-rise-1001888420
126.0,4/3/2017 1:10:51 PM,"RPT-The cost of cancer: new drugs show success at a steep price (BMY, MRK, ESRX, PFE, AZN)",Reuters,http://www.businessinsider.com/r-rpt-the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-2017-4
127.0,4/3/2017 3:22:53 PM,BRIEF-Bristol-Myers says Opdivo in combination with Yervoy and Opdivo Monotherapy significantly improved overall survival (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-says-opdivo-in-combination-with-yervoy-and-opdivo-monotherapy-significantly-improved-overall-survival-2017-4
128.0,4/3/2017 3:56:23 PM,"New cancer drugs can cost more than $250,000 a year (BMY, MRK, ESRX, PFE, AZN)",Reuters,http://www.businessinsider.com/r-the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-2017-4
129.0,4/3/2017 4:46:09 PM,"A combination of cancer drugs work better together than on their own — but there's a catch (BMY, MRK)",Reuters,http://www.businessinsider.com/r-bristol-myers-immunotherapy-combination-extends-survival-in-melanoma-2017-4
130.0,4/3/2017 5:00:00 PM,Bristol-Myers Says CheckMate -143 Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/bristol-myers-says-checkmate-143-fails-to-meet-primary-endpoint-1001891098
131.0,4/4/2017 5:03:37 AM,"FDA Nod For TEVA, Cheers For PRTK, SRNE Hits Goal, SNY Launches Kids Toothpaste ",RTTNews,/news/stocks/fda-nod-for-teva-cheers-for-prtk-srne-hits-goal-sny-launches-kids-toothpaste-1001892460
132.0,4/4/2017 10:40:50 PM,BRIEF-FDA accepts for priority review Bristol-Myers' application for Opdivo in previously treated metastatic colorectal cancer (BMY),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-for-priority-review-bristol-myers-application-for-opdivo-in-previously-treated-metastatic-colorectal-cancer-2017-4
133.0,4/5/2017 8:28:48 AM,"INNL To Be Acquired, ELGX Seeks Funds, Opdivo At FDA Altar Again, NLNK Abuzz ",RTTNews,/news/stocks/innl-to-be-acquired-elgx-seeks-funds-opdivo-at-fda-altar-again-nlnk-abuzz-1001896978
134.0,4/6/2017 2:25:00 PM,"Global Oncology Market Gains Ground, Driven by Innovative Cancer Treatment Therapies",PR Newswire,/news/stocks/global-oncology-market-gains-ground-driven-by-innovative-cancer-treatment-therapies-1001902626
135.0,4/11/2017 1:40:54 AM,UK cost agency turns down Bristol drug for head and neck cancer,Reuters,http://www.businessinsider.com/r-uk-cost-agency-turns-down-bristol-drug-for-head-and-neck-cancer-2017-4
136.0,4/11/2017 1:16:57 PM,BRIEF-Bristol-Myers and Apexigen announce clinical collaboration to evaluate Opdivo in combination with APX005M in advanced solid tumors (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-and-apexigen-announce-clinical-collaboration-to-evaluate-opdivo-in-combination-with-apx005m-in-advanced-solid-tumors-2017-4
137.0,4/13/2017 1:21:00 PM,"Bristol-Myers To Get $470 Mln Upfront From Licensing Deals With Biogen, Roche ",RTTNews,/news/stocks/bristol-myers-to-get-470-mln-upfront-from-licensing-deals-with-biogen-roche-1001920351
138.0,4/13/2017 1:23:07 PM,"BRIEF-Bristol-Myers Squibb enters into separate agreements with Biogen and Roche (BMY, BIIB)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-enters-into-separate-agreements-with-biogen-and-roche-2017-4
139.0,4/13/2017 1:45:07 PM,"Bristol-Myers to license two of its drugs to Biogen, Roche",Reuters,http://www.businessinsider.com/r-bristol-myers-to-license-two-of-its-drugs-to-biogen-roche-2017-4
140.0,4/13/2017 2:07:04 PM,"BRIEF-Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb (BIIB, BMY)",Reuters,http://www.businessinsider.com/r-brief-biogen-licenses-phase-2-anti-tau-antibody-from-bristol-myers-squibb-2017-4
141.0,4/13/2017 2:11:12 PM,"UPDATE 1-Bristol-Myers to license two drugs to Biogen, Roche (BMY, BIIB, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-to-license-two-drugs-to-biogen-roche-2017-4
142.0,4/17/2017 1:08:19 PM,"Bristol-Myers, Nordic Bioscience To Develop Fibrosis Biomarker Technology ",RTTNews,/news/stocks/bristol-myers-nordic-bioscience-to-develop-fibrosis-biomarker-technology-1001923803
143.0,4/17/2017 5:01:07 PM,"BRIEF-Bristol-Myers,Nordic Bioscience announce collaboration for fibrosis biomarker technology (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myersnordic-bioscience-announce-collaboration-for-fibrosis-biomarker-technology-2017-4
144.0,4/18/2017 11:31:03 AM,Novartis advances with push on cancer and liver disease,Reuters,http://www.businessinsider.com/r-novartis-advances-with-push-on-cancer-and-liver-disease-2017-4
145.0,4/21/2017 3:55:06 PM,Only one person has used the Western world's first gene therapy so its maker is pulling it off the market (QURE),Reuters,http://www.businessinsider.com/r-biotech-firm-pulls-pioneering-gene-therapy-due-to-no-demand-2017-4
146.0,4/21/2017 9:37:05 PM,BRIEF-Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-gets-positive-chmp-opinion-recommending-approval-of-opdivo-for-treatment-of-a-type-of-bladder-cancer-2017-4
147.0,4/23/2017 8:53:05 PM,Bristol-Myers NASH drug reduces liver fat in midstage study (BMY),Reuters,http://www.businessinsider.com/r-bristol-myers-nash-drug-reduces-liver-fat-in-midstage-study-2017-4
148.0,4/24/2017 12:25:00 PM,"Drug Makers Stocks Under Scanner -- Bristol-Myers, AstraZeneca, Eli Lilly, and Immune Pharma",PR Newswire,/news/stocks/drug-makers-stocks-under-scanner-bristol-myers-astrazeneca-eli-lilly-and-immune-pharma-1001941450
149.0,4/24/2017 1:11:08 PM,"RPT-INSIGHT-NASH: The next untapped pharma market gives investors many options (PFE, BMY, GILD, AGN, MRK, JNJ, DRRX)",Reuters,http://www.businessinsider.com/r-rpt-insight-nash-the-next-untapped-pharma-market-gives-investors-many-options-2017-4
150.0,4/24/2017 8:17:06 PM,"UPDATE 1-NASH: The next untapped pharma market gives investors many options (PFE, BMY, GILD, AGN, MRK, JNJ, DRRX)",Reuters,http://www.businessinsider.com/r-update-1-nash-the-next-untapped-pharma-market-gives-investors-many-options-2017-4
151.0,4/25/2017 6:43:08 PM,"U.S. Supreme Court may limit where companies can be sued (BMY, BRK.)",Reuters,http://www.businessinsider.com/r-us-supreme-court-may-limit-where-companies-can-be-sued-2017-4
152.0,4/25/2017 9:45:06 PM,"UPDATE 1-U.S. Supreme Court may limit where companies can be sued (BMY, BRK.)",Reuters,http://www.businessinsider.com/r-update-1-us-supreme-court-may-limit-where-companies-can-be-sued-2017-4
153.0,4/27/2017 10:01:11 AM,"UPDATE 1-Strong pharma unit drives Bayer earnings beat (BAYN, MON, JNJ, PFE, BMY)",Reuters,http://www.businessinsider.com/r-update-1-strong-pharma-unit-drives-bayer-earnings-beat-2017-4
154.0,4/27/2017 1:20:56 PM,Bristol-Myers Squibb Q1 Profit Rises; Lifts 2017 Profit View ,RTTNews,/news/stocks/bristol-myers-squibb-q1-profit-rises-lifts-2017-profit-view-1001956263
155.0,4/27/2017 1:33:33 PM,Bristol-Myers Squibb Co. Reveals 13% Rise In Q1 Bottom Line,RTTNews,/news/stocks/bristol-myers-squibb-co-reveals-13-rise-in-q1-bottom-line-1001956363
156.0,4/27/2017 3:09:06 PM,"US STOCKS-Wall St set to open higher with earnings in focus (BMY, RTN, MSFT, AMZN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-higher-with-earnings-in-focus-2017-4
157.0,4/27/2017 4:21:11 PM,"US STOCKS-Wall St little changed with eyes on earnings (CMCSA, BMY, DAL, UAL, MSFT, AMZN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-little-changed-with-eyes-on-earnings-2017-4
158.0,4/27/2017 4:27:47 PM,"AstraZeneca wants to escape from its falling drug sales in the second half of 2017 (AZN, MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-astrazeneca-hopes-to-escape-drug-sales-trough-in-second-half-2017-4
159.0,4/27/2017 4:55:06 PM,"UPDATE 1-Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo (BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-beats-wall-st-estimates-helped-by-cancer-drug-opdivo-2017-4
160.0,4/27/2017 6:11:13 PM,BRIEF-Bristol-Myers CFO: potential for 2017 U.S. growth for Opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-cfo-potential-for-2017-us-growth-for-opdivo-2017-4
161.0,4/27/2017 6:17:09 PM,BRIEF-Bristol-Myers says discontinued development of drug to treat breast and gastric cancer in Q1 (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-says-discontinued-development-of-drug-to-treat-breast-and-gastric-cancer-in-q1-2017-4
162.0,4/28/2017 1:53:22 PM,"Bristol-Myers: China FDA Oks Daklinza, Sunvepra Combination For HCV ",RTTNews,/news/stocks/bristol-myers-china-fda-oks-daklinza-sunvepra-combination-for-hcv-1001961578
163.0,4/28/2017 2:09:09 PM,BRIEF-China FDA approves country's first all-oral regimen for chronic Hepatitis C (BMY),Reuters,http://www.businessinsider.com/r-brief-china-fda-approves-countrys-first-all-oral-regimen-for-chronic-hepatitis-c-2017-4
164.0,5/1/2017 10:20:05 PM,"UPDATE 2-AstraZeneca immunotherapy wins first approval in bladder cancer (AZN, BMY, MRK, MRK, PFE)",Reuters,http://www.businessinsider.com/r-update-2-astrazeneca-immunotherapy-wins-first-approval-in-bladder-cancer-2017-5
165.0,5/3/2017 11:10:05 PM,"UPDATE 1-Bayer, J&J win first trial over Xarelto bleeding risks (BAYN, JNJ, BMY)",Reuters,http://www.businessinsider.com/r-update-1-bayer-jj-win-first-trial-over-xarelto-bleeding-risks-2017-5
166.0,5/10/2017 1:16:08 PM,"BRIEF-Bristol-Myers Squibb, Calithera Biosciences expand collaboration (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-calithera-biosciences-expand-collaboration-2017-5
167.0,5/11/2017 12:00:05 AM,"UPDATE 1-U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer (MRK, LLY, BMY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-merck-immunotherapy-chemo-combo-for-lung-cancer-2017-5
168.0,5/15/2017 10:30:51 AM,Agilent Announces Expanded Use For PD-L1 IHC 28-8 PharmDx Diagnostic In Europe ,RTTNews,/news/stocks/agilent-announces-expanded-use-for-pd-l1-ihc-28-8-pharmdx-diagnostic-in-europe-1002011377
169.0,5/16/2017 12:06:02 AM,BRIEF-Jana Partners cuts sole share stake in Bristol-Myers Squibb (BMY),Reuters,http://www.businessinsider.com/r-brief-jana-partners-cuts-sole-share-stake-in-bristol-myers-squibb-2017-5
170.0,5/17/2017 2:42:03 PM,BRIEF-Health Canada approves Bristol-Myers' opdivo(nivolumab) (BMY),Reuters,http://www.businessinsider.com/r-brief-health-canada-approves-bristol-myers-opdivonivolumab-2017-5
171.0,5/17/2017 11:12:03 PM,"Merck says test shows Keytruda improves survival for bladder cancer patients (MRK, AZN, BMY, PFE)",Reuters,http://www.businessinsider.com/r-merck-says-test-shows-keytruda-improves-survival-for-bladder-cancer-patients-2017-5
172.0,5/18/2017 1:56:03 AM,"UPDATE 1-Merck says test shows Keytruda improves survival for bladder cancer patients (MRK, AZN, BMY, PFE, MRK)",Reuters,http://www.businessinsider.com/r-update-1-merck-says-test-shows-keytruda-improves-survival-for-bladder-cancer-patients-2017-5
173.0,5/18/2017 9:06:03 AM,"UK Stocks-Factors to watch on May 18 (UKX, BHP, BLT, BP., SKT, VOD, BIR, HSBA, TATASTEEL, TKA, CPG, ITRK, RDSA, ERM, BOK, HL., RNK, LAND, BBY, BRBY, TCG, DCG, NG., III, BMY, MARS, INVP)",Reuters,http://www.businessinsider.com/r-uk-stocks-factors-to-watch-on-may-18-2017-5
174.0,5/18/2017 10:16:10 AM,"UPDATE 1-UK Stocks-Factors to watch on May 18 (UKX, TCG, HL., BRBY, BHP, BLT, BP., SKT, VOD, BIR, HSBA, TATASTEEL, TKA, CPG, ITRK, RDSA, ERM, BOK, RNK, LAND, BBY, DCG, BMY, INVP, III, NG., MARS)",Reuters,http://www.businessinsider.com/r-update-1-uk-stocks-factors-to-watch-on-may-18-2017-5
175.0,5/19/2017 2:30:05 AM,"For millions of Chinese with rare diseases, some relief in sight (CELG, BMY, JNJ, SHP, SAN, PFE, MRK, SAPL, ALXN)",Reuters,http://www.businessinsider.com/r-for-millions-of-chinese-with-rare-diseases-some-relief-in-sight-2017-5
176.0,5/19/2017 2:19:02 PM,EMA Validates Application For Bristol-Myers' Sprycel In Children With CML ,RTTNews,/news/stocks/ema-validates-application-for-bristol-myers-sprycel-in-children-with-cml-1002028867
177.0,5/30/2017 11:30:07 AM,"Novartis has assets to sell, investors wary of what it might buy (GSK, MRK, BMY, AZN, JNJ)",Reuters,http://www.businessinsider.com/r-novartis-has-assets-to-sell-investors-wary-of-what-it-might-buy-2017-5
178.0,5/30/2017 11:30:07 AM,"RPT-Novartis has assets to sell, investors wary of what it might buy (GSK, MRK, BMY, AZN, JNJ)",Reuters,http://www.businessinsider.com/r-rpt-novartis-has-assets-to-sell-investors-wary-of-what-it-might-buy-2017-5
179.0,5/30/2017 12:59:00 PM,Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration,PR Newswire,/news/stocks/array-biopharma-and-bristol-myers-squibb-announce-strategic-collaboration-1002050073
180.0,5/30/2017 1:15:24 PM,"Array BioPharma, Bristol-Myers Squibb Announce Strategic Collaboration ",RTTNews,/news/stocks/array-biopharma-bristol-myers-squibb-announce-strategic-collaboration-1002050158
181.0,5/30/2017 1:18:02 PM,"BRIEF-Array BioPharma and Bristol-Myers Squibb announce strategic collaboration (ARRY, BMY)",Reuters,http://www.businessinsider.com/r-brief-array-biopharma-and-bristol-myers-squibb-announce-strategic-collaboration-2017-5
182.0,5/30/2017 1:18:02 PM,BRIEF-Advaxis and Bristol-Myers Squibb announce clinical collaboration to evaluate ADXS-DUAL and Opdivo in metastatic cervical cancer (BMY),Reuters,http://www.businessinsider.com/r-brief-advaxis-and-bristol-myers-squibb-announce-clinical-collaboration-to-evaluate-adxs-dual-and-opdivo-in-metastatic-cervical-cancer-2017-5
183.0,5/30/2017 4:58:03 PM,"U.S. top court tightens rules on where companies can be sued (BRK., BMY)",Reuters,http://www.businessinsider.com/r-us-top-court-tightens-rules-on-where-companies-can-be-sued-2017-5
184.0,5/30/2017 5:18:05 PM,"UPDATE 1-U.S. top court tightens rules on where companies can be sued (BRK., BMY)",Reuters,http://www.businessinsider.com/r-update-1-us-top-court-tightens-rules-on-where-companies-can-be-sued-2017-5
185.0,6/1/2017 12:20:00 PM,"Drug Makers Stocks on Investors' Radar -- AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Sanofi",PR Newswire,/news/stocks/drug-makers-stocks-on-investors-radar-astrazeneca-bristol-myers-squibb-eli-lilly-and-sanofi-1002058233
186.0,6/2/2017 12:15:03 PM,Bristol-Myers & Seattle Genetics To Evaluate Combination Of Opdivo And ADCETRIS ,RTTNews,/news/stocks/bristol-myers-seattle-genetics-to-evaluate-combination-of-opdivo-and-adcetris-1002062780
187.0,6/2/2017 12:36:07 PM,"BRIEF-Bristol-Myers Squibb and Seattle Genetics expand collaboration to evaluate combination of opdivo and adcetris (BMY, SGEN)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-seattle-genetics-expand-collaboration-to-evaluate-combination-of-opdivo-and-adcetris-2017-6
188.0,6/2/2017 1:21:08 PM,"Bristol-Myers Reports Opdivo Data, Shows Overall Response Rate Of 26.3% ",RTTNews,/news/stocks/bristol-myers-reports-opdivo-data-shows-overall-response-rate-of-26-3-1002063031
189.0,6/2/2017 1:28:03 PM,BRIEF-Bristol-Myers announces first disclosure of data from a cohort of phase 1/2 CheckMate-358 study (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-announces-first-disclosure-of-data-from-a-cohort-of-phase-1-2-checkmate-358-study-2017-6
190.0,6/2/2017 11:22:05 PM,BRIEF-European commission approves Bristol-Myers Squibb’s opdivo (nivolumab) (BMY),Reuters,http://www.businessinsider.com/r-brief-european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-2017-6
191.0,6/3/2017 7:00:00 PM,Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies,PR Newswire,/news/stocks/bristol-myers-squibb-and-qiagen-sign-agreement-for-use-of-ngs-technology-to-develop-gene-expression-profiles-for-immuno-oncology-therapies-1002065369
192.0,6/5/2017 1:28:05 PM,BRIEF-Bristol-Myers Squibb says early responses seen with Sprycel in first and second line treatment of pediatric patients with chronic myeloid leukemia in chronic phase (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-early-responses-seen-with-sprycel-in-first-and-second-line-treatment-of-pediatric-patients-with-chronic-myeloid-leukemia-in-chronic-phase-2017-6
193.0,6/5/2017 1:48:05 PM,"BRIEF-Incyte says epacadostat, Bristol-Myers' Opdivo combo data positive in head and neck cancer patients (INCY, BMY)",Reuters,http://www.businessinsider.com/r-brief-incyte-says-epacadostat-bristol-myers-opdivo-combo-data-positive-in-head-and-neck-cancer-patients-2017-6
194.0,6/5/2017 10:22:06 PM,"US STOCKS-Wall St dips; 2017's laggards tick up, Apple slips (AAPL, BMY, HLF)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-dips-2017s-laggards-tick-up-apple-slips-2017-6
195.0,6/5/2017 10:28:06 PM,BRIEF-Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-new-collaboration-to-evaluate-combination-therapy-in-colorectal-cancer-2017-6
196.0,6/6/2017 3:05:40 AM,"Novartis, Bristol-Myers To Evaluate Treatments In Metastatic Colorectal Cancer ",RTTNews,/news/stocks/novartis-bristol-myers-to-evaluate-treatments-in-metastatic-colorectal-cancer-1002068811
197.0,6/8/2017 1:42:06 PM,BRIEF-Bristol-Myers announces availability of Orencia subcutaneous administration option for patients above 2 yrs of age with moderately to severely active polyarticular JIA (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-announces-availability-of-orencia-subcutaneous-administration-option-for-patients-above-2-yrs-of-age-with-moderately-to-severely-active-polyarticular-jia-2017-6
198.0,6/13/2017 10:12:08 PM,BRIEF-Bristol-Myers Squibb declares quarterly dividend of $0.39/shr (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-declares-quarterly-dividend-of-039-shr-2017-6
199.0,6/14/2017 3:28:05 PM,BRIEF-Bristol-Myers Squibb announces cash tender offer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-cash-tender-offer-2017-6
200.0,6/16/2017 11:18:28 AM,"Bristol-Myers To Sell Manufacturing Facility In Swords, Ireland - Quick Facts ",RTTNews,/news/stocks/bristol-myers-to-sell-manufacturing-facility-in-swords-ireland-quick-facts-1002098897
201.0,6/16/2017 12:02:05 PM,"BRIEF-Bristol-Myers Squibb to sell manufacturing facility to SK Biotek Co (BMY, 034730)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-to-sell-manufacturing-facility-to-sk-biotek-co-2017-6
202.0,6/16/2017 1:11:48 PM,Bristol-Myers Reports Opdivo Follow-Up Data - Quick Facts ,RTTNews,/news/stocks/bristol-myers-reports-opdivo-follow-up-data-quick-facts-1002099243
203.0,6/19/2017 4:52:06 PM,"U.S. Supreme Court limits where companies can be sued (BMY, BRK.)",Reuters,http://www.businessinsider.com/r-us-supreme-court-limits-where-companies-can-be-sued-2017-6
204.0,6/19/2017 6:18:05 PM,"UPDATE 1-U.S. Supreme Court again limits where companies can be sued (BMY, BRK.)",Reuters,http://www.businessinsider.com/r-update-1-us-supreme-court-again-limits-where-companies-can-be-sued-2017-6
205.0,6/21/2017 1:18:03 AM,"U.S. Supreme Court ruling threatens massive talc litigation against J&J (JNJ, BMY, BAYN, GSK, MCK)",Reuters,http://www.businessinsider.com/r-us-supreme-court-ruling-threatens-massive-talc-litigation-against-jj-2017-6
206.0,6/21/2017 1:10:06 PM,BRIEF-Bristol-Myers Squibb announces expiration of cash tender offer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-expiration-of-cash-tender-offer-2017-6
207.0,6/21/2017 1:10:09 PM,"RPT-U.S. Supreme Court ruling threatens massive talc litigation against J&J (JNJ, BMY, BAYN, GSK, MCK)",Reuters,http://www.businessinsider.com/r-rpt-us-supreme-court-ruling-threatens-massive-talc-litigation-against-jj-2017-6
208.0,6/21/2017 4:00:00 PM,S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017,PR Newswire,/news/stocks/s-p-500-buybacks-fall-17-5-year-over-year-to-133-1-billion-for-q1-2017-1002112472
209.0,6/26/2017 1:12:03 PM,"Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial (SGEN, 4502, BMY)",Reuters,http://www.businessinsider.com/r-seattle-genetics-takeda-lymphoma-drug-succeeds-late-stage-trial-2017-6
210.0,6/26/2017 3:58:03 PM,"UPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails (SGEN, 4502, BMY)",Reuters,http://www.businessinsider.com/r-update-1-seattle-genetics-takeda-lymphoma-drug-success-fails-2017-6
211.0,6/26/2017 6:40:18 PM,"UPDATE 2-Seattle Genetics slumps as cancer drug data fails to impress (SGEN, 4502, BMY)",Reuters,http://www.businessinsider.com/r-update-2-seattle-genetics-slumps-as-cancer-drug-data-fails-to-impress-2017-6
212.0,6/27/2017 7:08:03 PM,"AstraZeneca cancer drug trial prompts investors to take options cover (AZN, MRK, BMY)",Reuters,http://www.businessinsider.com/r-astrazeneca-cancer-drug-trial-prompts-investors-to-take-options-cover-2017-6
213.0,7/5/2017 12:34:00 PM,Bristol-Myers Phase 3 Study Of Opdivo Vs Yervoy Meets Primary Goal ,RTTNews,/news/stocks/bristol-myers-phase-3-study-of-opdivo-vs-yervoy-meets-primary-goal-1002148519
214.0,7/5/2017 12:38:04 PM,BRIEF-Bristol-Myers Squibb says phase 3 study evaluating the safety and efficacy of adjuvant Opdivo in resected high-risk melanoma patients meets main goal (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-phase-3-study-evaluatingthe-safety-and-efficacy-of-adjuvant-opdivoin-resected-high-risk-melanoma-patients-meets-main-goal-2017-7
215.0,7/5/2017 7:02:05 PM,"New cancer treatments that are programmed to treat a person's specific tumor just passed 2 early tests (MRK, BMY, SAN, LLY)",Reuters,http://www.businessinsider.com/r-personalised-vaccines-hold-cancer-at-bay-in-two-early-trials-2017-7
216.0,7/5/2017 11:42:05 PM,"UPDATE 1-FDA puts hold on Merck multiple myeloma trials after deaths (MRK, BMY, CELG)",Reuters,http://www.businessinsider.com/r-update-1-fda-puts-hold-on-merck-multiple-myeloma-trials-after-deaths-2017-7
217.0,7/6/2017 1:48:03 PM,BRIEF-Bristol-Myers Squibb's Orencia receives FDA approval (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibbs-orencia-receives-fda-approval-2017-7
218.0,7/7/2017 7:36:45 AM,"BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track ",RTTNews,/news/stocks/bmy-s-orencia-scores-another-fda-nod-janssen-ends-deal-with-capr-pbyi-on-track-1002154681
219.0,7/10/2017 1:22:37 PM,FDA Accepts For Priority Review Bristol-Myers' SNDA For Sprycel For Children ,RTTNews,/news/stocks/fda-accepts-for-priority-review-bristol-myers-snda-for-sprycel-for-children-1002159701
220.0,7/10/2017 1:30:06 PM,BRIEF-FDA accepts for priority review Bristol-Myers Squibb's application for sprycel (BMY),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-sprycel-2017-7
221.0,7/10/2017 3:06:03 PM,"BRIEF-Exelixis, Bristol-Myers Squibb initiate phase 3 trial (BMY, EXEL, IPN)",Reuters,http://www.businessinsider.com/r-brief-exelixis-bristol-myers-squibb-initiate-phase-3-trial-2017-7
222.0,7/11/2017 7:59:29 AM,"ARNA Heartened By Phase II Trial, BMY To Face FDA In Nov., Concert Back In Play ",RTTNews,/news/stocks/arna-heartened-by-phase-ii-trial-bmy-to-face-fda-in-nov-concert-back-in-play-1002161941
223.0,7/13/2017 12:02:03 PM,"T-cell cancer therapy holds promise, longer-term results await (MRK, BMY, AET)",Reuters,http://www.businessinsider.com/r-t-cell-cancer-therapy-holds-promise-longer-term-results-await-2017-7
224.0,7/14/2017 10:34:08 PM,BRIEF-Bristol-Myers Squibb Co says Laurie Glimcher notified co that she will retire from board (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-co-says-laurie-glimcher-notified-co-that-she-will-retire-from-board-2017-7
225.0,7/24/2017 1:38:42 PM,Bristol-Myers Squibb Reports Expanded Approval For Yervoy - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-reports-expanded-approval-for-yervoy-quick-facts-1002198278
226.0,7/24/2017 2:22:05 PM,BRIEF-Bristol-Myers Squibb says Yervoy showed a consistent safety profile and comparable drug levels across pediatric and adult patients​ (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-yervoy-showed-a-consistent-safety-profile-and-comparable-drug-levels-across-pediatric-and-adult-patients-2017-7
227.0,7/24/2017 10:38:05 PM,BRIEF-FDA accepts Bristol-Myers Squibb's applications for Opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-bristol-myers-squibbs-applications-for-opdivo-2017-7
228.0,7/26/2017 2:20:13 PM,BRIEF-Bristol-Myers Squibb’s Orencia receives second European Commission approval (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibbs-orencia-receives-second-european-commission-approval-2017-7
229.0,7/27/2017 1:06:04 PM,"Bristol-Myers quarterly sales meet Wall Street estimates (BMY, MRK)",Reuters,http://www.businessinsider.com/r-bristol-myers-quarterly-sales-meet-wall-street-estimates-2017-7
230.0,7/27/2017 2:38:05 PM,"UPDATE 1-Bristol-Myers shares fall after failed AstraZeneca drug trial (BMY, AZN, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-shares-fall-after-failed-astrazeneca-drug-trial-2017-7
231.0,7/27/2017 5:02:03 PM,"Hepatitis drugs more affordable but disease still deadly - WHO (MYL, BMY)",Reuters,http://www.businessinsider.com/r-hepatitis-drugs-more-affordable-but-disease-still-deadly---who-2017-7
232.0,7/27/2017 10:28:03 PM,"US STOCKS-Tech, transports drag on Wall Street; Dow hits record (UPS, FDX, AMZN, BMY, AZN, VZ, T)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-transports-drag-on-wall-street-dow-hits-record-2017-7
233.0,7/31/2017 7:47:51 AM,Biotech Stocks Facing FDA Decision In August ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-1002217371
234.0,8/1/2017 11:12:04 PM,"BRIEF-Seattle Genetics to buy Bothell plant from Bristol-Myers Squibb (BMY, SGEN)",Reuters,http://www.businessinsider.com/r-brief-seattle-genetics-to-buy-bothell-plant-from-bristol-myers-squibb-2017-8
235.0,8/2/2017 8:28:58 AM,"FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount ",RTTNews,/news/stocks/fda-nod-for-agio-s-idhifa-bmy-expands-opdivo-use-ocul-reduces-headcount-1002224912
236.0,8/3/2017 10:03:05 PM,Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy (BMY),Business Insider,http://www.businessinsider.com/bristol-myers-squibb-acquires-ifm-therapeutics-for-up-to-232-billion-2017-8
237.0,8/3/2017 10:17:03 PM,BRIEF-Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-to-acquire-ifm-therapeutics-to-strengthen-oncology-pipeline-focus-on-innate-immunity-2017-8
238.0,8/3/2017 10:19:36 PM,Bristol-Myers Squibb To Acquire IFM Therapeutics - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-to-acquire-ifm-therapeutics-quick-facts-1002231883
239.0,8/3/2017 11:17:03 PM,"Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline (BMY, MRK)",Reuters,http://www.businessinsider.com/r-bristol-myers-to-buy-ifm-therapeutics-to-strengthen-cancer-pipeline-2017-8
240.0,8/4/2017 12:07:03 PM,"Deals of the day-Mergers and acquisitions (GAS, BMY, MRK, 7261, BX, 2914, VNM)",Reuters,http://www.businessinsider.com/r-deals-of-the-day-mergers-and-acquisitions-2017-8
241.0,8/10/2017 12:15:00 PM,"Technical Snapshots for These Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson",PR Newswire,/news/stocks/technical-snapshots-for-these-drug-makers-stocks-abbvie-astrazeneca-bristol-myers-squibb-and-johnson-johnson-1002247897
242.0,8/14/2017 4:47:05 PM,"BRIEF-Jana Partners dissolves sole share stake in Snap Inc, Shire Plc (BMY, SHP, NUVA, CRM, UHS)",Reuters,http://www.businessinsider.com/r-brief-jana-partners-dissolves-sole-share-stake-in-snap-inc-shire-plc-2017-8
243.0,8/15/2017 10:42:14 PM,BRIEF-Bristol-Myers Squibb announces topline results (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-topline-results-2017-8
244.0,8/15/2017 10:57:14 PM,Bristol-Myers kidney cancer drug fails late-stage trial (BMY),Reuters,http://www.businessinsider.com/r-bristol-myers-kidney-cancer-drug-fails-late-stage-trial-2017-8
245.0,8/16/2017 8:01:41 AM,"ALXN's Strengthening Patents, FOLD's Fabry Drug Approved In OZ, VBIV Surges ",RTTNews,/news/stocks/alxn-s-strengthening-patents-fold-s-fabry-drug-approved-in-oz-vbiv-surges-1002260660
246.0,8/16/2017 1:37:03 PM,"US STOCKS-Futures higher ahead of Fed minutes (TGT, URBN, AMZN, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-higher-ahead-of-fed-minutes-2017-8
247.0,8/16/2017 3:07:03 PM,"US STOCKS-U.S. stocks set to open higher ahead of Fed minutes (TGT, URBN, AMZN, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-us-stocks-set-to-open-higher-ahead-of-fed-minutes-2017-8
248.0,8/27/2017 11:27:08 AM,"Bayer, J&J in frame for bigger anti-clotting market opportunity (BAYN, JNJ, PFE, BMY)",Reuters,http://www.businessinsider.com/r-bayer-jj-in-frame-for-bigger-anti-clotting-market-opportunity-2017-8
249.0,8/28/2017 8:47:13 AM,Bristol-Myers: Eliquis Shows Lower Risk Of Stroke In NVAF Patient Subgroups ,RTTNews,/news/stocks/bristol-myers-eliquis-shows-lower-risk-of-stroke-in-nvaf-patient-subgroups-1002287443
250.0,8/28/2017 11:26:34 AM,"Bristol-Myers, Pfizer Report Investigational Eliquis Data - Quick Facts ",RTTNews,/news/stocks/bristol-myers-pfizer-report-investigational-eliquis-data-quick-facts-1002287826
251.0,8/28/2017 10:17:03 PM,"BRIEF-Bristol-Myers Squibb and Daiichi Sankyo collaborate to evaluate Opdivo (Nivolumab) and DS-8201 (4568, BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-daiichi-sankyo-collaborate-to-evaluate-opdivo-nivolumab-and-ds-8201-2017-8
252.0,8/28/2017 10:47:07 PM,"Bristol-Myers, Daiichi Sankyo to test combo therapy for breast, bladder cancers (BMY, 4568)",Reuters,http://www.businessinsider.com/r-bristol-myers-daiichi-sankyo-to-test-combo-therapy-for-breast-bladder-cancers-2017-8
253.0,8/28/2017 11:12:03 PM,"UPDATE 1-Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers (BMY, 4568, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-daiichi-sankyo-to-test-opdivo-combo-for-cancers-2017-8
254.0,8/29/2017 10:56:50 AM,"KMDA Slips On AAT Therapy Concerns, ETRM Gains Weight, LJPC On Watch ",RTTNews,/news/stocks/kmda-slips-on-aat-therapy-concerns-etrm-gains-weight-ljpc-on-watch-1002290567
255.0,8/29/2017 2:23:52 PM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1002291346
256.0,8/31/2017 2:52:03 PM,"AstraZeneca aims to offset drug setback at big cancer congress (AZN, LLY, PFE, BMY, MRK, INCY)",Reuters,http://www.businessinsider.com/r-astrazeneca-aims-to-offset-drug-setback-at-big-cancer-congress-2017-8
257.0,9/6/2017 4:07:03 PM,"Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln (MRK, BMY)",Reuters,http://www.businessinsider.com/r-merck--co-snaps-up-3-yr-old-german-biotech-firm-for-up-to-550-mln-2017-9
258.0,9/7/2017 12:22:13 AM,"Bristol-Myers says FDA places partial hold on Opdivo myeloma trials (BMY, MRK, CELG)",Reuters,http://www.businessinsider.com/r-bristol-myers-says-fda-places-partial-hold-on-opdivo-myeloma-trials-2017-9
259.0,9/7/2017 1:27:07 PM,Bristol-Myers kidney cancer drug meets main goal of late-stage trial (BMY),Reuters,http://www.businessinsider.com/r-bristol-myers-kidney-cancer-drug-meets-main-goal-of-late-stage-trial-2017-9
260.0,9/7/2017 1:41:15 PM,Bristol-Myers: Phase 3 Study Of Opdivo Plus Yervoy Met Co-primary Endpoint ,RTTNews,/news/stocks/bristol-myers-phase-3-study-of-opdivo-plus-yervoy-met-co-primary-endpoint-1002349426
261.0,9/7/2017 1:57:06 PM,BRIEF-‍Bristol-Myers Squibb says Opdivo plus Yervoy showed superior overall survival (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-opdivo-plus-yervoy-showed-superior-overall-survival-2017-9
262.0,9/7/2017 1:57:06 PM,"UPDATE 1-Bristol-Myers kidney cancer drug meets main goal of late-stage trial (BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-kidney-cancer-drug-meets-main-goal-of-late-stage-trial-2017-9
263.0,9/7/2017 10:32:09 PM,"US STOCKS-Wall St ends flat as media stocks slump, healthcare gains (CMCSA, BMY, MSFT, AMZN, GE, AAPL, LLY, CBS)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-ends-flat-as-media-stocks-slump-healthcare-gains-2017-9
264.0,9/7/2017 11:02:18 PM,BRIEF-Bristol-Myers Squibb completes acquisition of IFM Therapeutics (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-completes-acquisition-of-ifm-therapeutics-2017-9
265.0,9/8/2017 12:07:09 AM,"Roche blood test could help 'personalize' cancer immunotherapy (MRK, BMY)",Reuters,http://www.businessinsider.com/r-roche-blood-test-could-help-personalize-cancer-immunotherapy-2017-9
266.0,9/8/2017 12:07:10 AM,"Merck's immunotherapy, chemo mix shows extended lung cancer gains (MRK, BMY, AZN)",Reuters,http://www.businessinsider.com/r-mercks-immunotherapy-chemo-mix-shows-extended-lung-cancer-gains-2017-9
267.0,9/8/2017 9:02:03 AM,"UPDATE 1-Roche blood test could help 'personalise' cancer immunotherapy (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-blood-test-could-help-personalise-cancer-immunotherapy-2017-9
268.0,9/8/2017 11:51:28 AM,Bristol-Myers: Phase 3 Data Reinforce Sustained Survival Benefit Of Opdivo ,RTTNews,/news/stocks/bristol-myers-phase-3-data-reinforce-sustained-survival-benefit-of-opdivo-1002353010
269.0,9/9/2017 12:07:13 AM,"AstraZeneca rebuilds cancer drug hopes with new lung data (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-astrazeneca-rebuilds-cancer-drug-hopes-with-new-lung-data-2017-9
270.0,9/9/2017 11:02:03 AM,"UPDATE 1-AstraZeneca rebuilds cancer drug hopes with new lung data (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-astrazeneca-rebuilds-cancer-drug-hopes-with-new-lung-data-2017-9
271.0,9/10/2017 5:57:04 PM,"Bristol kidney cancer drug cut death risk 37 pct in key patients (BMY, AZN, PFE, MRK)",Reuters,http://www.businessinsider.com/r-bristol-kidney-cancer-drug-cut-death-risk-37-pct-in-key-patients-2017-9
272.0,9/10/2017 6:39:55 PM,Bristol-Myers Announces Results From The Phase 3 CheckMate ,RTTNews,/news/stocks/bristol-myers-announces-results-from-the-phase-3-checkmate-1002356021
273.0,9/10/2017 7:02:03 PM,"UPDATE 1-Bristol's drug cocktail cuts kidney cancer death risk 37 pct (BMY, AZN, PFE, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristols-drug-cocktail-cuts-kidney-cancer-death-risk-37-pct-2017-9
274.0,9/11/2017 12:17:08 AM,"After melanoma surgery, Bristol's Opdivo offers new care standard (BMY)",Reuters,http://www.businessinsider.com/r-after-melanoma-surgery-bristols-opdivo-offers-new-care-standard-2017-9
275.0,9/11/2017 12:17:09 AM,"Novartis posts a win, Roche a flop in skin cancer trials (BMY, GSK)",Reuters,http://www.businessinsider.com/r-novartis-posts-a-win-roche-a-flop-in-skin-cancer-trials-2017-9
276.0,9/11/2017 6:58:22 AM,"New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch ",RTTNews,/news/stocks/new-hope-for-azn-s-old-drug-more-about-bmy-s-opdivo-imdz-on-watch-1002356354
277.0,9/11/2017 8:17:03 AM,"RPT-UPDATE 1-AstraZeneca rebuilds cancer drug hopes with new lung data (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-rpt-update-1-astrazeneca-rebuilds-cancer-drug-hopes-with-new-lung-data-2017-9
278.0,9/11/2017 12:07:03 PM,"Cancer immunotherapy proves itself in earlier-stage disease (MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-cancer-immunotherapy-proves-itself-in-earlier-stage-disease-2017-9
279.0,9/13/2017 12:25:00 PM,"Breakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson",PR Newswire,/news/stocks/breakfast-technical-briefing-on-drug-makers-stocks-abbvie-astrazeneca-bristol-myers-squibb-and-johnson-johnson-1002365439
280.0,9/13/2017 10:37:14 PM,BRIEF-Bristol-Myers Squibb Co says ‍declared a quarterly dividend (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-co-says-declared-a-quarterly-dividend-2017-9
281.0,9/13/2017 10:42:16 PM,BRIEF-Bristol-Myers Squibb says Karen Vousden elected as member of board (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-karen-vousden-elected-as-member-of-board-2017-9
282.0,9/14/2017 1:08:34 PM,Bristol-Myers Partners With Halozyme; Gains Access To ENHANZE Technology ,RTTNews,/news/stocks/bristol-myers-partners-with-halozyme-gains-access-to-enhanze-technology-1002369805
283.0,9/14/2017 1:17:04 PM,"BRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology (BMY, HALO)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-halozyme-enter-global-collaboration-and-license-agreement-for-enhanze-technology-2017-9
284.0,9/14/2017 2:02:03 PM,"Halozyme to license drug delivery tech to Roche, Bristol-Myers (HALO, BMY)",Reuters,http://www.businessinsider.com/r-halozyme-to-license-drug-delivery-tech-to-roche-bristol-myers-2017-9
285.0,9/14/2017 3:31:00 PM,"Stock Score Reports for Bristol-Myers Squibb, Cliffs Natural Resources, Hertz Global Holdings, Nordstrom and Oclaro Inc.",PR Newswire,/news/stocks/stock-score-reports-for-bristol-myers-squibb-cliffs-natural-resources-hertz-global-holdings-nordstrom-and-oclaro-inc--671790
286.0,9/22/2017 11:12:00 AM,Bristol-Myers Reports Approval Of Opdivo For Recurrent Gastric Cancer In Japan ,RTTNews,/news/stocks/bristol-myers-reports-approval-of-opdivo-for-recurrent-gastric-cancer-in-japan-1002419060
287.0,9/22/2017 1:00:00 PM,AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors,PR Newswire,/news/stocks/abbvie-and-bristol-myers-squibb-announce-clinical-research-collaboration-to-evaluate-a-therapeutic-regimen-in-advanced-solid-tumors-1002421197
288.0,9/22/2017 1:17:03 PM,BRIEF-AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors (BMY),Reuters,http://www.businessinsider.com/r-brief-abbvie-and-bristol-myers-squibb-announce-clinical-research-collaboration-to-evaluate-a-therapeutic-regimen-in-advanced-solid-tumors-2017-9
289.0,9/23/2017 12:17:15 AM,BRIEF-Bristol-Myers says ‍FDA approves Opdivo(Nivolumab) injection for intravenous use in certain patients (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-says-fda-approves-opdivonivolumab-injection-for-intravenous-use-in-certain-patients-2017-9
290.0,9/25/2017 4:36:05 AM,"Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes ",RTTNews,/news/stocks/opdivo-keytruda-back-in-the-news-fda-snubs-agn-ears-catches-eyes-1002503240
291.0,9/25/2017 2:12:08 PM,"BRIEF-Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration (BMY, INFI)",Reuters,http://www.businessinsider.com/r-brief-infinity-pharmaceuticals-and-bristol-myers-squibb-expand-clinical-collaboration-2017-9
292.0,9/25/2017 2:21:45 PM,"Infinity Pharma, Bristol-Myers Collaborate; Expands IPI-549 Study ",RTTNews,/news/stocks/infinity-pharma-bristol-myers-collaborate-expands-ipi-549-study-1002518792
293.0,9/29/2017 5:27:05 PM,"Puerto Rico power outage set to hurt global reinsurers (MAP, QBE, AIG, BMY, LLY, PFE, AMGN, AZN, MMC)",Reuters,http://www.businessinsider.com/r-puerto-rico-power-outage-set-to-hurt-global-reinsurers-2017-9
294.0,10/5/2017 11:42:17 PM,"BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification (AVEO, BMY)",Reuters,http://www.businessinsider.com/r-brief-aveo-pharmaceuticals--tivo-3-study-will-continue-as-planned-without-modification-2017-10
295.0,10/9/2017 1:32:04 PM,BRIEF-Bristol-Myers Squibb names Saurabh Saha as senior vice president (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-names-saurabh-saha-as-senior-vice-president-2017-10
296.0,10/12/2017 3:00:00 PM,Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH,PR Newswire,/news/stocks/bristol-myers-squibb-bmy-extends-strategic-partnership-with-target-pharmasolutions-for-target-nash-1003980998
297.0,10/12/2017 3:22:25 PM,BRIEF-Bristol-Myers Squibb extends strategic partnership with Target Pharmasolutions (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-extends-strategic-partnership-with-target-pharmasolutions-2017-10
298.0,10/12/2017 4:12:03 PM,"NIH partners 11 drugmakers to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-nih-partners-11-drugmakers-to-accelerate-cancer-therapy-research-2017-10
299.0,10/12/2017 6:27:06 PM,"UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-us-nih-11-drugmakers-partner-to-accelerate-cancer-therapy-research-2017-10
300.0,10/12/2017 10:12:15 PM,"UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-us-nih-11-drugmakers-partner-to-accelerate-cancer-therapy-research-2017-10
301.0,10/16/2017 9:42:11 AM,BRIEF-Bristol-Myers ‍announces data for Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer​ (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-announces-data-for-opdivo-and-opdivo-plus-yervoy-in-previously-treated-small-cell-lung-cancer-2017-10
302.0,10/16/2017 9:45:48 AM,"Bristol-Myers: Opdivo Shows Encouraging Response, Survival Rates - Quick Facts ",RTTNews,/news/stocks/bristol-myers-opdivo-shows-encouraging-response-survival-rates-quick-facts-1004461009
303.0,10/16/2017 7:22:12 PM,"US STOCKS-Wall St higher as bank stocks rebound, Apple gains (JPM, BAC, AAPL, BMY, ADBE, FCX, NFLX, GS, MS)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-higher-as-bank-stocks-rebound-apple-gains-2017-10
304.0,10/16/2017 10:27:09 PM,BRIEF-FDA accepts Bristol-Myers Squibb’s application for Opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-bristol-myers-squibbs-application-for-opdivo-2017-10
305.0,10/17/2017 7:46:16 AM,"ANIK Expands Horizons, FENC Hits Study Goals, IMDZ Abuzz, One More For Opdivo ",RTTNews,/news/stocks/anik-expands-horizons-fenc-hits-study-goals-imdz-abuzz-one-more-for-opdivo-1004579305
306.0,10/20/2017 2:01:28 PM,Bristol-Myers To Present Data Across Serious Liver Diseases - Quick Facts ,RTTNews,/news/stocks/bristol-myers-to-present-data-across-serious-liver-diseases-quick-facts-1005028356
307.0,10/24/2017 8:07:14 AM,"UK Stocks-Factors to watch on Oct 24 (UKX, RBS, BARC, LLOY, RIO, RIO, GKN, WTB, BNZL, AAL, BMY, STJ, IPF)",Reuters,http://www.businessinsider.com/r-uk-stocks-factors-to-watch-on-oct-24-2017-10
308.0,10/25/2017 2:37:12 PM,"UPDATE 1-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria (BAX, MRK, JNJ, PFE, GSK, MDT, DEPO, AMGN, BMY, LLY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-baxter-expects-70-mln-hit-to-4th-qtr-sales-from-hurricane-maria-2017-10
309.0,10/26/2017 1:07:08 PM,"Bristol Myers posts in-line sales, but profit margins worsen (BMY)",Reuters,http://www.businessinsider.com/r-bristol-myers-posts-in-line-sales-but-profit-margins-worsen-2017-10
310.0,10/26/2017 1:21:38 PM,Bristol-Myers Squibb Co. Reports 8% Decline In Q3 Bottom Line,RTTNews,/news/stocks/bristol-myers-squibb-co-reports-8-decline-in-q3-bottom-line-1005694605
311.0,10/26/2017 1:21:56 PM,Bristol-Myers Squibb Increases 2017 Non-GAAP EPS Guidance - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-increases-2017-non-gaap-eps-guidance-quick-facts-1005694603
312.0,10/26/2017 4:12:03 PM,"US STOCKS-Dow advances at open; Celgene holds back S&P, Nasdaq (AMZN, MSFT, INTC, CELG, BMY, F)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-advances-at-open-celgene-holds-back-sp-nasdaq-2017-10
313.0,10/26/2017 5:27:03 PM,"UPDATE 1-Bristol-Myers sales in line, but profit margins worsen (BMY, MRK, PFE)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-sales-in-line-but-profit-margins-worsen-2017-10
314.0,10/26/2017 5:42:05 PM,"US STOCKS-Financial, tech stocks drive Wall St higher (CELG, BMY, MSFT, INTC, JPM, BAC)",Reuters,http://www.businessinsider.com/r-us-stocks-financial-tech-stocks-drive-wall-st-higher-2017-10
315.0,10/26/2017 6:45:00 PM,M2Gen® Announces Bristol-Myers Squibb's Participation in ORIEN Avatar™ Research Program,PR Newswire,/news/stocks/m2gen-announces-bristol-myers-squibb-s-participation-in-orien-avatar-research-program-1005725025
316.0,10/26/2017 7:07:03 PM,"US STOCKS-Upbeat earnings keep Wall St on firm footing (CELG, JPM, BAC, BMY, NKE)",Reuters,http://www.businessinsider.com/r-us-stocks-upbeat-earnings-keep-wall-st-on-firm-footing-2017-10
317.0,10/26/2017 8:42:14 PM,"US STOCKS-Wall St advances on earnings but healthcare lags (CELG, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-advances-on-earnings-but-healthcare-lags-2017-10
318.0,10/27/2017 11:04:05 AM,Biotech Stocks Facing FDA Decision In November ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-1005814640
319.0,10/30/2017 12:17:08 PM,BRIEF-EMA validates Bristol-Myers' type II variation application for Opdivo for treatment of patients with resected high-risk advanced melanoma (BMY),Reuters,http://www.businessinsider.com/r-brief-ema-validates-bristol-myers-type-ii-variation-application-for-opdivo-for-treatment-of-patients-with-resected-high-risk-advanced-melanoma-2017-10
320.0,10/30/2017 12:34:05 PM,EMA Validates Bristol-Myers' Type II Variation Application For Opdivo ,RTTNews,/news/stocks/ema-validates-bristol-myers-type-ii-variation-application-for-opdivo-1006167862
321.0,10/31/2017 9:37:06 AM,"AstraZeneca plans new pivotal lung cancer trial with Incyte (AZN, INCY, MRK, BMY)",Reuters,http://www.businessinsider.com/r-astrazeneca-plans-new-pivotal-lung-cancer-trial-with-incyte-2017-10
322.0,10/31/2017 1:32:13 PM,"MSF charity secures generic hepatitis C drugs for $1.40 a day (GILD, BMY)",Reuters,http://www.businessinsider.com/r-msf-charity-secures-generic-hepatitis-c-drugs-for-140-a-day-2017-10
323.0,11/6/2017 10:42:03 AM,"Bayer in bid to broaden use of anti-clotting drug Xarelto (BAYN, JNJ, MON, PFE, BMY)",Reuters,http://www.businessinsider.com/r-bayer-in-bid-to-broaden-use-of-anti-clotting-drug-xarelto-2017-11
324.0,11/6/2017 1:27:06 PM,BRIEF-Opdivo demonstrates superior 3-yr survival benefit for patients with previously treated advanced RCC (BMY),Reuters,http://www.businessinsider.com/r-brief-opdivo-demonstrates-superior-3-yr-survival-benefit-for-patients-with-previously-treated-advanced-rcc-2017-11
325.0,11/6/2017 1:46:26 PM,Bristol-Myers Reports Overall Survival Update From Phase 3 CheckMate -025 Study ,RTTNews,/news/stocks/bristol-myers-reports-overall-survival-update-from-phase-3-checkmate-025-study-1007054167
326.0,11/9/2017 2:32:03 PM,BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-and-five-prime-present-early-stage-data-evaluating-cabiralizumab-with-opdivo-in-patients-with-advanced-solid-tumors-2017-11
327.0,11/10/2017 12:45:43 PM,Bristol-Myers Says FDA Expands Approval Of Sprycel ,RTTNews,/news/stocks/bristol-myers-says-fda-expands-approval-of-sprycel-1007544696
328.0,11/10/2017 12:52:04 PM,BRIEF-U.S. Food and Drug Administration expands approval of Sprycel (dasatinib) (BMY),Reuters,http://www.businessinsider.com/r-brief-us-food-and-drug-administration-expands-approval-of-sprycel-dasatinib-2017-11
329.0,11/10/2017 1:17:03 PM,"BRIEF-Bristol-Myers says encouraging response observed with Opdivo plus BMS-986205, in heavily pre-treated patients with advanced cancers in early-stage study (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-says-encouraging-response-observed-with-opdivo-plus-bms-986205-in-heavily-pre-treated-patients-with-advanced-cancers-in-early-stage-study-2017-11
330.0,11/10/2017 1:25:51 PM,Bistol-Myers: Encouraging Response Observed With Opdivo Plus IDO1 Inhibitor ,RTTNews,/news/stocks/bistol-myers-encouraging-response-observed-with-opdivo-plus-ido1-inhibitor-1007548045
331.0,11/11/2017 11:54:00 PM,"First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative...",PR Newswire,/news/stocks/first-data-for-nktr-214-in-combination-with-opdivo-nivolumab-for-patients-with-stage-iv-melanoma-renal-cell-carcinoma-and-non-small-cell-lung-cancers-including-patients-with-pd-l1-negative-1007713046
332.0,11/13/2017 3:58:00 AM,"FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE ",RTTNews,/news/stocks/fda-nod-for-bmy-s-sprycel-arna-to-report-data-in-q1-myl-delists-from-tase-1007827172
333.0,11/14/2017 4:17:03 AM,BRIEF-Syngene International ‍expands collaboration with Bristol-Myers Squibb​ (BMY),Reuters,http://www.businessinsider.com/r-brief-syngene-international-expands-collaboration-with-bristol-myers-squibb-2017-11
334.0,11/14/2017 3:57:05 PM,BRIEF-Bristol-Myers and Syngene expand ongoing research collaboration (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-and-syngene-expand-ongoing-research-collaboration-2017-11
335.0,11/15/2017 3:22:04 PM,"BRIEF-Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo (LH, BMY)",Reuters,http://www.businessinsider.com/r-brief-labcorp-announces-new-expanded-use-for-pd-l1-test-with-bristol-myers-squibbs-opdivo-2017-11
336.0,11/20/2017 8:17:03 AM,"UPDATE 1-Roche says Tecentriq combination cuts lung cancer risk (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-says-tecentriq-combination-cuts-lung-cancer-risk-2017-11
337.0,11/20/2017 3:22:03 PM,"Roche win boosts case for adding chemo to cancer immunotherapy (MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-roche-win-boosts-case-for-adding-chemo-to-cancer-immunotherapy-2017-11
338.0,11/20/2017 5:37:03 PM,"US STOCKS-Tech stocks help Wall Street higher (VZ, CSCO, IBM, CAVM, MRVL, MRK, BMY, WMT)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-stocks-help-wall-street-higher-2017-11
339.0,11/20/2017 7:02:03 PM,"US STOCKS-Industrials, techs lift Wall St, health stocks limit gains (VZ, CAVM, MRVL, MRK, BMY, WMT)",Reuters,http://www.businessinsider.com/r-us-stocks-industrials-techs-lift-wall-st-health-stocks-limit-gains-2017-11
340.0,11/20/2017 9:47:03 PM,"US STOCKS-Telecoms rise, buoy Wall St as quiet week kicks off (VZ, CAVM, MRVL, TWX, T, MRK, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-telecoms-rise-buoy-wall-st-as-quiet-week-kicks-off-2017-11
341.0,11/20/2017 10:27:09 PM,"US STOCKS-Wall St ticks up, lifted by Verizon, chipmakers (VZ, CAVM, MRVL, TWX, T, MRK, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-ticks-up-lifted-by-verizon-chipmakers-2017-11
342.0,11/28/2017 12:53:10 PM,Bristol-Myers: EMA To Review Opdivo Plus Yervoy In Expanded Indications ,RTTNews,/news/stocks/bristol-myers-ema-to-review-opdivo-plus-yervoy-in-expanded-indications-1009779212
343.0,11/28/2017 1:27:04 PM,BRIEF-European Medicines Agency Validates Bristol-Myers's Type II Variation Application For Opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-european-medicines-agency-validates-bristol-myerss-type-ii-variation-application-for-opdivo-2017-11
344.0,11/28/2017 2:42:04 PM,BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic (BMY),Reuters,http://www.businessinsider.com/r-brief-cytomx-therapeutics-says-fda-accepts-ind-for-ctla-4-probody-therapeutic-2017-11
345.0,11/28/2017 3:42:03 PM,"UPDATE 1-Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial (MRK, PFE, MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-update-1-merck-kgaa-pfizers-immunotherapy-fails-in-gastric-cancer-trial-2017-11
346.0,12/1/2017 1:47:04 AM,BRIEF-Bristol-Myers says Checkmate -078 trial stopped early for demonstrating superior overall survival (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-says-checkmate--078-trial-stopped-early-for-demonstrating-superior-overall-survival-2017-11
347.0,12/6/2017 4:02:03 PM,BRIEF-Ayala Enters Exclusive Worldwide License Agreement With Bristol-Myers Squibb (BMY),Reuters,http://www.businessinsider.com/r-brief-ayala-enters-exclusive-worldwide-license-agreement-with-bristol-myers-squibb-2017-12
348.0,12/6/2017 7:37:03 PM,"UPDATE 1-Roche to seize leap-frog opportunity in lung cancer (MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-to-seize-leap-frog-opportunity-in-lung-cancer-2017-12
349.0,12/7/2017 7:02:04 AM,"Roche drug cocktail doubles chance of holding lung cancer at bay (MRK, BMY)",Reuters,http://www.businessinsider.com/r-roche-drug-cocktail-doubles-chance-of-holding-lung-cancer-at-bay-2017-12
350.0,12/7/2017 8:27:03 AM,"UPDATE 1-Roche drug cocktail doubles chance of holding lung cancer at bay (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-drug-cocktail-doubles-chance-of-holding-lung-cancer-at-bay-2017-12
351.0,12/7/2017 10:27:08 PM,BRIEF-Bristol-Myers Squibb Announces 2.6 Pct Increase In Quarterly Dividend Beginning Q1 2018 (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-26-pct-increase-in-quarterly-dividend-beginning-q1-2018-2017-12
352.0,12/8/2017 4:48:10 AM,New Drugs Approved In November ,RTTNews,/news/stocks/new-drugs-approved-in-november-1010552162
353.0,12/9/2017 12:32:03 AM,"UPDATE 1-Lilly's stomach cancer drug meets main goal, but fails to improve survival rate (LLY, BMY)",Reuters,http://www.businessinsider.com/r-update-1-lillys-stomach-cancer-drug-meets-main-goal-but-fails-to-improve-survival-rate-2017-12
354.0,12/11/2017 8:02:03 AM,"UPDATE 1-Roche: Tecentriq cocktail slows kidney cancer progression (BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-roche-tecentriq-cocktail-slows-kidney-cancer-progression-2017-12
355.0,12/14/2017 12:47:04 AM,"BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment (BMY, 4528)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-granted-exclusive-license-by-ono-pharmaceutical-for-multiple-programs-targeting-immuno-suppressive-factors-in-the-tumor-microenvironment-2017-12
356.0,12/14/2017 1:02:03 AM,"Bumper crop of new drugs fails to lift big pharma R&D returns (BION, NOVO , PFE, SAN, GSK, JNJ, AZN, MRK, LLY, BMY, 4502, AMGN, BIIB, CELG, GILD)",Reuters,http://www.businessinsider.com/r-bumper-crop-of-new-drugs-fails-to-lift-big-pharma-rd-returns-2017-12
357.0,12/18/2017 1:15:30 PM,Bristol-Myers Gets Positive CHMP Opinion Recommending Approval Of Yervoy ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-recommending-approval-of-yervoy-1011615898
358.0,12/18/2017 3:52:03 PM,BRIEF-Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Yervoy (ipilimumab) (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-yervoy-ipilimumab-2017-12
359.0,12/20/2017 1:04:37 PM,TARIS And Bristol-Myers Enter Into Clinical Trial Collaboration ,RTTNews,/news/stocks/taris-and-bristol-myers-enter-into-clinical-trial-collaboration-1011680090
360.0,12/20/2017 9:42:03 PM,BRIEF-Bristol-Myers Squibb Receives FDA Approval For Opdivo As Treatment For Patients With A Type Of Skin Cancer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-receives-fda-approval-for-opdivo-as-treatment-for-patients-with-a-type-of-skin-cancer-2017-12
361.0,1/2/2018 7:02:04 PM,"BRIEF-Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg (ACET, BMY)",Reuters,http://www.businessinsider.com/r-brief-acetos-unit-launches-efavirenz-capsules-50mg-200mg-2018-1
362.0,1/16/2018 6:57:37 AM,The Race To Find A Treatment For NASH ,RTTNews,/news/stocks/the-race-to-find-a-treatment-for-nash-1013102677
363.0,1/18/2018 11:50:00 PM,Bear Stearns Commercial Mortgage Securities Trust 2007-PWR15 -- Moody's Affirms Four Classes of BSCMS 2007-PWR15,Moodys,/news/bonds/bear-stearns-commercial-mortgage-securities-trust-2007-pwr15-moody-s-affirms-four-classes-of-bscms-2007-pwr15-1013256086
364.0,2/5/2018 1:02:36 PM,Bristol-Myers Squibb Co. Reveals Increase In Q4 Earnings,RTTNews,/news/stocks/bristol-myers-squibb-co-reveals-increase-in-q4-earnings-1014966487
365.0,2/5/2018 1:28:23 PM,Bristol-Myers Squibb Phase 3 CheckMate -227 Study Meets Co-primary Endpoint ,RTTNews,/news/stocks/bristol-myers-squibb-phase-3-checkmate-227-study-meets-co-primary-endpoint-1014966699
366.0,2/5/2018 1:53:56 PM,Bristol-Myers Q4 Results Top View; Meets Primary Endpoint In Lung Cancer Trail ,RTTNews,/news/stocks/bristol-myers-q4-results-top-view-meets-primary-endpoint-in-lung-cancer-trail-1014967061
367.0,2/7/2018 9:43:00 PM,Bristol-Myers Squibb Company -- Moody's affirms Bristol-Myers at A2; revises outlook to stable,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-affirms-bristol-myers-at-a2-revises-outlook-to-stable-1015068897
368.0,2/12/2018 4:15:00 PM,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bristol-Myers Squibb Company (BMY) & Lead Plaintiff Deadline: April 10, 2018",PR Newswire,/news/stocks/shareholder-alert-bronstein-gewirtz-grossman-llc-notifies-investors-of-class-action-against-bristol-myers-squibb-company-bmy-lead-plaintiff-deadline-april-10-2018-1015522327
369.0,2/12/2018 10:20:00 PM,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY,PR Newswire,/news/stocks/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bristol-myers-squibb-company-bmy-1015552149
370.0,2/15/2018 7:17:49 AM,"AMAG Gets FDA Nod, ABMD Hits All-time High, GLMD's NAFLD Trial Flops, NKTR Abuzz ",RTTNews,/news/stocks/amag-gets-fda-nod-abmd-hits-all-time-high-glmd-s-nafld-trial-flops-nktr-abuzz-1015856809
371.0,2/27/2018 8:41:40 AM,Biotech Stocks Facing FDA Decision In March ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-1017268709
372.0,3/4/2018 3:19:34 AM,An Ear To The Pharma: 7 Stocks To Watch This Week ,RTTNews,/news/stocks/an-ear-to-the-pharma-7-stocks-to-watch-this-week-1017867022
373.0,3/6/2018 1:33:36 PM,Bristol-Myers: Opdivo The Only FDA-approved PD-1 Inhibitor With 4-week Dosing ,RTTNews,/news/stocks/bristol-myers-opdivo-the-only-fda-approved-pd-1-inhibitor-with-4-week-dosing-1018125373
374.0,3/11/2018 1:00:00 PM,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bristol-Myers Squibb Company of Class Action Lawsuit and Upcoming Deadline - BMY,PR Newswire,/news/stocks/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-bristol-myers-squibb-company-of-class-action-lawsuit-and-upcoming-deadline-bmy-1018613044
375.0,3/12/2018 8:00:00 AM,Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading...,PR Newswire,/news/stocks/biohaven-restructures-license-agreement-with-bristol-myers-squibb-to-reduce-royalties-payable-on-its-migraine-product-candidates-transaction-financed-through-private-placement-with-leading-1018615221
376.0,3/13/2018 12:12:00 PM,GRYT Health and Bristol-Myers Squibb Announce New Digital Pilot to Advance Cancer Care through Patient-Driven Insights,PR Newswire,/news/stocks/gryt-health-and-bristol-myers-squibb-announce-new-digital-pilot-to-advance-cancer-care-through-patient-driven-insights-1018643977
377.0,3/13/2018 6:00:00 PM,"Lifshitz & Miller LLP Announces Investigation of Bristol-Myers Squibb Company, Freshpet, Inc., Geothermal, Inc., Henry Schein, Inc., Ply Gem Holdings, Inc., United American Bank and Xunlei Limited",PR Newswire,/news/stocks/lifshitz-miller-llp-announces-investigation-of-bristol-myers-squibb-company-freshpet-inc-geothermal-inc-henry-schein-inc-ply-gem-holdings-inc-united-american-bank-and-xunlei-limited-1018654893
378.0,3/26/2018 1:05:42 PM,BRIEF-Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/hqgNgqyCAgI/brief-bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-four-week-dosing-schedule-for-advanced-melanoma-and-previously-treated-renal-cell-carcinoma-idUSFWN1R80DM
379.0,3/26/2018 1:06:52 PM,Bristol-Myers Reports Positive CHMP Opinion For Opdivo - Quick Facts ,RTTNews,/news/stocks/bristol-myers-reports-positive-chmp-opinion-for-opdivo-quick-facts-1019446515
380.0,3/27/2018 1:23:51 PM,Bristol-Myers: FDA To Review SBLA For Opdivo Plus Yervoy - Quick Facts ,RTTNews,/news/stocks/bristol-myers-fda-to-review-sbla-for-opdivo-plus-yervoy-quick-facts-1019568215
381.0,3/28/2018 1:58:32 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1019706162
382.0,3/29/2018 8:42:00 PM,"Bristol-Myers Squibb Stock Shareholder Alert - Kehoe Law Firm, P.C. Investigating",PR Newswire,/news/stocks/bristol-myers-squibb-stock-shareholder-alert-kehoe-law-firm-p-c-investigating-1019877873
383.0,4/8/2018 5:02:20 AM,"An Ear To The Pharma: 9 Stocks To Watch This Week (SELB, AGLE, BPMC, MNOV…) ",RTTNews,/news/stocks/an-ear-to-the-pharma-9-stocks-to-watch-this-week-selb-agle-bpmc-mnov-1020830236
384.0,4/12/2018 1:39:48 PM,BRIEF-Bristol Myers Squibb And Harvard Announce New Fibrosis Research Collaboration,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Gs4YVlJ4GGo/brief-bristol-myers-squibb-and-harvard-announce-new-fibrosis-research-collaboration-idUSFWN1RP0MH
385.0,4/13/2018 10:28:52 PM,BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/kBeU8w8WqNg/brief-bristol-myers-squibb-and-illumina-announce-collaboration-to-develop-companion-diagnostics-for-bristol-myers-squibbs-oncology-immunotherapies-idUSFWN1RQ0M2
386.0,4/16/2018 3:23:52 PM,Bristol-Myers Reports Initial Results From Phase 3 Study With Opdivo ,RTTNews,/news/stocks/bristol-myers-reports-initial-results-from-phase-3-study-with-opdivo-1021399095
387.0,4/16/2018 3:33:04 PM,BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/R6LSVq0tHJk/brief-bristol-myers-squibb-says-cancer-drug-combo-reduces-death-risk-by-42-pct-idUSFWN1RT0N8
388.0,4/16/2018 3:33:04 PM,"'We are going to have lung cancer patients living longer and better': A new kind of cancer treatment is about to change how we treat the disease (MRK, BMY)",Business Insider,http://www.businessinsider.com/merck-bms-roche-lung-cancer-immunotherapy-data-2018-4
389.0,4/16/2018 4:27:33 PM,"2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner (MRK, BMY)",Business Insider,http://markets.businessinsider.com/news/stocks/merck-bristol-myers-squibb-stock-price-lung-cancer-data-at-aacr-2018-4-1021400484
390.0,4/16/2018 11:08:23 PM,BRIEF-Janssen Collaborates With Bristol-Myers Squibb To Develop & Commercialize Factor XIa Inhibitors,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/-c4kHdp1h1Y/brief-janssen-collaborates-with-bristol-myers-squibb-to-develop-commercialize-factor-xia-inhibitors-idUSB8N1RF003
391.0,4/16/2018 11:10:55 PM,BRIEF-Bristol-Myers Squibb Collaborates With Janssen To Develop & Commercialize Factor XIa Inhibitors,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/BdzHVnX1-zc/brief-bristol-myers-squibb-collaborates-with-janssen-to-develop-commercialize-factor-xia-inhibitors-idUSB8N1KT00R
392.0,4/17/2018 8:40:29 AM,"ALKS Pulls Off Sweet Surprise, APRI Thrashed, BMY Gets FDA Nod ",RTTNews,/news/stocks/alks-pulls-off-sweet-surprise-apri-thrashed-bmy-gets-fda-nod-1021423487
393.0,4/19/2018 7:57:13 AM,"ANIP, CMD Get FDA Nod, BMY Seeks New Use For Opdivo, Eloxx On Watch ",RTTNews,/news/stocks/anip-cmd-get-fda-nod-bmy-seeks-new-use-for-opdivo-eloxx-on-watch-1021553499
394.0,4/26/2018 1:10:21 PM,Bristol-Myers Squibb Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q1-adjusted-earnings-beat-estimates-1022391368
395.0,4/26/2018 1:36:31 PM,Bristol-Myers Squibb Boosts 2018 Adj. EPS Outlook - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-boosts-2018-adj-eps-outlook-quick-facts-1022394341
396.0,4/27/2018 1:23:54 PM,Advantagene Enters Clinical Trial Collaboration With Bristol-Myers Squibb ,RTTNews,/news/stocks/advantagene-enters-clinical-trial-collaboration-with-bristol-myers-squibb-1022535590
397.0,5/2/2018 2:33:05 PM,BRIEF-Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/dspEXo_hJwk/brief-bristol-myers-squibb-and-flatiron-health-expand-collaboration-with-a-three-year-agreement-idUSFWN1S9105
398.0,5/3/2018 2:53:45 PM,EMA Validates BMY's Type II Application For Opdivo Plus Yervoy Combination ,RTTNews,/news/stocks/ema-validates-bmy-s-type-ii-application-for-opdivo-plus-yervoy-combination-1023264394
399.0,5/4/2018 2:27:09 PM,"Inside New York City's struggle to become a biotech hub (PFE, BMY)",Business Insider,http://www.businessinsider.com/new-york-city-biotech-hub-ambitions-2018-5
400.0,6/1/2018 1:09:34 PM,Bristol-Myers: CheckMate Trial Shows Benefits Of Opdivo Plus Low-dose Yervoy ,RTTNews,/news/stocks/bristol-myers-checkmate-trial-shows-benefits-of-opdivo-plus-low-dose-yervoy-1026104351
401.0,6/2/2018 9:00:11 AM,Bristol-Myers Squibb: FDA Action Removes Partial Hold On CheckMate -602 ,RTTNews,/news/stocks/bristol-myers-squibb-fda-action-removes-partial-hold-on-checkmate-602-1026211397
402.0,6/3/2018 12:10:00 AM,"Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018",PR Newswire,/news/stocks/preliminary-data-for-nktr-214-in-combination-with-opdivo-nivolumab-for-patients-with-stage-iv-metastatic-melanoma-renal-cell-carcinoma-and-urothelial-cancers-presented-at-asco-2018-1026280697
403.0,6/4/2018 1:20:52 PM,Bristol-Myers: Opdivo Plus Chemotherapy Shows Improved PFS In CheckMate Study ,RTTNews,/news/stocks/bristol-myers-opdivo-plus-chemotherapy-shows-improved-pfs-in-checkmate-study-1026435628
404.0,6/4/2018 8:45:03 PM,"We just got a lot of updates on the state of cancer treatments — here are the winners and losers (BLUE, NKTR, LOXO, MRK, BMY)",Business Insider,http://www.businessinsider.com/asco-updates-on-the-state-of-cancer-treatments-2018-6
405.0,6/17/2018 12:43:57 PM,Bristol-Myers Squibb Announces ELOQUENT-3 Trial Result ,RTTNews,/news/stocks/bristol-myers-squibb-announces-eloquent-3-trial-result-1027158926
406.0,6/29/2018 2:03:45 PM,Bristol-Myers Gets Positive CHMP Opinion Recommending Approval Of Opdivo ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-recommending-approval-of-opdivo-1027330690
407.0,7/5/2018 1:10:35 PM,Bristol-Myers: European Commission Approves Expanded Indication For Sprycel ,RTTNews,/news/stocks/bristol-myers-european-commission-approves-expanded-indication-for-sprycel-1027343804
408.0,7/7/2018 5:03:29 PM,Week Ahead In Pharmaceuticals - Stocks To Watch ,RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-stocks-to-watch-1027348479
409.0,7/11/2018 1:16:33 PM,Bristol-Myers: Opdivo + Low-Dose Yervoy Approved For MSI-H/dMMR MCRC Patients ,RTTNews,/news/stocks/bristol-myers-opdivo-low-dose-yervoy-approved-for-msi-h-dmmr-mcrc-patients-1027358042
410.0,7/12/2018 8:32:29 AM,"AKCA Gets EC Nod, FDA Panel To Review Malaria Drug Today, OVID Awaits Data In Q3 ",RTTNews,/news/stocks/akca-gets-ec-nod-fda-panel-to-review-malaria-drug-today-ovid-awaits-data-in-q3-1027360877
411.0,7/14/2018 1:56:09 AM,Week Ahead In Pharmaceuticals - 7 Stocks To Watch ,RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-7-stocks-to-watch-1027367265
412.0,7/19/2018 1:17:57 PM,"Bristol-Myers, Gritstone Oncology Collaborate To Evaluate GRANITE-001 ",RTTNews,/news/stocks/bristol-myers-gritstone-oncology-collaborate-to-evaluate-granite-001-1027381818
413.0,7/24/2018 3:02:12 PM,What Wall Street expects from Bristol-Myers Squibb's earnings,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-quarter-earnings-preview-q2-1027394080
414.0,7/26/2018 9:39:05 AM,Biotech Stocks Facing FDA Decision In August ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-1027401882
415.0,7/26/2018 1:09:14 PM,Bristol-Myers Squibb Updates 2018 EPS Guidance - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-updates-2018-eps-guidance-quick-facts-1027402788
416.0,7/26/2018 2:11:24 PM,Bristol-Myers Squibb Co. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q2-adjusted-earnings-beat-estimates-1027403210
417.0,7/31/2018 2:06:19 PM,Bristol-Myers Squibb: EC Approves Opdivo For Adjuvant Treatment Of Melanoma ,RTTNews,/news/stocks/bristol-myers-squibb-ec-approves-opdivo-for-adjuvant-treatment-of-melanoma-1027416139
418.0,8/2/2018 8:09:00 PM,Moody's: US drug makers face heightened pricing pressure as regulatory risks pick up steam,Moodys,/news/bonds/moody-s-us-drug-makers-face-heightened-pricing-pressure-as-regulatory-risks-pick-up-steam-1027427408
419.0,8/11/2018 5:17:06 AM,"Week Ahead In Pharmaceuticals: 5 Stocks To Watch (REGN, PFE, ALT...) ",RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-5-stocks-to-watch-regn-pfe-alt-1027451315
420.0,8/17/2018 1:05:36 PM,Bristol-Myers Squibb Says FDA Approves Opdivo ,RTTNews,/news/stocks/bristol-myers-squibb-says-fda-approves-opdivo-1027466998
421.0,8/23/2018 1:17:14 PM,"Bristol-Myers: FDA To Review SBLA For Empliciti With Pomalidomide, Dexamethasone ",RTTNews,/news/stocks/bristol-myers-fda-to-review-sbla-for-empliciti-with-pomalidomide-dexamethasone-1027480033
422.0,8/30/2018 2:09:02 PM,FDA Accepts Bristol-Myers' SBLA For Sprycel ,RTTNews,/news/stocks/fda-accepts-bristol-myers-sbla-for-sprycel-1027497049
423.0,9/12/2018 8:16:54 AM,Bristol-Myers Reports Positive Results From Phase 2 Study Of BMS-986165 ,RTTNews,/news/stocks/bristol-myers-reports-positive-results-from-phase-2-study-of-bms-986165-1027526577
424.0,9/18/2018 2:15:44 PM,EMA Validates Bristol Myers' Application For New Empliciti-based Combination ,RTTNews,/news/stocks/ema-validates-bristol-myers-application-for-new-empliciti-based-combination-1027543441
425.0,10/11/2018 1:36:23 PM,"Bristol-Myers, Compugen To Jointly Evaluate Combination Of COM701 With Opdivo ",RTTNews,/news/stocks/bristol-myers-compugen-to-jointly-evaluate-combination-of-com701-with-opdivo-1027608539
426.0,10/12/2018 1:16:29 PM,Bristol-Myers Says Phase 3 CheckMate -331 Study Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/bristol-myers-says-phase-3-checkmate-331-study-fails-to-meet-primary-endpoint-1027612295
427.0,10/20/2018 10:51:57 AM,Bristol-Myers Says Follow-up Data Of Opdivo With Yervoy Shows Promising Results ,RTTNews,/news/stocks/bristol-myers-says-follow-up-data-of-opdivo-with-yervoy-shows-promising-results-1027635443
428.0,10/22/2018 5:43:33 AM,"FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch ",RTTNews,/news/stocks/fda-extends-date-on-bmy-s-sbla-genmab-meets-phase-3-goals-ncna-lptx-on-watch-1027636442
429.0,10/22/2018 9:59:55 AM,Bristol-Myers Announces Data From Two CheckMate Studies Of Opdivo - Quick Facts ,RTTNews,/news/stocks/bristol-myers-announces-data-from-two-checkmate-studies-of-opdivo-quick-facts-1027637567
430.0,10/23/2018 3:02:10 PM,Bristol-Myers Squibb earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-q3-earnings-preview-1027644299
431.0,10/25/2018 1:12:09 PM,Bristol-Myers Squibb Raises FY18 Outlook - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-raises-fy18-outlook-quick-facts-1027654142
432.0,11/5/2018 1:18:55 PM,"Bristol-Myers, Infinity Pharma To Evaluate Opdivo In Combination With IPI-549 ",RTTNews,/news/stocks/bristol-myers-infinity-pharma-to-evaluate-opdivo-in-combination-with-ipi-549-1027690497
433.0,11/26/2018 6:56:25 AM,Biotech Stocks Facing FDA Decision In December ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-1027753358
434.0,11/26/2018 10:46:24 PM,Bristol-Myers Squibb says cancer drug combination fails maintenance trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/p_2HK_rNAXY/bristol-myers-squibb-says-cancer-drug-combination-fails-maintenance-trial-idUSL4N1Y1597
435.0,11/26/2018 11:04:26 PM,UPDATE 1-Bristol-Myers Squibb says cancer drug combination fails late-stage trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wrWlpe96z2o/update-1-bristol-myers-squibb-says-cancer-drug-combination-fails-late-stage-trial-idUSL4N1Y15CE
436.0,12/10/2018 8:22:58 AM,"Bristol-Myers Squibb, Vedanta Biosciences In Clinical Collaboration ",RTTNews,/news/stocks/bristol-myers-squibb-vedanta-biosciences-in-clinical-collaboration-1027793190
437.0,12/19/2018 10:00:10 AM,Taisho Offers To Purchase Bristol-Myers Squibb's UPSA Consumer Health Unit ,RTTNews,/news/stocks/taisho-offers-to-purchase-bristol-myers-squibb-s-upsa-consumer-health-unit-1027820345
438.0,1/3/2019 8:04:06 AM,"GNMX Plunges On ASCEND Data, FLZN On Track, ALNA To Report Phase 3 Data In 2H ",RTTNews,/news/stocks/gnmx-plunges-on-ascend-data-flzn-on-track-alna-to-report-phase-3-data-in-2h-1027840697
439.0,1/3/2019 1:17:53 PM,Bristol-Myers To Acquire Celgene; To Be Above 40% EPS Accretive In First Year ,RTTNews,/news/stocks/bristol-myers-to-acquire-celgene-to-be-above-40-eps-accretive-in-first-year-1027841399
440.0,1/3/2019 1:36:04 PM,"Bristol-Myers Squibb is buying Celgene in a $74 billion deal (BMY, CELG)",Business Insider,https://www.businessinsider.com/bristol-myers-squibb-buys-celgene-in-74-billion-deal-2019-1
441.0,1/3/2019 9:16:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's reviews Bristol-Myers Squibb for downgrade,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-reviews-bristol-myers-squibb-for-downgrade-1027842816
442.0,1/3/2019 9:26:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's reviews Bristol-Myers Squibb for downgrade,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-reviews-bristol-myers-squibb-for-downgrade-1027842828
443.0,1/3/2019 11:45:00 PM,Celgene Corporation -- Moody's reviews Celgene's Baa2 rating for upgrade,Moodys,/news/bonds/celgene-corporation-moody-s-reviews-celgene-s-baa2-rating-for-upgrade-1027843083
444.0,1/4/2019 7:47:18 AM,"BTAI Up 105% In 5 Days, NVAX Gets A Shot In The Arm, BMY Snaps Up CELG ",RTTNews,/news/stocks/btai-up-105-in-5-days-nvax-gets-a-shot-in-the-arm-bmy-snaps-up-celg-1027843507
445.0,1/23/2019 3:01:34 PM,What Wall Street expects from Bristol-Myers Squibb's earnings,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-q4-earnings-preview-1027889665
446.0,1/24/2019 1:10:52 PM,Bristol-Myers Squibb Co. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q4-adjusted-earnings-beat-estimates-1027892744
447.0,1/24/2019 1:44:15 PM,Bristol-Myers Q4 Adj. Profit Beats View; Withdraws SBLA For Opdivo Plus Yervoy ,RTTNews,/news/stocks/bristol-myers-q4-adj-profit-beats-view-withdraws-sbla-for-opdivo-plus-yervoy-1027892882
448.0,2/7/2019 3:36:00 PM,Moody's -  Accelerating efforts to lower drug prices raise financial risk for drug companies,Moodys,/news/bonds/moody-s-accelerating-efforts-to-lower-drug-prices-raise-financial-risk-for-drug-companies-1027934159
449.0,2/11/2019 1:15:10 PM,Bristol-Myers: European Commission Approves Sprycel Plus Chemotherapy ,RTTNews,/news/stocks/bristol-myers-european-commission-approves-sprycel-plus-chemotherapy-1027940623
450.0,2/15/2019 10:11:00 PM,Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-bristol-myers-squibb-company-1027957877
451.0,2/28/2019 2:53:11 AM,Wellington Management Opposes Bristol-Myers Squibb's Acquisition Of Celgene ,RTTNews,/news/stocks/wellington-management-opposes-bristol-myers-squibb-s-acquisition-of-celgene-1027991293
452.0,2/28/2019 2:12:06 PM,"Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardy (BMY, CELG)",Business Insider,https://www.businessinsider.com/bristol-myers-squibb-celgene-deal-in-jeopardy-investor-concerns-2019-2
453.0,2/28/2019 3:54:11 PM,Starboard Value Opposes Bristol-Myers Squibb's Acquisition Of Celgene ,RTTNews,/news/stocks/starboard-value-opposes-bristol-myers-squibb-s-acquisition-of-celgene-1027993990
454.0,3/6/2019 1:26:55 PM,Bristol-Myers Says 'acquiring Celgene Is Best Path Forward' For Its Shareholders ,RTTNews,/news/stocks/bristol-myers-says-acquiring-celgene-is-best-path-forward-for-its-shareholders-1028008407
455.0,3/6/2019 1:50:17 PM,Starboard Urges All Holders To Vote Against Bristol-Myers - Celgene Merger ,RTTNews,/news/stocks/starboard-urges-all-holders-to-vote-against-bristol-myers-celgene-merger-1028008482
456.0,3/19/2019 12:18:05 PM,Starboard Value Urges All Shareholders To Reject Bristol-Myers - Celgene Merger ,RTTNews,/news/stocks/starboard-value-urges-all-shareholders-to-reject-bristol-myers-celgene-merger-1028040959
457.0,3/25/2019 12:36:15 PM,Bristol-Myers Urges Shareholders To Vote For Merger Deal With Celgene ,RTTNews,/news/stocks/bristol-myers-urges-shareholders-to-vote-for-merger-deal-with-celgene-1028055275
458.0,3/26/2019 3:09:43 PM,FTC Seeks Additional Information On Bristol-Myers - Celgene Merger ,RTTNews,/news/stocks/ftc-seeks-additional-information-on-bristol-myers-celgene-merger-1028059724
459.0,3/28/2019 3:29:35 PM,Starboard Urges Shareholders To Vote Against Bristol-Myers - Celgene Deal ,RTTNews,/news/stocks/starboard-urges-shareholders-to-vote-against-bristol-myers-celgene-deal-1028067305
460.0,4/12/2019 5:40:39 PM,Bristol-Myers Shareholders Approve Celgene Deal ,RTTNews,/news/stocks/bristol-myers-shareholders-approve-celgene-deal-1028107799
461.0,4/17/2019 6:10:00 PM,Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's exchange notes; under review for downgrade,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-assigns-a2-to-bristol-myers-s-exchange-notes-under-review-for-downgrade-1028119344
462.0,4/23/2019 3:02:22 PM,Bristol-Myers Squibb earnings preview: what to expect,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q1-earnings-preview-1028129924
463.0,4/25/2019 1:39:42 PM,Bristol-Myers Q1 Results Top Estimates ,RTTNews,/news/stocks/bristol-myers-q1-results-top-estimates-1028138610
464.0,4/25/2019 11:11:57 PM,Bristol-Myers Squibb Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q1-adjusted-earnings-beat-estimates-1028141003
465.0,5/2/2019 6:07:00 PM,Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's sr. notes; under review for downgrade,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-assigns-a2-to-bristol-myers-s-sr-notes-under-review-for-downgrade-1028163037
466.0,5/8/2019 1:16:24 PM,Bristol-Myers Prices $19 Bln Of Senior Unsecured Notes ,RTTNews,/news/stocks/bristol-myers-prices-19-bln-of-senior-unsecured-notes-1028181292
467.0,6/5/2019 1:23:23 PM,Bristol-Myers To Appoint David Elkins As EVP And CFO ,RTTNews,/news/stocks/bristol-myers-to-appoint-david-elkins-as-evp-and-cfo-1028255928
468.0,6/6/2019 7:13:05 PM,5 Healthcare Stocks to Pick Up From the Wreckage,InvestorPlace,/news/stocks/5-healthcare-stocks-to-pick-up-from-the-wreckage-1028262327
469.0,6/7/2019 5:06:26 PM,2 Dividend Stocks to Buy That Are Better Than 3M Stock,InvestorPlace,/news/stocks/2-dividend-stocks-to-buy-that-are-better-than-3m-stock-1028264953
470.0,6/14/2019 6:59:58 PM,7 Top-Rated Biotech Stocks to Invest In Today,InvestorPlace,/news/stocks/7-healthy-biotech-stocks-to-invest-in-1028281710
471.0,6/19/2019 1:17:07 PM,Catalent To Buy Bristol-Myers Squibb's Manufacturing Facility In Italy ,RTTNews,/news/stocks/catalent-to-buy-bristol-myers-squibb-s-manufacturing-facility-in-italy-1028290995
472.0,6/24/2019 1:12:40 PM,Bristol-Myers Squibb: Phase 3 Study With Opdivo Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/bristol-myers-squibb-phase-3-study-with-opdivo-fails-to-meet-primary-endpoint-1028301437
473.0,6/24/2019 1:23:42 PM,Bristol-Myers Squibb Plans To Divest OTEZLA - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-plans-to-divest-otezla-quick-facts-1028301457
474.0,6/24/2019 4:51:13 PM,Bristol-Meyers Squibb News: Why BMY Stock Is Falling Today,InvestorPlace,/news/stocks/bristol-meyers-squibb-news-why-bmy-stock-is-falling-today-1028303872
475.0,6/24/2019 7:33:11 PM,The 7 Best Acquisitions of 2019,InvestorPlace,/news/stocks/the-7-best-acquisitions-of-2019-1028303860
476.0,6/24/2019 7:47:34 PM,"5 Top Stock Trades for Tuesday: CELG, BMY, CZR",InvestorPlace,/news/stocks/5-top-stock-trades-for-tuesday-bmy-celg-czr-newr-mtch-1028303858
477.0,6/24/2019 8:27:04 PM,"Bristol-Myers Squibb is selling off a blockbuster drug to help its $74 billion merger with Celgene get approved — and now both stocks are tumbling (BMY, CELG)",Business Insider,https://markets.businessinsider.com/news/stocks/bristol-myers-squibb-celgene-stock-price-reaction-to-otezla-divestiture-2019-6-1028303108
478.0,6/24/2019 8:42:02 PM,"Nasdaq Today: Celgene, Ulta, Caesars’ Buyout",InvestorPlace,/news/stocks/nasdaq-today-celgene-ulta-caesars-buyout-1028303856
479.0,6/24/2019 9:50:00 PM,Bristol-Myers Squibb Company -- Moody's: Bristol's Otezla divestiture credit negative,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-bristol-s-otezla-divestiture-credit-negative-1028303268
480.0,6/25/2019 12:05:35 PM,"3 Big Stock Charts for Tuesday: MGM Resorts, Electronic Arts and Advance Auto Parts",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-mgm-aap-ea-1028307959
481.0,6/25/2019 8:11:08 PM,"5 Top Stock Trades for Wednesday — AGN, ABBV, FDX, MSFT, BB",InvestorPlace,/news/stocks/5-top-stock-trades-for-wednesday-agn-abbv-fdx-msft-bb-1028307924
482.0,6/26/2019 4:10:10 PM,The Top 8 Tech Stocks of 2019 (So Far),InvestorPlace,/news/stocks/the-top-8-tech-stocks-of-2019-so-far-1028312008
483.0,6/26/2019 8:46:45 PM,"Nasdaq Today: Semis Rally, Micron Earnings, Suing FB and GOOGL?",InvestorPlace,/news/stocks/nasdaq-today-semis-rally-micron-earnings-suing-fb-and-googl-1028311984
484.0,6/27/2019 12:10:29 PM,Remember Your History When It Comes to United Technologies Stock,InvestorPlace,/news/stocks/remember-history-united-technologies-stock-1028315919
485.0,7/2/2019 7:38:28 PM,3 Dow Jones Stocks to Buy for the Second Half,InvestorPlace,/news/stocks/3-dow-jones-stocks-to-buy-for-the-second-half-1028326563
486.0,7/11/2019 7:00:51 PM,4 Drug Stocks Getting Smashed,InvestorPlace,/news/stocks/4-drug-stocks-getting-smashed-1028347976
487.0,7/11/2019 8:54:32 PM,Nasdaq Today: Biotech Wrecked; Buy Microsoft? ,InvestorPlace,/news/stocks/nasdaq-today-biotech-wrecked-buy-microsoft-1028347970
488.0,7/18/2019 1:08:54 PM,"Bayer, Bristol-Myers Squibb, Ono Pharma Enter Into Clinical Collaboration ",RTTNews,/news/stocks/bayer-bristol-myers-squibb-ono-pharma-enter-into-clinical-collaboration-1028364102
489.0,7/19/2019 9:49:41 AM,"BMY To Explore Stivarga/Opdivo Combo, MYOK Ahead Of Timeline, UNH On Watch ",RTTNews,/news/stocks/bmy-to-explore-stivarga-opdivo-combo-myok-ahead-of-timeline-unh-on-watch-1028367064
490.0,7/23/2019 6:03:36 PM,Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings,InvestorPlace,/news/stocks/why-bristol-myers-is-down-ahead-of-its-earnings-report-1028378737
491.0,7/24/2019 3:02:07 PM,What Wall Street expects from Bristol-Myers Squibb's earnings,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q2-earnings-preview-stock-1028380528
492.0,7/24/2019 3:51:40 PM,"Notable Earnings To Watch On July 25 - MMM, AMZN, GOOGL, LH, AAL, LUV, BMY, HSY ",RTTNews,/news/stocks/notable-earnings-to-watch-on-july-25-mmm-amzn-googl-lh-aal-luv-bmy-hsy-1028381012
493.0,7/24/2019 3:56:48 PM,3 Ways to Play the Historic Bargain In Chinese Stocks,InvestorPlace,/news/stocks/3-ways-to-play-the-historic-bargain-in-chinese-stocks-1028383015
494.0,7/24/2019 11:43:04 PM,Bristol-Myers Squibb Reports Phase 3 CheckMate -227 Trial Results - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-reports-phase-3-checkmate-227-trial-results-quick-facts-1028382526
495.0,7/25/2019 12:10:53 PM,"GEMP Gets Facelift, Castle Bio To Debut Today, What's The Buzz About Baqsimi? ",RTTNews,/news/stocks/gemp-gets-facelift-castle-bio-to-debut-today-what-s-the-buzz-about-baqsimi-1028384130
496.0,7/25/2019 1:16:13 PM,Bristol-Myers Squibb Raises Earnings Guidance - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-raises-earnings-guidance-quick-facts-1028384454
497.0,7/25/2019 5:59:38 PM,"Bristol-Myers Squibb Earnings: BMY Stock Bounces on Strong Q2, Guidance",InvestorPlace,/news/stocks/bristol-myers-squibb-earnings-boosts-bmy-stock-1028387217
498.0,7/25/2019 8:50:54 PM,"Stock Market Today: Boeing, Tesla Tumble on More Worries",InvestorPlace,/news/stocks/stock-market-today-boeing-tesla-tumble-on-more-worries-1028387202
499.0,7/26/2019 1:29:36 PM,Bristol-Myers Gets Positive CHMP Opinion For Empliciti ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-empliciti-1028388214
500.0,8/1/2019 8:37:20 PM,Stock Market Today: The Tariff Man Is Back,InvestorPlace,/news/stocks/stock-market-today-the-tariff-man-is-back-1028410613
501.0,8/6/2019 6:29:21 AM,Fear Around Bristol-Myers Squibb Stock is Starting to Fade,InvestorPlace,/news/stocks/bristol-myers-squibb-bmy-stock-opdivo-otezla-1028422590
502.0,8/9/2019 2:04:08 PM,Risk-Takers Have a Reasonable Shot with BMY Stock,InvestorPlace,/news/stocks/risk-takers-have-a-reasonable-shot-with-bmy-stock-1028435580
503.0,8/12/2019 4:10:53 PM,Bristol-Myers Squibb Stock Has Upside — But Mind the Risks,InvestorPlace,/news/stocks/bristol-myers-squibb-stock-upside-mind-risks-1028440085
504.0,8/23/2019 6:00:29 PM,5 Healthcare Stocks to Buy for Healthy Dividends,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-for-healthy-dividends-1028470706
505.0,8/23/2019 6:37:40 PM,Will Lawsuits Sink Johnson & Johnson Stock?,InvestorPlace,/news/stocks/lawsuits-jnj-stock-probably-not-1028470702
506.0,8/26/2019 1:04:31 PM,Amgen To Acquire Otezla For $13.4 Billion In Cash - Quick Facts ,RTTNews,/news/stocks/amgen-to-acquire-otezla-for-13-4-billion-in-cash-quick-facts-1028472744
507.0,8/26/2019 3:51:06 PM,"Amgen will buy a blockbuster psoriasis drug for $13.4 billion — and it's part of a plan to get Celgene's mega-merger with Bristol-Myers Squibb approved (AMGN, CELG, BMY)",Business Insider,https://www.businessinsider.com/amgen-buys-celgene-psoriasis-drug-for-13-billion-antitrust-implications-2019-8
508.0,8/26/2019 5:53:32 PM,Celgene News: CELG Stock Jumps on Sale of Otezla to Amgen,InvestorPlace,/news/stocks/celgene-news-has-celg-stock-up-1028475034
509.0,8/26/2019 7:32:00 PM,"5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY",InvestorPlace,/news/stocks/top-stock-trades-bmy-amgn-nflx-acb-fl-1028475024
510.0,8/26/2019 8:34:50 PM,"Stock Market Today: Biotech in Focus, Trade Talks Steady Stocks",InvestorPlace,/news/stocks/stock-market-today-biotech-in-focus-trade-talks-steady-stocks-1028475022
511.0,8/27/2019 3:01:27 PM,4 Biotech Stocks to Buy That Are on the Move,InvestorPlace,/news/stocks/4-biotech-stocks-to-buy-that-are-on-the-move-1028478921
512.0,8/28/2019 2:00:36 PM,10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond,InvestorPlace,/news/stocks/10-best-dividend-stocks-to-buy-2019-beyond-1028347974
513.0,9/4/2019 1:14:03 PM,Bristol-Myers Squibb To Become Limited Partner Of BioMotiv - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-to-become-limited-partner-of-biomotiv-quick-facts-1028497144
514.0,9/5/2019 1:55:45 PM,Bristol-Myers' Opdivo Fails To Meet Primary Endpoint In Brain Tumor Study ,RTTNews,/news/stocks/bristol-myers-opdivo-fails-to-meet-primary-endpoint-in-brain-tumor-study-1028501466
515.0,9/18/2019 7:35:32 PM,"4 Top Stock Trades for Thursday: ROKU, ADBE, BYND",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-roku-adbe-bynd-1028536148
516.0,9/24/2019 1:37:12 PM,Bristol-Myers Squibb Says CHMP Recommends Approval Of Opdivo - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-says-chmp-recommends-approval-of-opdivo-quick-facts-1028547939
517.0,9/24/2019 5:45:00 PM,Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-china-s-rising-demand-for-drugs-will-fuel-foreign-pharma-companies-growth-into-2023-1028549476
518.0,9/25/2019 6:36:00 AM,Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-china-s-rising-demand-for-drugs-will-fuel-foreign-pharma-companies-growth-into-2023-1028550761
519.0,9/27/2019 7:10:39 PM,10 Cheap Stocks to Buy at Less Than 10x Forward Earnings,InvestorPlace,/news/stocks/10-stocks-to-buy-less-10x-forward-earnings-1028560648
520.0,9/27/2019 7:34:40 PM,7 Big Biotech Stocks to Watch,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-watch-1028560645
521.0,9/30/2019 7:38:31 PM,"4 Top Stock Trades for Tuesday: AAPL, DIS, BMY",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-aapl-dis-bmy-1028565203
522.0,10/1/2019 3:08:33 PM,4 Healthcare Stocks to Buy Now,InvestorPlace,/news/stocks/4-healthcare-stocks-to-buy-now-1028569344
523.0,10/3/2019 7:02:17 PM,3 Cancer-Fighting Drug Stocks to Buy Right Now,InvestorPlace,/news/stocks/3-cancer-fighting-drug-stocks-to-buy-right-now-1028575928
524.0,10/7/2019 4:17:20 PM,10 Great Biotech Stocks to Buy in Q4,InvestorPlace,/news/stocks/great-biotech-stocks-to-buy-q4-1028581895
525.0,10/7/2019 6:51:22 PM,Why Johnson & Johnson Stock Is Not a Screaming Buy,InvestorPlace,/news/stocks/johnson-johnson-jnj-stock-not-screaming-buy-1028581887
526.0,10/7/2019 7:52:32 PM,"5 Top Stock Trades for Tuesday: AAPL, GM, SRPT",InvestorPlace,/news/stocks/5-top-stock-trades-for-tuesday-aapl-gm-srpt-1028581882
527.0,10/22/2019 12:40:32 PM,These New Partnerships are Game Changers for Fitbit Stock,InvestorPlace,/news/stocks/partnerships-game-changers-fitbit-stock-1028619586
528.0,10/22/2019 5:23:57 PM,5 Healthcare Stocks to Buy,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-2-1028620498
529.0,10/22/2019 6:15:57 PM,Fitbit Stock Needs a Viable Growth Narrative for Q3,InvestorPlace,/news/stocks/fitbit-stock-needs-a-viable-growth-narrative-for-q3-1028620791
530.0,10/23/2019 11:18:09 AM,"3 Big Stock Charts for Wednesday: Starbucks, Nordstrom, and Salesforce",InvestorPlace,/news/stocks/3-big-stock-charts-wednesday-starbucks-nordstrom-salesforce-com-1028622958
531.0,10/23/2019 12:40:24 PM,"Healthcare Stocks That Hit New Highs ( BNTX, INMD,  BMY,...) ",RTTNews,/news/stocks/healthcare-stocks-that-hit-new-highs-bntx-inmd-bmy-1028622408
532.0,10/24/2019 10:36:53 AM,"3 Big Stock Charts for Thursday: Cisco Systems, Eli Lilly, and Colgate-Palmolive",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-cisco-systems-eli-lilly-colgate-palmolive-1028627304
533.0,10/31/2019 11:27:44 AM,"3 Big Stock Charts for Thursday: Merck, Anheuser-Busch InBev, and PPG Industries",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-merck-anheuser-busch-inbev-ppg-industries-1028648405
534.0,10/31/2019 12:33:48 PM,Bristol-Myers Squibb Boosts FY19 Adj. EPS Outlook - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-boosts-fy19-adj-eps-outlook-quick-facts-1028647708
535.0,11/4/2019 12:10:45 PM,"The Gilead Stock Price Might Be Down, but That Doesn’t Mean It’s Cheap",InvestorPlace,/news/stocks/gilead-stock-price-down-mean-cheap-1028656095
536.0,11/7/2019 12:19:09 PM,"3 Big Stock Charts for Thursday: Kraft Heinz, Wabtec, and Regeneron Pharmaceuticals",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-kraft-heinz-wabtec-and-regeneron-pharmaceuticals-1028669126
537.0,11/7/2019 7:05:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's confirms Bristol-Myers Squibb at A2; negative outlook,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-confirms-bristol-myers-squibb-at-a2-negative-outlook-1028670686
538.0,11/8/2019 9:31:09 PM,This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma,InvestorPlace,/news/stocks/biotech-stocks-big-pharma-deal-1028674828
539.0,11/15/2019 12:45:45 PM,"3 Big Stock Charts for Friday: Snap, Pfizer and Splunk",InvestorPlace,/news/stocks/3-big-stock-charts-for-friday-snap-pfizer-and-splunk-1028692749
540.0,11/15/2019 11:00:11 PM,Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/3KiEXjb4848/bristol-myers-squibb-wins-antitrust-approval-to-buy-celgene-on-condition-it-sell-psoriasis-drug-idUSKBN1XP2CH
541.0,11/15/2019 11:18:42 PM,"UPDATE 1-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/dVBtPm8Bozg/update-1-bristol-myers-squibb-wins-antitrust-approval-to-buy-celgene-but-must-divest-psoriasis-drug-idUSL2N27V1N8
542.0,11/15/2019 11:19:17 PM,"Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/KH3WRo0-CG0/bristol-myers-squibb-wins-antitrust-approval-to-buy-celgene-but-must-divest-psoriasis-drug-idUSKBN1XP2CH
543.0,11/16/2019 12:01:34 AM,"UPDATE 2-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/4YttIb-Awc8/update-2-bristol-myers-squibb-wins-antitrust-approval-to-buy-celgene-but-must-divest-psoriasis-drug-idUSL2N27V1N8
544.0,11/16/2019 4:50:19 PM,Bristol-Myers Squibb Gets FTC Clearance For Celgene Acquisition ,RTTNews,/news/stocks/bristol-myers-squibb-gets-ftc-clearance-for-celgene-acquisition-1028694334
545.0,11/21/2019 9:22:03 PM,Stock Market Today: The Deals Are Getting Done,InvestorPlace,/news/stocks/stock-market-today-the-deals-are-getting-done-1028709885
546.0,11/27/2019 5:17:03 PM,10 Stocks Owned by the World’s Richest and Most Powerful,InvestorPlace,/news/stocks/billionaire-stocks-to-buy-1028722718
547.0,12/2/2019 8:39:48 PM,"4 Top Stock Trades for Tuesday: ROKU, GOGO, BAC, BMY",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-roku-gogo-bac-bmy-1028731358
548.0,12/5/2019 2:30:18 PM,"Thursday’s Vital Data: Bristol-Myers Squibb, Shopify and Walmart",InvestorPlace,/news/stocks/thursdays-vital-data-bristol-myers-squibb-shopify-and-walmart-1028741424
549.0,12/6/2019 8:54:36 PM,"4 Top Stock Trades for Monday: GS, BIG, BMY",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-gs-big-bmy-1028745177
550.0,12/6/2019 9:29:00 PM,Bristol-Myers Squibb Company -- Moody's upgrades Celgene to A3,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-upgrades-celgene-to-a3-1028745124
551.0,12/11/2019 3:38:32 PM,"Amarin Stock Has Lower Risk, But How Much Reward?",InvestorPlace,/news/stocks/amarin-stock-lower-risk-how-much-reward-1028756113
552.0,12/14/2019 11:17:30 AM,Bristol-Myers Wins $752 Mln In US Patent Case Against Gilead Sciences ,RTTNews,/news/stocks/bristol-myers-wins-752-mln-in-us-patent-case-against-gilead-sciences-1028763479
553.0,12/16/2019 9:26:31 PM,"Stock Market Today: New Highs; Buy Micron, Nvidia?",InvestorPlace,/news/stocks/stock-market-today-new-highs-buy-micron-nvidia-1028767135
554.0,1/2/2020 2:27:25 PM,"Thursday’s Vital Data: Bristol-Myers Squibb, Cronos and Canopy Growth",InvestorPlace,/news/stocks/thursdays-vital-data-bristol-myers-squibb-cronos-and-canopy-growth-1028791689
555.0,1/6/2020 3:12:34 PM,Is Amarin Stock a Top Pick for 2020?,InvestorPlace,/news/stocks/is-amarin-stock-a-top-pick-for-2020-1028796965
556.0,1/14/2020 7:01:00 PM,Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-bristol-myers-squibb-company-1028817175
557.0,1/14/2020 7:01:00 PM,Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc.,Moodys,/news/bonds/biogen-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-biogen-inc-1028817172
558.0,1/14/2020 7:01:00 PM,Celgene Corporation -- Moody's announces completion of a periodic review of ratings of Celgene Corporation,Moodys,/news/bonds/celgene-corporation-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-celgene-corporation-1028817168
559.0,1/21/2020 2:22:04 PM,"Buffett Owns Teva Stock, But Should You?",InvestorPlace,/news/stocks/buffett-owns-teva-stock-but-should-you-1028832732
560.0,1/27/2020 3:11:27 PM,3 Healthcare Stocks Under Pressure from Bernie,InvestorPlace,/news/stocks/3-healthcare-stocks-under-pressure-from-bernie-1028847131
561.0,1/31/2020 10:29:42 PM,CORRECTED-UPDATE 1-Bristol-Myers Squibb pulls Opdivo+Yervoy lung application in Europe,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/mduzsprQfAM/corrected-update-1-bristol-myers-squibb-pulls-opdivoyervoy-lung-application-in-europe-idUSL1N2A0237
562.0,2/5/2020 3:02:20 PM,Bristol-Myers Squibb is about to announce its earnings — here's what to expect,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-quarter-earnings-preview-q4-1028876977
563.0,2/6/2020 1:13:55 PM,Bristol-Myers +3% premarket on Q4 beat,Seeking Alpha,https://seekingalpha.com/news/3539183-bristol-myersplus-3-premarket-on-q4-beat?utm_source=markets.businessinsider.com&utm_medium=referral
564.0,2/6/2020 1:35:31 PM,Bristol-Myers Squibb Guides FY20 In Line With Estimates - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-guides-fy20-in-line-with-estimates-quick-facts-1028880754
565.0,2/6/2020 4:49:53 PM,Merck’s Spinoff Plans Place a Big Bet on Cancer-Fighting Keytruda,InvestorPlace,/news/stocks/mercks-spinoff-plans-place-a-big-bet-on-cancer-fighting-keytruda-1028882432
566.0,2/6/2020 6:06:01 PM,Bristol-Myers Squibb and Merck going opposite ways with PD-1 inhibitors,Seeking Alpha,https://seekingalpha.com/news/3539335-bristol-myers-squibb-and-merck-going-opposite-ways-pdminus-1-inhibitors?utm_source=markets.businessinsider.com&utm_medium=referral
567.0,2/7/2020 5:11:04 PM,Gilead an acquisition target? Deep pockets required,Seeking Alpha,https://seekingalpha.com/news/3539763-gilead-acquisition-target-deep-pockets-required?utm_source=markets.businessinsider.com&utm_medium=referral
568.0,2/7/2020 5:50:31 PM,Sell-siders on board with Bristol-Myers Squibb's Q4 & outlook,Seeking Alpha,https://seekingalpha.com/news/3539775-sell-siders-on-board-bristol-myers-squibbs-q4-outlook?utm_source=markets.businessinsider.com&utm_medium=referral
569.0,2/13/2020 2:58:33 PM,Bristol-Myers: FDA To Review BLA For Liso-cel - Quick Facts ,RTTNews,/news/stocks/bristol-myers-fda-to-review-bla-for-liso-cel-quick-facts-1028903081
570.0,2/20/2020 1:10:52 PM,"At This Point, Even the Coronavirus Can’t Save MMM Stock",InvestorPlace,/news/stocks/the-coronavirus-cant-save-mmm-stock-1028924391
571.0,2/20/2020 4:25:14 PM,VBL Therapeutics announces new study of VB-111 in CRC,Seeking Alpha,https://seekingalpha.com/news/3544020-vbl-therapeutics-announces-new-study-of-vbminus-111-in-crc?utm_source=markets.businessinsider.com&utm_medium=referral
572.0,2/21/2020 2:32:53 PM,Dems attack Trump over stalled efforts to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3544481-dems-attack-trump-over-stalled-efforts-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral
573.0,2/24/2020 3:10:04 PM,Sanders' big Nevada primary win shakes health-related stocks,Seeking Alpha,https://seekingalpha.com/news/3544817-sanders-big-nevada-primary-win-shakes-health-related-stocks?utm_source=markets.businessinsider.com&utm_medium=referral
574.0,2/28/2020 3:49:19 PM,Traders Are Treating Inovio Like 2018’s Pot Stock Stars,InvestorPlace,/news/stocks/inovio-ino-stock-coronavirus-speculation-1028950545
575.0,3/2/2020 6:26:00 AM,Biotech Stocks Facing FDA Decision In March 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2020-1028953479
576.0,3/2/2020 5:51:53 PM,FDA OKs Sanofi drug for previously treated multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3547590-fda-oks-sanofi-drug-for-previously-treated-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral
577.0,3/3/2020 7:38:35 PM,Inovio Has Potential Beyond Its Speculative Coronavirus Vaccine,InvestorPlace,/news/stocks/inovio-has-potential-beyond-its-speculative-coronavirus-vaccine-1028961374
578.0,3/5/2020 3:40:49 PM,Idera Pharma completes enrollment in late-stage tilsotolimod study in melanoma,Seeking Alpha,https://seekingalpha.com/news/3549060-idera-pharma-completes-enrollment-in-late-stage-tilsotolimod-study-in-melanoma?utm_source=markets.businessinsider.com&utm_medium=referral
579.0,3/6/2020 1:09:09 PM,Key events next week - healthcare,Seeking Alpha,https://seekingalpha.com/news/3549367-key-events-next-week-healthcare?utm_source=markets.businessinsider.com&utm_medium=referral
580.0,3/6/2020 9:28:29 PM,Ayala Pharmaceuticals on deck for IPO,Seeking Alpha,https://seekingalpha.com/news/3549519-ayala-pharmaceuticals-on-deck-for-ipo?utm_source=markets.businessinsider.com&utm_medium=referral
581.0,3/10/2020 8:28:49 PM,"5 Top Stock Trades for Wednesday: AMZN, DKS, AAL, BMY, UAL",InvestorPlace,/news/stocks/5-top-stock-trades-for-wednesday-amzn-dks-aal-bmy-ual-1028982887
582.0,3/11/2020 11:11:10 AM,FDA OKs Opdivo + Yervoy for certain liver cancer patients,Seeking Alpha,https://seekingalpha.com/news/3550459-fda-oks-opdivo-yervoy-for-certain-liver-cancer-patients?utm_source=markets.businessinsider.com&utm_medium=referral
583.0,3/13/2020 12:36:02 PM,Healthcare stocks set for rally today,Seeking Alpha,https://seekingalpha.com/news/3551531-healthcare-stocks-set-for-rally-today?utm_source=markets.businessinsider.com&utm_medium=referral
584.0,3/13/2020 9:21:00 PM,Celgene Corporation -- Moody's withdraws Celgene's ratings,Moodys,/news/bonds/celgene-corporation-moody-s-withdraws-celgene-s-ratings-1028995440
585.0,3/16/2020 11:14:02 AM,U.S. stocks set to gap down at open,Seeking Alpha,https://seekingalpha.com/news/3551922-u-s-stocks-set-to-gap-down-open?utm_source=markets.businessinsider.com&utm_medium=referral
586.0,3/20/2020 3:23:46 PM,Key events next week - healthcare,Seeking Alpha,https://seekingalpha.com/news/3553839-key-events-next-week-healthcare?utm_source=markets.businessinsider.com&utm_medium=referral
587.0,3/20/2020 7:12:58 PM,"Bristol-Myers Squibb , Sanofi strike out in bid to stop Plavix litigation",Seeking Alpha,https://seekingalpha.com/news/3553920-bristol-myers-squibb-sanofi-strike-out-in-bid-to-stop-plavix-litigation?utm_source=markets.businessinsider.com&utm_medium=referral
588.0,3/23/2020 10:58:56 AM,SocGen cuts view on AbbVie in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3554092-socgen-cuts-view-on-abbvie-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
589.0,3/23/2020 11:07:49 AM,Bristol-Myers Squibb nixes investor event due to coronavirus outbreak,Seeking Alpha,https://seekingalpha.com/news/3554101-bristol-myers-squibb-nixes-investor-event-due-to-coronavirus-outbreak?utm_source=markets.businessinsider.com&utm_medium=referral
590.0,3/24/2020 10:04:14 AM,Inovio Rise is Today’s Sign of the Stockocalypse,InvestorPlace,/news/stocks/inovio-rise-is-todays-sign-of-the-stockocalypse-1029026114
591.0,3/26/2020 11:01:49 AM,FDA OKs Bristol-Myers Squibb's ozanimod for types of multiple sclerosis,Seeking Alpha,https://seekingalpha.com/news/3555365-fda-oks-bristol-myers-squibbs-ozanimod-for-types-of-multiple-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral
592.0,3/27/2020 6:44:44 AM,"U.S. Now Has Most Virus Cases, BSGM To Develop COVID-19 Drug, FDA Nod For BMY ",RTTNews,/news/stocks/u-s-now-has-most-virus-cases-bsgm-to-develop-covid-19-drug-fda-nod-for-bmy-1029037921
593.0,3/27/2020 1:35:58 PM,European advisory group backs Celgene's ozanimod for type of multiple sclerosis,Seeking Alpha,https://seekingalpha.com/news/3555874-european-advisory-group-backs-celgenes-ozanimod-for-type-of-multiple-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral
594.0,3/31/2020 11:40:22 AM,Celgene CVR holders near finish line with bb2121 filing in U.S.,Seeking Alpha,https://seekingalpha.com/news/3556691-celgene-cvr-holders-near-finish-line-bb2121-filing-in-u-s?utm_source=markets.businessinsider.com&utm_medium=referral
595.0,3/31/2020 2:59:16 PM,Searching for a Coronavirus Cure? Avoid Allied Healthcare Stock,InvestorPlace,/news/stocks/searching-for-coronavirus-cure-avoid-ahpi-stock-1029050330
596.0,3/31/2020 6:18:24 PM,Goldman Sachs names top picks for dividend stability,Seeking Alpha,https://seekingalpha.com/news/3556934-goldman-sachs-names-top-picks-for-dividend-stability?utm_source=markets.businessinsider.com&utm_medium=referral
597.0,4/2/2020 11:20:53 AM,Morgan Stanley likes Bristol-Myers Squibb in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3557718-morgan-stanley-likes-bristol-myers-squibb-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
598.0,4/3/2020 9:26:07 PM,FDA's OKs new use of Acceleron and Bristol-Myers Squibb's luspatercept,Seeking Alpha,https://seekingalpha.com/news/3558395-fdas-oks-new-use-of-acceleron-and-bristol-myers-squibbs-luspatercept?utm_source=markets.businessinsider.com&utm_medium=referral
599.0,4/3/2020 9:26:07 PM,FDA OKs new use of Acceleron and Bristol-Myers Squibb's luspatercept,Seeking Alpha,https://seekingalpha.com/news/3558395-fda-oks-new-use-of-acceleron-and-bristol-myers-squibbs-luspatercept?utm_source=markets.businessinsider.com&utm_medium=referral
600.0,4/6/2020 9:16:17 AM,New Drugs Approved In The Month Of March ,RTTNews,/news/stocks/new-drugs-approved-in-the-month-of-march-1029066601
601.0,4/6/2020 1:07:43 PM,Is Bitcoin a Safe Haven from the Pandemic?,InvestorPlace,/news/stocks/is-bitcoin-a-safe-haven-from-the-pandemic-1029068176
602.0,4/7/2020 11:22:40 AM,Bristol-Myers Squibb to provide medicines to the unemployed and uninsured,Seeking Alpha,https://seekingalpha.com/news/3558885-bristol-myers-squibb-to-provide-medicines-to-unemployed-and-uninsured?utm_source=markets.businessinsider.com&utm_medium=referral
603.0,4/9/2020 5:13:49 AM,"BMY Awaits FDA Decision, LQDA On Watch, MNOV To Begin Clinical Trial In COVID-19 ",RTTNews,/news/stocks/bmy-awaits-fda-decision-lqda-on-watch-mnov-to-begin-clinical-trial-in-covid-19-1029078082
604.0,4/9/2020 11:43:12 AM,Bristol Myers teams up with NeoImmuneTech to evaluate Nivolumab + NT-17,Seeking Alpha,https://seekingalpha.com/news/3559612-bristol-myers-teams-up-neoimmunetech-to-evaluate-nivolumab-ntminus-17?utm_source=markets.businessinsider.com&utm_medium=referral
605.0,4/14/2020 11:24:00 PM,"Becton, Dickinson and Company -- Moody's corrects the rating on CUSIP 110122BD9",Moodys,/news/bonds/becton-dickinson-and-company-moody-s-corrects-the-rating-on-cusip-110122bd9-1029091545
606.0,4/15/2020 3:38:52 PM,Buying Gilead Sciences Stock Means Buying Into Political Risk,InvestorPlace,/news/stocks/gilead-gild-stock-remdesivir-political-risk-1029095249
607.0,4/20/2020 11:19:12 AM,Opdivo/Cabometyx combo successful in first-line kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3561978-opdivo-cabometyx-combo-successful-in-first-line-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
608.0,4/20/2020 1:46:26 PM,"Trading at 52-Week Highs, LLY Stock Is Already Priced to Perfection",InvestorPlace,/news/stocks/hold-off-overvalued-lly-stock-1029107790
609.0,4/21/2020 7:39:42 AM,"CYCC In STOPCOVID, EXEL Hits New High, NVS Trialing Malaria Drug For COVID-19 ",RTTNews,/news/stocks/cycc-in-stopcovid-exel-hits-new-high-nvs-trialing-malaria-drug-for-covid-19-1029110457
610.0,4/21/2020 3:09:34 PM,Idera's tilsotolimod shows positive effect in mid-stage melanoma study,Seeking Alpha,https://seekingalpha.com/news/3562623-ideras-tilsotolimod-shows-positive-effect-in-mid-stage-melanoma-study?utm_source=markets.businessinsider.com&utm_medium=referral
611.0,4/24/2020 3:41:09 PM,7 Beautiful Biotech Stocks to Buy Here,InvestorPlace,/news/stocks/7-beautiful-biotech-stocks-to-buy-here-1029127761
612.0,4/28/2020 11:28:34 AM,"3 Big Stock Charts for Tuesday: Johnson & Johnson, Merck, and Bristol-Myers Squibb",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-johnson-johnson-merck-and-bristol-myers-squibb-1029137983
613.0,5/6/2020 3:57:21 PM,Bristol-Myers Squibb Q1 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3570141-bristol-myers-squibb-q1-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
614.0,5/7/2020 5:33:38 AM,"FDA Decision On BMY's Drug Postponed, ENTA's PBC Study Fails, MGNX Turns Heads ",RTTNews,/news/stocks/fda-decision-on-bmy-s-drug-postponed-enta-s-pbc-study-fails-mgnx-turns-heads-1029173451
615.0,5/7/2020 12:10:44 PM,"Bristol-Myers Squibb affirms guidance, sees 20% earnings growth in 2021",Seeking Alpha,https://seekingalpha.com/news/3571113-bristol-myers-squibb-affirms-guidance-sees-20-earnings-growth-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral
616.0,5/7/2020 2:18:09 PM,Bristol-Myers Q1 Results Beat View; Cuts 2020 GAAP Profit Outlook ,RTTNews,/news/stocks/bristol-myers-q1-results-beat-view-cuts-2020-gaap-profit-outlook-1029176995
617.0,5/7/2020 2:18:29 PM,Bristol-Myers Squibb Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q1-adjusted-earnings-beat-estimates-1029176994
618.0,5/7/2020 3:02:03 PM,Here's what Wall Street expects from Bristol-Myers Squibb's earnings,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q1-earnings-preview-stock-1029177189
619.0,5/8/2020 12:25:16 PM,"3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline",InvestorPlace,/news/stocks/3-big-stock-charts-for-friday-bristol-myers-squibb-eli-lilly-and-glaxosmithkline-1029182410
620.0,5/8/2020 7:34:55 PM,"Time to buy these biopharma names is now, BofA says",Seeking Alpha,https://seekingalpha.com/news/3572315-time-to-buy-biopharma-names-is-now-bofa-says?utm_source=markets.businessinsider.com&utm_medium=referral
621.0,5/11/2020 12:00:46 PM,Bristol-Myers buys out of milestone and royalty commitment with bluebird for $200M,Seeking Alpha,https://seekingalpha.com/news/3572635-bristol-myers-buys-out-of-milestone-and-royalty-commitment-bluebird-for-200m?utm_source=markets.businessinsider.com&utm_medium=referral
622.0,5/13/2020 12:29:00 PM,It’s Time to Buy AbbVie Stock Now After Its Allergan Purchase,InvestorPlace,/news/stocks/its-time-to-buy-abbvie-now-after-its-agn-stock-purchase-1029197990
623.0,5/14/2020 5:15:21 AM,"FDA Snubs BMY And BLUE, Stocks That Moved On ASCO Abstracts (ARVN, CTMX, MGNX) ",RTTNews,/news/stocks/fda-snubs-bmy-and-blue-stocks-that-moved-on-asco-abstracts-arvn-ctmx-mgnx-1029199834
624.0,5/14/2020 9:29:32 PM,"Klarman buys Alphabet, exits Bristol Myers",Seeking Alpha,https://seekingalpha.com/news/3574838-klarman-buys-alphabet-exits-bristol-myers?utm_source=markets.businessinsider.com&utm_medium=referral
625.0,5/15/2020 7:59:31 PM,FDA OKs Bristol Myers doublet therapy for first-line lung cancer,Seeking Alpha,https://seekingalpha.com/news/3575215-fda-oks-bristol-myers-doublet-therapy-for-first-line-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
626.0,5/19/2020 12:07:33 PM,AbbVie Is More Than Just a Portfolio of Drugs and Acquisitions,InvestorPlace,/news/stocks/whole-of-abbv-stock-more-than-sum-of-parts-1029214731
627.0,5/22/2020 11:46:36 AM,EMA accepts Bristol Myers applications for blood cancer treatments,Seeking Alpha,https://seekingalpha.com/news/3577105-ema-accepts-bristol-myers-applications-for-blood-cancer-treatments?utm_source=markets.businessinsider.com&utm_medium=referral
628.0,5/27/2020 11:23:43 AM,Bristol-Myers' ozanimod OK'd in Europe for type of MS,Seeking Alpha,https://seekingalpha.com/news/3577815-bristol-myers-ozanimod-okd-in-europe-for-type-of-ms?utm_source=markets.businessinsider.com&utm_medium=referral
629.0,5/27/2020 1:38:39 PM,European Commission Approves Bristol Myers' Zeposia - Quick Facts ,RTTNews,/news/stocks/european-commission-approves-bristol-myers-zeposia-quick-facts-1029237130
630.0,5/29/2020 6:00:00 AM,All eyes on ASCO,Seeking Alpha,https://seekingalpha.com/news/3578520-all-eyes-on-asco?utm_source=markets.businessinsider.com&utm_medium=referral
631.0,5/29/2020 12:01:48 PM,European advisory group backs Herceptin biosimilar and generic Eliquis,Seeking Alpha,https://seekingalpha.com/news/3578611-european-advisory-group-backs-herceptin-biosimilar-and-generic-eliquis?utm_source=markets.businessinsider.com&utm_medium=referral
632.0,6/1/2020 12:05:19 PM,Bristol Myers launches MS med Zeposia in U.S.,Seeking Alpha,https://seekingalpha.com/news/3578930-bristol-myers-launches-ms-med-zeposia-in-u-s?utm_source=markets.businessinsider.com&utm_medium=referral
633.0,6/1/2020 1:59:55 PM,Compugen: FDA Allows Phase 1/2 Study Evaluating COM701 With BMS-986207 And Nivolumab ,RTTNews,/news/stocks/compugen-fda-allows-phase-1-2-study-evaluating-com701-with-bms-986207-and-nivolumab-1029268522
634.0,6/3/2020 11:49:25 AM,Replimune lead drug shows benefit in non-melanoma skin cancer,Seeking Alpha,https://seekingalpha.com/news/3579961-replimune-lead-drug-shows-benefit-in-non-melanoma-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
635.0,6/4/2020 2:36:10 PM,Jounce regains rights to cancer candidate from Bristol Myers Squibb,Seeking Alpha,https://seekingalpha.com/news/3580481-jounce-regains-rights-to-cancer-candidate-from-bristol-myers-squibb?utm_source=markets.businessinsider.com&utm_medium=referral
636.0,6/6/2020 3:10:22 PM,AbbVie's Rinvoq tops Bristol-Myers' Orencia in rheumatoid arthritis study,Seeking Alpha,https://seekingalpha.com/news/3580955-abbvies-rinvoq-tops-bristol-myers-orencia-in-rheumatoid-arthritis-study?utm_source=markets.businessinsider.com&utm_medium=referral
637.0,6/9/2020 3:10:56 PM,Aggressive Investors Can Do Much Better Than Merck Stock,InvestorPlace,/news/stocks/aggressive-investors-better-mrk-stock-1029293865
638.0,6/9/2020 4:08:46 PM,Bristol Myers teams up with UbiVac in study of triplet therapy for breast cancer,Seeking Alpha,https://seekingalpha.com/news/3581599-bristol-myers-teams-up-ubivac-in-study-of-triplet-therapy-for-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
639.0,6/16/2020 11:31:16 AM,Bristol-Myers initiates debt exchange offers,Seeking Alpha,https://seekingalpha.com/news/3583339-bristol-myers-initiates-debt-exchange-offers?utm_source=markets.businessinsider.com&utm_medium=referral
640.0,6/17/2020 4:24:13 PM,3 Dow Jones Companies to Buy When Profit-Taking Kicks In,InvestorPlace,/news/stocks/3-dow-jones-companies-to-buy-when-profit-taking-kicks-in-1029319033
641.0,6/18/2020 11:24:57 AM,Roche's Tecentriq improves response rate in early triple-negative breast cancer,Seeking Alpha,https://seekingalpha.com/news/3584069-roches-tecentriq-improves-response-rate-in-early-triple-negative-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
642.0,6/26/2020 1:50:19 PM,10 Value Stocks to Keep on Your Short List,InvestorPlace,/news/stocks/10-value-stocks-keep-short-list-1029346120
643.0,7/2/2020 5:02:06 PM,"Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO",InvestorPlace,/news/stocks/keep-eye-rprx-stock-2020-1029363917
644.0,7/10/2020 2:55:15 PM,The 7 Best Dividend-Paying Stocks for Cautious Investors,InvestorPlace,/news/stocks/the-7-best-dividend-paying-stocks-for-cautious-investors-1029384331
645.0,7/15/2020 10:50:50 AM,Microsoft gains foothold in healthcare,InvestorPlace,/news/stocks/microsofts-cloud-gains-foothold-in-healthcare-1029397797
646.0,7/22/2020 12:48:58 PM,Undervalued Bristol-Myers Squibb Stock Is Worth 50% More,InvestorPlace,/news/stocks/bmy-stock-very-undervalued-making-stock-a-buy-1029420799
647.0,7/30/2020 9:08:15 AM,"ALEC Falls Despite Promising Results, DNLI Makes Progress In COVID-19 Trial, EARS, ONTX On Watch ",RTTNews,/news/stocks/alec-falls-despite-promising-results-dnli-makes-progress-in-covid-19-trial-ears-ontx-on-watch-1029449238
648.0,7/30/2020 2:41:26 PM,5 Undervalued Stocks Cooking Up Must-Have Technologies,InvestorPlace,/news/stocks/5-undervalued-stocks-cooking-up-must-have-tech-1029452323
649.0,8/3/2020 2:54:47 PM,5 Healthcare Stocks for Good (Portfolio) Health,InvestorPlace,/news/stocks/5-healthcare-stocks-for-good-portfolio-health-1029462755
650.0,8/4/2020 11:00:14 AM,Bristol-Myers Squibb Has Great Potential Ahead of Earnings,InvestorPlace,/news/stocks/bmy-stock-earnings-great-upside-potential-1029466313
651.0,8/4/2020 1:14:21 PM,Bristol-Myers Squibb Is a Dirt-Cheap Buy Before Earnings,InvestorPlace,/news/stocks/buy-bmy-stock-before-earnings-while-its-still-dirt-cheap-1029467829
652.0,8/5/2020 3:04:13 PM,Here's what Wall Street expects from Bristol-Myers Squibb's earnings report,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-q2-earnings-preview-1029473227
653.0,8/6/2020 8:49:18 AM,"ABIO To Start Phase 2 COVID-19 Trial In Q4, ACIU On Track, BCLI Expects ALS Trial Data In Nov. ",RTTNews,/news/stocks/abio-to-start-phase-2-covid-19-trial-in-q4-aciu-on-track-bcli-expects-als-trial-data-in-nov-1029476415
654.0,8/6/2020 12:42:21 PM,"Pre-market Movers In Healthcare Sector: AVXL, BEAM, AVGR, BMY... ",RTTNews,/news/stocks/pre-market-movers-in-healthcare-sector-avxl-beam-avgr-bmy-1029477136
655.0,8/6/2020 1:47:07 PM,"Bristol-Myers Slips To Loss In Q2, But Results Top Estimates ",RTTNews,/news/stocks/bristol-myers-slips-to-loss-in-q2-but-results-top-estimates-1029477570
656.0,8/6/2020 3:13:08 PM,Bristol-Myers Squibb Earnings: BMY Stock Jumps 2% on Q2 Beats,InvestorPlace,/news/stocks/bristol-myers-squibb-earnings-bmy-stock-jumps-2-on-q2-beats-1029479311
657.0,8/6/2020 8:52:05 PM,"5 Top Stock Trades for Friday: UBER, FB, BMY, MU, TWLO",InvestorPlace,/news/stocks/5-top-stock-trades-for-friday-uber-fb-bmy-mu-twlo-1029480516
658.0,8/7/2020 1:36:32 PM,This Company is the Landlord of Life Sciences,InvestorPlace,/news/stocks/this-company-is-the-landlord-of-life-sciences-1029482490
659.0,8/8/2020 9:05:22 PM,Bristol Myers' O+Y extends survival in rare type of thoracic cancer,Seeking Alpha,https://seekingalpha.com/news/3603107-bristol-myers-o-y-extends-survival-in-rare-type-of-thoracic-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
660.0,8/21/2020 3:31:12 PM,Eli Lilly (Still) Looks Like the Best Buy in Large-Cap Pharma,InvestorPlace,/news/stocks/lly-stock-still-looks-like-best-buy-large-cap-pharma-1029524567
661.0,8/27/2020 2:45:32 AM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1029537919
662.0,9/14/2020 10:46:52 AM,Avoid General Electric Amid the Current Stock Market Dip,InvestorPlace,/news/stocks/avoid-general-electric-amid-the-current-stock-market-dip-1029585706
663.0,9/17/2020 2:18:31 PM,"Celgene, Dr. Reddy's Reach Settlement Agreement On Patents For REVLIMID Capsules ",RTTNews,/news/stocks/celgene-dr-reddy-s-reach-settlement-agreement-on-patents-for-revlimid-capsules-1029598528
664.0,9/22/2020 5:15:55 PM,Pfizer Shares May Catch Momentum Soon From Vaccine Work,InvestorPlace,/news/stocks/pfizer-stock-may-catch-positive-momentum-soon-1029612590
665.0,9/25/2020 9:16:35 AM,Patient Investors Will Stick With Very Cheap Bristol-Myers Squibb Stock,InvestorPlace,/news/stocks/bmy-stock-worth-46-percent-more-based-on-history-and-comps-1029623231
666.0,9/29/2020 2:26:20 PM,"Bristol Myers, Acceleron Pharma Announce Health Canada Approval Of Reblozyl ",RTTNews,/news/stocks/bristol-myers-acceleron-pharma-announce-health-canada-approval-of-reblozyl-1029630634
667.0,9/30/2020 10:54:07 AM,Abbott Labs Stock is Not Cheap But Should Do Well as Virus Test Debuts,InvestorPlace,/news/stocks/abt-stock-should-do-well-with-its-new-covid-19-test-1029635842
668.0,10/5/2020 11:17:06 AM,FDA Approves Drug Combination To Treat Mesothelioma ,RTTNews,/news/stocks/fda-approves-drug-combination-to-treat-mesothelioma-1029647276
669.0,10/5/2020 1:16:00 PM,Bristol Myers Squibb To Buy MyoKardia For $13.1 Bln In Cash - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-to-buy-myokardia-for-13-1-bln-in-cash-quick-facts-1029647715
670.0,10/5/2020 2:36:03 PM,MyoKardia soars 59% after Bristol-Myers agrees to acquire it for $13 billion in cash,Business Insider,https://www.businessinsider.com/myokardia-stock-price-bristol-myers-acquire-billion-cash-drug-pharma-2020-10
671.0,10/5/2020 3:09:53 PM,Bristol Myers Snaps Up MyoKardia For $225/Share ,RTTNews,/news/stocks/bristol-myers-snaps-up-myokardia-for-225-share-1029648357
672.0,10/5/2020 5:26:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's affirms Bristol-Myers at A2; outlook remains negative,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-affirms-bristol-myers-at-a2-outlook-remains-negative-1029649061
673.0,10/5/2020 5:35:25 PM,M&A News: MyoKardia (MYOK) Stock Soars on Bristol Myers Squibb Deal,InvestorPlace,/news/stocks/ma-news-myokardia-myok-stock-soars-on-bristol-myers-squibb-deal-1029649497
674.0,10/7/2020 12:15:39 PM,Bristol Myers' Opdivo shows incremental benefit over chemo in lung cancer study,Seeking Alpha,https://seekingalpha.com/news/3620396-bristol-myers-opdivo-shows-incremental-benefit-over-chemo-in-lung-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral
675.0,10/7/2020 12:33:51 PM,Bristol Myers' ozanimod OK'd in Canada for multiple sclerosis,Seeking Alpha,https://seekingalpha.com/news/3620424-bristol-myers-ozanimod-okd-in-canada-for-multiple-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral
676.0,10/7/2020 2:23:48 PM,Canada Approves Bristol-Myers' Zeposia To Treat Relapsing Remitting Multiple Sclerosis ,RTTNews,/news/stocks/canada-approves-bristol-myers-zeposia-to-treat-relapsing-remitting-multiple-sclerosis-1029656920
677.0,10/7/2020 4:12:52 PM,"Opdivo Plus Chemotherapy As Neoadjuvant Treatment In Resectable NSCLC Trial Hits Key Goal, Says BMY ",RTTNews,/news/stocks/opdivo-plus-chemotherapy-as-neoadjuvant-treatment-in-resectable-nsclc-trial-hits-key-goal-says-bmy-1029657815
678.0,10/7/2020 4:27:48 PM,7 Biotech Stocks To Buy For Profit From The Vaccine Crunch,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-for-profit-from-the-vaccine-crunch-1029658673
679.0,10/8/2020 7:48:40 AM,"Evotec, Bristol Myers Expand Neuroscience Partnership; Evotec Gains Milestone Payment ",RTTNews,/news/stocks/evotec-bristol-myers-expand-neuroscience-partnership-evotec-gains-milestone-payment-1029659830
680.0,10/8/2020 10:01:14 AM,Evotec earns $6M milestone from BMY under neurodegeneration collaboration,Seeking Alpha,https://seekingalpha.com/news/3620685-evotec-earns-6m-milestone-from-bmy-under-neurodegeneration-collaboration?utm_source=markets.businessinsider.com&utm_medium=referral
681.0,10/9/2020 7:00:01 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3621193-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
682.0,10/12/2020 3:23:34 PM,Bristol-Myers announces detailed ozanimod data from pivotal ulcerative colitis study,Seeking Alpha,https://seekingalpha.com/news/3621433-bristol-myers-announces-detailed-ozanimod-data-from-pivotal-ulcerative-colitis-study?utm_source=markets.businessinsider.com&utm_medium=referral
683.0,10/12/2020 5:58:46 PM,Surface Oncology hires bankers to explore sale - StreetInsider,Seeking Alpha,https://seekingalpha.com/news/3621490-surface-oncology-hires-bankers-to-explore-sale-streetinsider?utm_source=markets.businessinsider.com&utm_medium=referral
684.0,10/16/2020 11:53:54 AM,EMA backs Bristol Myers' Opdivo as second-line treatment in esophageal cancer,Seeking Alpha,https://seekingalpha.com/news/3622822-ema-backs-bristol-myers-opdivo-second-line-treatment-in-esophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
685.0,10/16/2020 11:53:54 AM,European advisory group backs Bristol Myers' Opdivo as second-line treatment in esophageal cancer,Seeking Alpha,https://seekingalpha.com/news/3622822-european-advisory-group-backs-bristol-myers-opdivo-second-line-treatment-in-esophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
686.0,10/16/2020 11:02:00 PM,JPM picks big pharma names to benefit with busy catalyst calendar ahead,Seeking Alpha,https://seekingalpha.com/news/3623038-jpm-picks-big-pharma-names-to-benefit-busy-catalyst-calendar-ahead?utm_source=markets.businessinsider.com&utm_medium=referral
687.0,10/19/2020 11:10:42 AM,FDA OKs accelerated review for Opdivo/Cabometyx combo for kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3623133-fda-oks-accelerated-review-for-opdivo-cabometyx-combo-for-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
688.0,10/26/2020 6:45:58 AM,Biotech Stocks Facing FDA Decision In November 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-2020-1029718001
689.0,10/28/2020 12:59:39 PM,7 Cutting-Edge Biotech Stocks for Tomorrow ,InvestorPlace,/news/stocks/7-cutting-edge-biotech-stocks-for-tomorrow-1029734117
690.0,11/2/2020 7:10:18 AM,Will Eiger's Zokinvy Make History To Become First-ever Progeria Treatment? ,RTTNews,/news/stocks/will-eiger-s-zokinvy-make-history-to-become-first-ever-progeria-treatment-1029751571
691.0,11/2/2020 3:23:08 PM,7 Healthcare Stocks That Can Survive Massive Reform,InvestorPlace,/news/stocks/7-healthcare-stocks-that-can-survive-massive-reform-1029754648
692.0,11/3/2020 12:23:20 PM,Bristol Myers' deucravacitinib tops Amgen's Otezla in late-stage psoriasis study,Seeking Alpha,https://seekingalpha.com/news/3630264-bristol-myers-deucravacitinib-tops-amgens-otezla-in-late-stage-psoriasis-study?utm_source=markets.businessinsider.com&utm_medium=referral
693.0,11/4/2020 1:29:39 PM,Bristol Myers - MyoKardia Deal Receives U.S. Regulatory Approval ,RTTNews,/news/stocks/bristol-myers-myokardia-deal-receives-u-s-regulatory-approval-1029764781
694.0,11/4/2020 4:24:35 PM,Bristol Myers Squibb Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3631153-bristol-myers-squibb-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
695.0,11/4/2020 5:09:18 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3631230-notable-earnings-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
696.0,11/5/2020 1:24:14 PM,Bristol Myers Squibb Raises FY20 Earnings Guidance - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-raises-fy20-earnings-guidance-quick-facts-1029769963
697.0,11/5/2020 2:50:57 PM,"Bristol Myers posts solid Q3 beat with strong performance in key franchises, FY20 outlook raised",Seeking Alpha,https://seekingalpha.com/news/3632257-bristol-myers-posts-solid-q3-beat-strong-performance-in-key-franchises-fy20-outlook-raised?utm_source=markets.businessinsider.com&utm_medium=referral
698.0,11/6/2020 12:40:29 PM,Bristol Myers' O+Y OK'd in Europe for first-line lung cancer,Seeking Alpha,https://seekingalpha.com/news/3633098-bristol-myers-o-y-okd-in-europe-for-first-line-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
699.0,11/9/2020 1:06:38 PM,Bristol Myers' deucravacitinib successful in mid-stage psoriatic arthritis study,Seeking Alpha,https://seekingalpha.com/news/3633585-bristol-myers-deucravacitinib-successful-in-mid-stage-psoriatic-arthritis-study?utm_source=markets.businessinsider.com&utm_medium=referral
700.0,11/9/2020 4:02:00 PM,Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers' sr. notes; outlook negative,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-assigns-a2-to-bristol-myers-sr-notes-outlook-negative-1029782082
701.0,11/9/2020 9:50:39 PM,Bristol Myers' Yervoy shows no incremental benefit over Merck's Keytruda alone in lung cancer study,Seeking Alpha,https://seekingalpha.com/news/3634036-bristol-myers-yervoy-shows-no-incremental-benefit-over-mercks-keytruda-alone-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
702.0,11/11/2020 4:50:34 PM,7 Biotech Penny Stocks Worth a Gamble,InvestorPlace,/news/stocks/7-biotech-stocks-to-gamble-with-1029793010
703.0,11/11/2020 8:52:12 PM,Nektar Therapeutics immuno-oncology candidates show positive action in early-stage studies,Seeking Alpha,https://seekingalpha.com/news/3635108-nektar-therapeutics-immuno-oncology-candidates-show-positive-action-in-early-stage-studies?utm_source=markets.businessinsider.com&utm_medium=referral
704.0,11/13/2020 8:00:17 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3636251-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
705.0,11/15/2020 4:37:27 PM,"Week Ahead In Pharma: FDA Decisions, Data Readouts (ADMP, EIGR, KZIA, AVRO…) ",RTTNews,/news/stocks/week-ahead-in-pharma-fda-decisions-data-readouts-admp-eigr-kzia-avro-1029803879
706.0,11/16/2020 9:48:23 PM,FDA review for Bristol-Myers's liso-cel marketing application to miss the action date,Seeking Alpha,https://seekingalpha.com/news/3636821-fda-review-for-bristol-myerss-liso-cel-marketing-application-to-miss-action-date?utm_source=markets.businessinsider.com&utm_medium=referral
707.0,11/17/2020 8:10:16 AM,"ADMP Snubbed Again, FDA Delay's Decision On BMY's Liso-cel, MRNA's COVID-19 Vaccine 94.5% Effective ",RTTNews,/news/stocks/admp-snubbed-again-fda-delay-s-decision-on-bmy-s-liso-cel-mrna-s-covid-19-vaccine-94-5-effective-1029809234
708.0,11/17/2020 10:41:52 AM,"Buffett’s Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks",InvestorPlace,/news/stocks/buffets-berkshire-hathaway-stock-buys-new-stakes-in-vaccine-makers-cut-banks-1029809986
709.0,11/17/2020 2:04:21 PM,Bristol Myers completes acquisition of MyoKardia,Seeking Alpha,https://seekingalpha.com/news/3637079-bristol-myers-completes-acquisition-of-myokardia?utm_source=markets.businessinsider.com&utm_medium=referral
710.0,11/17/2020 3:10:41 PM,7 Pharmaceutical Stocks to Buy for 2021 and Beyond ,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-to-buy-for-2021-and-beyond-1029811903
711.0,11/23/2020 11:52:19 AM,Schrödinger inks multi-target drug discovery deal with Bristol-Myers Squibb,Seeking Alpha,https://seekingalpha.com/news/3638576-schrodinger-inks-multi-target-drug-discovery-deal-bristol-myers-squibb?utm_source=markets.businessinsider.com&utm_medium=referral
712.0,11/23/2020 12:53:41 PM,Schrdinger Enters Into Discovery Collaboration With Bristol Myers Squibb - Quick Facts ,RTTNews,/news/stocks/schrdinger-enters-into-discovery-collaboration-with-bristol-myers-squibb-quick-facts-1029829012
713.0,11/23/2020 8:28:57 PM,"Schrödinger stock scales, upgraded by BofA after collaboration with BMY",Seeking Alpha,https://seekingalpha.com/news/3638810-schrodinger-stock-scales-upgraded-bofa-after-collaboration-bmy?utm_source=markets.businessinsider.com&utm_medium=referral
714.0,11/24/2020 4:22:14 PM,Bristol Myers wins EU approval of Opdivo for esophageal cancer,Seeking Alpha,https://seekingalpha.com/news/3639128-bristol-myers-wins-eu-approval-of-opdivo-for-esophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
715.0,12/4/2020 4:46:01 PM,Sutro Biopharma: 7 Things for STRO Stock Investors to Know About the Biotech Company,InvestorPlace,/news/stocks/sutro-biopharma-what-to-know-about-stro-stock-1029865897
716.0,12/7/2020 10:52:00 AM,Moody's - Outlook for global pharmaceutical industry revised to positive as COVID-19 vaccines and treatments boost earnings,Moodys,/news/bonds/moody-s-outlook-for-global-pharmaceutical-industry-revised-to-positive-as-covid-19-vaccines-and-treatments-boost-earnings-1029868484
717.0,12/7/2020 5:20:23 PM,Johnson & Johnson sees positive data from pair of multiple myeloma approaches at ASH,Seeking Alpha,https://seekingalpha.com/news/3642175-johnson-johnson-sees-positive-data-from-pair-of-multiple-myeloma-approaches-ash?utm_source=markets.businessinsider.com&utm_medium=referral
718.0,12/8/2020 5:08:03 PM,"Checkmate Pharma, Bristol Myers team up for CMP-001/nivolumab combo trial in melanoma",Seeking Alpha,https://seekingalpha.com/news/3642567-checkmate-pharma-bristol-myers-team-up-for-cmpminus-001-nivolumab-combo-trial-in-melanoma?utm_source=markets.businessinsider.com&utm_medium=referral
719.0,12/8/2020 6:57:24 PM,3 Cheap Dividend Stocks For High Total Returns,InvestorPlace,/news/stocks/3-cheap-dividend-stocks-for-high-total-returns-intc-bmy-kmi-1029874781
720.0,12/9/2020 2:24:20 PM,7 Undervalued Stocks to Buy Now,InvestorPlace,/news/stocks/7-undervalued-stocks-to-buy-now-1029877954
721.0,12/10/2020 9:17:58 PM,Bristol Myers Squibb hikes dividend by 9% to $0.49,Seeking Alpha,https://seekingalpha.com/news/3643487-bristol-myers-squibb-hikes-dividend-9-to-0_49?utm_source=markets.businessinsider.com&utm_medium=referral
722.0,12/11/2020 12:38:48 PM,European advisory group backs Bristol Myers' Inrebic in myelofibrosis,Seeking Alpha,https://seekingalpha.com/news/3643650-european-advisory-group-backs-bristol-myers-inrebic-in-myelofibrosis?utm_source=markets.businessinsider.com&utm_medium=referral
723.0,12/11/2020 1:24:46 PM,"Bristol Myers, Cipla settle Revlimid U.S. patent litigation",Seeking Alpha,https://seekingalpha.com/news/3643679-bristol-myers-cipla-settle-revlimid-u-s-patent-litigation?utm_source=markets.businessinsider.com&utm_medium=referral
724.0,12/11/2020 1:42:12 PM,"Bristol Myers' Celgene, Cipla Settle U.S. Patent Litigation On Lenalidomide ",RTTNews,/news/stocks/bristol-myers-celgene-cipla-settle-u-s-patent-litigation-on-lenalidomide-1029885163
725.0,12/15/2020 3:52:00 PM,Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-bristol-myers-squibb-company-1029894437
726.0,12/16/2020 10:47:45 AM,Micro-cap oncology biotech Scopus Biopharma prices downsized $2.75M IPO,Seeking Alpha,https://seekingalpha.com/news/3644762-micro-cap-oncology-biotech-scopus-biopharma-prices-downsized-2_75m-ipo?utm_source=markets.businessinsider.com&utm_medium=referral
727.0,12/17/2020 7:52:45 AM,Evotec Meets Key Milestones In Partnership With Bristol Myers On Targeted Protein Degradation ,RTTNews,/news/stocks/evotec-meets-key-milestones-in-partnership-with-bristol-myers-on-targeted-protein-degradation-1029900939
728.0,12/17/2020 11:33:41 AM,Evotec achieves milestones in Bristol Myers pact in targeted protein degradation,Seeking Alpha,https://seekingalpha.com/news/3645207-evotec-achieves-milestones-in-bristol-myers-pact-in-targeted-protein-degradation?utm_source=markets.businessinsider.com&utm_medium=referral
729.0,12/23/2020 12:30:41 PM,Bristol-Myers says Opdivo brain cancer study unlikely to meet overall survival endpoint,Seeking Alpha,https://seekingalpha.com/news/3646910-bristol-myers-says-opdivo-brain-cancer-study-unlikely-to-meet-overall-survival-endpoint?utm_source=markets.businessinsider.com&utm_medium=referral
730.0,12/23/2020 1:42:55 PM,Bristol-Myers: Phase 3 CheckMate -548 Trial Will Not Meet Primary Endpoint Of Overall Survival ,RTTNews,/news/stocks/bristol-myers-phase-3-checkmate-548-trial-will-not-meet-primary-endpoint-of-overall-survival-1029916785
731.0,12/24/2020 5:12:44 PM,"Analysts predict M&A poised to rebound in next year, fueled by $1.47T in deal making capital",Seeking Alpha,https://seekingalpha.com/news/3647399-analysts-predict-m-poised-to-rebound-in-next-year-fueled-1_47t-in-deal-making-capital?utm_source=markets.businessinsider.com&utm_medium=referral
732.0,12/26/2020 3:15:52 PM,"The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-27-jan-2-data-releases-regulatory-filings-to-move-stocks-1029919761
733.0,12/28/2020 3:33:59 AM,Biotech Stock Picks That Delivered Triple-digit Gains - Is There More Room To Run? ,RTTNews,/news/stocks/biotech-stock-picks-that-delivered-triple-digit-gains-is-there-more-room-to-run-1029920417
734.0,12/28/2020 12:29:09 PM,Bristol-Myers Squibb’s ulcerative colitis therapy goes under review in Europe,Seeking Alpha,https://seekingalpha.com/news/3647472-bristol-myers-squibb-s-ulcerative-colitis-therapy-goes-under-review-in-europe?utm_source=markets.businessinsider.com&utm_medium=referral
735.0,12/28/2020 1:09:50 PM,Bristol Myers Squibb: EMA Validates Marketing Authorization Application For Zeposia ,RTTNews,/news/stocks/bristol-myers-squibb-ema-validates-marketing-authorization-application-for-zeposia-1029921156
736.0,12/29/2020 2:09:37 PM,"The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-amphastar-s-generic-glucagon-arcturus-sinks-on-vaccine-data-decision-day-for-osmotica-1029923067
737.0,12/30/2020 6:19:15 PM,Celgene CVRs lose 21% as the deadline for liso-cel approval nears,Seeking Alpha,https://seekingalpha.com/news/3647946-celgene-cvrs-lose-21-deadline-for-liso-cel-approval-nears?utm_source=markets.businessinsider.com&utm_medium=referral
738.0,12/31/2020 5:45:27 PM,7 Cheap Stocks That Can’t Wait for 2021 ,InvestorPlace,/news/stocks/7-cheap-stocks-to-buy-now-that-cant-wait-for-2021-1029927440
739.0,1/1/2021 1:30:00 PM,Bristol-Myers says CVR Agreement is terminated,Seeking Alpha,https://seekingalpha.com/news/3648168-bristol-myers-says-cvr-agreement-is-terminated?utm_source=markets.businessinsider.com&utm_medium=referral
740.0,1/4/2021 5:03:29 PM,7 Cheap Stocks to Buy in January For a Quick Buck,InvestorPlace,/news/stocks/7-cheap-stocks-to-buy-in-january-for-a-quick-buck-1029931161
741.0,1/5/2021 7:49:35 AM,Evotec Receives $6 Mln Payment From Bristol Myers On IPSC-based Neuroscience Partnership ,RTTNews,/news/stocks/evotec-receives-6-mln-payment-from-bristol-myers-on-ipsc-based-neuroscience-partnership-1029932303
742.0,1/5/2021 12:04:59 PM,Evotec earns $6 milestone under neurodegeneration deal with Bristol Myers,Seeking Alpha,https://seekingalpha.com/news/3648700-evotec-earns-6-milestone-under-neurodegeneration-deal-bristol-myers?utm_source=markets.businessinsider.com&utm_medium=referral
743.0,1/5/2021 3:53:58 PM,"Cramer Shares His Thoughts On AT&T, Nantkwest And More",Benzinga,/news/stocks/cramer-shares-his-thoughts-on-at-t-nantkwest-and-more-1029934280
744.0,1/5/2021 11:37:37 PM,"BofA's biopharma picks into 2021 set to build with new launches, 'beatable' expectations",Seeking Alpha,https://seekingalpha.com/news/3649105-bofas-biopharma-picks-2021-set-to-build-new-launches-beatable-expectations?utm_source=markets.businessinsider.com&utm_medium=referral
745.0,1/8/2021 3:45:12 PM,Dosing underway in OncoSec's Tavo combo trial in skin cancer,Seeking Alpha,https://seekingalpha.com/news/3649976-dosing-underway-in-oncosecs-tavo-combo-trial-in-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
746.0,1/8/2021 4:04:57 PM,"Avidity inks research deal with Bristol Myers' subsidiary, gives 2021 pipeline updates",Seeking Alpha,https://seekingalpha.com/news/3649984-avidity-inks-research-deal-bristol-myers-subsidiary-gives-2021-pipeline-updates?utm_source=markets.businessinsider.com&utm_medium=referral
747.0,1/9/2021 7:45:45 PM,"SPACs Attack Recap: SoFi, IPOE, GXGX, ACEV Deals Plus Rumors And Headlines For Week Ending January 8",Benzinga,/news/stocks/spacs-attack-recap-sofi-ipoe-gxgx-acev-deals-plus-rumors-and-headlines-for-week-ending-january-8-1029945206
748.0,1/11/2021 12:10:35 PM,Bristol Myers Squibb approves $2B incremental share repurchase authorization,Seeking Alpha,https://seekingalpha.com/news/3650178-bristol-myers-squibb-approves-2b-incremental-share-repurchase-authorization?utm_source=markets.businessinsider.com&utm_medium=referral
749.0,1/11/2021 1:21:55 PM,Bristol Myers Board Authorizes Incremental Share Repurchase - Quick Facts ,RTTNews,/news/stocks/bristol-myers-board-authorizes-incremental-share-repurchase-quick-facts-1029949273
750.0,1/11/2021 3:12:44 PM,"Amgen, AstraZeneca, Bristol Myers Squibb To Evaluate GRAIL's Cancer Early Detection Test ",RTTNews,/news/stocks/amgen-astrazeneca-bristol-myers-squibb-to-evaluate-grail-s-cancer-early-detection-test-1029955729
751.0,1/11/2021 4:59:22 PM,The Top 7 Pharmaceutical Stocks for the Next 10 Years ,InvestorPlace,/news/stocks/the-top-7-pharmaceutical-stocks-for-the-next-10-years-1029956488
752.0,1/11/2021 8:37:03 PM,"Illumina announces strategic partnership with BMY, KURA, MYGN and Merck to advance comprehensive genomic profiling; provides 2021 guidance",Seeking Alpha,https://seekingalpha.com/news/3650460-illumina-announces-strategic-partnership-bmy-kura-mygn-and-merck-to-advance-comprehensive?utm_source=markets.businessinsider.com&utm_medium=referral
753.0,1/12/2021 2:02:22 PM,Bristol Myers' Onureg OK'd in Canada for acute myeloid leukemia,Seeking Alpha,https://seekingalpha.com/news/3650696-bristol-myers-onureg-okd-in-canada-for-acute-myeloid-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral
754.0,1/12/2021 4:32:16 PM,"Even In This Market, There Are Better Choices Than Pfizer Stock",InvestorPlace,/news/stocks/better-choices-than-pfe-stock-1029961129
755.0,1/13/2021 1:25:38 PM,"The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations",Benzinga,/news/stocks/the-daily-biotech-pulse-bausch-health-issues-positive-pre-announcement-acorda-streamlines-operations-1029963908
756.0,1/13/2021 7:51:59 PM,7 Pharmaceutical Stocks With Exciting Plans for 2021,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-with-exciting-plans-for-2021-1029966098
757.0,1/14/2021 12:44:19 PM,"NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock Soars",Benzinga,/news/stocks/nantkwest-reports-positive-interim-data-in-pancreatic-cancer-trials-stock-soars-1029967953
758.0,1/14/2021 8:34:12 PM,Invitae teams up with healthcare giants to develop MRD detection panel,Seeking Alpha,https://seekingalpha.com/news/3651590-invitae-teams-up-healthcare-giants-to-develop-mrd-detection-panel?utm_source=markets.businessinsider.com&utm_medium=referral
759.0,1/20/2021 12:19:05 PM,Bristol Myers' two expanded use Opdivo applications accepted by FDA,Seeking Alpha,https://seekingalpha.com/news/3652585-bristol-myers-two-expanded-use-opdivo-applications-accepted-by-fda?utm_source=markets.businessinsider.com&utm_medium=referral
760.0,1/20/2021 1:32:35 PM,"The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-greenlights-merck-s-heart-failure-drug-histogen-hit-with-clinical-hold-aptorum-gets-nod-for-commencing-human-study-1029985849
761.0,1/21/2021 2:05:24 PM,"The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping",Benzinga,/news/stocks/the-daily-biotech-pulse-addex-jumps-on-positive-data-for-out-licensed-drug-covid-19-vaccine-developer-inovio-announces-150m-follow-on-offering-boston-scientific-goes-shopping-1029990203
762.0,1/22/2021 6:25:38 PM,Exelixis' CABOMETYX-OPDIVO combo wins FDA approval for renal cell carcinoma,Seeking Alpha,https://seekingalpha.com/news/3653645-exelixiss-cabometyx-opdivo-combo-wins-fda-approval-for-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
763.0,1/22/2021 7:36:14 PM,Exelixis' CABOMETYX-OPDIVO combo wins FDA approval for renal cell carcinoma,Seeking Alpha,https://seekingalpha.com/news/3653645-exelixis-cabometyx-opdivo-wins-fda-for-renal-cell-carcinoma?utm_source=markets.businessinsider.com&utm_medium=referral
764.0,1/29/2021 12:02:52 AM,"Major pharma set for strong 2021, and trading at a 35% discount to market - J.P. Morgan",Seeking Alpha,https://seekingalpha.com/news/3655985-major-pharma-set-for-strong-2021-and-trading-at-a-35-discount-to-market-jp-morgan?utm_source=markets.businessinsider.com&utm_medium=referral
765.0,1/31/2021 4:49:07 AM,Merck’s Keytruda with Yervoy fail to add clinical benefit in non-small cell lung cancer,Seeking Alpha,https://seekingalpha.com/news/3656446-mercks-keytruda-with-yervoy-fail-to-add-clinical-benefit-in-non-small-cell-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
766.0,2/1/2021 5:48:38 PM,Bristol Myers granted priority review for Zeposia in ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3656767-bristol-myers-granted-priority-review-for-zeposia-in-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral
767.0,2/2/2021 1:08:54 PM,Bristol Myers announces positive data for deucravacitinib in plaque psoriasis,Seeking Alpha,https://seekingalpha.com/news/3657156-bristol-myers-announced-positive-data-for-deucravacitinib-in-plaque-psoriasis?utm_source=markets.businessinsider.com&utm_medium=referral
768.0,2/2/2021 2:05:48 PM,"The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment",Benzinga,/news/stocks/the-daily-biotech-pulse-vertex-pfizer-earnings-tiziana-covid-19-vaccine-data-decision-day-for-mallinckrodt-s-burn-treatment-1030032611
769.0,2/2/2021 3:01:46 PM,Bristol-Myers Squibb earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q4-earnings-preview-stock-1030033135
770.0,2/3/2021 1:31:17 PM,"The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision",Benzinga,/news/stocks/the-daily-biotech-pulse-amgen-earnings-gsk-curevac-vaccine-collaboration-mallinckrodt-fda-decision-1030037844
771.0,2/3/2021 5:02:01 PM,Bristol Myers Squibb Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3657833-bristol-myers-squibb-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
772.0,2/3/2021 5:06:11 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3657838-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
773.0,2/3/2021 10:18:54 PM,"4 Top Stock Trades for Thursday: AMZN, SPOT, BMY, ABBV",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-amzn-spot-bmy-abbv-1030040762
774.0,2/4/2021 12:02:55 PM,"Bristol Myers Squibb EPS beats by $0.04, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3658273-bristol-myers-squibb-eps-beats-0_04-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
775.0,2/4/2021 12:52:45 PM,"Sana prices upsized IPO at $25, above the expected range, trades today",Seeking Alpha,https://seekingalpha.com/news/3658334-sana-prices-upsized-ipo-at-25-above-the-expected-range-trades-today?utm_source=markets.businessinsider.com&utm_medium=referral
776.0,2/4/2021 1:14:56 PM,Bristol Myers Squibb Raises 2021 Adj. Earnings Guidance ,RTTNews,/news/stocks/bristol-myers-squibb-raises-2021-adj-earnings-guidance-1030043107
777.0,2/4/2021 1:23:49 PM,Bristol-Myers Squibb Co. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q4-adjusted-earnings-beat-estimates-1030043142
778.0,2/4/2021 1:25:00 PM,Bristol Myers Squibb launches tender offers up to $4B,Seeking Alpha,https://seekingalpha.com/news/3658367-bristol-myers-squibb-launches-tender-offers-up-to-4b?utm_source=markets.businessinsider.com&utm_medium=referral
779.0,2/4/2021 1:30:31 PM,Bristol Myers Squibb rises slightly on Q4 results; raises 2021 earnings guidance,Seeking Alpha,https://seekingalpha.com/news/3658322-bristol-myers-squibb-rises-slightly-on-q4-results-raises-2021-earnings-guidance?utm_source=markets.businessinsider.com&utm_medium=referral
780.0,2/4/2021 4:13:16 PM,Mid-Morning Market Update: Markets Open Higher; Bristol-Myers Squibb Profit Beats Estimates,Benzinga,/news/stocks/mid-morning-market-update-markets-open-higher-bristol-myers-squibb-profit-beats-estimates-1030044505
781.0,2/4/2021 6:19:03 PM,Mid-Day Market Update: Gold Down 2.5%; Lizhi Shares Spike Higher,Benzinga,/news/stocks/mid-day-market-update-gold-down-2-5-lizhi-shares-spike-higher-1030044966
782.0,2/4/2021 9:07:00 PM,Mid-Afternoon Market Update: Dow Surges Over 250 Points; Lannett Shares Plummet,Benzinga,/news/stocks/mid-afternoon-market-update-dow-surges-over-250-points-lannett-shares-plummet-1030045428
783.0,2/4/2021 10:19:00 PM,"Onondaga County Industrial Dev. Agy., NY -- Moody's affirms Bristol's A2 rating; revises outlook to stable",Moodys,/news/bonds/onondaga-county-industrial-dev-agy-ny-moody-s-affirms-bristol-s-a2-rating-revises-outlook-to-stable-1030045764
784.0,2/4/2021 10:30:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's affirms Bristol's A2 rating; revises outlook to stable,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-affirms-bristol-s-a2-rating-revises-outlook-to-stable-1030045803
785.0,2/5/2021 11:13:17 AM,Bolt Biotherapeutics raises $230M in IPO,Seeking Alpha,https://seekingalpha.com/news/3658964-bolt-biotherapeutics-raises-230m-in-ipo?utm_source=markets.businessinsider.com&utm_medium=referral
786.0,2/5/2021 9:13:52 PM,Bristol Myers Squibb wins FDA approval for lymphoma treatment Breyanzi,Seeking Alpha,https://seekingalpha.com/news/3659240-bristol-myers-squibb-receives-fda-approval-for-liso-cel?utm_source=markets.businessinsider.com&utm_medium=referral
787.0,2/6/2021 6:42:05 PM,"The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-7-13-regeneron-fda-decision-earnings-ipos-and-conference-presentations-in-the-spotlight-1030050676
788.0,2/8/2021 1:46:43 PM,FDA OKs Bristol-Myers Squibb's Breyanzi To Treat Large-B-Cell Lymphoma ,RTTNews,/news/stocks/fda-oks-bristol-myers-squibb-s-breyanzi-to-treat-large-b-cell-lymphoma-1030054786
789.0,2/8/2021 5:36:14 PM,Bristol Myers Squibb's Inrebic nabs European Commission approval,Seeking Alpha,https://seekingalpha.com/news/3659568-bristol-myers-squibbs-inrebic-nabs-european-commission-approval?utm_source=markets.businessinsider.com&utm_medium=referral
790.0,2/9/2021 1:56:49 PM,Heat Biologics' shares take off after HS-110-OPDIVO combo shines in mid-stage trial,Seeking Alpha,https://seekingalpha.com/news/3659954-heat-biologics-shares-take-off-after-hs-110-opdivo-combo-shines-in-mid-stage-trial?utm_source=markets.businessinsider.com&utm_medium=referral
791.0,2/9/2021 5:03:37 PM,Bristol Myers announces late-stage data for Opdivo in bladder cancer,Seeking Alpha,https://seekingalpha.com/news/3660036-bristol-myers-announces-late-stage-data-for-opdivo-in-bladder-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
792.0,2/9/2021 6:54:56 PM,Infinity loses a fifth ahead of key data readout for eganelisib,Seeking Alpha,https://seekingalpha.com/news/3660119-infinity-loses-a-fifth-ahead-of-key-data-readout-for-eganelisib?utm_source=markets.businessinsider.com&utm_medium=referral
793.0,2/10/2021 2:50:03 PM,7 Retirement Stocks to Buy to Supplement Your 401k,InvestorPlace,/news/stocks/7-retirement-stocks-to-buy-to-supplement-your-401k-1030067410
794.0,2/11/2021 1:26:22 PM,"The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-dermtech-soars-on-contract-fluidigm-plunges-on-earnings-decision-day-for-regeneron-bioventus-debuts-1030072237
795.0,2/11/2021 3:13:56 PM,Molecular Templates Shares Jump On Research Pact With Bristol-Myers In Cancer Settings,Benzinga,/news/stocks/molecular-templates-shares-jump-on-research-pact-with-bristol-myers-in-cancer-settings-1030073166
796.0,2/16/2021 1:15:33 PM,"Bristol-Myers, Sanofi Ordered To Pay $834 Mln Over Plavix In Hawaii ",RTTNews,/news/stocks/bristol-myers-sanofi-ordered-to-pay-834-mln-over-plavix-in-hawaii-1030086313
797.0,2/16/2021 3:02:23 PM,Bristol Myers' REBLOZYL wins Health Canada approval for transfusion-dependent anemia,Seeking Alpha,https://seekingalpha.com/news/3662262-bristol-myers-reblozyl-wins-health-canada-approval-for-transfusion-dependent-anemia?utm_source=markets.businessinsider.com&utm_medium=referral
798.0,2/18/2021 7:55:17 PM,Barclays initiates Cytokinetics with an outperform rating,Seeking Alpha,https://seekingalpha.com/news/3663584-barclays-initiates-cytokinetics-with-outperform-rating?utm_source=markets.businessinsider.com&utm_medium=referral
799.0,2/18/2021 8:39:00 PM,Piper Sandler initiates Infinity Pharmaceuticals at overweight,Seeking Alpha,https://seekingalpha.com/news/3663603-piper-sandler-initiates-infinity-pharmaceuticals-at-overweight?utm_source=markets.businessinsider.com&utm_medium=referral
800.0,2/19/2021 1:00:31 PM,3 High-Quality Health Care Companies With Recession-Proof Dividends,InvestorPlace,/news/stocks/3-high-quality-health-care-companies-with-recession-proof-dividends-1030101483
801.0,2/22/2021 5:12:52 PM,Compugen expands deal with Bristol Myers for phase 1b COM701 combo study,Seeking Alpha,https://seekingalpha.com/news/3664386-compugen-expands-deal-with-bristol-myers-for-phase-1b-com701-combo-study?utm_source=markets.businessinsider.com&utm_medium=referral
802.0,2/22/2021 7:58:25 PM,"Compugen To Test COM701, Opdivo Combination In Solid Tumor Settings",Benzinga,/news/stocks/compugen-to-test-com701-opdivo-combination-in-solid-tumor-settings-1030109054
803.0,2/24/2021 5:36:40 PM,Bristol-Myers receives FDA’s orphan drug designation for multiple myeloma therapy,Seeking Alpha,https://seekingalpha.com/news/3665668-bristol-myers-receives-fdas-orphan-drug-designation-for-antibody-drug-conjugate?utm_source=markets.businessinsider.com&utm_medium=referral
804.0,2/25/2021 2:21:49 PM,Compugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor Studies,Benzinga,/news/stocks/compugen-s-com701-shows-ongoing-durable-signals-in-early-stage-solid-tumor-studies-1030123806
805.0,2/25/2021 3:29:30 PM,Bluebird bio up after peer-reviewed publication of ide-cel data in multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3666495-bluebird-bio-up-after-peer-reviewed-publication-of-ide-cel-data-in-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral
806.0,2/26/2021 11:59:05 AM,Bristol Myers' opdivo combo wins positive opinion from EU in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3667040-ema-backs-bristol-myers-opdivo--cabometyx-in-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
807.0,2/28/2021 4:54:54 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1030132296
808.0,3/1/2021 1:34:04 PM,"Citi reiterates buy, boosts price target of Acceleron shares",Seeking Alpha,https://seekingalpha.com/news/3667535-citi-reiterates-buy-boosts-price-target-of-acceleron-shares?utm_source=markets.businessinsider.com&utm_medium=referral
809.0,3/1/2021 7:11:23 PM,7 Value Stocks Ready for the Next 10 Years,InvestorPlace,/news/stocks/7-value-stocks-ready-for-the-next-10-years-1030136985
810.0,3/3/2021 2:10:42 PM,Heat Biologics shares surge 17% premarket as Cantor initiates with overweight rating,Seeking Alpha,https://seekingalpha.com/news/3668714-heat-biologics-shares-surge-premarket-as-cantor-initiates-with-an-overweight-rating?utm_source=markets.businessinsider.com&utm_medium=referral
811.0,3/8/2021 6:37:03 PM,NIH starts trial enrollment for Bristol/Pfizer's Eliquis for blood clots in COVID patients,Seeking Alpha,https://seekingalpha.com/news/3670365-nih-starts-trial-enrollment-for-bristol-pfizer-eliquis-for-blood-clots-in-covid-patients?utm_source=markets.businessinsider.com&utm_medium=referral
812.0,3/12/2021 12:15:36 PM,AVEO Oncology shares surge on Fotvida deal with BMY in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3672174-aveo-oncology-shares-surge-on-fotvida-deal-with-bmy-in-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
813.0,3/12/2021 1:20:50 PM,"AVEO, Bristol Myers To Evaluate Fotivda - Opdivo In Phase 3 Trial In Relapsed Renal Cell Carcinoma ",RTTNews,/news/stocks/aveo-bristol-myers-to-evaluate-fotivda-opdivo-in-phase-3-trial-in-relapsed-renal-cell-carcinoma-1030178326
814.0,3/12/2021 1:36:15 PM,"The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-vaccine-data-contrafect-secures-barda-funding-2-ipos-1030178427
815.0,3/12/2021 2:36:38 PM,Aveo Pharma's Tivozanib To Be Tested In Combination With Opdivo In Kidney Cancer,Benzinga,/news/stocks/aveo-pharma-s-tivozanib-to-be-tested-in-combination-with-opdivo-in-kidney-cancer-1030178971
816.0,3/12/2021 6:04:49 PM,Merck and Pfizer among top picks to lead 2021 biopharma M&A activity: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3672343-merck-and-pfizer-among-top-picks-to-lead-2021-biopharma-ma-activity-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral
817.0,3/14/2021 5:40:20 AM,"Big Pharma is pushing back the pandemic, but its stocks are cheap - Barron's",Seeking Alpha,https://seekingalpha.com/news/3672437-big-pharma-is-pushing-back-the-pandemic-but-its-stocks-are-cheap-barrons?utm_source=markets.businessinsider.com&utm_medium=referral
818.0,3/15/2021 3:41:39 PM,"AVEO Pharmaceuticals, CANbridge AV-203 Licensing Deal Axed, AVEO Regains Ex-North American Rights",Benzinga,/news/stocks/aveo-pharmaceuticals-canbridge-av-203-licensing-deal-axed-aveo-regains-ex-north-american-rights-1030205307
819.0,3/17/2021 2:15:17 PM,3 Biotech Stocks That Could Double In 12 Months,Benzinga,/news/stocks/3-biotech-stocks-that-could-double-in-12-months-1030219865
820.0,3/18/2021 8:42:08 AM,Laryngeal Cancer Therapeutics Market To See $635M Growth By 2025 And These 2 Companies Will Be Key Drivers: Research,Benzinga,/news/stocks/laryngeal-cancer-therapeutics-market-to-see-635m-growth-by-2025-and-these-2-companies-will-be-key-drivers-research-1030222527
821.0,3/18/2021 8:35:38 PM,Idera shares plunge 66% following phase 3 melanoma candidate failure (updated),Seeking Alpha,https://seekingalpha.com/news/3674219-idera-melanoma-candidate-tilsotolimod-fails-in-phase-3-trial?utm_source=markets.businessinsider.com&utm_medium=referral
822.0,3/19/2021 11:23:08 AM,FDA accepts Bristol Myers Squibb's mavacamten NDA for review,Seeking Alpha,https://seekingalpha.com/news/3674352-fda-accepts-bristol-myers-squibbs-mavacamten-nda-for-review?utm_source=markets.businessinsider.com&utm_medium=referral
823.0,3/19/2021 12:46:47 PM,"The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-sarepta-gene-therapy-data-idera-plunges-on-failed-skin-cancer-study-3-ipos-1030227585
824.0,3/19/2021 7:30:46 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3674473-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
825.0,3/19/2021 7:45:18 PM,Tomslist: The 5 Weirdest Penny Stock Stories of the Week,InvestorPlace,/news/stocks/tomslist-the-5-weirdest-penny-stock-stories-of-the-week-1030229255
826.0,3/20/2021 2:52:32 PM,"FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings",Benzinga,/news/stocks/fda-decisions-for-pfizer-eli-lilly-and-bluebird-bio-bristol-meyers-squibb-plus-new-data-and-earnings-1030229632
827.0,3/23/2021 4:46:16 PM,Drug pricing legislation introduced by Sanders weighs on pharmas,Seeking Alpha,https://seekingalpha.com/news/3675361-drug-pricing-legislation-introduced-by-sanders-weighs-on-pharmas?utm_source=markets.businessinsider.com&utm_medium=referral
828.0,3/25/2021 12:58:24 PM,"The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut",Benzinga,/news/stocks/the-daily-biotech-pulse-bristol-myers-squibb-s-skin-cancer-readout-cellect-strikes-reverse-merger-deal-lava-therapeutics-makes-nasdaq-debut-1030245316
829.0,3/25/2021 1:33:54 PM,Bristol Myers Squibb Announces Positive Results For Relativity-047 Study- Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-announces-positive-results-for-relativity-047-study-quick-facts-1030245546
830.0,3/25/2021 2:57:21 PM,Bristol-Myers’ win in melanoma described as ‘important' sparking gains in related stocks,Seeking Alpha,https://seekingalpha.com/news/3676307-bristol-myers-win-in-melanoma-described-as-important-sparking-gains-in-related-stocks?utm_source=markets.businessinsider.com&utm_medium=referral
831.0,3/25/2021 4:58:33 PM,IMMP Stock: Why Is Biotech Company Immutep Rocketing Higher Today?,InvestorPlace,/news/stocks/immp-stock-why-is-biotech-company-immutep-rocketing-higher-today-1030247058
832.0,3/25/2021 5:22:47 PM,"Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday",Benzinga,/news/stocks/why-cellect-immutep-f-star-proqr-and-evofem-are-moving-thursday-1030246880
833.0,3/27/2021 3:40:18 AM,Bristol Myers and Bluebird bio win FDA approval for ide-cel in multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3677011-bristol-myers-and-bluebird-bio-wins-fda-approval-for-ide-cel-in-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral
834.0,3/27/2021 6:09:12 AM,Biotech Stocks Facing FDA Decision In April 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-2021-1030251629
835.0,3/27/2021 3:40:07 PM,"The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-28-april-3-acadia-s-dementia-drug-update-clinical-readouts-few-earnings-in-holiday-shortened-week-1030251902
836.0,3/29/2021 2:01:21 PM,FDA Approves First Cell-Based Gene Therapy For Adult Multiple Myeloma Patients ,RTTNews,/news/stocks/fda-approves-first-cell-based-gene-therapy-for-adult-multiple-myeloma-patients-1030254249
837.0,3/29/2021 3:46:27 PM,"Why Humanigen, uniQure, bluebird bio, Amphastar Are Rallying Monday",Benzinga,/news/stocks/why-humanigen-uniqure-bluebird-bio-amphastar-are-rallying-monday-1030254941
838.0,3/30/2021 12:23:54 PM,Bristol-Myers Squibb and Huyabio partner for Opdivo combo,Seeking Alpha,https://seekingalpha.com/news/3677535-bristol-myers-squibb-and-huyabio-partner-for-opdivo-combo?utm_source=markets.businessinsider.com&utm_medium=referral
839.0,3/31/2021 1:41:12 PM,"The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-vaccine-100-effective-in-adolescents-equillium-readout-amgen-goes-shopping-achilles-ipo-1030263061
840.0,4/2/2021 5:20:07 PM,IRS alleges Bristol-Myers Squibb owes more than $1B in taxes from offshore scheme - NYT,Seeking Alpha,https://seekingalpha.com/news/3678983-irs-alleges-bristol-myers-squibb-owes-more-than-1b-in-taxes-from-offshore-scheme-nyt?utm_source=markets.businessinsider.com&utm_medium=referral
841.0,4/5/2021 6:29:38 PM,7 Stocks That Could Double by Summer,InvestorPlace,/news/stocks/7-stocks-that-could-double-by-summer-1030274749
842.0,4/8/2021 12:15:35 PM,The 7 Best Startups You Can Buy on StartEngine Right Now,InvestorPlace,/news/stocks/the-7-best-equity-crowdfunding-startups-you-can-buy-on-startengine-right-now-1029812989
843.0,4/8/2021 12:29:05 PM,IMMP Stock: The Big Patent News Boosting Immutep Today,InvestorPlace,/news/stocks/immp-stock-the-big-patent-news-boosting-immutep-today-1030286138
844.0,4/8/2021 2:14:49 PM,"The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data",Benzinga,/news/stocks/the-daily-biotech-pulse-immutep-extends-run-fda-nod-for-gilead-merck-bristol-myers-squibb-release-late-stage-cancer-immunotherapy-data-1030285466
845.0,4/9/2021 5:25:37 PM,Sanofi confirms partial response for cancer therapy in mid-stage study,Seeking Alpha,https://seekingalpha.com/news/3680754-sanofi-confirms-partial-response-for-cancer-therapy-in-mid-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral
846.0,4/10/2021 6:11:55 PM,Bristol Myers unveils positive data for Opdivo in late-stage lung cancer study,Seeking Alpha,https://seekingalpha.com/news/3680844-bristol-myers-unveils-positive-data-for-opdivo-in-late-stage-lung-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral
847.0,4/13/2021 12:58:17 PM,"IRhythm extends losses as more downgrades pile up, Aphria cut to neutral after earnings miss; and more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3681313-irhythm-extends-losses-as-more-downgrades-pile-up-aphria-cut-to-neutral?utm_source=markets.businessinsider.com&utm_medium=referral
848.0,4/13/2021 4:05:53 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-13-2021-1030299179
849.0,4/13/2021 4:27:08 PM,Bristol-Myers raised to buy at Truist on pipeline strength,Seeking Alpha,https://seekingalpha.com/news/3681434-bristol-myers-raised-to-buy-at-truist-on-pipeline-strength?utm_source=markets.businessinsider.com&utm_medium=referral
850.0,4/13/2021 6:03:06 PM,Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline,Benzinga,/news/stocks/why-this-bristol-myers-squibb-stock-analyst-is-turning-bullish-on-the-pharma-company-s-pipeline-1030299606
851.0,4/14/2021 11:25:26 PM,Bristol Myers' Nivolumab Approved By EU For Kidney Cancer Treatment ,RTTNews,/news/stocks/bristol-myers-nivolumab-approved-by-eu-for-kidney-cancer-treatment-1030305573
852.0,4/15/2021 1:49:24 PM,"The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-shelves-2-covid-19-studies-bristol-myers-squibb-gets-european-regulatory-nod-inspiremd-s-reverse-split-1030307762
853.0,4/16/2021 5:09:17 PM,FDA approves Bristol's Opdivo as first-line gastric cancer treatment,Seeking Alpha,https://seekingalpha.com/news/3682658-fda-approves-bristol-myers-squibb-opdivo-as-first-line-gastric-cancer-treatment?utm_source=markets.businessinsider.com&utm_medium=referral
854.0,4/18/2021 1:18:56 AM,AACR 2021 highlights Eli Lilly’s new KRAS battle; Affimed’s Natural Killer cell therapy,Seeking Alpha,https://seekingalpha.com/news/3682763-eli-lillys-kras-battle-affimeds-new-cell-therapy-graced-aacr-2021?utm_source=markets.businessinsider.com&utm_medium=referral
855.0,4/19/2021 12:35:28 PM,First FDA-approved Immunotherapy For First Treatment Of Gastric Cancer ,RTTNews,/news/stocks/first-fda-approved-immunotherapy-for-first-treatment-of-gastric-cancer-1030316894
856.0,4/20/2021 2:06:58 PM,"The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex",Benzinga,/news/stocks/the-daily-biotech-pulse-q1-beat-from-johnson-johnson-kalvista-study-placed-on-hold-european-label-expansion-for-gw-pharma-s-epidiolex-1030322640
857.0,4/21/2021 12:25:25 PM,"Intuitive Surgical upgraded after earnings beat; Oppenheimer sizes up new Vertex – CRISPR deal, and more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3683885-intuitive-surgical-upgraded-after-earnings-beat-oppenheimer-sizes-up-new-vertex-crispr-deal?utm_source=markets.businessinsider.com&utm_medium=referral
858.0,4/22/2021 7:47:21 PM,House Democrats reintroduce bill to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3684755-house-democrats-reintroduce-bill-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral
859.0,4/23/2021 11:03:22 AM,Bristol Myers' Opdivo + Yervoy gets positive CHMP opinion for malignant pleural mesothelioma,Seeking Alpha,https://seekingalpha.com/news/3685006-bristol-myers-opdivo-yervoy-gets-positive-chmp-opinion-for-malignant-pleural-mesothelioma?utm_source=markets.businessinsider.com&utm_medium=referral
860.0,4/23/2021 11:03:32 AM,"Accelerated approvals for cancer therapies from Merck, Bristol-Myers and Roche to come under FDA review next week",Seeking Alpha,https://seekingalpha.com/news/3685007-merck-bristol-myers-and-roche-cancer-therapies-to-come-under-fda-review-next-week?utm_source=markets.businessinsider.com&utm_medium=referral
861.0,4/23/2021 1:07:27 PM,Bristol Myers Gets Positive CHMP Opinion For Opdivo Plus Yervoy As First-Line Treatment For MPM ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-opdivo-plus-yervoy-as-first-line-treatment-for-mpm-1030338208
862.0,4/24/2021 3:24:00 PM,"The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-25-may-1-fda-decisions-for-sol-gel-protalix-bio-ardelyx-1030340692
863.0,4/27/2021 3:02:23 PM,Bristol-Myers Squibb is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-quarter-earnings-preview-q1-1030351680
864.0,4/27/2021 5:31:39 PM,4 Up-and-Coming Stocks to Buy in Shifting Sectors,InvestorPlace,/news/stocks/4-up-and-coming-stocks-to-buy-in-shifting-sectors-1030353596
865.0,4/28/2021 2:29:03 PM,7 Pharmaceutical Stocks With Dividends in Hand,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-dividends-in-hand-1030359387
866.0,4/29/2021 10:00:37 AM,7 Pharmaceutical Stocks To Buy For Valuation Plus Solid Dividends,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-to-buy-for-valuation-plus-solid-dividends-1030363716
867.0,4/29/2021 11:53:58 AM,Bristol Myers slips 3% as Q1 trails estimates; GAAP EPS guidance raised,Seeking Alpha,https://seekingalpha.com/news/3687774-bristol-myers-slips-3-as-q1-trails-estimates-gaap-eps-guidance-raised?utm_source=markets.businessinsider.com&utm_medium=referral
868.0,4/29/2021 1:40:50 PM,Bristol Myers Squibb Q1 Profit Misses Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-q1-profit-misses-estimates-1030364329
869.0,4/29/2021 2:15:50 PM,"The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx",Benzinga,/news/stocks/the-daily-biotech-pulse-clinical-setback-for-adverum-galera-posts-data-readout-moderna-to-invest-in-vaccine-manufacturing-decision-day-for-ardelyx-1030364740
870.0,4/30/2021 11:44:50 AM,FDA accepts Bristol Myers' Opdivo sBLA for priority review,Seeking Alpha,https://seekingalpha.com/news/3688578-fda-accepts-bristol-myers-opdivo-sbla-for-priority-review?utm_source=markets.businessinsider.com&utm_medium=referral
871.0,4/30/2021 12:29:16 PM,FDA panel denies support for maintaining Bristol's Opdivo as liver cancer treatment,Seeking Alpha,https://seekingalpha.com/news/3688609-fda-panel-denies-support-for-maintaining-bristol-opdivo-as-liver-cancer-treatment?utm_source=markets.businessinsider.com&utm_medium=referral
872.0,4/30/2021 1:25:49 PM,"Bristol-Myers cut to neutral, Community Health upgraded in today's healthcare analyst action",Seeking Alpha,https://seekingalpha.com/news/3688674-bristol-myers-cut-to-neutral-at-morgan-stanly-community-health-upgraded-after-q1-results?utm_source=markets.businessinsider.com&utm_medium=referral
873.0,4/30/2021 1:31:19 PM,"The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-hyperphosphatemia-drug-regulatory-review-extended-phathom-pharma-data-readout-2-ipos-1030369950
874.0,4/30/2021 3:26:18 PM,Bristol-Myers downgraded at Morgan Stanley citing uncertainty over pipeline,Seeking Alpha,https://seekingalpha.com/news/3688742-bristol-myers-downgraded-at-morgan-stanley-citing-uncertainty-over-pipeline?utm_source=markets.businessinsider.com&utm_medium=referral
875.0,4/30/2021 4:04:14 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 30, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-30-2021-1030370728
876.0,5/1/2021 5:43:35 PM,Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-may-pdufa-dates-1030373547
877.0,5/4/2021 3:40:26 PM,Shares of major drug makers in focus as House committees hold hearings on drug pricing bill,Seeking Alpha,https://seekingalpha.com/news/3690229-shares-of-major-drug-makers-in-focus-as-house-committees-hold-hearings-on-drug-pricing-bill?utm_source=markets.businessinsider.com&utm_medium=referral
878.0,5/8/2021 2:25:37 PM,Payrolls shock doesn't mean inflation reprieve; Here's a way to position: Alpha Tactics,Seeking Alpha,https://seekingalpha.com/news/3693599-payrolls-shock-doesnt-mean-inflation-reprieve-heres-a-way-to-position-alpha-tactics?utm_source=markets.businessinsider.com&utm_medium=referral
879.0,5/12/2021 3:18:26 PM,Why These 3 Top Stocks Are Better Buys Than Dogecoin,InvestorPlace,/news/stocks/why-these-3-top-stocks-are-better-buys-than-dogecoin-1030422217
880.0,5/12/2021 4:37:14 PM,Bristol presenting slew of Opdivo + Yervoy data at ASCO next month,Seeking Alpha,https://seekingalpha.com/news/3695373-bristol-presenting-slew-of-opdivo-yervoy-data-at-asco-next-month?utm_source=markets.businessinsider.com&utm_medium=referral
881.0,5/14/2021 7:04:33 AM,Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day,Benzinga,/news/stocks/cathie-wood-sheds-33-6m-alibaba-shares-on-earnings-day-1030429592
882.0,5/14/2021 2:25:03 PM,7 Reddit Penny Stocks Promising to Cure Cancer,InvestorPlace,/news/stocks/7-reddit-penny-stocks-promising-cure-cancer-1030431464
883.0,5/14/2021 7:30:08 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3696746-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
884.0,5/15/2021 3:48:59 PM,"The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off",Benzinga,/news/stocks/the-week-ahead-in-biotech-sanofi-bristol-myers-squibb-await-fda-decisions-earnings-news-flow-tapers-off-1030432632
885.0,5/16/2021 2:12:54 AM,Bristol Myers’ mavacamten improves health status in patients with obstructive hypertrophic cardiomyopathy,Seeking Alpha,https://seekingalpha.com/news/3696875-bristol-myers-mavacamten-improves-patients-with-obstructive-hypertrophic-cardiomyopathy?utm_source=markets.businessinsider.com&utm_medium=referral
886.0,5/17/2021 6:35:57 PM,"Wedgewood takes new position in ODFL, trims Apple, Visa adds Progressive",Seeking Alpha,https://seekingalpha.com/news/3697303-wedgewood-takes-new-position-in-odfl-trims-apple-visa-adds-progressive?utm_source=markets.businessinsider.com&utm_medium=referral
887.0,5/18/2021 7:20:45 AM,Cathie Wood Cuts Apple Stake Almost Entirely — And Buys More Coinbase,Benzinga,/news/stocks/cathie-wood-cuts-apple-stake-almost-entirely-—-and-buys-more-coinbase-1030439382
888.0,5/18/2021 11:43:46 AM,Bristol Myers Squibb and Agenus ink exclusive global license for antibody program,Seeking Alpha,https://seekingalpha.com/news/3697662-bristol-myers-squibb-and-agenus-ink-exclusive-global-license-for-antibody-program?utm_source=markets.businessinsider.com&utm_medium=referral
889.0,5/18/2021 2:12:49 PM,"Agenus Grants Bristol Myers Squibb License To Bispecific Antibody Program, AGEN1777 - Quick Facts ",RTTNews,/news/stocks/agenus-grants-bristol-myers-squibb-license-to-bispecific-antibody-program-agen1777-quick-facts-1030441057
890.0,5/18/2021 3:16:15 PM,Bristol Myers Inks $1.6B Licensing Agreement For Agenus' Bispecific Antibody Program In Solid Tumors,Benzinga,/news/stocks/bristol-myers-inks-1-6b-licensing-agreement-for-agenus-bispecific-antibody-program-in-solid-tumors-1030441819
891.0,5/18/2021 6:39:22 PM,"Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",Benzinga,/news/stocks/q1-13f-roundup-how-buffett-einhorn-ackman-and-others-adjusted-their-portfolios-1030442901
892.0,5/19/2021 10:35:54 AM,Bristol-Myers and Exscientia team up for an AI-driven approach to drug discovery,Seeking Alpha,https://seekingalpha.com/news/3698099-bristol-myers-and-exscientia-team-up-for-an-ai-driven-approach-to-drug-discovery?utm_source=markets.businessinsider.com&utm_medium=referral
893.0,5/19/2021 1:30:16 PM,"The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics",Benzinga,/news/stocks/the-daily-biotech-pulse-iovance-to-delay-regulatory-filing-for-cancer-therapy-departures-at-passage-bio-positive-readout-for-silence-therapeutics-1030445806
894.0,5/19/2021 9:45:01 PM,Bristol's Opdivo + relatlimab combo beats Opdivo alone in melanoma trial,Seeking Alpha,https://seekingalpha.com/news/3698472-bristol-opdivo-relatlimab-combo-beats-opdivo-alone-in-melanoma-trial?utm_source=markets.businessinsider.com&utm_medium=referral
895.0,5/20/2021 2:27:03 PM,"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-biontech-covid-19-order-flow-abounds-voyager-ceo-cmo-to-depart-decision-day-for-bristol-myers-squibb-asco-abstracts-move-stocks-1030450798
896.0,5/20/2021 4:29:42 PM,7 Value Stocks With at Least 50% Upside,InvestorPlace,/news/stocks/seven-value-stocks-with-at-least-fifty-percent-upside-1030452547
897.0,5/20/2021 5:48:09 PM,Bristol hits 52-week high following release of ASCO abstracts,Seeking Alpha,https://seekingalpha.com/news/3698807-bristol-hits-52-week-high-following-release-of-asco-abstracts?utm_source=markets.businessinsider.com&utm_medium=referral
898.0,5/21/2021 7:30:52 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3699216-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
899.0,5/21/2021 8:35:43 PM,Bristol Myers wins positive opinion in Europe for Opdivo and Yervoy combo for colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3699260-bristol-myers-wins-positive-opinion-in-europe-for-opdivo-and-yervoy-combo-for-colorectal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
900.0,5/24/2021 10:00:31 AM,Bristol releases positive new data on ulcerative colitis candidate Zeposia,Seeking Alpha,https://seekingalpha.com/news/3699309-bristol-releases-positive-new-data-on-ulcerative-colitis-candidate-zeposia?utm_source=markets.businessinsider.com&utm_medium=referral
901.0,5/24/2021 2:00:02 PM,CAR T therapy competition heats up as Allogene plans pivotal trial,Seeking Alpha,https://seekingalpha.com/news/3699437-car-t-therapy-competition-heats-up-as-allogene-plans-pivotal-trial?utm_source=markets.businessinsider.com&utm_medium=referral
902.0,5/25/2021 12:35:24 PM,Xencor and Bristol Myers Squibb ink technology license agreement,Seeking Alpha,https://seekingalpha.com/news/3699812-xencor-and-bristol-myers-squibb-ink-technology-license-agreement?utm_source=markets.businessinsider.com&utm_medium=referral
903.0,5/25/2021 1:53:39 PM,"The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-in-vaccine-supply-talks-with-india-provention-in-focus-ahead-of-briefing-doc-neurorx-to-list-via-spac-deal-1030461990
904.0,5/25/2021 2:33:06 PM,"Xencor, Bristol Myers Ink License Deal To Use Xtend XmAb Technology To Treat COVID-19 - Quick Facts ",RTTNews,/news/stocks/xencor-bristol-myers-ink-license-deal-to-use-xtend-xmab-technology-to-treat-covid-19-quick-facts-1030462328
905.0,5/27/2021 8:09:10 PM,Phase 2 trials begin of OSE's vaccine with Bristol's Opdivo in NSCLC,Seeking Alpha,https://seekingalpha.com/news/3700956-phase-2-trials-begins-of-oses-vaccine-with-bristols-opdivo-in-nsclc?utm_source=markets.businessinsider.com&utm_medium=referral
906.0,5/27/2021 8:28:59 PM,Bristol Myers wins FDA approval for expanded use of Zeposia in ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3700996-bristol-myers-wins-fda-approval-for-expanded-use-of-zeposia-in-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral
907.0,5/28/2021 2:02:01 PM,"The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq",Benzinga,/news/stocks/the-daily-biotech-pulse-biohaven-bristol-myers-squibb-snag-fda-approvals-iterum-uti-drug-review-on-track-centessa-pharmaceuticals-debuts-on-nasdaq-1030475070
908.0,5/28/2021 7:00:20 PM,Amgen's Lumakras can target 13% of the NSCLC market,Seeking Alpha,https://seekingalpha.com/news/3701338-amgen-mirati-lumakras-can-target-13-of-the-nsclc-market?utm_source=markets.businessinsider.com&utm_medium=referral
909.0,5/31/2021 5:06:35 PM,"The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes",Benzinga,/news/stocks/the-week-ahead-in-biotech-asco-presentations-front-and-center-fda-decisions-due-for-scynexis-liminal-and-alkermes-1030479173
910.0,6/1/2021 3:34:46 PM,BTIG's best and worst stocks for Operation Grand Slam,Seeking Alpha,https://seekingalpha.com/news/3701738-btigs-best-and-worst-stocks-for-operation-grand-slam?utm_source=markets.businessinsider.com&utm_medium=referral
911.0,6/2/2021 1:24:03 PM,EC Approves Bristol Myers' Opdivo Plus Yervoy To Treat Mesothelioma - Quick Facts ,RTTNews,/news/stocks/ec-approves-bristol-myers-opdivo-plus-yervoy-to-treat-mesothelioma-quick-facts-1030486584
912.0,6/2/2021 2:20:24 PM,"The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-novartis-irhythm-ceo-quits-abruptly-moderna-inks-vaccine-supply-agreements-1030486987
913.0,6/2/2021 2:21:09 PM,Health Canada Approves Bristol Myers' Opdivo Plus Yervoy To Treat Mesothelioma - Quick Facts ,RTTNews,/news/stocks/health-canada-approves-bristol-myers-opdivo-plus-yervoy-to-treat-mesothelioma-quick-facts-1030486996
914.0,6/3/2021 2:02:55 PM,Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics,Benzinga,/news/stocks/diversifying-to-conquer-fortress-biotech-fbio-partnering-expansion-driving-progress-in-cancer-immunotherapy-and-rare-disease-therapeutics-1030490924
915.0,6/3/2021 2:23:31 PM,"The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-completes-organon-spin-off-auris-repositions-as-rna-therapeutic-company-with-trasir-purchase-replimune-s-readout-1030491248
916.0,6/3/2021 4:15:41 PM,Bristol-Myers sued for $6.4 billion in alleged delay in seeking FDA approval for Celgene drug,Seeking Alpha,https://seekingalpha.com/news/3702981-bristol-myers-sued-for-64-billion-in-alleged-delay-in-seeking-fda-approval-for-celgene-drug?utm_source=markets.businessinsider.com&utm_medium=referral
917.0,6/4/2021 3:39:13 PM,"The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-astrazeneca-novartis-among-early-presenters-at-asco-sanofi-strikes-breast-cancer-study-pact-1030495387
918.0,6/7/2021 2:52:10 PM,"The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck",Benzinga,/news/stocks/the-week-ahead-in-biotech-biogen-alexion-and-vertex-fda-decisions-multiple-conference-presentations-on-the-deck-1030499585
919.0,6/8/2021 3:37:52 PM,5 Healthcare Stocks to Buy for Their Game-Changing Potential,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-for-their-game-changing-potential-1030504685
920.0,6/10/2021 11:21:12 AM,Bristol Myers announces positive topline data for Breyanzi in B-cell Lymphoma as second-line therapy,Seeking Alpha,https://seekingalpha.com/news/3704917-bristol-myers-announces-positive-topline-data-for-breyanzi-in-b-cell-lymphoma-as-second-line-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
921.0,6/10/2021 11:23:45 AM,Bristol Myers announces positive topline data for Breyanzi in B-cell Lymphoma as second-line therapy,Seeking Alpha,https://seekingalpha.com/news/3704923-bristol-myers-announces-positive-topline-data-for-breyanzi-in-b-cell-lymphoma-as-second-line-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
922.0,6/10/2021 1:59:24 PM,BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL ,RTTNews,/news/stocks/bmy-reports-positive-results-from-phase-3-breyanzi-trial-in-second-line-relapsed-or-refractory-lbcl-1030511321
923.0,6/10/2021 2:13:41 PM,"The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-us-to-procure-500m-pfizer-biontech-vaccine-doses-for-donation-verona-out-licenses-copd-drug-nautilus-lists-through-spac-deal-1030511571
924.0,6/11/2021 11:01:19 AM,"Bristol Myers, Acceleron's Reblozyl shows encouraging action in adults with beta thalassemia",Seeking Alpha,https://seekingalpha.com/news/3705553-bristol-myers-accelerons-reblozyl-shows-encouraging-action-in-adults-with-beta-thalassemia?utm_source=markets.businessinsider.com&utm_medium=referral
925.0,6/11/2021 11:43:09 AM,"BMY, Acceleron Announce New Data From Reblozyl Phase 2 Trial For Adults With NTD Beta Thalassemia ",RTTNews,/news/stocks/bmy-acceleron-announce-new-data-from-reblozyl-phase-2-trial-for-adults-with-ntd-beta-thalassemia-1030515035
926.0,6/14/2021 2:34:07 PM,"Exelixis, Bristol Myers To Evaluate XL092-Immuno-oncology Therapies In Advanced Solid Tumors ",RTTNews,/news/stocks/exelixis-bristol-myers-to-evaluate-xl092-immuno-oncology-therapies-in-advanced-solid-tumors-1030519727
927.0,6/16/2021 6:30:10 PM,"Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today",Benzinga,/news/stocks/why-kindred-biosciences-aprea-catabasis-and-inhibikase-are-moving-today-1030529318
928.0,6/17/2021 8:19:05 PM,Bristol-Myers Squibb Company declares $0.49 dividend,Seeking Alpha,https://seekingalpha.com/news/3707463-bristol-myers-squibb-company-declares-0_49-dividend?utm_source=markets.businessinsider.com&utm_medium=referral
929.0,6/18/2021 5:15:35 AM,Bristol Myers Enters Into Collaboration For Eisai's MORAb-202 Antibody Drug Conjugate ,RTTNews,/news/stocks/bristol-myers-enters-into-collaboration-for-eisai-s-morab-202-antibody-drug-conjugate-1030534186
930.0,6/18/2021 11:17:21 AM,Bristol Myers to pay more than $2 billion to Eisai in a deal for experimental cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3707580-bristol-myers-to-pay-more-than-2-billion-to-eisai-in-a-deal-for-experimental-cancer-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
931.0,6/18/2021 1:46:03 PM,"The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-orphazyme-falters-at-fda-athira-s-ceo-placed-on-temporary-leave-5-ipos-1030535179
932.0,6/18/2021 2:10:31 PM,Could Bristol's up to $3B Eisai deal follow in footsteps of 2019 AstraZeneca deal with Daiichi?,Seeking Alpha,https://seekingalpha.com/news/3707684-could-bristol-up-to-3b-eisai-deal-follow-in-footsteps-of-2019-astrazeneca-deal-with-daiichi?utm_source=markets.businessinsider.com&utm_medium=referral
933.0,6/18/2021 3:59:06 PM,Bristol's up to $3B deal with Eisai puts antibody drug conjugates in the spotlight,Seeking Alpha,https://seekingalpha.com/news/3707699-bristols-up-to-3b-deal-with-eisai-puts-antibody-drug-conjugates-in-the-spotlight?utm_source=markets.businessinsider.com&utm_medium=referral
934.0,6/22/2021 3:12:00 PM,Sen. Wyden releases 'principles for drug pricing reform',Seeking Alpha,https://seekingalpha.com/news/3708721-sen-wyden-releases-principles-for-drug-price-reform?utm_source=markets.businessinsider.com&utm_medium=referral
935.0,6/23/2021 6:44:55 PM,14 Biotech Stocks To Watch Over The Next 6 Months,Benzinga,/news/stocks/14-biotech-stocks-to-watch-over-the-next-6-months-1030548271
936.0,6/24/2021 12:55:16 PM,Prothena secures $80M from Bristol Myers for US license to PRX005,Seeking Alpha,https://seekingalpha.com/news/3709538-prothena-secures-80m-from-bristol-myers-for-us-license-to-prx005?utm_source=markets.businessinsider.com&utm_medium=referral
937.0,6/24/2021 2:59:21 PM,Prothena To Receive $80 Mln From Bristol Myers For US License To PRX005 On Alzheimer's Disease ,RTTNews,/news/stocks/prothena-to-receive-80-mln-from-bristol-myers-for-us-license-to-prx005-on-alzheimer-s-disease-1030551183
938.0,6/25/2021 11:33:44 AM,Bristol Myers wins positive CHMP opinion for Abecma in multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3710061-bristol-myers-wins-positive-chmp-opinion-for-abecma-in-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral
939.0,6/25/2021 11:40:28 AM,Bristol Myers wins positive CHMP opinion for Opdivo in esophageal cancer,Seeking Alpha,https://seekingalpha.com/news/3710065-bristol-myers-wins-positive-chmp-opinion-for-opdivo-in-esophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
940.0,6/25/2021 1:32:32 PM,"The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-roche-gets-authorization-for-covid-19-treatment-nods-for-sanofi-regeneron-in-europe-osmotica-divestment-2-ipos-1030554577
941.0,6/25/2021 1:40:07 PM,Bristol Myers Gets Positive CHMP Opinion For Opdivo To Treat Esophageal Cancer ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-opdivo-to-treat-esophageal-cancer-1030554603
942.0,6/25/2021 1:47:23 PM,Bristol Myers Gets Positive CHMP Opinion For Abecma On Relapsed & Refractory Multiple Myeloma ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-abecma-on-relapsed-refractory-multiple-myeloma-1030554633
943.0,6/28/2021 6:52:51 PM,"Bristol-Myers likely to settle lawsuit related to CVR for Celgene drug potentially for $3B-$4B, analyst says",Seeking Alpha,https://seekingalpha.com/news/3710675-bristol-meyers-likely-to-settle-lawsuit-related-to-cvr-for-celgene-drug-potentially-for-3b-4b-analyst-says?utm_source=markets.businessinsider.com&utm_medium=referral
944.0,6/28/2021 7:28:07 PM,"Bristol-Myers likely to settle lawsuit related to Celgene drug CVR, analyst says",Seeking Alpha,https://seekingalpha.com/news/3710675-bristol-myers-likely-to-settle-lawsuit-related-to-cvr-for-celgene-drug-potentially-for-3b-4b-analyst-says?utm_source=markets.businessinsider.com&utm_medium=referral
945.0,6/29/2021 11:19:02 AM,Bristol Myers' Opdivo + Yervoy combo OK'd in Europe for colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3710849-bristol-myers-opdivo-yervoy-combo-okd-in-europe-for-colorectal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
946.0,6/29/2021 1:38:19 PM,EC Approves Bristol Myers' Opdivo - Yervoy For Mismatch Repair Deficient Treatment ,RTTNews,/news/stocks/ec-approves-bristol-myers-opdivo-yervoy-for-mismatch-repair-deficient-treatment-1030562314
947.0,6/29/2021 1:55:35 PM,"Sensei downgraded, PT cut on program discontinuation, Gilead's Yescarta data, and more in analyst action",Seeking Alpha,https://seekingalpha.com/news/3710900-sensei-downgraded-price-target-cut-on-program-discontinuation-gileads-yescarta-data-and-more-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
948.0,6/30/2021 1:10:30 PM,Dosing underway in Compugen's COM701/Opdivo Phase 1b cohort expansion study,Seeking Alpha,https://seekingalpha.com/news/3711352-dosing-underway-in-compugens-com701opdivo-phase-1b-cohort-expansion-study?utm_source=markets.businessinsider.com&utm_medium=referral
949.0,7/1/2021 6:50:48 PM,Eisai and Lilly among top H1 gainers in big pharma; Viatris and Merck trail,Seeking Alpha,https://seekingalpha.com/news/3712052-eisai-and-lilly-among-top-h1-gainers-in-big-pharma-as-viatris-and-merck-trail?utm_source=markets.businessinsider.com&utm_medium=referral
950.0,7/6/2021 3:40:59 PM,Agenus receives $200M payment as part of agreement with Bristol-Myers Squibb,Seeking Alpha,https://seekingalpha.com/news/3712982-agenus-receives-200m-payment-as-part-of-agreement-with-bristol-myers-squibb?utm_source=markets.businessinsider.com&utm_medium=referral
951.0,7/7/2021 10:49:38 AM,Mid-size pharmaceutical firms lead bigger rivals in acquisitions this year,Seeking Alpha,https://seekingalpha.com/news/3713185-mid-size-pharmaceutical-firms-lead-bigger-rivals-in-acquisitions-this-year?utm_source=markets.businessinsider.com&utm_medium=referral
952.0,7/8/2021 4:00:00 PM,"After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold",Benzinga,/news/stocks/after-second-look-oncopeptides-melflufen-wins-head-to-head-myeloma-trial-but-difference-in-os-triggers-fda-hold-1030590169
953.0,7/8/2021 4:27:00 PM,Stay Away From Low-Growth Organon,InvestorPlace,/news/stocks/low-growth-weak-catalysts-ogn-stock-unattractive-1030590811
954.0,7/15/2021 12:38:46 PM,"XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences",Benzinga,/news/stocks/xoma-buys-royalty-milestone-interest-in-checkmate-s-vidutolimod-from-kuros-biosciences-1030610392
955.0,7/15/2021 2:07:56 PM,"The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-galapagos-sinks-on-data-j-j-recalls-sunscreen-products-fibrogen-awaits-adcom-verdict-3-ipos-1030610817
956.0,7/16/2021 11:46:00 AM,Bristol-Myers Squibb's Opdivo combo fails to meet main goals in late-stage cancer trial,Seeking Alpha,https://seekingalpha.com/news/3715897-bristol-myers-squibbs-opdivo-combo-fails-to-meet-main-goals-in-late-stage-cancer-trial?utm_source=markets.businessinsider.com&utm_medium=referral
957.0,7/16/2021 1:37:29 PM,"The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-to-join-s-p-500-index-thumbs-down-for-fibrogen-s-anemia-drug-corvus-shelves-covid-study-1030614895
958.0,7/16/2021 1:56:15 PM,Bristol Myer : Phase 3 Trial On Head & Neck Cancer Fails To Meet Primary Endpoints ,RTTNews,/news/stocks/bristol-myer-phase-3-trial-on-head-neck-cancer-fails-to-meet-primary-endpoints-1030614936
959.0,7/16/2021 4:29:34 PM,Bristol-Myers Squibb settles Spycel patent cases with Dr. Reddy's and Lupin,Seeking Alpha,https://seekingalpha.com/news/3716040-bristol-myers-squibb-settles-spycel-patent-cases-with-dr-reddys-and-lupin?utm_source=markets.businessinsider.com&utm_medium=referral
960.0,7/19/2021 5:26:39 PM,Cytokinetics extends gains as Needham lifts target on trial results for heart disease therapy,Seeking Alpha,https://seekingalpha.com/news/3716483-cytokinetics-extends-gains-as-needham-lifts-target-on-trial-results-for-heart-disease-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
961.0,7/19/2021 8:32:34 PM,Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data,Benzinga,/news/stocks/analysts-see-higher-success-chances-for-cytokinetics-heart-disease-candidate-after-positive-phase-2-data-1030621590
962.0,7/23/2021 1:45:07 PM,"The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-acorda-spikes-on-distribution-deal-alzamend-soars-on-data-pfizer-biontech-to-supply-more-vaccine-doses-3-ipos-1030638740
963.0,7/25/2021 3:26:31 PM,"The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More",Benzinga,/news/stocks/the-week-ahead-in-biotech-july-25-31-big-pharma-earnings-iterum-fda-decision-alzheimer-s-conference-ipos-and-more-1030641744
964.0,7/26/2021 12:25:29 AM,"Benzinga's Bulls And Bears Of The Week: Amazon, Apple, Bitcoin, GameStop, Netflix And More",Benzinga,/news/stocks/benzinga-s-bulls-and-bears-of-the-week-amazon-apple-bitcoin-gamestop-netflix-and-more-1030641885
965.0,7/26/2021 1:57:03 PM,Bristol Myers pulls Opdivo indication for post-Sorafenib hepatocellular carcinoma in U.S.,Seeking Alpha,https://seekingalpha.com/news/3719042-bristol-myers-pulls-opdivo-indication-for-post-sorafenib-hepatocellular-carcinoma-in-us?utm_source=markets.businessinsider.com&utm_medium=referral
966.0,7/26/2021 3:01:46 PM,Here's what Wall Street expects from Bristol-Myers Squibb's earnings report,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q2-earnings-preview-stock-1030644802
967.0,7/27/2021 12:05:28 PM,BridgeBio and Bristol Myers ink deal to study Opdivo/BBP-398 combo in KRAS mutation cancers,Seeking Alpha,https://seekingalpha.com/news/3719567-bridgebio-and-bristol-myers-ink-deal-to-study-opdivobbp-398-combo-in-kras-mutation-cancers?utm_source=markets.businessinsider.com&utm_medium=referral
968.0,7/27/2021 12:43:54 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3719608-notable-earnings-before-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
969.0,7/27/2021 1:57:04 PM,"BridgeBio, Bristol Myers To Study BBP-398 In Combination With OPDIVO In Advanced Solid Tumors ",RTTNews,/news/stocks/bridgebio-bristol-myers-to-study-bbp-398-in-combination-with-opdivo-in-advanced-solid-tumors-1030649733
970.0,7/28/2021 11:00:13 AM,"Bristol Myers Squibb EPS beats by $0.03, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3720300-bristol-myers-squibb-eps-beats-0_03-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
971.0,7/28/2021 11:54:11 AM,Bristol Myers posts Q2 earnings beat on Opdivo Strength,Seeking Alpha,https://seekingalpha.com/news/3720379-bristol-myers-posts-q2-earnings-beat-on-opdivo-strength?utm_source=markets.businessinsider.com&utm_medium=referral
972.0,7/28/2021 1:41:09 PM,Bristol-Myers Squibb Reaffirms FY21 Adj. EPS Outlook - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-reaffirms-fy21-adj-eps-outlook-quick-facts-1030655923
973.0,7/28/2021 1:43:00 PM,Bristol-Myers Squibb Co. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q2-adjusted-earnings-beat-estimates-1030655922
974.0,7/30/2021 11:31:17 AM,Bristol Myers Squibb wins European approval for Opdivo in two GIT cancers,Seeking Alpha,https://seekingalpha.com/news/3722247-bristol-myers-squibb-wins-european-approval-for-opdivo-in-two-git-cancers?utm_source=markets.businessinsider.com&utm_medium=referral
975.0,7/30/2021 1:53:58 PM,"The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-erytech-jumps-on-fast-track-designation-glaxosmithkline-fda-nod-alnylam-s-clinical-collaboration-4-ipos-1030667906
976.0,7/30/2021 5:21:53 PM,Biogen: Does Aduhelm Make it the Next Dendreon?,InvestorPlace,/news/stocks/biib-stock-does-aduhelm-make-it-the-next-dendreon-1030669123
977.0,8/1/2021 4:13:48 PM,"The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-aug-1-7-biopharma-earnings-pick-up-pace-eton-awaits-fda-decision-focus-on-pending-clinical-readouts-and-ipos-1030671679
978.0,8/2/2021 9:50:15 PM,Bristol withdraws Istodax lymphoma indication after confirmatory trial fails,Seeking Alpha,https://seekingalpha.com/news/3723556-bristol-withdraws-istodax-lymphoma-indication-after-confirmatory-trial-fails?utm_source=markets.businessinsider.com&utm_medium=referral
979.0,8/3/2021 1:55:12 PM,"The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business",Benzinga,/news/stocks/the-daily-biotech-pulse-sanofi-buys-translate-bio-in-3-2b-deal-lilly-s-q2-earnings-disappoint-bausch-to-spin-off-medical-aesthetics-business-1030682672
980.0,8/3/2021 11:42:24 PM,'Fast Money Halftime Report' Picks For August 3,Benzinga,/news/stocks/fast-money-halftime-report-picks-for-august-3-1030685950
981.0,8/4/2021 1:52:10 PM,"The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-s-positive-readout-nrx-strikes-r-d-collaboration-with-mannkind-cerus-invitae-jump-on-earnings-1030688766
982.0,8/4/2021 4:04:19 PM,4 Stocks Insiders Are Selling,Benzinga,/news/stocks/4-stocks-insiders-are-selling-1030689983
983.0,8/5/2021 2:07:56 PM,"The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-reports-positive-keytruda-readout-moderna-slips-despite-q2-beat-bayer-to-buy-vividion-for-up-to-2b-glycomimetics-gets-new-ceo-1030695873
984.0,8/6/2021 1:42:39 PM,"The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-dicerna-slips-on-data-novavax-tightlipped-on-us-vaccine-approval-adagio-ipo-1030701132
985.0,8/6/2021 8:00:09 PM,Bioethicist Ezekiel Emanuel under consideration for FDA commissioner - Politico,Seeking Alpha,https://seekingalpha.com/news/3727179-bioethicist-ezekiel-emanuel-under-consideration-for-fda-commissioner-politico?utm_source=markets.businessinsider.com&utm_medium=referral
986.0,8/7/2021 6:34:16 PM,UBS highlights 20 top dividend stocks in tough times for yield: Alpha Tactics,Seeking Alpha,https://seekingalpha.com/news/3727237-ubs-highlights-top-divident-stocks-in-tough-times-for-yield?utm_source=markets.businessinsider.com&utm_medium=referral
987.0,8/10/2021 4:55:01 PM,Moderna's Stock Valuation Goes From 'Unreasonable To Ridiculous': Analyst,Benzinga,/news/stocks/moderna-s-stock-valuation-goes-from-unreasonable-to-ridiculous-analyst-1030714344
988.0,8/12/2021 10:00:53 AM,3 Best Biotech Stocks To Buy for Upcoming Catalysts,InvestorPlace,/news/stocks/3-best-biotech-stocks-to-buy-for-upcoming-catalysts-1030723346
989.0,8/12/2021 4:07:52 PM,CytoSorbents' Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag,Benzinga,/news/stocks/cytosorbents-antithrombotic-removal-system-scores-second-fda-breakthrough-device-tag-1030724927
990.0,8/16/2021 7:26:06 PM,Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization,Benzinga,/news/stocks/novavax-appoints-new-cfo-amid-inordinate-delay-in-covid-19-vaccine-authorization-1030735356
991.0,8/17/2021 2:28:53 PM,"The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-reorganizes-business-units-in-neuroscience-focus-helius-medical-spikes-on-breakthrough-designation-ra-medical-sells-dermatology-business-1030738023
992.0,8/17/2021 6:50:26 PM,"Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",Benzinga,/news/stocks/q2-13f-roundup-how-buffett-einhorn-ackman-and-others-adjusted-their-portfolios-1030739447
993.0,8/17/2021 7:04:09 PM,7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire,InvestorPlace,/news/stocks/7-buffett-stocks-to-buy-and-sell-if-you-want-to-be-like-berkshire-1030739695
994.0,8/20/2021 2:14:06 AM,Acting FDA head Woodcock ruled out as permanent nominee - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3732564-acting-fda-head-woodcock-ruled-out-as-permanent-nominee-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral
995.0,8/24/2021 2:09:21 PM,"The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-cara-s-korsuva-greenlighted-by-fda-clinical-trial-disappointments-for-novartis-theravance-vertex-inks-crispr-licensing-deal-1030754775
996.0,8/27/2021 1:35:25 PM,"The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration",Benzinga,/news/stocks/the-daily-biotech-pulse-morphosys-incyte-snag-european-nod-immutep-granted-chinese-patent-bolt-biotherapeutics-strike-oncology-collaboration-1030763431
997.0,8/31/2021 5:06:03 PM,4 Specialized AI Stocks to Buy for the Boom,InvestorPlace,/news/stocks/4-specialized-ai-stocks-to-buy-for-the-boom-1030770860
998.0,9/2/2021 7:59:28 AM,Evotec Says Bristol Myers Squibb Exercises Option To Enter Global License For EVT8683 ,RTTNews,/news/stocks/evotec-says-bristol-myers-squibb-exercises-option-to-enter-global-license-for-evt8683-1030775347
999.0,9/2/2021 2:19:58 PM,"The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab",Benzinga,/news/stocks/the-daily-biotech-pulse-assembly-bio-halts-hbv-study-moderna-initiates-submission-for-covid-19-booster-dose-fda-nod-for-beigene-tiziana-out-licenses-foralumab-1030776427
1000.0,9/3/2021 6:50:43 PM,Wall Street Crime And Punishment: Martha Stewart's Perfectly Ridiculous Stock Scandal,Benzinga,/news/stocks/wall-street-crime-and-punishment-martha-stewart-s-perfectly-ridiculous-stock-scandal-1030780207
1001.0,9/5/2021 7:14:08 PM,The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week,Benzinga,/news/stocks/the-week-ahead-in-biotech-sept-5-11-focus-on-conferences-and-clinical-readouts-in-another-quiet-week-1030781044
1002.0,9/8/2021 1:32:08 PM,"The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod",Benzinga,/news/stocks/the-daily-biotech-pulse-macrogenics-clinical-trial-disappointment-sanofi-to-buy-kadmon-alector-loses-2-key-executives-adma-s-fda-nod-1030786678
1003.0,9/10/2021 10:30:38 AM,7 Stocks To Buy To Bet on Underappreciated CEOs,InvestorPlace,/news/stocks/7-stocks-to-buy-to-bet-on-underappreciated-ceos-1030792285
1004.0,9/13/2021 5:31:10 PM,7 Stocks to Buy if the Market Crashes in September,InvestorPlace,/news/stocks/7-stocks-to-buy-if-the-market-crashes-in-september-1030796461
1005.0,9/15/2021 8:23:34 PM,Narrower drug pricing bill introduced in House by centrist Democrats,Seeking Alpha,https://seekingalpha.com/news/3740127-narrower-drug-pricing-bill-introduced-in-house-by-centrist-democrats?utm_source=markets.businessinsider.com&utm_medium=referral
1006.0,9/15/2021 9:20:09 PM,House committee approves portion of spending package that includes drug price negotiation,Seeking Alpha,https://seekingalpha.com/news/3740192-house-committee-approves-portion-of-spending-package-that-includes-drug-price-negotiation?utm_source=markets.businessinsider.com&utm_medium=referral
1007.0,9/16/2021 10:19:48 AM,Exelixis/Bristol Myers report new exploratory data for Cabometyx + Opdivo in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3740291-exelixisbristol-myers-report-new-exploratory-data-for-cabometyx-opdivo-in-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1008.0,9/16/2021 11:30:02 AM,7 Stocks to Buy to Invest Like Jim Cramer,InvestorPlace,/news/stocks/7-stocks-to-buy-to-invest-like-jim-cramer-1030804231
1009.0,9/17/2021 2:32:49 PM,Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer,Benzinga,/news/stocks/gritstone-presents-data-from-individualized-neoantigen-immunotherapy-in-colorectal-cancer-1030807151
1010.0,9/17/2021 2:41:12 PM,"Gritstone Unveils ""Off-The-Shelf"" Neoantigen Immunotherapy Data In Lung Cancer",Benzinga,/news/stocks/gritstone-unveils-off-the-shelf-neoantigen-immunotherapy-data-in-lung-cancer-1030807189
1011.0,9/19/2021 3:46:51 PM,"The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-sept-19-25-incyte-verrica-fda-decisions-and-conference-presentations-in-the-spotlight-1030808489
1012.0,9/20/2021 2:24:00 PM,Bristol Myers Reports FDA Priority Review For Relatlimab And Nivolumab Combination ,RTTNews,/news/stocks/bristol-myers-reports-fda-priority-review-for-relatlimab-and-nivolumab-combination-1030809791
1013.0,9/22/2021 1:01:09 PM,3 Cheap Healthcare Stocks to Buy Right Now,InvestorPlace,/news/stocks/3-cheap-healthcare-stocks-to-buy-right-now-1030815956
1014.0,9/27/2021 2:22:45 PM,"Bristol Myers: FDA Accepts SBLA For Opdivo Plus Yervoy, Opdivo Plus Chemotherapy In ESCC Patients ",RTTNews,/news/stocks/bristol-myers-fda-accepts-sbla-for-opdivo-plus-yervoy-opdivo-plus-chemotherapy-in-escc-patients-1030825490
1015.0,9/30/2021 4:20:02 PM,Acceleron downgraded by Piper Sandler on $11.5B Merck acquisition,Seeking Alpha,https://seekingalpha.com/news/3746658-acceleron-downgraded-by-piper-sandler-on-115b-merck-acquisition?utm_source=markets.businessinsider.com&utm_medium=referral
1016.0,9/30/2021 6:01:30 PM,House Judiciary Committee approves bill to expedite biosimilar drugs to market,Seeking Alpha,https://seekingalpha.com/news/3746703-house-judiciary-committee-approves-bill-to-expedite-biosimilar-drugs-to-market?utm_source=markets.businessinsider.com&utm_medium=referral
1017.0,10/1/2021 1:56:15 PM,"The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-rallies-on-antiviral-pill-data-gilead-files-for-yescarta-label-expansion-exscientia-ipo-1030836939
1018.0,10/7/2021 2:07:25 PM,Bristol Myers Squibb Says Its Phase 2 LATTICE-UC Study Did Not Meet Primary Objective ,RTTNews,/news/stocks/bristol-myers-squibb-says-its-phase-2-lattice-uc-study-did-not-meet-primary-objective-1030850067
1019.0,10/7/2021 2:23:53 PM,"The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-invests-in-africa-amgen-announces-neuroscience-r-d-collaboration-decision-day-for-chemocentryx-biophytis-to-restate-results-1030850125
1020.0,10/12/2021 1:15:38 PM,Agenus to receive $20M from Bristol Myers as dosing starts for AGEN1777 study,Seeking Alpha,https://seekingalpha.com/news/3751566-agenus-to-receive-20m-from-bristol-myers-as-dosing-starts-for-agen1777-study?utm_source=markets.businessinsider.com&utm_medium=referral
1021.0,10/12/2021 2:13:34 PM,"The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology",Benzinga,/news/stocks/the-daily-biotech-pulse-nrx-stitches-covid-19-drug-partnership-protara-gets-nod-for-starting-bladder-cancer-study-igm-moves-beyond-oncology-1030858924
1022.0,10/19/2021 6:51:54 AM,Dr. Reddy's Labs Announces FDA Approval For Lenalidomide Capsules - Quick Facts ,RTTNews,/news/stocks/dr-reddy-s-labs-announces-fda-approval-for-lenalidomide-capsules-quick-facts-1030875763
1023.0,10/19/2021 10:08:05 AM,FDA approves Dr. Reddy’s Laboratories' generic version of Revlimid,Seeking Alpha,https://seekingalpha.com/news/3754845-fda-approves-dr-reddys-laboratories-generic-version-of-revlimid?utm_source=markets.businessinsider.com&utm_medium=referral
1024.0,10/19/2021 2:23:01 PM,"The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio",Benzinga,/news/stocks/the-daily-biotech-pulse-entasis-dermata-spike-higher-on-positive-readouts-j-j-q3-eps-beats-estimates-wave-life-sciences-regains-right-to-cns-portfolio-1030877269
1025.0,10/19/2021 6:10:09 PM,Abbott Laboratories Q3 earnings preview and review,Seeking Alpha,https://seekingalpha.com/news/3755153-abbott-laboratories-q3-earnings-preview-and-review?utm_source=markets.businessinsider.com&utm_medium=referral
1026.0,10/21/2021 2:05:16 PM,"The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-authorizes-moderna-j-j-booster-shots-regulatory-approvals-for-bristol-myers-squibb-sanofi-regeneron-ventyx-ipo-1030885538
1027.0,10/24/2021 5:45:47 PM,"The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-24-30-eyenovia-ani-pharma-clearside-medical-fda-decisions-merck-bristol-myers-squibb-earnings-ipos-and-more-1030891741
1028.0,10/25/2021 12:30:12 PM,"Trump's SPAC Partner Emerges As Top WallStreetBets Interest; Facebook, Snapchat, Tesla And These Are Other Top Trends",Benzinga,/news/stocks/trump-s-spac-partner-emerges-as-top-wallstreetbets-interest-facebook-snapchat-tesla-and-these-are-other-top-trends-1030894092
1029.0,10/25/2021 3:02:03 PM,Here's what Wall Street expects from Bristol-Myers Squibb's earnings report,Markets Insider Automation,/news/stocks/bristol-myers_squibb-quarter-earnings-preview-q3-1030894951
1030.0,10/26/2021 2:59:35 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3758153-notable-earnings-before-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1031.0,10/27/2021 1:27:47 PM,Bristol-Myers Squibb Boosts FY21 Outlook As Q3 Results Top Estimates - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-boosts-fy21-outlook-as-q3-results-top-estimates-quick-facts-1030904590
1032.0,10/28/2021 1:26:15 PM,"Oppenheimer cuts Aurinia to perform on M&A chatter, recent share price rise",Seeking Alpha,https://seekingalpha.com/news/3760060-oppenheimer-cuts-aurinia-to-perform-on-ma-chatter-recent-share-price-rise?utm_source=markets.businessinsider.com&utm_medium=referral
1033.0,10/29/2021 1:12:21 PM,Dr. Reddy’s launches generic version of low blood pressure drug Akovaz in US,Seeking Alpha,https://seekingalpha.com/news/3760843-dr-reddys-launches-generic-version-of-low-blood-pressure-drug-akovaz-in-us?utm_source=markets.businessinsider.com&utm_medium=referral
1034.0,11/1/2021 3:37:12 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-1-2021-1030922174
1035.0,11/2/2021 12:12:34 PM,Baird initiates Geron with an outperform on outlook for lead candidate imetelstat,Seeking Alpha,https://seekingalpha.com/news/3762773-baird-initiates-geron-with-an-outperform-on-outlook-for-lead-candidate-imetelstat?utm_source=markets.businessinsider.com&utm_medium=referral
1036.0,11/4/2021 12:59:34 PM,Bristol to collaborate with Inspirna on combination using Yervoy for endometrial cancer,Seeking Alpha,https://seekingalpha.com/news/3765156-bristol-to-collaborate-with-inspirna-on-combination-using-yervoy-for-endometrial-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1037.0,11/8/2021 1:05:04 PM,Bristol Myers Squibb posts encouraging data from late-stage Opdivo lung cancer trial,Seeking Alpha,https://seekingalpha.com/news/3766692-bristol-myers-squibb-posts-encouraging-data-from-late-stage-opdivo-lung-cancer-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1038.0,11/8/2021 2:24:25 PM,"The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-nov-7-nov-13-earnings-taper-off-multiple-conference-presentations-ipos-and-more-1030949001
1039.0,11/10/2021 10:00:31 AM,Evotec Reaches Additional Programme Designations Within Collaboration With Bristol Myers ,RTTNews,/news/stocks/evotec-reaches-additional-programme-designations-within-collaboration-with-bristol-myers-1030958174
1040.0,11/11/2021 12:27:37 PM,Bristol-Myers Squibb completes $20M investment in Compugen,Seeking Alpha,https://seekingalpha.com/news/3769400-bristol-myers-squibb-completes-20m-investment-in-compugen?utm_source=markets.businessinsider.com&utm_medium=referral
1041.0,11/12/2021 1:18:49 PM,Compugen posts early Phase 1 data for anti-TIGIT antibody in advanced solid tumors,Seeking Alpha,https://seekingalpha.com/news/3770031-compugen-posts-early-phase-1-data-for-anti-tigit-antibody-in-advanced-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral
1042.0,11/14/2021 3:57:21 PM,"The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-nov-14-nov-20-biomarin-fda-decision-tapering-earnings-news-flow-conference-presentations-and-more-1030972118
1043.0,11/15/2021 5:28:52 PM,Anti-platelet drugs don't help survival in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3770794-anti-platelet-drugs-dont-help-survival-in-hospitalized-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1044.0,11/15/2021 9:47:35 PM,"Warren Buffett's Berkshire Hathaway adds Royalty Pharma, exits Merck",Seeking Alpha,https://seekingalpha.com/news/3770994-warren-buffetts-berkshire-hathaway-adds-royalty-pharma-exits-merck?utm_source=markets.businessinsider.com&utm_medium=referral
1045.0,11/16/2021 1:53:22 PM,Phase 2 results show promise for Bristol/J&J venous thromboembolism drug milvexian,Seeking Alpha,https://seekingalpha.com/news/3771370-phase-2-results-show-promise-for-bristol-johnson-johnson-janssen-venous-thromboembolism-drug-milvexian?utm_source=markets.businessinsider.com&utm_medium=referral
1046.0,11/16/2021 3:21:46 PM,"Bristol Myers CEO looking for small,  medium-sized deals - WSJ",Seeking Alpha,https://seekingalpha.com/news/3771472-bristol-myers-ceo-looking-for-small-medium-sized-deals-wsj?utm_source=markets.businessinsider.com&utm_medium=referral
1047.0,11/18/2021 2:33:44 PM,J&J expects to file for 14 new drugs by 2025 - Reuters,Seeking Alpha,https://seekingalpha.com/news/3772449-johnson-johnson-janssen-expects-to-file-for-14-new-drugs-by-2025-reuters?utm_source=markets.businessinsider.com&utm_medium=referral
1048.0,11/18/2021 9:48:24 PM,BMO initiates Bristol-Myers Squibb at outperform; sees 22% upside,Seeking Alpha,https://seekingalpha.com/news/3772655-bmo-initiates-bristol-myers-squibb-at-outperform-sees-22-upside?utm_source=markets.businessinsider.com&utm_medium=referral
1049.0,11/19/2021 12:31:32 PM,FDA extends action date for Bristol-Myers Squibb's mavacamten by three months,Seeking Alpha,https://seekingalpha.com/news/3772791-fda-extends-action-date-for-bristol-myers-squibb-mavacamten-by-three-months?utm_source=markets.businessinsider.com&utm_medium=referral
1050.0,11/19/2021 2:20:15 PM,"The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial",Benzinga,/news/stocks/the-daily-biotech-pulse-connect-biopharma-sinks-on-eczema-drug-readout-enanta-pulls-plug-on-hbv-drug-clinical-setback-for-merck-in-hiv-trial-1030991438
1051.0,11/19/2021 4:08:55 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-19-2021-1030991825
1052.0,11/22/2021 5:43:00 PM,"Aurinia falls 28% amid mixed shelf offering, skepticism on buyout rumors",Seeking Alpha,https://seekingalpha.com/news/3773453-aurinia-falls-28-following-amid-mixed-shelf-offering-skepticism-on-buyout-rumors?utm_source=markets.businessinsider.com&utm_medium=referral
1053.0,11/22/2021 6:30:58 PM,AUPH Stock: 13 Things to Know About Aurinia Pharma as Shares Crash Today,InvestorPlace,/news/stocks/auph-stock-13-things-to-know-about-aurinia-pharma-as-shares-crash-today-1030995927
1054.0,11/23/2021 12:25:48 PM,Bristol Myers' Zeposia OK'd in Europe for ulcerative colitis in adults,Seeking Alpha,https://seekingalpha.com/news/3773705-bristol-myers-zeposia-okd-in-europe-for-ulcerative-colitis-in-adults?utm_source=markets.businessinsider.com&utm_medium=referral
1055.0,11/23/2021 2:10:10 PM,"The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-arrowhead-out-licenses-nash-drug-tonix-touts-covid-19-treatment-data-aadi-jumps-on-fda-nod-for-rare-tumor-drug-1030997811
1056.0,11/23/2021 2:35:29 PM,Bristol's Zeposia Gets Market Authorization From European Commission ,RTTNews,/news/stocks/bristol-s-zeposia-gets-market-authorization-from-european-commission-1030997886
1057.0,11/23/2021 3:33:18 PM,AbbVie upgraded to buy at Societe Generale; sees 48% upside,Seeking Alpha,https://seekingalpha.com/news/3773845-societe-generale-upgrades-abbvie-to-buy-sees-48-upside?utm_source=markets.businessinsider.com&utm_medium=referral
1058.0,11/26/2021 5:30:33 PM,5 Stocks Insiders Are Selling,Benzinga,/news/stocks/5-stocks-insiders-are-selling-1031006181
1059.0,11/29/2021 8:53:36 AM,Biotech Stocks Facing FDA Decision In December 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2021-1031007771
1060.0,11/29/2021 1:02:12 PM,FDA and EMA accepts Bristol Myers' applications for deucravacitinib in plaque psoriasis,Seeking Alpha,https://seekingalpha.com/news/3774805-fda-and-ema-accepts-bristol-myers-applications-for-deucravacitinib-in-plaque-psoriasis?utm_source=markets.businessinsider.com&utm_medium=referral
1061.0,11/29/2021 2:13:12 PM,Bristol Myers Says FDA Accepts NDA For For Deucravacitinib - Quick Facts ,RTTNews,/news/stocks/bristol-myers-says-fda-accepts-nda-for-for-deucravacitinib-quick-facts-1031008730
1062.0,11/30/2021 5:13:05 PM,"Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More",Benzinga,/news/stocks/jim-cramer-shares-his-thoughts-on-chegg-bristol-myers-squibb-and-more-1031012906
1063.0,11/30/2021 7:29:27 PM,7 Drug Stocks to Buy Now While They’re Still on Sale,InvestorPlace,/news/stocks/7-drug-stocks-to-buy-now-while-theyre-still-on-sale-1031013701
1064.0,12/2/2021 4:06:41 PM,Aurinia Pharmaceuticals gains amid takeover speculation,Seeking Alpha,https://seekingalpha.com/news/3776494-aurinia-pharmaceuticals-gains-on-takeover-speculation?utm_source=markets.businessinsider.com&utm_medium=referral
1065.0,12/2/2021 5:16:48 PM,AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today,InvestorPlace,/news/stocks/auph-stock-the-novartis-takeover-talk-that-has-aurinia-pharma-shares-taking-off-today-1031020928
1066.0,12/2/2021 6:02:11 PM,Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-december-pdufa-dates-1031020805
1067.0,12/3/2021 12:12:59 PM,FDA accepts for priority review Bristol Myers's Reblozyl application in beta thalassemia,Seeking Alpha,https://seekingalpha.com/news/3776813-fda-accepts-for-priority-review-bristol-myerss-reblozyl-application-in-beta-thalassemia?utm_source=markets.businessinsider.com&utm_medium=referral
1068.0,12/3/2021 1:40:11 PM,"The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering",Benzinga,/news/stocks/the-daily-biotech-pulse-protagonist-pulls-plug-on-phase-1-asset-xenon-aces-mid-stage-epilepsy-study-esperion-prices-offering-1031022833
1069.0,12/4/2021 9:00:00 PM,Bristol is one of the worst performing biopharmas this year. Will 2022 be different?,Seeking Alpha,https://seekingalpha.com/news/3777064-bristol-myers-squibb-is-one-of-the-worst-performing-pharmas-this-year-will-2022-be-different?utm_source=markets.businessinsider.com&utm_medium=referral
1070.0,12/6/2021 7:17:48 PM,Bolt Biotherapeutics sheds half its value following mid-stage solid tumor data,Seeking Alpha,https://seekingalpha.com/news/3777497-bolt-biotherapeutics-sheds-half-its-value-following-mid-stage-solid-tumor-data?utm_source=markets.businessinsider.com&utm_medium=referral
1071.0,12/9/2021 2:03:57 PM,Vir begins mid-stage trial of combo candidate for chronic hepatitis B virus,Seeking Alpha,https://seekingalpha.com/news/3778701-vir-begins-mid-stage-trial-of-combo-candidate-for-chronic-hepatitis-b-virus?utm_source=markets.businessinsider.com&utm_medium=referral
1072.0,12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161
1073.0,12/9/2021 5:07:53 PM,Where Bristol-Myers Squibb Stands With Analysts,Benzinga,/news/stocks/where-bristol-myers-squibb-stands-with-analysts-1031036366
1074.0,12/10/2021 11:00:33 AM,Why You Should Buy Moderna Stock at Every Dip,InvestorPlace,/news/stocks/why-you-should-buy-mrna-stock-at-every-dip-1031038543
1075.0,12/13/2021 4:05:33 AM,"Antengene, Bristol Myers To Evaluate ATG-017 In Combination With Opdivo In Advanced Solid Tumors ",RTTNews,/news/stocks/antengene-bristol-myers-to-evaluate-atg-017-in-combination-with-opdivo-in-advanced-solid-tumors-1031040414
1076.0,12/13/2021 12:13:52 PM,"Bristol Myers Squibb raises dividend by 10% to $0.54, announces $15B buyback",Seeking Alpha,https://seekingalpha.com/news/3779415-bristol-myers-squibb-company-declares-0_54-dividend?utm_source=markets.businessinsider.com&utm_medium=referral
1077.0,12/13/2021 1:57:06 PM,Bristol Myers Board Approves Increase In Quarterly Dividend; Authorizes Additional Share Repurchase ,RTTNews,/news/stocks/bristol-myers-board-approves-increase-in-quarterly-dividend-authorizes-additional-share-repurchase-1031041501
1078.0,12/13/2021 7:32:25 PM,Why does Pfizer's $6.7B acquisition of Arena Pharmaceuticals make sense? Etrasimod,Seeking Alpha,https://seekingalpha.com/news/3779629-why-does-pfizer-67b-acquisition-of-arena-pharmaceuticals-make-sense-etrasimod?utm_source=markets.businessinsider.com&utm_medium=referral
1079.0,12/13/2021 10:24:33 PM,Bristol-Myers Squibb files for mixed shelf offering,Seeking Alpha,https://seekingalpha.com/news/3779710-bristol-myers-squibb-files-for-mixed-shelf-offering?utm_source=markets.businessinsider.com&utm_medium=referral
1080.0,12/14/2021 8:50:07 PM,3 Stocks That Can Make You Rich in Just a Few Years,InvestorPlace,/news/stocks/3-stocks-that-can-make-you-rich-in-just-a-few-years-1031044575
1081.0,12/15/2021 1:26:51 PM,Exelixis initiates Phase 1b XL092 combo trial in solid tumors,Seeking Alpha,https://seekingalpha.com/news/3780318-exelixis-initiates-phase-1b-xl092-combo-trial-in-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral
1082.0,12/15/2021 5:15:24 PM,Bristol-Myers Squibb wins FDA approval for first graft versus host disease therapy,Seeking Alpha,https://seekingalpha.com/news/3780453-bristol-myers-squibb-wins-fda-approval-for-first-graft-versus-host-disease-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1083.0,12/16/2021 12:56:47 PM,FDA Oks Bristol Myers' Orencia To Prevent Graft Versus Host Disease ,RTTNews,/news/stocks/fda-oks-bristol-myers-orencia-to-prevent-graft-versus-host-disease-1031049863
1084.0,12/17/2021 4:17:57 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-17-2021-1031053650
1085.0,12/23/2021 12:27:47 PM,Top 10 Blockbuster Drugs In 2021 ,RTTNews,/news/stocks/top-10-blockbuster-drugs-in-2021-1031063755
1086.0,12/30/2021 7:20:31 PM,Best Stocks for 2022: Bristol-Myers Squibb Will Offer Huge Returns,InvestorPlace,/news/stocks/best-stocks-for-2022-bristol-myers-squibb-will-offer-huge-returns-1031071810
1087.0,1/6/2022 12:56:30 PM,7 Pharmaceutical Stocks That Could Make You Rich,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-that-could-make-you-rich-1031081342
1088.0,1/10/2022 12:47:19 PM,Century jumps 14% on collaboration with Bristol Myers to develop cell therapies in solid tumor,Seeking Alpha,https://seekingalpha.com/news/3786536-century-jumps-14-on-collaboration-with-bristol-myers-to-develop-cell-therapies-in-solid-tumor?utm_source=markets.businessinsider.com&utm_medium=referral
1089.0,1/10/2022 1:13:56 PM,Bristol-Myers sets in-line guidance for 2022; announces $5B accelerated share buybacks,Seeking Alpha,https://seekingalpha.com/news/3786556-bristol-myers-sets-in-line-guidance-for-2022-announces-5b-accelerated-share-buybacks?utm_source=markets.businessinsider.com&utm_medium=referral
1090.0,1/10/2022 2:08:00 PM,"Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies",Benzinga,/news/stocks/bristol-myers-century-therapeutics-ink-pact-for-ipsc-derived-allogeneic-cell-therapies-1031090714
1091.0,1/10/2022 8:01:06 PM,"3 Top Stock Trades for the Week of Jan. 10, 2022",InvestorPlace,/news/stocks/3-top-stock-trades-for-the-week-of-jan-10-2022-1031091902
1092.0,1/10/2022 9:35:50 PM,BioAtla collaborates with Bristol Myers Squibb for lead assets,Seeking Alpha,https://seekingalpha.com/news/3786864-bioatla-collaborates-with-bristol-myers-squibb-for-lead-assets?utm_source=markets.businessinsider.com&utm_medium=referral
1093.0,1/10/2022 10:05:00 PM,BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of So...,PR Newswire,/news/stocks/bioatla-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-mecbotamab-vedotin-ba3011-and-ozuriftamab-vedotin-ba3021-in-combination-with-opdivo-nivolumab-for-treatment-of-so-1031092010
1094.0,1/11/2022 8:02:31 AM,Evotec Gets $15 Mln From Bristol Myers Squibb On Expansion Of Neuroscience Collaboration ,RTTNews,/news/stocks/evotec-gets-15-mln-from-bristol-myers-squibb-on-expansion-of-neuroscience-collaboration-1031092736
1095.0,1/11/2022 1:18:04 PM,Biomica/Bristol Myers on go with Phase I study of BMC-128 + Opdivo in cancer,Seeking Alpha,https://seekingalpha.com/news/3787035-biomicabristol-myers-on-go-with-phase-i-study-of-bmc-128-opdivo-in-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1096.0,1/11/2022 2:20:34 PM,"The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In",Benzinga,/news/stocks/the-daily-biotech-pulse-illunina-announces-multiple-partnerships-immunome-slides-on-regulatory-setback-for-covid-antibody-drug-preannouncements-pour-in-1031093838
1097.0,1/11/2022 7:55:53 PM,"Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum",Benzinga,/news/stocks/bristol-myers-2seventy-pull-plug-on-multiple-myeloma-car-t-as-abecma-sales-gain-momentum-1031095004
1098.0,1/13/2022 12:57:52 PM,Gritstone begins phase 2/3 colorectal cancer trial dosing; positive data in early study,Seeking Alpha,https://seekingalpha.com/news/3787803-gritstone-begins-phase3-colorectal-cancer-trial-dosing-positive-data-in-phase-12-study?utm_source=markets.businessinsider.com&utm_medium=referral
1099.0,1/13/2022 2:18:12 PM,"The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact",Benzinga,/news/stocks/the-daily-biotech-pulse-adagio-s-antibody-effective-against-omicron-sarepta-terminates-gene-therapy-deal-astrazeneca-inks-oncology-pact-1031100084
1100.0,1/13/2022 5:57:53 PM,Aurinia Pharmaceuticals drops amid silence on M&A after conference presentations,Seeking Alpha,https://seekingalpha.com/news/3788016-aurinia-pharmaceuticals-drops-amid-silence-on-ma-after-conference-presentations?utm_source=markets.businessinsider.com&utm_medium=referral
1101.0,1/13/2022 7:49:28 PM,Aurinia Pharmaceuticals reverses decline after report on potential M&A interest,Seeking Alpha,https://seekingalpha.com/news/3788045-aurinia-pharmaceuticals-reverses-decline-after-report-on-potential-ma-interest?utm_source=markets.businessinsider.com&utm_medium=referral
1102.0,1/19/2022 4:54:28 PM,3 Healthcare Stocks Ignoring the Market Mayhem,InvestorPlace,/news/stocks/3-healthcare-stocks-ignoring-the-market-mayhem-1031113540
1103.0,1/25/2022 6:17:15 PM,"CBO report finds skyrocketing price increases for brand Rx drugs for Medicare, Medicaid",Seeking Alpha,https://seekingalpha.com/news/3791432-cbo-report-finds-skyrocketing-price-increases-for-brand-rx-drugs-for-medicare-medicaid?utm_source=markets.businessinsider.com&utm_medium=referral
1104.0,1/26/2022 2:29:25 PM,"The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data",Benzinga,/news/stocks/the-daily-biotech-pulse-gilead-s-blood-cancer-studies-placed-on-partial-clinical-hold-immunocore-gets-fda-nod-nrx-touts-positive-covid-19-data-1031130804
1105.0,1/27/2022 6:57:41 PM,Say Hello to 2022’s Dogs of the Dow: 10 Dividend Stocks to Watch,InvestorPlace,/news/stocks/say-hello-to-2022s-dogs-of-the-dow-10-dividend-stocks-to-watch-1031136826
1106.0,1/28/2022 12:27:13 PM,Bristol Myers Squibb granted EU recommendation for CAR T therapy in lymphoma,Seeking Alpha,https://seekingalpha.com/news/3792973-bristol-myers-squibb-granted-eu-recommendation-for-car-t-therapy-in-lymphoma?utm_source=markets.businessinsider.com&utm_medium=referral
1107.0,1/28/2022 3:27:36 PM,Aurinia Pharmaceuticals quick uptick on renewed takeover speculation on Biogen news,Seeking Alpha,https://seekingalpha.com/news/3793129-aurinia-pharmaceuticals-quick-uptick-on-renewed-takeover-speculation-on-biogen-news?utm_source=markets.businessinsider.com&utm_medium=referral
1108.0,1/28/2022 6:15:32 PM,7 Technology Stocks Reporting Earnings the Week of January 31,InvestorPlace,/news/stocks/earnings-reports-to-watch-next-week-1028709625
1109.0,1/29/2022 9:00:00 PM,"Vaccines to dominate pharma sales this year, but Bristol could have most best-sellers",Seeking Alpha,https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers?utm_source=markets.businessinsider.com&utm_medium=referral
1110.0,1/31/2022 2:20:54 PM,"The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-31-feb-5-merck-bristol-myers-squibb-lilly-novartis-headline-large-cap-biopharma-earnings-news-1031144306
1111.0,1/31/2022 9:38:38 PM,5 Things To Expect This Week,InvestorPlace,/news/stocks/5-things-to-expect-this-week-1031147156
1112.0,2/3/2022 12:13:04 PM,Can Bristol Myers (BMY) maintain positive earnings momentum in Q4?,Seeking Alpha,https://seekingalpha.com/news/3795418-can-bristol-myers-bmy-maintain-positive-earnings-momentum-in-q4?utm_source=markets.businessinsider.com&utm_medium=referral
1113.0,2/3/2022 2:13:03 PM,"The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation",Benzinga,/news/stocks/the-daily-biotech-pulse-big-pharma-earnings-prove-lackluster-mersana-inks-1b-adc-r-d-deal-syros-gets-orphan-drug-designation-1031158702
1114.0,2/3/2022 3:01:13 PM,Bristol-Myers Squibb earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q4-earnings-preview-1031158985
1115.0,2/3/2022 3:48:38 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3795618-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1116.0,2/4/2022 12:00:46 PM,"Bristol Myers Squibb Non-GAAP EPS of $1.83 beats by $0.03, revenue of $12B in-line",Seeking Alpha,https://seekingalpha.com/news/3795965-bristol-myers-squibb-non-gaap-eps-of-1_83-beats-0_03-revenue-of-12b-in-line?utm_source=markets.businessinsider.com&utm_medium=referral
1117.0,2/4/2022 12:32:17 PM,Bristol-Myers sets 2022 guidance ahead of consensus after earnings beat,Seeking Alpha,https://seekingalpha.com/news/3795982-bristol-myers-sets-2022-guidance-ahead-of-consensus-after-earnings-beat?utm_source=markets.businessinsider.com&utm_medium=referral
1118.0,2/4/2022 1:07:05 PM,Bristol-Myers Squibb Co. Q4 Earnings Summary,RTTNews,/news/stocks/bristol-myers-squibb-co-q4-earnings-summary-1031162269
1119.0,2/4/2022 1:19:26 PM,Bristol-Myers Squibb Reaffirms FY22 Adj. EPS Outlook; Swings To Profit In Q4 - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-reaffirms-fy22-adj-eps-outlook-swings-to-profit-in-q4-quick-facts-1031162301
1120.0,2/4/2022 1:34:06 PM,"The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures",Benzinga,/news/stocks/the-daily-biotech-pulse-sanofi-bristol-myers-squibb-gain-on-earnings-valneva-pfizer-tout-positive-lyme-disease-vaccine-data-unity-biotech-restructures-1031162384
1121.0,2/4/2022 4:36:55 PM,5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet,InvestorPlace,/news/stocks/5-biotech-stocks-to-buy-to-benefit-from-bidens-new-cancer-cabinet-1031163083
1122.0,2/8/2022 1:12:54 PM,Bristol Myers awards ~$8M in health equity grants for medically underserved patients,Seeking Alpha,https://seekingalpha.com/news/3797142-bristol-myers-awards-8m-in-health-equity-grants-for-medically-underserved-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1123.0,2/8/2022 9:03:43 PM,2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch,Benzinga,/news/stocks/2-natural-killer-cell-therapy-oncology-companies-investors-should-watch-1031173167
1124.0,2/9/2022 12:09:17 PM,Bristol Myers Squibb announces $5B in accelerated share repurchase agreements,Seeking Alpha,https://seekingalpha.com/news/3797712-bristol-myers-squibb-announces-5b-in-accelerated-share-repurchase-agreements?utm_source=markets.businessinsider.com&utm_medium=referral
1125.0,2/9/2022 2:31:47 PM,"The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In",Benzinga,/news/stocks/the-daily-biotech-pulse-bristol-myers-squibb-announces-5b-accelerated-buyback-qiagen-reaps-covid-testing-windfall-worldsymposium-presentations-kick-in-1031176974
1126.0,2/9/2022 2:47:07 PM,Bristol Myers Enters Into $5 Bln ASR Agreements ,RTTNews,/news/stocks/bristol-myers-enters-into-5-bln-asr-agreements-1031177060
1127.0,2/14/2022 9:35:53 PM,"Buffett's Berkshire Hathaway adds Activision Blizzard stake, exists Teva",Seeking Alpha,https://seekingalpha.com/news/3799802-buffetts-berkshire-hathaway-adds-activision-blizzard-stake-exists-teva?utm_source=markets.businessinsider.com&utm_medium=referral
1128.0,2/15/2022 11:36:33 AM,Exelixis/Bristol-Myers' drug combo shows sustained survival benefits in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3799945-exelixisbristol-myers-drug-combo-shows-sustained-survival-benefits-in-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1129.0,2/15/2022 5:41:23 PM,GlaxoSmithKline the latest drugmaker to restrict discounts under 340B program,Seeking Alpha,https://seekingalpha.com/news/3800248-glaxosmithkline-latest-drugmaker-restrict-discounts-340b-safety-net-program?utm_source=markets.businessinsider.com&utm_medium=referral
1130.0,2/15/2022 7:18:10 PM,Bristol-Myers begins tender offers to buy notes for up to $4B,Seeking Alpha,https://seekingalpha.com/news/3800317-bristol-myers-begins-tender-offers-to-buy-notes-for-up-to-4b?utm_source=markets.businessinsider.com&utm_medium=referral
1131.0,2/15/2022 9:53:21 PM,Bristol Myers Squibb to raise $6B in senior notes offering,Seeking Alpha,https://seekingalpha.com/news/3800455-bristol-myers-squibb-to-raise-6b-in-senior-notes-offering?utm_source=markets.businessinsider.com&utm_medium=referral
1132.0,2/16/2022 10:18:00 AM,AstraZeneca's Saphnelo gets approval in EU for systemic lupus erythematosus,Seeking Alpha,https://seekingalpha.com/news/3800544-astrazenecas-saphnelo-gets-approval-in-eu-for-systemic-lupus-erythematosus?utm_source=markets.businessinsider.com&utm_medium=referral
1133.0,2/16/2022 12:59:56 PM,Bristol Myers mavacamten for heart disease meets main goal in late-stage study,Seeking Alpha,https://seekingalpha.com/news/3800653-bristol-myers-mavacamten-for-heart-disease-meets-main-goal-in-late-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral
1134.0,2/16/2022 3:39:01 PM,3 Desirable Drug Stocks With Very Promising Pipelines,InvestorPlace,/news/stocks/3-desirable-drug-stocks-with-very-promising-pipelines-1031201417
1135.0,2/17/2022 2:00:05 PM,"The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-unit-announces-research-collaboration-with-remix-regencell-touts-covid-data-decision-day-for-agios-1031204785
1136.0,2/17/2022 2:26:08 PM,Bristol Myers Says FDA Accepts SBLA For Breyanzi As Second-Line Therapy For LBCL - Quick Facts ,RTTNews,/news/stocks/bristol-myers-says-fda-accepts-sbla-for-breyanzi-as-second-line-therapy-for-lbcl-quick-facts-1031204935
1137.0,2/18/2022 10:08:16 AM,Bristol Myers' Breyanzi gets FDA priority review for expanded use in blood cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype?utm_source=markets.businessinsider.com&utm_medium=referral
1138.0,2/18/2022 12:38:41 PM,Novartis launches generic version of Bristol Myers’ Revlimid in Europe,Seeking Alpha,https://seekingalpha.com/news/3801888-novartis-launches-generic-version-of-bristol-myers-revlimid-in-europe?utm_source=markets.businessinsider.com&utm_medium=referral
1139.0,2/18/2022 1:22:40 PM,"The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-regeneron-sanofi-halt-late-stage-dupixent-study-agios-gets-fda-nod-safety-scare-for-gsk-s-rsv-vaccine-shockwave-jumps-on-earnings-1031208337
1140.0,2/18/2022 2:09:33 PM,Agios vindicated with FDA approval for Pyrukynd - H.C. Wainwright,Seeking Alpha,https://seekingalpha.com/news/3801942-agios-stock-gains-as-hc-wainwright-raises-target-on-fda-approval?utm_source=markets.businessinsider.com&utm_medium=referral
1141.0,2/22/2022 7:57:48 PM,7 New ETFs To Consider if You Want To Play Today’s Top Trends,InvestorPlace,/news/stocks/7-new-etfs-to-consider-if-you-want-to-play-todays-top-trends-1031217554
1142.0,2/25/2022 12:44:30 PM,Bristol Myers Opdivo gets EMA panel nod for use as adjuvant therapy in urothelial cancer,Seeking Alpha,https://seekingalpha.com/news/3805853-bristol-myers-opdivo-gets-ema-panel-nod-for-use-as-adjuvant-therapy-in-urothelial-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1143.0,2/28/2022 7:41:42 AM,Biotech Stocks Facing FDA Decision In March 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2022-1031236842
1144.0,3/1/2022 7:00:00 PM,Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb,PR Newswire,/news/stocks/dragonfly-therapeutics-announces-achievement-of-phase-1-clinical-development-milestone-for-il-12-investigational-immunotherapy-program-with-bristol-myers-squibb-1031244173
1145.0,3/1/2022 9:34:32 PM,Bristol Myers Squibb declares $0.54 dividend,Seeking Alpha,https://seekingalpha.com/news/3808072-bristol-myers-squibb-declares-054-dividend?utm_source=markets.businessinsider.com&utm_medium=referral
1146.0,3/2/2022 1:08:52 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1031247139
1147.0,3/2/2022 8:48:55 PM,36 Stocks To Watch After Biden's First State of The Union Address,Benzinga,/news/stocks/36-stocks-to-watch-after-biden-s-first-state-of-the-union-address-1031248946
1148.0,3/3/2022 6:43:20 PM,Companies warn sanctions can disrupt medical supplies to Russia - Reuters,Seeking Alpha,https://seekingalpha.com/news/3809259-companies-warn-sanctions-can-disrupt-medical-supplies-to-russia?utm_source=markets.businessinsider.com&utm_medium=referral
1149.0,3/7/2022 9:27:58 AM,Bristol Myers Opdivo combo gets FDA nod for expanded use in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3810049-bristol-myers-opdivo-combo-gets-fda-nod-for-expanded-use-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1150.0,3/7/2022 1:16:21 PM,Teva launches first generic of Bristol's Revlimid,Seeking Alpha,https://seekingalpha.com/news/3810142-teva-launches-first-generic-of-bristol-myers-squibb-revlimid?utm_source=markets.businessinsider.com&utm_medium=referral
1151.0,3/7/2022 3:50:09 PM,Aurinia Pharmaceuticals gains on report investors pushing for sale,Seeking Alpha,https://seekingalpha.com/news/3810237-aurinia-pharmaceuticals-gains-on-report-investor-pushing-for-sale?utm_source=markets.businessinsider.com&utm_medium=referral
1152.0,3/9/2022 11:24:06 AM,7 Biotech Stocks With Key Catalysts in March,InvestorPlace,/news/stocks/7-biotech-stocks-with-key-catalysts-in-march-1031265751
1153.0,3/9/2022 11:40:07 AM,8 Strong Uptrend Stocks to Buy on the Next Dip,InvestorPlace,/news/stocks/8-strong-uptrend-stocks-to-buy-on-the-next-dip-1031265802
1154.0,3/9/2022 4:35:04 PM,What Stocks Does 'The Big Short' Investor Michael Burry Own?,Benzinga,/news/stocks/what-stocks-does-the-big-short-investor-michael-burry-own-1031267025
1155.0,3/10/2022 12:35:12 PM,7 Drug Stocks to Consider After the Viatris Plunge,InvestorPlace,/news/stocks/7-drug-stocks-to-consider-after-the-viatris-plunge-abbv-bmy-gsk-vtrs-jnj-teva-pfe-nvs-mrk-1031269941
1156.0,3/12/2022 7:20:14 PM,Drugmakers face clinical trial disruptions amid Russia - Ukraine conflict,Seeking Alpha,https://seekingalpha.com/news/3812903-drugmakers-face-clinical-trial-disruptions-amid-russia-ukraine-conflict?utm_source=markets.businessinsider.com&utm_medium=referral
1157.0,3/13/2022 10:37:36 PM,"The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-13-19-bristol-myers-squibb-s-melanoma-drug-decision-multiple-conference-presentations-and-earnings-dominate-proceedings-1031275983
1158.0,3/14/2022 12:38:57 PM,"Bristol Myers Squibb, Nektar Say Phase 3 PIVOT IO-001 Trial Fails To Meet Endpoints ",RTTNews,/news/stocks/bristol-myers-squibb-nektar-say-phase-3-pivot-io-001-trial-fails-to-meet-endpoints-1031277512
1159.0,3/14/2022 1:29:23 PM,Nektar slips after setback for lead asset bringing similar drugs into focus,Seeking Alpha,https://seekingalpha.com/news/3813105-alks-stock-slips-after-setback-for-nektars-lead-asset?utm_source=markets.businessinsider.com&utm_medium=referral
1160.0,3/14/2022 2:17:48 PM,Why Nektar Therapeutics Shares Are Falling Today,Benzinga,/news/stocks/why-nektar-therapeutics-shares-are-falling-today-1031277975
1161.0,3/14/2022 2:47:17 PM,Nektar hit by “major” setback with melanoma trial failure for lead asset - BofA,Seeking Alpha,https://seekingalpha.com/news/3813147-nektar-hit-by-major-setback-with-melanoma-trial-failure---bofa?utm_source=markets.businessinsider.com&utm_medium=referral
1162.0,3/14/2022 4:07:30 PM,"Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit",Benzinga,/news/stocks/bristol-myers-nektar-melanoma-doublet-therapy-trial-fails-to-show-clinical-benefit-1031278396
1163.0,3/14/2022 5:43:17 PM,Why is Nektar Therapeutics (NKTR) Stock Down Today?,InvestorPlace,/news/stocks/why-is-nektar-therapeutics-nktr-stock-down-today-1031278798
1164.0,3/15/2022 5:02:42 PM,3 Top Stock Trades for This Week,InvestorPlace,/news/stocks/3-top-stock-trades-for-this-week-1031282462
1165.0,3/17/2022 11:00:45 AM,7 Michael Burry Stocks to Buy as ‘The Big Short’ Investor Makes Moves,InvestorPlace,/news/stocks/7-michael-burry-stocks-to-buy-as-the-big-short-investor-makes-moves-1031288213
1166.0,3/19/2022 2:11:59 PM,Bristol Myers Squibb: FDA Approves Opdualag For Patients With Unresectable Or Metastatic Melanoma ,RTTNews,/news/stocks/bristol-myers-squibb-fda-approves-opdualag-for-patients-with-unresectable-or-metastatic-melanoma-1031292986
1167.0,3/19/2022 5:10:09 PM,Bristol gains approval of first-in-class immunotherapy for melanoma Opdualag,Seeking Alpha,https://seekingalpha.com/news/3815159-bristol-gains-approval-of-first-in-class-immunotherapy-for-melanoma-opdualag?utm_source=markets.businessinsider.com&utm_medium=referral
1168.0,3/20/2022 1:40:47 PM,MDNA: No Read-Through for MDNA11 Based on Nektar Failure…,Benzinga,/news/stocks/mdna-no-read-through-for-mdna11-based-on-nektar-failure…-1031293351
1169.0,3/20/2022 4:42:56 PM,"The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-20-26-focus-on-zogenix-fda-decision-dermatology-conference-presentations-earnings-1031293398
1170.0,3/21/2022 1:29:17 PM,Volastra in up to $1.1B development deal with Bristol-Myers Squibb for oncology candidates,Seeking Alpha,https://seekingalpha.com/news/3815353-volastra-in-up-to-11b-development-deal-with-bristol-myers-squibb-for-oncology-candidates?utm_source=markets.businessinsider.com&utm_medium=referral
1171.0,3/22/2022 3:50:28 AM,"Transcenta, Bristol To Evaluate TST001 - Opdivo Combination For Gastroesophageal Junction Cancer ",RTTNews,/news/stocks/transcenta-bristol-to-evaluate-tst001-opdivo-combination-for-gastroesophageal-junction-cancer-1031296718
1172.0,3/23/2022 12:43:16 PM,"The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-reports-positive-ulcerative-colitis-study-data-novavax-covid-shot-authorized-for-adolescents-in-india-argenx-stock-sale-1031301077
1173.0,3/25/2022 11:33:49 AM,Bristol Myers Squibb announces a delay for FDA review of beta thalassemia therapy,Seeking Alpha,https://seekingalpha.com/news/3817401-bristol-myers-squibb-announces-a-delay-for-fda-review-of-beta-thalassemia-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1174.0,3/25/2022 12:19:39 PM,Bristol Myers Squibb: FDA Extends PDUFA Goal Date For Reblozy By Three Months For Full Review ,RTTNews,/news/stocks/bristol-myers-squibb-fda-extends-pdufa-goal-date-for-reblozy-by-three-months-for-full-review-1031307751
1175.0,3/25/2022 12:50:02 PM,"The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-mei-pharma-wilts-on-adverse-regulatory-development-decision-day-for-zogenix-an2-therapeutics-ipo-1031307839
1176.0,3/27/2022 10:40:40 PM,"The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck  Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-27-april-2-lipocine-akebia-merck-await-fda-verdicts-adcom-test-for-amylyx-biontech-earnings-and-more-1031310198
1177.0,3/28/2022 7:31:43 AM,Biotech Stocks Facing FDA Decision In April 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-2022-1031310826
1178.0,3/28/2022 10:25:11 AM,Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs,InvestorPlace,/news/stocks/which-chinese-stocks-will-be-delisted-8-in-u-s-crosshairs-1031311449
1179.0,3/29/2022 12:26:22 PM,Bristol Myers’ lung cancer therapy undergoes EU review for use before surgery,Seeking Alpha,https://seekingalpha.com/news/3818366-bristol-myerss-lung-cancer-therapy-undergoes-eu-review-for-use-before-surgery?utm_source=markets.businessinsider.com&utm_medium=referral
1180.0,3/30/2022 2:05:30 PM,How to Buy Digital World Acquisition at Nearly Half the Price,InvestorPlace,/news/stocks/how-to-buy-digital-world-acquisition-dwac-stock-half-price-1031319385
1181.0,4/1/2022 9:16:51 PM,Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates-1031327374
1182.0,4/3/2022 11:32:49 PM,"The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-3-april-9-bioxcel-fda-decision-neurology-conference-presentations-take-the-spotlight-1031328267
1183.0,4/4/2022 11:00:37 AM,7 No-Brainer Stocks to Buy for April,InvestorPlace,/news/stocks/7-no-brainer-stocks-to-buy-for-april-ko-intc-bmy-skws-nflx-grmn-ttd-1031329577
1184.0,4/4/2022 11:06:57 AM,Bristol Myers posts long-term data for heart-disease drug in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/3820260-bristol-myers-posts-long-term-data-for-heart-disease-drug-in-late-stage-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1185.0,4/5/2022 10:59:46 AM,7 Biotech Stocks to Buy With Key Catalysts for April,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-with-key-catalysts-for-april-1031332726
1186.0,4/5/2022 11:16:29 AM,Bristol Myers's Opdivo gets approval for 2 cancer types in EU,Seeking Alpha,https://seekingalpha.com/news/3820670-bristol-myerss-opdivo-gets-approval-for-2-cancer-types-in-eu?utm_source=markets.businessinsider.com&utm_medium=referral
1187.0,4/5/2022 1:48:52 PM,"The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel",Benzinga,/news/stocks/the-daily-biotech-pulse-thervance-gains-on-positive-late-stage-readout-bristol-myers-squibb-snags-3-approvals-in-europe-decision-day-for-bioxcel-1031332845
1188.0,4/5/2022 3:55:53 PM,Bristol Myers' CAR T cell therapy Breyanzi gets approval in EU to treat certain blood cancers,Seeking Alpha,https://seekingalpha.com/news/3820839-bristol-myers-car-t-cell-therapy-breyanzi-gets-approval-in-eu-to-treat-certain-blood-cancers?utm_source=markets.businessinsider.com&utm_medium=referral
1189.0,4/5/2022 9:37:56 PM,MindMed Appoints Francois Lilienthal As New CCO,Benzinga,/news/stocks/mindmed-appoints-francois-lilienthal-as-new-cco-1031334555
1190.0,4/6/2022 1:51:54 PM,Bristol-Myers Squibb downgraded at Morgan Stanley on revenue growth concerns,Seeking Alpha,https://seekingalpha.com/news/3821149-bristol-myers-squibb-downgraded-at-morgan-stanley-on-revenue-growth-concerns?utm_source=markets.businessinsider.com&utm_medium=referral
1191.0,4/6/2022 4:16:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-6-2022-1031337076
1192.0,4/7/2022 7:38:30 PM,Life sciences companies drive healthcare stocks to lead S&P 500,Seeking Alpha,https://seekingalpha.com/news/3821820-life-sciences-companies-drive-healthcare-stocks-to-lead-sp-500?utm_source=markets.businessinsider.com&utm_medium=referral
1193.0,4/8/2022 11:25:37 AM,Best Stocks for 2022: Bristol-Myers Squibb Isn’t Done Growing,InvestorPlace,/news/stocks/best-stocks-for-2022-bmy-stock-isnt-done-growing-1031342774
1194.0,4/8/2022 12:12:15 PM,Bipartisan legislation aims to increase value-based purchasing for pricey drugs in Medicaid,Seeking Alpha,https://seekingalpha.com/news/3821989-bipartisan-legislation-aims-to-increase-value-based-purchasing-for-pricey-drugs-in-medicaid?utm_source=markets.businessinsider.com&utm_medium=referral
1195.0,4/8/2022 1:52:26 PM,"The Daily Biotech Pulse: Evotec Earns $16M Milestone Payment, Genmab Hit With Adverse Tribunal Ruling, Quidel Announces Above-Consensus Q1 Revenues And More",Benzinga,/news/stocks/the-daily-biotech-pulse-evotec-earns-16m-milestone-payment-genmab-hit-with-adverse-tribunal-ruling-quidel-announces-above-consensus-q1-revenues-and-more-1031342792
1196.0,4/8/2022 6:38:50 PM,3 Recession-Proof Dividend Stocks to Buy,InvestorPlace,/news/stocks/3-recession-proof-stocks-to-buy-for-income-1031343772
1197.0,4/8/2022 9:02:51 PM,Why Bicycle Therapeutics Stock Is Soaring Today,Benzinga,/news/stocks/why-bicycle-therapeutics-stock-is-soaring-today-1031343779
1198.0,4/9/2022 4:00:14 PM,Healthcare stocks outperform as investors look for safety,Seeking Alpha,https://seekingalpha.com/news/3822171-healthcare-stocks-outperform-as-investors-look-for-safety?utm_source=markets.businessinsider.com&utm_medium=referral
1199.0,4/11/2022 4:34:55 PM,Bristol Myers highlights potential of Opdivo when used before surgery in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3822396-bristol-myers-says-opdivo-was-effective-when-used-before-surgery-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1200.0,4/14/2022 8:45:21 PM,"Nektar, Bristol Myers to end development program for bempegaldesleukin/Opdivo combo",Seeking Alpha,https://seekingalpha.com/news/3823602-nektar-bristol-myers-to-end-development-program-for-bempegaldesleukinopdivo-combo?utm_source=markets.businessinsider.com&utm_medium=referral
1201.0,4/14/2022 10:30:00 PM,Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab),PR Newswire,/news/stocks/nektar-and-bristol-myers-squibb-announce-update-on-clinical-development-program-for-bempegaldesleukin-bempeg-in-combination-with-opdivo-nivolumab-1031357993
1202.0,4/15/2022 9:15:54 AM,"Nektar, Bristol Myers To Discontinue Clinical Program For Bempegaldesleukin With Opdivo ",RTTNews,/news/stocks/nektar-bristol-myers-to-discontinue-clinical-program-for-bempegaldesleukin-with-opdivo-1031358564
1203.0,4/18/2022 2:25:31 PM,Nektar stock slumps 36% on Goldman Sachs downgrade following bempeg program termination,Seeking Alpha,https://seekingalpha.com/news/3823886-nektar-stock-slumps-36-on-goldman-sachs-downgrade-following-bempeg-program-termination?utm_source=markets.businessinsider.com&utm_medium=referral
1204.0,4/18/2022 2:49:10 PM,Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program,Benzinga,/news/stocks/read-why-did-bristol-myers-and-nektar-end-3-6b-immuno-oncology-program-1031360967
1205.0,4/18/2022 3:25:20 PM,"Benzinga's Daily Brief On Trending Tickers For April 18, 2022: Casa Systems, Twitter, DiDi Global, And More",Benzinga,/news/stocks/benzinga-s-daily-brief-on-trending-tickers-for-april-18-2022-casa-systems-twitter-didi-global-and-more-1031361132
1206.0,4/19/2022 6:07:59 AM,"Bristol-Myers to begin including R&D charges with Q1, sees 10c impact from IPRD",Seeking Alpha,https://seekingalpha.com/news/3824123-bristol-myers-to-begin-including-rd-charges-with-q1-sees-10c-impact-from-iprd?utm_source=markets.businessinsider.com&utm_medium=referral
1207.0,4/22/2022 12:00:43 AM,Pfizer: What Comes After the Covid-19 Fire?,InvestorPlace,/news/stocks/pfe-stock-what-comes-after-the-covid-fire-1031373557
1208.0,4/22/2022 5:35:18 PM,"Evelo Biosciences names former Alnylam, MyoKardia CEOs as strategic advisors",Seeking Alpha,https://seekingalpha.com/news/3825890-evelo-biosciences-names-former-alnylam-myokardia-ceos-as-strategic-advisors?utm_source=markets.businessinsider.com&utm_medium=referral
1209.0,4/23/2022 8:00:00 PM,COVID therapies and vaccines propel rise in spending on medicines in 2021,Seeking Alpha,https://seekingalpha.com/news/3825965-covid-therapies-and-vaccines-propel-rise-in-spending-on-medicines-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral
1210.0,4/25/2022 9:26:09 PM,"Nektar Therapeutics unveils restructuring plan, laying off 70% of its workforce",Seeking Alpha,https://seekingalpha.com/news/3826475-nektar-therapeutics-unveils-restructuring-plan-laying-off-70-of-its-workforce?utm_source=markets.businessinsider.com&utm_medium=referral
1211.0,4/28/2022 2:55:37 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3828682-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1212.0,4/28/2022 3:01:13 PM,Here's what Wall Street expects from Bristol-Myers Squibb's earnings report,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-q1-earnings-preview-1031397521
1213.0,4/28/2022 3:54:00 PM,Will Bristol Myers Squibb positive earnings momentum continue in Q1?,Seeking Alpha,https://seekingalpha.com/news/3828705-will-bristol-myers-squibb-positive-earnings-momentum-continue-in-q1?utm_source=markets.businessinsider.com&utm_medium=referral
1214.0,4/29/2022 5:22:31 AM,FDA Approves Bristol Myers' Camzyos For Heart Disease ,RTTNews,/news/stocks/fda-approves-bristol-myers-camzyos-for-heart-disease-1031399608
1215.0,4/29/2022 10:24:10 AM,LianBio stock soars 20% as partner Bristol Myers wins FDA nod for Camzyos to treat heart disorder,Seeking Alpha,https://seekingalpha.com/news/3829239-lianbio-stock-soars-20-as-partner-bristol-myers-wins-fda-nod-for-camzyos-to-treat-heart-disorder?utm_source=markets.businessinsider.com&utm_medium=referral
1216.0,4/29/2022 11:01:43 AM,"Bristol Myers Squibb Non-GAAP EPS of $1.96 beats by $0.07, revenue of $11.6B beats by $260M",Seeking Alpha,https://seekingalpha.com/news/3829265-bristol-myers-squibb-non-gaap-eps-of-1_96-beats-0_07-revenue-of-11_6b-beats-260m?utm_source=markets.businessinsider.com&utm_medium=referral
1217.0,4/29/2022 12:06:32 PM,"Bristol Myers stock dips despite Q1 beat, as FY22 EPS outlook trimmed, Revlimid to see decline",Seeking Alpha,https://seekingalpha.com/news/3829329-bristol-myers-stock-dips-despite-q1-beat-as-fy22-eps-outlook-trimmed-revlimid-to-see-decline?utm_source=markets.businessinsider.com&utm_medium=referral
1218.0,4/29/2022 1:33:01 PM,"Bristol-Myers Squibb Slashes FY22 EPS, Adj. EPS Outlook; Q1 Results Top Estimates ",RTTNews,/news/stocks/bristol-myers-squibb-slashes-fy22-eps-adj-eps-outlook-q1-results-top-estimates-1031402185
1219.0,4/29/2022 3:00:32 PM,"The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-approves-bristol-myers-oral-heart-disease-drug-european-approval-for-merck-s-keytruda-genocea-restructures-zymeworks-takeover-bid-1031402592
1220.0,4/29/2022 3:06:28 PM,Bristol Myers Squibb Reports FDA Approval Of Camzyos - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-reports-fda-approval-of-camzyos-quick-facts-1031402643
1221.0,4/29/2022 4:43:00 PM,"Despite FDA approval for heart condition drug mavacamten, LianBio stock falls 24%",Seeking Alpha,https://seekingalpha.com/news/3829552-despite-fda-approval-for-heart-condition-drug-mavacamten-lianbio-stock-falls-24?utm_source=markets.businessinsider.com&utm_medium=referral
1222.0,4/30/2022 8:00:00 PM,U.S. pharmaceutical sector fails to spring higher amid lackluster April performance,Seeking Alpha,https://seekingalpha.com/news/3829651-us-pharmaceutical-sector-fails-to-spring-higher-amid-lackluster-april-performance?utm_source=markets.businessinsider.com&utm_medium=referral
1223.0,5/1/2022 2:31:26 PM,Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-may-pdufa-dates-1031404843
1224.0,5/2/2022 6:05:13 AM,Biotech Stocks Facing FDA Decision In May 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-2022-1031405313
1225.0,5/2/2022 1:16:21 PM,Gilead to develop Dragonfly natural killer cell engager immunotherapy; $300M upfront,Seeking Alpha,https://seekingalpha.com/news/3829992-gilead-to-develop-dragonfly-natural-killer-cell-engager-immunotherapy-300m-upfront?utm_source=markets.businessinsider.com&utm_medium=referral
1226.0,5/2/2022 3:44:25 PM,What 4 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-4-analyst-ratings-have-to-say-about-bristol-myers-squibb-1031409196
1227.0,5/3/2022 10:34:01 AM,Goldman highlights top sector picks for high dividend growth and yield,Seeking Alpha,https://seekingalpha.com/news/3830044-goldman-highlights-sector-picks-for-high-dividend-growth-and-yield?utm_source=markets.businessinsider.com&utm_medium=referral
1228.0,5/10/2022 3:23:19 PM,"The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-acquires-migraine-drugmaker-for-11b-biogen-files-for-second-alzheimer-s-drug-approval-longeveron-ceo-leaves-1031442487
1229.0,5/10/2022 3:28:57 PM,Bristol Myers extends protein degradation deal with Evotec,Seeking Alpha,https://seekingalpha.com/news/3836012-bristol-myers-extends-protein-degradation-deal-with-evotec?utm_source=markets.businessinsider.com&utm_medium=referral
1230.0,5/10/2022 4:46:58 PM,"Evotec, Bristol Myers Extend Partnership In Protein Degradation ",RTTNews,/news/stocks/evotec-bristol-myers-extend-partnership-in-protein-degradation-1031442825
1231.0,5/11/2022 10:26:59 PM,The Top 10 Stocks Helping Warren Buffett Beat the Market,InvestorPlace,/news/stocks/the-top-10-stocks-helping-warren-buffett-beat-the-market-1031450438
1232.0,5/12/2022 11:56:14 AM,Bristol Myers and BridgeBio Pharma partner for cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3837652-bbio-stock-climbs-after-agreement-with-bristol-myers-squibb?utm_source=markets.businessinsider.com&utm_medium=referral
1233.0,5/12/2022 11:57:47 AM,Bristol Myers' deucravacitinib maintains efficacy at 2 years against plaque psoriasis in study,Seeking Alpha,https://seekingalpha.com/news/3837653-bristol-myers-deucravacitinib-maintains-efficacy-at-2-years-against-plaque-psoriasis-in-study?utm_source=markets.businessinsider.com&utm_medium=referral
1234.0,5/12/2022 2:42:55 PM,"The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More",Benzinga,/news/stocks/the-daily-biotech-pulse-bristol-myers-bridgebio-ink-oncology-pact-fda-nod-for-lava-therapeutics-blood-cancer-study-and-more-1031453570
1235.0,5/12/2022 3:48:34 PM,BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology,Benzinga,/news/stocks/bridgebio-inks-licensing-pact-with-bristol-myers-for-shp2-inhibitor-in-oncology-1031454165
1236.0,5/13/2022 11:19:50 AM,"Bristol Myers to sell East Syracuse, New York production facility",Seeking Alpha,https://seekingalpha.com/news/3838497-bristol-myers-to-sell-east-syracuse-new-york-production-facility?utm_source=markets.businessinsider.com&utm_medium=referral
1237.0,5/13/2022 1:21:36 PM,Bristol Myers To Sell East Syracuse Manufacturing Facility To Korea's LOTTE; Terms Not Disclosed ,RTTNews,/news/stocks/bristol-myers-to-sell-east-syracuse-manufacturing-facility-to-korea-s-lotte-terms-not-disclosed-1031458433
1238.0,5/13/2022 4:38:25 PM,"The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-orphan-drug-tags-for-neurocrine-editas-candidates-sale-of-bridgebio-s-prv-rmat-designation-for-polarityte-s-product-1031459211
1239.0,5/16/2022 12:01:25 PM,Bristol Myers' Opdivo/Yervoy combo fails to improve overall survival in certain bladder cancer patients in trial,Seeking Alpha,https://seekingalpha.com/news/3839084-bristol-myers-opdivoyervoy-combo-fails-to-improve-overall-survival-in-certain-bladder-cancer-patients-in-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1240.0,5/16/2022 1:23:58 PM,Bristol Myers Squibb: Phase 3 CheckMate -901 Trial Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/bristol-myers-squibb-phase-3-checkmate-901-trial-fails-to-meet-primary-endpoint-1031464053
1241.0,5/16/2022 10:31:40 PM,"Berkshire Hathaway takes 2.5% stake in Citi in Q1, exits Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/3839678-berkshire-hathaway-takes-25-stake-in-citi-in-q1-exits-wells-fargo?utm_source=markets.businessinsider.com&utm_medium=referral
1242.0,5/17/2022 12:39:47 PM,Idera halts melanoma trial for cancer candidate after early positive results,Seeking Alpha,https://seekingalpha.com/news/3839915-idra-stock-surges-on-positive-results-for-melanoma-candidate?utm_source=markets.businessinsider.com&utm_medium=referral
1243.0,5/17/2022 4:20:53 PM,7 ETFs to Pick-Up From the Tech Wreck,InvestorPlace,/news/stocks/7-etfs-to-pick-up-from-the-tech-wreck-1031469495
1244.0,5/18/2022 12:05:08 PM,Immatics begins dosing of IMA203 with Bristol Myers' Opdivo in trial to treat solid tumors,Seeking Alpha,https://seekingalpha.com/news/3840366-immatics-begins-dosing-of-ima203-with-bristol-myers-opdivo-in-trial-to-treat-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral
1245.0,5/18/2022 1:45:06 PM,Purple Biotech initiates phase 2 study for its antibody CM24 in pancreatic cancer patients,Seeking Alpha,https://seekingalpha.com/news/3840457-purple-biotech-initiates-phase-2-study-for-its-antibody-cm24-in-pancreatic-cancer-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1246.0,5/20/2022 4:32:44 PM,Legendary Investor Michael Burry Is Betting Against Apple (AAPL) Stock,InvestorPlace,/news/stocks/legendary-investor-michael-burry-is-betting-against-apple-aapl-stock-1031479283
1247.0,5/20/2022 8:54:19 PM,Bristol-Myers Squibb's azacitidine granted additional indication for juvenile leukemia,Seeking Alpha,https://seekingalpha.com/news/3841501-bristol-myers-squibbs-azacitidine-granted-additional-indication-for-juvenile-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral
1248.0,5/22/2022 9:58:01 PM,"The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-22-28-verrica-bristol-myers-squibb-fda-decisions-medtronic-earnings-conference-presentations-more-1031480317
1249.0,5/24/2022 7:43:07 PM,Michael Burry Says 2022 Is a ‘Plane Crash.’ Here’s What the Legendary Investor Is Betting On.,InvestorPlace,/news/stocks/michael-burry-says-2022-is-a-plane-crash-heres-what-the-legendary-investor-is-betting-on-1031486237
1250.0,5/25/2022 12:35:58 PM,Karyopharm begins dosing in late-stage study of selinexor combo therapy for multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3842591-karyopharm-begins-dosing-in-late-stage-study-of-selinexor-combo-therapy-for-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral
1251.0,5/27/2022 4:04:02 PM,Biotech Stocks Facing FDA Decision In June 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2022-1031493578
1252.0,5/30/2022 1:56:19 PM,"Bristol-Myers, Novartis win FDA label expansions for cancer medications",Seeking Alpha,https://seekingalpha.com/news/3843682-bristol-myers-novartis-win-fda-label-expansions-for-cancer-medications?utm_source=markets.businessinsider.com&utm_medium=referral
1253.0,5/31/2022 7:44:43 PM,Takeda CEO says drugmakers face pricing pressure due to global crises,Seeking Alpha,https://seekingalpha.com/news/3844113-takeda-ceo-says-drugmakers-face-pricing-pressure-due-to-global-crises?utm_source=markets.businessinsider.com&utm_medium=referral
1254.0,5/31/2022 9:42:54 PM,Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-june-pdufa-dates-1031499656
1255.0,6/1/2022 12:39:43 PM,Bristol Myers' deucravacitinib improves disease activity in lupus patients in mid-stage study,Seeking Alpha,https://seekingalpha.com/news/3844340-bristol-myers-deucravacitinib-improves-disease-activity-in-lupus-patients-in-mid-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral
1256.0,6/1/2022 8:44:10 PM,Sana Biotechnology to develop Washington manufacturing facility saving $100M,Seeking Alpha,https://seekingalpha.com/news/3844761-sana-biotechnology-to-develop-washington-manufacturing-facility-saving-100m?utm_source=markets.businessinsider.com&utm_medium=referral
1257.0,6/2/2022 1:23:43 PM,Immatics stock rises on cell therapy program collaboration with Bristol Myers,Seeking Alpha,https://seekingalpha.com/news/3845000-immatics-stock-rises-on-cell-therapy-program-collaboration-with-bristol-myers?utm_source=markets.businessinsider.com&utm_medium=referral
1258.0,6/2/2022 2:18:11 PM,"Immatics, Bristol Myers Squibb Expand Strategic Alliance To Develop TCR-T, CAR-T Programs ",RTTNews,/news/stocks/immatics-bristol-myers-squibb-expand-strategic-alliance-to-develop-tcr-t-car-t-programs-1031505159
1259.0,6/2/2022 3:54:05 PM,Bristol Myers discloses topline results for arthritis drug in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3845077-bmy-stock-lower-after-topline-results-for-arthritis-drug-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1260.0,6/2/2022 4:25:53 PM,Johnson & Johnson arthritis drug leads to clinical improvement in hospitalized COVID-19,Seeking Alpha,https://seekingalpha.com/news/3845099-johnson-johnson-arthritis-drug-leads-to-clinical-improvement-in-hospitalized-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1261.0,6/3/2022 1:36:50 PM,Turning Point climbs 116% on buyout deal with Bristol Myers for over $4B in cash,Seeking Alpha,https://seekingalpha.com/news/3845418-bmy-stock-flat-tptx-stock-surges-on-4b-acquisition-deal?utm_source=markets.businessinsider.com&utm_medium=referral
1262.0,6/3/2022 2:43:41 PM,TPTX Stock Soars 115% as Bristol-Myers Announces Takeover of Turning Point Therapeutics,InvestorPlace,/news/stocks/tptx-stock-soars-115-as-bristol-myers-announces-takeover-of-turning-point-therapeutics-1031508825
1263.0,6/3/2022 3:14:31 PM,Bristol Myers Squibb To Acquire Turning Point Therapeutics - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-to-acquire-turning-point-therapeutics-quick-facts-1031508506
1264.0,6/3/2022 3:35:19 PM,Bristol Myers downgraded at Raymond James after Turning Point acquisition,Seeking Alpha,https://seekingalpha.com/news/3845549-bmy-stock-downgraded-at-raymond-james-after-turning-point-acquisition?utm_source=markets.businessinsider.com&utm_medium=referral
1265.0,6/3/2022 4:16:56 PM,"Blueprint Medicines, Mirati, Immunogen gain following Turning Point sale to Bristol Myers (update)",Seeking Alpha,https://seekingalpha.com/news/3845503-blueprint-medicines-deciphera-black-diamond-gain-following-turning-point-sale-to-bristol-myers?utm_source=markets.businessinsider.com&utm_medium=referral
1266.0,6/3/2022 7:22:52 PM,What 7 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-7-analyst-ratings-have-to-say-about-bristol-myers-squibb-1031509118
1267.0,6/3/2022 9:11:37 PM,6 Biotech Stocks to Buy Now Ahead of These June Catalysts,InvestorPlace,/news/stocks/6-biotech-stocks-june-catalysts-1031509381
1268.0,6/3/2022 9:31:45 PM,Bristol-Myers Squibb withdraws sBLA for Reblozyl in non-transfusion beta thalassemia,Seeking Alpha,https://seekingalpha.com/news/3845696-bristol-myers-squibb-withdraws-sbla-for-reblozyl-in-non-transfusion-beta-thalassemia?utm_source=markets.businessinsider.com&utm_medium=referral
1269.0,6/5/2022 10:09:23 PM,"The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-june-5-11-adcom-test-for-novavax-asco-presentations-enzo-biochem-earnings-and-more-1031509946
1270.0,6/6/2022 11:00:51 AM,7 Cheap Growth Stocks That Won’t Stay That Way for Long,InvestorPlace,/news/stocks/7-cheap-growth-stocks-that-wont-stay-that-way-for-long-1031510595
1271.0,6/6/2022 11:49:52 AM,Bristol Myers Opdivo/Yervoy combo shows survival benefit for lung cancer patients in 3-year data,Seeking Alpha,https://seekingalpha.com/news/3845848-bristol-myers-opdivoyervoy-combo-shows-survival-benefit-for-lung-cancer-patients-in-3-year-data?utm_source=markets.businessinsider.com&utm_medium=referral
1272.0,6/6/2022 5:12:03 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-6-2022-1031511325
1273.0,6/7/2022 8:00:16 PM,"New drugs cost an average of $180K per year, new study finds",Seeking Alpha,https://seekingalpha.com/news/3846439-new-drugs-cost-an-average-of-180k-per-year-new-study-finds?utm_source=markets.businessinsider.com&utm_medium=referral
1274.0,6/9/2022 6:26:10 PM,Wells Fargo highlights potential targets as biotech M&A accelerates,Seeking Alpha,https://seekingalpha.com/news/3847403-wells-fargo-highlights-potential-targets-as-biotech-ma-accelerates?utm_source=businessinsider&utm_medium=referral
1275.0,6/9/2022 11:15:00 PM,7 Blue-Chip Stocks With Strong Dividend Yields,InvestorPlace,/news/stocks/7-blue-chip-stocks-with-strong-dividend-yields-2-1031520851
1276.0,6/10/2022 6:00:59 PM,"Catalyst watch: Kroger earnings, Powell speaks, Cisco event, Ethereum PoS test",Seeking Alpha,https://seekingalpha.com/news/3847702-catalyst-watch-kroger-earnings-powell-speaks-cisco-event-ethereum-pos-test?utm_source=businessinsider&utm_medium=referral
1277.0,6/10/2022 9:53:38 PM,Goldman Sachs comes under SEC civil probe over ESG funds - WSJ,Seeking Alpha,https://seekingalpha.com/news/3847829-goldman-sachs-comes-under-sec-probe-on-esg-funds-wsj?utm_source=businessinsider&utm_medium=referral
1278.0,6/13/2022 8:43:01 PM,HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications,Benzinga,/news/stocks/hc-wainwright-says-this-lymphoma-candidate-has-better-response-rates-than-approved-medications-1031526010
1279.0,6/14/2022 1:28:36 PM,Bristol Myers tops S&P 500 with largest intangible adjustment in 2021,Seeking Alpha,https://seekingalpha.com/news/3848429-bristol-myers-tops-sp-500-with-largest-intangible-adjustment-in-2021?utm_source=businessinsider&utm_medium=referral
1280.0,6/14/2022 1:57:38 PM,Wells Fargo unveils its recession stock portfolio,Seeking Alpha,https://seekingalpha.com/news/3848418-wells-fargo-unveils-its-recession-stock-portfolio?utm_source=businessinsider&utm_medium=referral
1281.0,6/15/2022 8:18:17 PM,Bristol Myers Squibb declares $0.54 dividend,Seeking Alpha,https://seekingalpha.com/news/3849008-bristol-myers-squibb-company-declares-0_54-dividend?utm_source=businessinsider&utm_medium=referral
1282.0,6/17/2022 8:23:52 PM,The 5 Top Profit & Protection Stocks to Buy for 2022,InvestorPlace,/news/stocks/the-5-top-profit-protection-stocks-to-buy-for-2022-1031536315
1283.0,6/24/2022 3:30:56 PM,Bristol-Myers Squibb hits 52-week high; shares up 27% YTD,Seeking Alpha,https://seekingalpha.com/news/3851621-bristol-myers-squibb-hits-52-week-high-shares-up-27-ytd?utm_source=businessinsider&utm_medium=referral
1284.0,6/24/2022 6:13:59 PM,Bristol-Myers MS drug linked to better COVID response with mRNA shots,Seeking Alpha,https://seekingalpha.com/news/3851697-bristol-myers-ms-drug-linked-to-better-covid-response-with-mrna-shots?utm_source=businessinsider&utm_medium=referral
1285.0,6/24/2022 9:29:05 PM,Bristol-Myers Squibb bid to dismiss $6.4B lawsuit from Celgene shareholders denied - Reuters,Seeking Alpha,https://seekingalpha.com/news/3851842-bristol-myers-squibb-bid-to-dismiss-64b-lawsuit-from-celgene-shareholders-denied-reuters?utm_source=businessinsider&utm_medium=referral
1286.0,6/28/2022 3:48:01 PM,Canada approves Bristol-Myers' Opdivo for bladder cancer patients with certain conditions,Seeking Alpha,https://seekingalpha.com/news/3852526-canada-approves-bristol-myers-opdivo-for-bladder-cancer-patients-with-certain-conditions?utm_source=businessinsider&utm_medium=referral
1287.0,6/29/2022 3:36:20 AM,BMY : Canada Approves OPDIVO For Treatment Of Certain Patients Diagnosed With Urothelial Cancer ,RTTNews,/news/stocks/bmy-canada-approves-opdivo-for-treatment-of-certain-patients-diagnosed-with-urothelial-cancer-1031556062
1288.0,6/29/2022 3:50:08 PM,5 S&P 500 Stocks Ready to Break Out,InvestorPlace,/news/stocks/sp-500-stocks-ready-to-break-out-1031558401
1289.0,6/29/2022 6:06:23 PM,"The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data",Benzinga,/news/stocks/the-daily-biotech-pulse-eli-lilly-modifies-covid-19-treatment-pact-oyster-point-outlines-restructuring-plan-icosavax-posts-interim-rsv-vaccine-data-1031558382
1290.0,7/1/2022 11:26:23 AM,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-july-pdufa-dates-1031562548
1291.0,7/3/2022 6:00:00 PM,"With just 16 new drugs approved in H1 2022, FDA poised for slew of approvals in H2",Seeking Alpha,https://seekingalpha.com/news/3853856-with-just-16-new-drugs-approved-in-h1-2022-fda-poised-for-slew-of-approvals-in-h2?utm_source=businessinsider&utm_medium=referral
1292.0,7/6/2022 2:23:02 PM,6 Stocks Hedge Funds Love in a Recession,InvestorPlace,/news/stocks/stocks-hedge-funds-love-in-a-recession-1031570801
1293.0,7/6/2022 5:22:36 PM,U.S. Senate Democrats advance deal to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3854684-us-senate-democrats-in-agreement-to-lower-drug-prices?utm_source=businessinsider&utm_medium=referral
1294.0,7/8/2022 4:17:59 PM,Best Stocks for 2022: Bristol-Myers Squibb Is Having a Great Year,InvestorPlace,/news/stocks/best-stocks-for-2022-bristol-myers-squibb-1031576071
1295.0,7/15/2022 2:31:31 PM,"Aurinia Pharma tumbles after takeover speculation cools on new exec hires, exec departure",Seeking Alpha,https://seekingalpha.com/news/3857223-aurinia-pharma-tumbles-after-takeover-speculation-cools-on-new-exec-hires-exec-departure?utm_source=businessinsider&utm_medium=referral
1296.0,7/17/2022 10:50:02 AM,"Best Stocks for 2022: After Two Quarters, Who Holds The Lead?",InvestorPlace,/news/stocks/best-stocks-for-2022-after-two-quarters-who-holds-lead-1031591864
1297.0,7/18/2022 6:58:43 PM,Top pharma lobby says R&D spending reached a peak in 2021,Seeking Alpha,https://seekingalpha.com/news/3857699-top-pharma-lobby-says-rd-spending-reached-a-peak-in-2021?utm_source=businessinsider&utm_medium=referral
1298.0,7/19/2022 12:09:23 PM,Bristol Myers extends tender offer period for $4.1B Turning Point acquisition,Seeking Alpha,https://seekingalpha.com/news/3857977-bristol-myers-extends-tender-offer-period-for-41b-turning-point-acquisition?utm_source=businessinsider&utm_medium=referral
1299.0,7/19/2022 6:33:55 PM,Cancer immunotherapy biotech Immatics up 18% on 4x normal volume,Seeking Alpha,https://seekingalpha.com/news/3858219-cancer-immunotherapy-biotech-immatics-up-17-on-4x-normal-volume?utm_source=businessinsider&utm_medium=referral
1300.0,7/19/2022 8:30:19 PM,"Psychedelics Management Updates: Two Top Companies Appoint New CEOs, Here's What We Know",Benzinga,/news/stocks/psychedelics-management-updates-two-top-companies-appoint-new-ceos-here-s-what-we-know-1031598273
1301.0,7/20/2022 4:18:23 PM,Arcellx named new buy at Canaccord Genuity on multiple myeloma candidate,Seeking Alpha,https://seekingalpha.com/news/3858614-arcellx-named-new-buy-at-canaccord-genuity-on-multiple-myeloma-candidate?utm_source=businessinsider&utm_medium=referral
1302.0,7/20/2022 10:00:43 PM,7 Best Pharmaceutical Stocks to Buy Now,InvestorPlace,/news/stocks/best-pharmaceutical-stocks-1031602627
1303.0,7/22/2022 11:23:46 AM,Bristol-Myers new immunotherapy Opdualag gets EMA panel nod to treat skin cancer,Seeking Alpha,https://seekingalpha.com/news/3859540-bristol-myers-new-immunotherapy-opdualag-gets-ema-panel-nod-to-treat-skin-cancer?utm_source=businessinsider&utm_medium=referral
1304.0,7/22/2022 3:21:00 PM,"Bristol Myers U.S., German antitrust filings for Turning Point expected very soon (update)",Seeking Alpha,https://seekingalpha.com/news/3859302-bristol-myers-us-german-antitrust-filings-for-turning-point-expected-very-soon-report?utm_source=businessinsider&utm_medium=referral
1305.0,7/22/2022 11:59:12 PM,Recap Of Friday's Biotech Catalysts - End Of The Day Summary,Benzinga,/news/stocks/recap-of-friday-s-biotech-catalysts---end-of-the-day-summary-1031608647
1306.0,7/23/2022 8:15:00 PM,"Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC",Seeking Alpha,https://seekingalpha.com/news/3859761-drug-pricing-legislation-will-affect-biopharma-revenue-but-impact-is-manageable-rbc?utm_source=businessinsider&utm_medium=referral
1307.0,7/24/2022 3:00:43 PM,7 Best Cash Cow Stocks to Buy for Stable Returns,InvestorPlace,/news/stocks/best-cash-cow-stocks-1031609438
1308.0,7/24/2022 10:37:06 PM,"Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earnings Pick Up Pace",Benzinga,/news/stocks/apple-meta-pfizer-among-key-companies-reporting-in-the-week-ahead-as-earning-picks-up-pace-1031609526
1309.0,7/26/2022 1:50:58 PM,Will Bristol Myers Squibb positive earnings momentum continue in Q2?,Seeking Alpha,https://seekingalpha.com/news/3860531-will-bristol-myers-squibb-positive-earnings-momentum-continue-in-q2?utm_source=businessinsider&utm_medium=referral
1310.0,7/26/2022 3:01:13 PM,What Wall Street expects from Bristol-Myers Squibb's earnings,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-q2-earnings-preview-1031615553
1311.0,7/26/2022 3:50:03 PM,Patent challenge on Aurinia's Lupkynis could impact takeover interest near-term - Cantor,Seeking Alpha,https://seekingalpha.com/news/3860602-patent-challenge-on-aurinias-lupkynis-could-impact-takeover-interest-near-term-cantor?utm_source=businessinsider&utm_medium=referral
1312.0,7/26/2022 4:08:38 PM,Patent challenge on Aurinia's Lupkynis could impact takeover interest near-term - Cantor,Seeking Alpha,https://seekingalpha.com/news/3860602-patent-challenge-on-aurinia-lupkynis-could-impact-takeover-interest-near-term-cantor?utm_source=businessinsider&utm_medium=referral
1313.0,7/27/2022 11:02:11 AM,"Bristol Myers Squibb Non-GAAP EPS of $1.93 beats by $0.12, revenue of $11.9B beats by $400M, cuts FY22 outlook",Seeking Alpha,https://seekingalpha.com/news/3861183-bristol-myers-squibb-non-gaap-eps-of-193-beats-by-012-revenue-of-119b-beats-by-400m-cuts-fy22-outlook?utm_source=businessinsider&utm_medium=referral
1314.0,7/27/2022 12:00:03 PM,Bristol Myers slips as forex impact triggers 2022 guidance cut,Seeking Alpha,https://seekingalpha.com/news/3861255-bmy-stock-slips-as-forex-impact-triggers-2022-guidance-cut?utm_source=businessinsider&utm_medium=referral
1315.0,7/27/2022 1:32:41 PM,Bristol-Myers Squibb Reaffirms FY22 Adj. EPS Outlook; Q2 Results Top Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-reaffirms-fy22-adj-eps-outlook-q2-results-top-estimates-1031620017
1316.0,7/27/2022 3:28:18 PM,"Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy",Benzinga,/news/stocks/daily-biotech-pulse-teva-s-opioids-settlement-criminal-investigation-against-cassava-durable-responses-for-in8bio-s-leukemia-therapy-1031621034
1317.0,7/28/2022 5:39:16 PM,Expert Ratings for Bristol-Myers Squibb,Benzinga,/news/stocks/expert-ratings-for-bristol-myers-squibb-1031626653
1318.0,7/29/2022 11:22:02 AM,Bristol Myers Opdivo/Yervoy combo fails as post-surgical therapy in kidney cancer in phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3863067-bristol-myers-opdivoyervoy-combo-fails-as-post-surgical-therapy-in-kidney-cancer-in-phase-3-trial?utm_source=businessinsider&utm_medium=referral
1319.0,7/29/2022 1:56:39 PM,Bristol Myers: CheckMate -914 Part A Trial With Opdivo Plus Yervoy Fails To Meet Primary Goal ,RTTNews,/news/stocks/bristol-myers-checkmate-914-part-a-trial-with-opdivo-plus-yervoy-fails-to-meet-primary-goal-1031629807
1320.0,7/29/2022 4:27:45 PM,"Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update",Benzinga,/news/stocks/daily-biotech-pulse-bausch-health-to-appeal-xifaxan-patent-decision-bristol-myers-drug-combo-fails-in-kidney-cancer-trial-sarepta-s-duchenne-candidate-update-1031630398
1321.0,7/29/2022 11:24:17 PM,Recap Of Friday's Biotech Catalysts - End of The Day Summary,Benzinga,/news/stocks/recap-of-friday-s-biotech-catalysts---end-of-the-day-summary-1031631044
1322.0,8/4/2022 5:18:38 PM,Eli Lilly ordered to pay $183M in whistleblower Medicaid fraud case - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3867381-eli-lilly-ordered-to-pay-183m-in-whistleblower-medicaid-fraud-case-bloomberg?utm_source=businessinsider&utm_medium=referral
1323.0,8/7/2022 10:19:22 PM,$35 per month capped insulin for private insurance kept out of Inflation Reduction Act,Seeking Alpha,https://seekingalpha.com/news/3868539-35-per-month-capped-insulin-for-private-insurance-kept-out-of-inflation-reduction-act-passed-by-senate?utm_source=businessinsider&utm_medium=referral
1324.0,8/8/2022 3:44:30 PM,Nektar downgraded at JPMorgan citing setup after end to anti-cancer program,Seeking Alpha,https://seekingalpha.com/news/3868851-nektar-downgraded-at-jpmorgan-citing-setup-after-end-to-anti-cancer-program?utm_source=businessinsider&utm_medium=referral
1325.0,8/10/2022 11:16:16 AM,"Bristol Myers, 2seventy bio score trial win for multiple myeloma candidate",Seeking Alpha,https://seekingalpha.com/news/3870557-tsvt-stock-soars-after-trial-win-with-bristol-myers-for-multiple-myeloma-drug?utm_source=businessinsider&utm_medium=referral
1326.0,8/10/2022 11:25:30 AM,"Bristol Myers, GentiBio ink up to $1.9B pact to develop therapies for inflammatory bowel diseases",Seeking Alpha,https://seekingalpha.com/news/3870566-bristol-myers-gentibio-ink-up-to-19b-pact-to-develop-therapies-for-inflammatory-bowel-diseases?utm_source=businessinsider&utm_medium=referral
1327.0,8/10/2022 2:30:31 PM,2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy,Benzinga,/news/stocks/2seventy-bio-shares-jump-on-positive-data-from-bristol-myers-partnered-cancer-immunotherapy-1031670516
1328.0,8/10/2022 5:33:08 PM,"Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial",Benzinga,/news/stocks/biotech-daily-cancer-causing-impurities-in-merck-s-diabetic-drug-vir-bio-gsk-shun-fda-submission-plans-for-covid-19-treatment-aethlon-s-monkeypox-trial-1031671419
1329.0,8/11/2022 12:23:03 AM,Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-wednesday-s-biotech-catalysts---end-of-the-day-summary-1031672483
1330.0,8/14/2022 5:48:06 PM,Analysts rule out major industry impact from drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3872629-analysts-rule-out-major-industry-impact-from-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral
1331.0,8/15/2022 8:46:33 PM,Why Michael Burry Is Betting Big on Just ONE Secretive Stock,InvestorPlace,/news/stocks/why-michael-burry-is-betting-big-on-just-one-secretive-stock-1031685177
1332.0,8/16/2022 11:45:24 AM,"Bristol Myers' $4.1B Turning Point acquisition gets clearance in US, Germany, set to close",Seeking Alpha,https://seekingalpha.com/news/3873537-bristol-myers-41b-turning-point-acquisition-gets-clearance-in-us-germany-set-to-close?utm_source=businessinsider&utm_medium=referral
1333.0,8/16/2022 3:54:34 PM,"Scion Asset Management exits all positions, holding just one stock- Geo Group",Seeking Alpha,https://seekingalpha.com/news/3873725-scion-asset-management-exits-all-positions-holding-just-one-stock-geo-group?utm_source=businessinsider&utm_medium=referral
1334.0,8/17/2022 6:58:50 PM,Michael Burry Puts His Money Where His Mouth Is For Market Crash Prediction: But Did He Sell Too Soon?,Benzinga,/news/stocks/michael-burry-puts-his-money-where-his-mouth-is-for-market-crash-prediction-but-did-he-sell-too-soon-1031690845
1335.0,8/23/2022 1:01:38 PM,Bristol Myers gets Health Canada nod for Opdivo combo use before surgery in lung cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3875777-bristol-myers-gets-health-canada-nod-for-opdivo-combo-use-before-surgery-in-lung-cancer-subtype?utm_source=businessinsider&utm_medium=referral
1336.0,8/23/2022 2:52:48 PM,Bristol Myers: Health Canada Approves OPDIVO Plus Platinum-doublet Chemotherapy ,RTTNews,/news/stocks/bristol-myers-health-canada-approves-opdivo-plus-platinum-doublet-chemotherapy-1031700513
1337.0,8/24/2022 12:53:43 AM,Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-tuesday-s-biotech-catalysts---end-of-the-day-summary-1031701797
1338.0,8/27/2022 9:08:07 AM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1031709034
1339.0,8/29/2022 4:44:50 PM,"Bristol-Myers falls 5%, most in two years, after mid-stage data for blood thinner",Seeking Alpha,https://seekingalpha.com/news/3877518-bmy-stock-falls-after-mid-stage-data-for-blood-thinner?utm_source=businessinsider&utm_medium=referral
1340.0,8/31/2022 8:52:36 PM,"Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know",Benzinga,/news/stocks/bluebird-bio-seeks-back-to-back-nods-go-or-no-go-for-revance-s-botox-rival-amylyx-twin-hurdles-and-more-september-s-key-pdufa-catalysts-biotech-investors-must-know-1031717312
1341.0,9/1/2022 11:30:33 AM,5 Stocks That Michael Burry Just Dumped From His Portfolio,InvestorPlace,/news/stocks/5-stocks-that-michael-burry-just-dumped-from-his-portfolio-1031718929
1342.0,9/7/2022 2:14:42 PM,Cipla Gets Final Approval For Generic Version Of Revlimid - Quick Facts ,RTTNews,/news/stocks/cipla-gets-final-approval-for-generic-version-of-revlimid-quick-facts-1031728987
1343.0,9/11/2022 11:03:19 PM,7 Blue-Chip Stocks to Buy Before the Bull Market Returns,InvestorPlace,/news/stocks/blue-chip-stocks-to-buy-before-bull-market-returns-1031630381
1344.0,9/12/2022 10:22:20 AM,Bristol Myers stock rises on FDA approval of psoriasis therapy Sotyktu; presents long-term efficacy data,Seeking Alpha,https://seekingalpha.com/news/3881893-bristol-myers-stock-rises-on-fda-approval-of-psoriasis-therapy-sotyktu-presents-long-term-efficacy-data?utm_source=businessinsider&utm_medium=referral
1345.0,9/12/2022 12:30:53 PM,Why Clovis Oncology Is Trading Higher By 14%; Here Are 28 Stocks Moving Premarket,Benzinga,/news/stocks/why-clovis-oncology-is-trading-higher-by-14-here-are-28-stocks-moving-premarket-1031736782
1346.0,9/12/2022 12:40:20 PM,"ASTS, ONTX and BITF among pre market gainers",Seeking Alpha,https://seekingalpha.com/news/3881955-asts-ontx-and-bitf-among-pre-market-gainers?utm_source=businessinsider&utm_medium=referral
1347.0,9/12/2022 1:30:50 PM,Bristol-Myers Squibb To $87? Here Are 5 Other Price Target Changes For Monday,Benzinga,/news/stocks/bristol-myers-squibb-to-87-here-are-5-other-price-target-changes-for-monday-1031736928
1348.0,9/12/2022 1:35:31 PM,"Bristol-Myers Squibb, Carvana And Some Other Big Stocks Recording Gains In Today's Pre-Market Session",Benzinga,/news/stocks/bristol-myers-squibb-carvana-and-some-other-big-stocks-recording-gains-in-today-s-pre-market-session-1031736970
1349.0,9/12/2022 1:37:05 PM,Bristol-Myers Squibb (BMY) Stock Jumps 8% as FDA Approves Psoriasis Treatment,InvestorPlace,/news/stocks/bristol-myers-squibb-bmy-stock-jumps-8-as-fda-approves-psoriasis-treatment-1031737488
1350.0,9/12/2022 1:50:38 PM,Adobe (ADBE) Stock Slips on Analyst Downgrade,InvestorPlace,/news/stocks/adobe-adbe-stock-slips-on-analyst-downgrade-1031737531
1351.0,9/12/2022 2:03:30 PM,QSR Stock Pops as Burger Kings Announces $400 Million Investment,InvestorPlace,/news/stocks/qsr-stock-pops-as-burger-kings-announces-400-million-investment-1031737598
1352.0,9/12/2022 2:44:36 PM,"HC Wainwright Cuts Price Target On This Stock By 73%, Also Check Out Other Major PT Changes Here",Benzinga,/news/stocks/hc-wainwright-cuts-price-target-on-this-stock-by-73-also-check-out-other-major-pt-changes-here-1031737265
1353.0,9/12/2022 2:48:55 PM,Ventyx stock soars 69% as analysts see Sotyktu approval sans warning a 'win' for TYK2 class,Seeking Alpha,https://seekingalpha.com/news/3882039-ventyx-stock-soars-as-analysts-see-sotyktu-approval-sans-warning-a-win-for-tyk2-class?utm_source=businessinsider&utm_medium=referral
1354.0,9/12/2022 4:19:33 PM,Onconova rigosertib/Opdivo combo shows promise in advanced lung cancer in trial,Seeking Alpha,https://seekingalpha.com/news/3882075-onconova-rigosertibopdivo-combo-shows-promise-in-advanced-lung-cancer-in-trial?utm_source=businessinsider&utm_medium=referral
1355.0,9/12/2022 6:45:41 PM,"Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session",Benzinga,/news/stocks/why-ventyx-biosciences-is-trading-higher-by-70-here-are-46-stocks-moving-in-monday-s-mid-day-session-1031737993
1356.0,9/12/2022 10:04:36 PM,5 Analysts Have This to Say About Bristol-Myers Squibb,Benzinga,/news/stocks/5-analysts-have-this-to-say-about-bristol-myers-squibb-1031738282
1357.0,9/12/2022 11:06:14 PM,Expert Ratings for Bristol-Myers Squibb,Benzinga,/news/stocks/expert-ratings-for-bristol-myers-squibb-1031738397
1358.0,9/13/2022 9:01:20 AM,"NIO, Lucid Group And Other Big Gainers From Monday",Benzinga,/news/stocks/nio-lucid-group-and-other-big-gainers-from-monday-1031738922
1359.0,9/13/2022 10:30:24 AM,7 Screaming Buy Stock Picks to Beat the September Market Slump,InvestorPlace,/news/stocks/7-screaming-buy-stock-picks-to-beat-the-september-market-slump-1031739340
1360.0,9/13/2022 11:15:00 AM,Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-tuesday-morning-shares-tumbled-31-here-are-66-biggest-movers-from-yesterday-1031739149
1361.0,9/13/2022 8:38:58 PM,Amgen drops to six-month low amid latest challenges to pipeline,Seeking Alpha,https://seekingalpha.com/news/3882497-amgn-stock-drops-to-six-month-low-amid-latest-challenges?utm_source=businessinsider&utm_medium=referral
1362.0,9/14/2022 11:58:17 AM,US Stock Futures Rise After Recording Worst Sell-Off Since June 2020; PPI Data In Focus,Benzinga,/news/stocks/us-stock-futures-rise-after-recording-worst-sell-off-since-june-2020-ppi-data-in-focus-1031742133
1363.0,9/14/2022 1:18:29 PM,"Bristol-Myers cut to hold at Bereneberg citing U.S. pricing reforms, patent cliff",Seeking Alpha,https://seekingalpha.com/news/3882692-bmy-stock-cut-to-hold-at-bereneberg-on-us-pricing-reforms-patent-cliff?utm_source=businessinsider&utm_medium=referral
1364.0,9/14/2022 4:07:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-14-2022-1031743148
1365.0,9/14/2022 8:18:51 PM,Bristol Myers Squibb declares $0.54 dividend,Seeking Alpha,https://seekingalpha.com/news/3882835-bristol-myers-squibb-company-declares-0_54-dividend?utm_source=businessinsider&utm_medium=referral
1366.0,9/14/2022 8:46:14 PM,These 5 Experts See A Market Crash Ahead: What Do BZ Readers Think?,Benzinga,/news/etf/these-5-experts-see-a-market-crash-ahead-what-do-bz-readers-think-1031743729
1367.0,9/15/2022 12:10:24 PM,Bristol Myers Opdivo shows survival benefit as adjuvant therapy for skin cancer in trial,Seeking Alpha,https://seekingalpha.com/news/3882972-bristol-myers-opdivo-shows-survival-benefit-as-adjuvant-therapy-for-skin-cancer-in-trial?utm_source=businessinsider&utm_medium=referral
1368.0,9/19/2022 10:00:06 AM,7 Penny Stocks That Actually Have a Buy Rating,InvestorPlace,/news/stocks/7-penny-stocks-with-buy-ratings-to-keep-your-eye-on-1031750175
1369.0,9/19/2022 10:09:27 AM,"AutoZone, bluebird bio And 3 Stocks To Watch Heading Into Monday",Benzinga,/news/stocks/autozone-bluebird-bio-and-3-stocks-to-watch-heading-into-monday-1031749980
1370.0,9/19/2022 11:32:56 AM,"US Stock Futures Down Ahead Of Fed's Rate Decision This Week, Crude Oil Drops Over 1%",Benzinga,/news/stocks/us-stock-futures-down-ahead-of-fed-s-rate-decision-this-week-crude-oil-drops-over-1-1031750084
1371.0,9/20/2022 8:18:52 PM,3 Stocks That Could Rocket on Biden’s Cancer Moonshot,InvestorPlace,/news/stocks/3-stocks-that-could-rocket-on-bidens-cancer-moonshot-1031754919
1372.0,9/21/2022 10:13:03 PM,"CPRX, BMY: Insiders are Selling These 2 Pharma Stocks; Should You?",TipRanks,/news/stocks/cprx-bmy-insiders-are-selling-these-2-pharma-stocks-should-you-1031757894
1373.0,9/23/2022 11:46:34 AM,Artivion stock falls as apixaban fails vs warfarin in reducing blood clots in aortic valve patients; reaffirms outlook,Seeking Alpha,https://seekingalpha.com/news/3885575-artivion-stock-falls-as-apixaban-fails-vs-warfarin-in-reducing-blood-clots-in-aortic-valve-patients-stops-trial-reaffirms-outlook?utm_source=businessinsider&utm_medium=referral
1374.0,9/23/2022 5:05:53 PM,"Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock",Benzinga,/news/stocks/insiders-selling-nasdaq-bristol-myers-squibb-and-this-consumer-defensive-stock-1031762182
1375.0,9/28/2022 10:17:23 PM,These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win,Benzinga,/news/stocks/these-stocks-are-on-the-radar-after-biogen-eisai-s-surprising-alzheimer-s-trial-win-1031771238
1376.0,10/4/2022 4:30:31 AM,"LLY, ISRG, or BMY: Which Healthcare Stock Could Yield Better Returns?",TipRanks,/news/stocks/lly-isrg-or-bmy-which-healthcare-stock-could-yield-better-returns-1031780497
1377.0,10/4/2022 12:18:44 PM,Autolus stock rises on Bristol Myers contract for use of safety switch with cell therapies,Seeking Alpha,https://seekingalpha.com/news/3888414-autolus-stock-rises-on-bristol-myers-contract-for-use-of-safety-switch-with-cell-therapies?utm_source=businessinsider&utm_medium=referral
1378.0,10/4/2022 1:00:39 PM,Exelixis expands cancer clinical trial collaboration & supply pact with Bristol-Myers,Seeking Alpha,https://seekingalpha.com/news/3888447-exelixis-expands-cancer-clinical-trial-collaboration--supply-pact-with-bristol-myers?utm_source=businessinsider&utm_medium=referral
1379.0,10/4/2022 2:25:03 PM,Exelixis Expands Agreement With Bristol Myers For STELLAR-002 Trial - Quick Facts ,RTTNews,/news/stocks/exelixis-expands-agreement-with-bristol-myers-for-stellar-002-trial-quick-facts-1031781492
1380.0,10/4/2022 4:50:57 PM,Bristol in collaboration pact with tiny biotech SyntheX on targeted protein degraders,Seeking Alpha,https://seekingalpha.com/news/3888591-bristol-in-collaboration-pact-with-tiny-biotech-synthex-on-targeted-protein-degraders?utm_source=businessinsider&utm_medium=referral
1381.0,10/4/2022 6:09:33 PM,HHS change to Medicare payments for biosimilars aims to spur uptake,Seeking Alpha,https://seekingalpha.com/news/3888611-hhs-change-to-medicare-payments-for-biosimilars-aims-to-spur-uptake?utm_source=businessinsider&utm_medium=referral
1382.0,10/4/2022 8:09:04 PM,Best Stocks 2022: These 3 Factors Can Send Sonic Automotive (SAH) Stock Soaring in Q4,InvestorPlace,/news/stocks/best-stocks-2022-these-3-factors-can-send-sonic-automotive-sah-stock-soaring-in-q4-1031782939
1383.0,10/5/2022 8:01:34 PM,Best Stocks 2022: Why Bristol-Myers Squibb (BMY) Stock Is a Clear Winner,InvestorPlace,/news/stocks/best-stocks-2022-why-bristol-myers-squibb-bmy-stock-is-a-clear-winner-1031785682
1384.0,10/7/2022 11:25:53 AM,Knight's affiliate files for Brazilian approval of cancer drug tafasitamab,Seeking Alpha,https://seekingalpha.com/news/3889584-knights-affiliate-files-for-brazilian-approval-of-cancer-drug-tafasitamab?utm_source=businessinsider&utm_medium=referral
1385.0,10/7/2022 5:21:22 PM,PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics,Benzinga,/news/stocks/puretech-health-confirms-possible-merger-with-nektar-therapeutics-1031790389
1386.0,10/10/2022 11:35:59 AM,Merck's Acceleron buy shows results as sotatercept meets main goal in trial to treat high pressure in lungs,Seeking Alpha,https://seekingalpha.com/news/3889939-mercks-acceleron-buy-shows-results-as-sotatercept-meets-main-goal-in-trial-to-treat-high-pressure-in-lungs?utm_source=businessinsider&utm_medium=referral
1387.0,10/10/2022 1:06:03 PM,Bristol-Myers cut to Neutral at Guggenheim citing overly bullish consensus,Seeking Alpha,https://seekingalpha.com/news/3889989-bmy-stock-cut-to-neutral-at-guggenheim-citing-overly-bullish-consensus?utm_source=businessinsider&utm_medium=referral
1388.0,10/10/2022 3:59:33 PM,6 Analysts Have This to Say About Bristol-Myers Squibb,Benzinga,/news/stocks/6-analysts-have-this-to-say-about-bristol-myers-squibb-1031793346
1389.0,10/10/2022 4:08:11 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-10-2022-1031793370
1390.0,10/10/2022 5:04:52 PM,What 6 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-6-analyst-ratings-have-to-say-about-bristol-myers-squibb-1031793557
1391.0,10/10/2022 6:09:22 PM,GOP senators introduce bill to undo Medicare prescription drug negotiation,Seeking Alpha,https://seekingalpha.com/news/3890099-gop-senators-introduce-bill-to-undo-medicare-prescription-drug-negotiation?utm_source=businessinsider&utm_medium=referral
1392.0,10/10/2022 8:10:08 PM,The 7 Most Undervalued Value Stocks to Buy Now,InvestorPlace,/news/stocks/the-7-most-undervalued-value-stocks-to-buy-now-1031794052
1393.0,10/11/2022 5:49:38 PM,"BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status",Seeking Alpha,https://seekingalpha.com/news/3890439-bridgebio-stock-rises-as-bbp-398-lumakras-combo-gets-fda-fast-track-status?utm_source=businessinsider&utm_medium=referral
1394.0,10/14/2022 12:24:33 PM,Biden to sign Executive Order tasking HHS to find additional ways to lower drug costs,Seeking Alpha,https://seekingalpha.com/news/3891387-biden-to-sign-executive-order-tasking-hhs-to-find-additional-ways-to-lower-drug-costs-medicare?utm_source=businessinsider&utm_medium=referral
1395.0,10/17/2022 2:34:50 PM,Morgan Stanley says large cap healthcare remains attractive amid macro concerns,Seeking Alpha,https://seekingalpha.com/news/3891861-morgan-stanely-says-large-cap-healthcare-remains-attractive-amid-macro-concerns?utm_source=businessinsider&utm_medium=referral
1396.0,10/18/2022 1:59:33 PM,What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?,InvestorPlace,/news/stocks/what-is-going-on-with-aveo-pharmaceuticals-aveo-stock-today-1031813929
1397.0,10/19/2022 9:36:38 PM,Bristol-Myers' Opdivo cancer drug reduces risk of death in resected stage II melanoma,Seeking Alpha,https://seekingalpha.com/news/3892931-bristol-myers-opdivo-cancer-drug-reduces-risk-of-death-in-resected-stage-ii-melanoma?utm_source=businessinsider&utm_medium=referral
1398.0,10/20/2022 5:19:54 PM,Prescription drugs make up a rising share of Medicare spending – study,Seeking Alpha,https://seekingalpha.com/news/3893317-prescription-drugs-account-for-a-rising-chunk-of-medicare-spending-study?utm_source=businessinsider&utm_medium=referral
1399.0,10/21/2022 10:39:48 AM,Aurinia announces resignations of medical chief and senior research executive,Seeking Alpha,https://seekingalpha.com/news/3893596-auph-stock-slips-on-resignations-of-medical-chief-senior-research-executive?utm_source=businessinsider&utm_medium=referral
1400.0,10/21/2022 11:24:42 AM,Bristol Myers heart drug Camzyos gets FDA review for expanded use,Seeking Alpha,https://seekingalpha.com/news/3893619-bristol-myers-heart-drug-camzyos-gets-fda-review-for-expanded-use?utm_source=businessinsider&utm_medium=referral
1401.0,10/21/2022 5:16:55 PM,"Earnings week ahead: Apple, Alphabet, Amazon, Meta, Boeing and more",Seeking Alpha,https://seekingalpha.com/news/3893730-earnings-week-ahead-apple-alphabet-amazon-meta-boeing-and-more?utm_source=businessinsider&utm_medium=referral
1402.0,10/21/2022 5:56:11 PM,"Talks begin with pharma, health insurers over negotiating drug prices for Medicare",Seeking Alpha,https://seekingalpha.com/news/3893788-talks-begin-with-pharma-health-insurers-over-negotiating-drug-prices-for-medicare?utm_source=businessinsider&utm_medium=referral
1403.0,10/25/2022 2:07:37 PM,Bristol Myers Squibb Q3 2022 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3894760-bristol-myers-squibb-q3-2022-earnings-preview?utm_source=businessinsider&utm_medium=referral
1404.0,10/25/2022 3:01:13 PM,Bristol-Myers Squibb earnings: here's what to expect,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-quarter-earnings-preview-q3-1031832929
1405.0,10/25/2022 3:10:05 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3894799-notable-earnings-before-wednesdays-open?utm_source=businessinsider&utm_medium=referral
1406.0,10/26/2022 7:17:42 AM,"Bristol Myers Squibb Non-GAAP EPS of $1.99 beats by $0.16, revenue of $11.22B beats by $40M, re-affirms FY22 outlook",Seeking Alpha,https://seekingalpha.com/news/3895253-bristol-myers-squibb-non-gaap-eps-of-199-beats-by-016-revenue-of-1122b-beats-by-40m-re-affirms-fy22-outlook?utm_source=businessinsider&utm_medium=referral
1407.0,10/26/2022 9:04:38 AM,"Bristol Myers Q3 sales fall amid generic competition to Revlimid, forex woes",Seeking Alpha,https://seekingalpha.com/news/3895281-bristol-myers-q3-sales-fall-amid-generic-competition-to-revlimid-forex-woes?utm_source=businessinsider&utm_medium=referral
1408.0,10/26/2022 10:18:48 AM,Bristol Myers MS drug Zeposia recipients mounted serologic response to COVID vaccines in trial,Seeking Alpha,https://seekingalpha.com/news/3895308-bristol-myers-ms-drug-zeposia-recipients-mounted-serologic-response-to-covid-vaccines-in-trial?utm_source=businessinsider&utm_medium=referral
1409.0,10/27/2022 12:35:35 PM,Morgan Stanley Sticks to Its Sell Rating for Bristol Myers (BMY),TipRanks,/news/stocks/morgan-stanley-sticks-to-its-sell-rating-for-bristol-myers-bmy-1031843403
1410.0,10/27/2022 12:38:16 PM,Atlantic Equities Sticks to Its Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/atlantic-equities-sticks-to-its-buy-rating-for-bristol-myers-bmy-1031843386
1411.0,10/27/2022 1:00:07 PM,Bristol extends agreement with Obsidian Therapeutics for cell therapies for cancer,Seeking Alpha,https://seekingalpha.com/news/3896463-bristol-extends-agreement-with-obsidian-therapeutics-for-cell-therapies-for-cancer?utm_source=businessinsider&utm_medium=referral
1412.0,10/27/2022 1:40:59 PM,Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-bmy-and-abbvie-abbv-1031843968
1413.0,10/27/2022 2:30:00 PM,Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb,PR Newswire,/news/stocks/obsidian-therapeutics-announces-extension-of-multi-year-collaboration-agreement-with-bristol-myers-squibb-1031843274
1414.0,10/27/2022 4:00:39 PM,Analyst Ratings for Bristol-Myers Squibb,Benzinga,/news/stocks/analyst-ratings-for-bristol-myers-squibb-1031844083
1415.0,10/27/2022 4:08:59 PM,Where Bristol-Myers Squibb Stands With Analysts,Benzinga,/news/stocks/where-bristol-myers-squibb-stands-with-analysts-1031844124
1416.0,10/27/2022 7:30:41 PM,Wingstop To Rally Around 13%? Plus This Analyst Cuts PT On Cano Health By 50%,Benzinga,/news/stocks/wingstop-to-rally-around-13-plus-this-analyst-cuts-pt-on-cano-health-by-50-1031844778
1417.0,10/27/2022 8:37:46 PM,"Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock",Benzinga,/news/stocks/analyst-sees-market-potential-for-arcellx-multiple-myeloma-candidate-sees-50-upside-in-stock-1031844903
1418.0,10/28/2022 1:55:45 PM,Geron draws Outperform rating at Wedbush on prospects for blood disease therapy,Seeking Alpha,https://seekingalpha.com/news/3897283-gern-stock-gains-on-outperform-rating-at-wedbush?utm_source=businessinsider&utm_medium=referral
1419.0,10/31/2022 11:42:01 AM,Bristol Myers says Merck-partnered blood cancer therapy met main goal in Phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3897653-bristol-myers-merck-partnered-blood-cancer-therapy-succeeds-in-phase-3-trial?utm_source=businessinsider&utm_medium=referral
1420.0,11/1/2022 10:31:39 AM,"Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY), Hologic (HOLX) and Genmab (GMAB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-bmy-hologic-holx-and-genmab-gmab-1031857622
1421.0,11/1/2022 5:26:53 PM,Legend Biotech initiated at outperform at Cowen on strength of Carvykti,Seeking Alpha,https://seekingalpha.com/news/3898764-legend-biotech-initiated-at-outperform-at-cowen-on-strength-of-carvykti?utm_source=businessinsider&utm_medium=referral
1422.0,11/3/2022 12:33:42 PM,Kura Oncology rises on $25M equity investment from Bristol Myers,Seeking Alpha,https://seekingalpha.com/news/3900908-kura-oncology-rises-on-25m-equity-investment-from-bristol-myers?utm_source=businessinsider&utm_medium=referral
1423.0,11/3/2022 4:30:26 PM,"Cancer drugs launch prices soaring, straining Medicare, report finds",Seeking Alpha,https://seekingalpha.com/news/3901117-cancer-drugs-launch-prices-soaring-straining-medicare-report-finds?utm_source=businessinsider&utm_medium=referral
1424.0,11/4/2022 11:38:11 AM,BioAtla soars 47% as drug shows response in lung cancer patients in trial,Seeking Alpha,https://seekingalpha.com/news/3901838-bioatla-stock-soars-as-drug-shows-response-in-lung-cancer-patients-in-trial?utm_source=businessinsider&utm_medium=referral
1425.0,11/7/2022 9:47:57 AM,GSK's blood cancer therapy Blenrep fails to meet main goal in phase 3 study,Seeking Alpha,https://seekingalpha.com/news/3902419-gsks-blood-cancer-therapy-blenrep-fails-to-meet-main-goal-in-phase-3-study?utm_source=businessinsider&utm_medium=referral
1426.0,11/7/2022 6:50:06 PM,Bristol Myers bid for $1.2B Gilead patent award rejected by Supreme Court,Seeking Alpha,https://seekingalpha.com/news/3902906-bristol-myers-bid-for-12b-gilead-patent-award-rejected-by-supreme-court?utm_source=businessinsider&utm_medium=referral
1427.0,11/8/2022 7:04:04 PM,The 7 Best Pharma Stocks to Buy Now,InvestorPlace,/news/stocks/the-7-best-pharma-stocks-to-buy-now-1031893081
1428.0,11/10/2022 3:20:42 PM,Bristol Myers Squibb's Camzyos approved in Canada for hypertrophic cardiomyopathy,Seeking Alpha,https://seekingalpha.com/news/3905690-bristol-myers-squibbs-camzyos-approved-in-canada-for-hypertrophic-cardiomyopathy?utm_source=businessinsider&utm_medium=referral
1429.0,11/10/2022 4:40:43 PM,"Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY), Precision BioSciences (DTIL) and Immunocore Holdings (IMCR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-bmy-precision-biosciences-dtil-and-immunocore-holdings-imcr-1031899596
1430.0,11/10/2022 4:40:50 PM,Bristol-Myers Squibb To Surge Over 10%? Plus Morgan Stanley Predicts $263 For L3Harris Technologies,Benzinga,/news/stocks/bristol-myers-squibb-to-surge-over-10-plus-morgan-stanley-predicts-263-for-l3harris-technologies-1031899394
1431.0,11/11/2022 8:16:39 PM,"Healthcare stocks come off lows, worst performing sector among defensive losers (update)",Seeking Alpha,https://seekingalpha.com/news/3906637-healthcare-stocks-fall-across-the-board-as-traders-move-out-of-defensive-sectors?utm_source=businessinsider&utm_medium=referral
1432.0,11/11/2022 9:31:43 PM,Why Are Healthcare Stocks Down Today?,InvestorPlace,/news/stocks/why-are-healthcare-stocks-down-today-1031905660
1433.0,11/18/2022 1:02:32 PM,8 Analysts Have This to Say About Bristol-Myers Squibb,Benzinga,/news/stocks/8-analysts-have-this-to-say-about-bristol-myers-squibb-1031924934
1434.0,11/18/2022 5:58:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-18-2022-1031925925
1435.0,11/18/2022 7:00:33 PM,Where Bristol-Myers Squibb Stands With Analysts,Benzinga,/news/stocks/where-bristol-myers-squibb-stands-with-analysts-1031926074
1436.0,11/18/2022 8:42:20 PM,Credit Suisse Sees Uncertainty On New Product Launch Execution & Growth For Bristol Myers,Benzinga,/news/stocks/credit-suisse-sees-uncertainty-on-new-product-launch-execution-growth-for-bristol-myers-1031926213
1437.0,11/28/2022 4:27:50 PM,"US Stocks Start Week On Lower Note, Dow Drops Over 100 Points",Benzinga,/news/stocks/us-stocks-start-week-on-lower-note-dow-drops-over-100-points-1031940167
1438.0,11/28/2022 7:01:49 PM,Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/why-taboola-shares-are-trading-higher-by-around-53-here-are-53-stocks-moving-in-monday-s-mid-day-session-1031940469
1439.0,11/29/2022 2:00:00 PM,Envisagenics Announces Research Collaboration with Bristol Myers Squibb,PR Newswire,/news/stocks/envisagenics-announces-research-collaboration-with-bristol-myers-squibb-1031941958
1440.0,11/29/2022 2:19:53 PM,"Envisagenics, Bristol Myers Squibb Enter Research Collaboration - Quick Facts ",RTTNews,/news/stocks/envisagenics-bristol-myers-squibb-enter-research-collaboration-quick-facts-1031942037
1441.0,12/6/2022 2:42:02 PM,Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial,Seeking Alpha,https://seekingalpha.com/news/3914333-compugen-com701-in-dualtriple-combo-shows-promise-in-ovarian-cancer-patients-in-trial?utm_source=businessinsider&utm_medium=referral
1442.0,12/7/2022 12:32:42 PM,Replimune in pact with Roche to study cancer drug combos,Seeking Alpha,https://seekingalpha.com/news/3914812-repl-stock-on-watch-after-deal-with-roche-to-study-cancer-drug-combos?utm_source=businessinsider&utm_medium=referral
1443.0,12/7/2022 4:05:11 PM,Replimune Shares Surge After Early Data From Pretreated Melanoma Patients,Benzinga,/news/stocks/replimune-shares-surge-after-early-data-from-pretreated-melanoma-patients-1031958227
1444.0,12/8/2022 10:00:13 PM,Bristol-Myers Squibb Company  raises quarterly dividend by 5.6% to $0.57/share,Seeking Alpha,https://seekingalpha.com/news/3915505-bristol-myers-squibb-company-declares-0_57-dividend?utm_source=businessinsider&utm_medium=referral
1445.0,12/12/2022 6:50:22 PM,Seagen buoyed by Adcetris combo data for classical Hodgkin lymphoma,Seeking Alpha,https://seekingalpha.com/news/3916234-seagen-buoyed-by-adcetris-combo-data-for-classical-hodgkin-lymphoma?utm_source=businessinsider&utm_medium=referral
1446.0,12/13/2022 2:35:32 PM,"Takeda drives Schrödinger, Ventyx higher after deal for psoriasis candidate",Seeking Alpha,https://seekingalpha.com/news/3916513-sdgr-stock-vtyx-stock-rise-takeda-deal-for-psoriasis-candidate?utm_source=businessinsider&utm_medium=referral
1447.0,12/14/2022 7:02:53 PM,Colorado becomes fourth state to ask feds to import drugs from Canada,Seeking Alpha,https://seekingalpha.com/news/3917055-colorado-becomes-fourth-state-to-ask-feds-to-import-drugs-from-canada?utm_source=businessinsider&utm_medium=referral
1448.0,12/16/2022 10:02:23 AM,"Evotec to get $26M from Bristol Myers as drug projects added under neuroscience 
pact",Seeking Alpha,https://seekingalpha.com/news/3917904-evotec-to-get-26m-from-bristol-myers-as-drug-projects-added-under-neuroscience-pact?utm_source=businessinsider&utm_medium=referral
1449.0,12/16/2022 11:25:27 AM,7 Top-Rated Large-Cap Stocks to Buy and Hold,InvestorPlace,/news/stocks/large-cap-stocks-to-buy-and-hold-1031827937
1450.0,12/23/2022 8:21:12 PM,"Tax-loss selling, window dressing will likely ruin Santa Claus rally - DCLA's Sarat Sethi",Seeking Alpha,https://seekingalpha.com/news/3920543-fed-spooks-santa-claus-rally-dclas-sarat-sethi?utm_source=businessinsider&utm_medium=referral
1451.0,12/28/2022 10:30:16 AM,InnoCare tafasitamab combo gets approval in Hong Kong for blood cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3920864-innocare-tafasitamab-combo-gets-approval-in-hong-kong-for-blood-cancer-subtype?utm_source=businessinsider&utm_medium=referral
1452.0,12/30/2022 5:45:22 PM,Merck is best performing large U.S. pharma of 2022,Seeking Alpha,https://seekingalpha.com/news/3921306-merck-is-best-performing-large-us-pharma-of-2022?utm_source=businessinsider&utm_medium=referral
1453.0,12/31/2022 3:00:00 PM,"Align, Invitae among healthcare stocks SA contributors correctly said to avoid in 2022",Seeking Alpha,https://seekingalpha.com/news/3920820-align-invitae-among-health-names-sa-contributors-correctly-said-to-avoid-in-2022?utm_source=businessinsider&utm_medium=referral
1454.0,1/3/2023 8:00:43 PM,What 6 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-6-analyst-ratings-have-to-say-about-bristol-myers-squibb-1031998485
1455.0,1/4/2023 3:30:34 PM,Aurinia Pharmaceuticals gains amid M&A speculation following patent settlement,Seeking Alpha,https://seekingalpha.com/news/3922000-aurinia-pharmaceuticals-gains-amid-ma-speculation-following-patent-settlement?utm_source=businessinsider&utm_medium=referral
1456.0,1/5/2023 9:24:26 PM,"Century Therapeutics cutting 25% of staff, prioritizing pipeline programs",Seeking Alpha,https://seekingalpha.com/news/3922512-century-therapeutics-cutting-25-of-staff-prioritizing-pipeline-programs?utm_source=businessinsider&utm_medium=referral
1457.0,1/6/2023 2:23:25 PM,"Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive",Benzinga,/news/stocks/century-therapeutics-announces-internal-portfolio-prioritization-analyst-views-it-as-incrementally-positive-1032004211
1458.0,1/6/2023 6:30:04 PM,"Catalyst watch: ICR Conference, JPMorgan Healthcare Conference, CPI, major bank reports",Seeking Alpha,https://seekingalpha.com/news/3922727-catalyst-watch-icr-conference-jpmorgan-healthcare-conference-cpi-major-banks-report?utm_source=businessinsider&utm_medium=referral
1459.0,1/6/2023 11:26:24 PM,5 Top Pharma Stocks of 2022 to Buy for the Long Haul,InvestorPlace,/news/stocks/5-top-pharma-stocks-of-2022-to-buy-for-the-long-haul-1032005182
1460.0,1/8/2023 5:33:53 PM,The 7 Most Undervalued Value Stocks to Buy Now   ,InvestorPlace,/news/stocks/undervalued-value-stocks-1031662465
1461.0,1/9/2023 1:31:54 PM,"Schrödinger inks drug discovery licensing deals with Bristol Myers, Otsuka",Seeking Alpha,https://seekingalpha.com/news/3922934-schrdinger-inks-drug-discovery-licensing-deals-with-bristol-myers-otsuka?utm_source=businessinsider&utm_medium=referral
1462.0,1/9/2023 3:43:18 PM,Bristol-Myers Squibb rebuffed again by Supreme Court on $1.2B Gilead patent dispute,Seeking Alpha,https://seekingalpha.com/news/3923014-bristol-myers-squibb-rebuffed-again-by-supreme-court-on-12b-gilead-patent-dispute?utm_source=businessinsider&utm_medium=referral
1463.0,1/10/2023 5:32:45 PM,BioAtla sinks 47% after early results for lead candidate in solid tumor,Seeking Alpha,https://seekingalpha.com/news/3923414-bcab-stock-sinks-early-results-for-lead-candidate-in-solid-tumor?utm_source=businessinsider&utm_medium=referral
1464.0,1/11/2023 6:26:34 PM,Supreme Court declines to hear Pfizer case on financial assistance to Medicare enrollees,Seeking Alpha,https://seekingalpha.com/news/3923848-supreme-court-declines-to-hear-pfizer-case-on-financial-assistance-to-medicare-enrollees?utm_source=businessinsider&utm_medium=referral
1465.0,1/11/2023 8:35:28 PM,Medicare to publish drugs targeted for pricing negotiations in September,Seeking Alpha,https://seekingalpha.com/news/3923880-medicare-publish-drugs-targeted-pricing-negotiations-in-september?utm_source=businessinsider&utm_medium=referral
1466.0,1/13/2023 1:19:29 PM,7 Dividend-Paying Large-Cap Stocks to Buy in January,InvestorPlace,/news/stocks/7-dividend-paying-large-cap-stocks-to-buy-in-january-1032017485
1467.0,1/15/2023 5:00:03 PM,Drugmakers welcome new year with 450 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/3924676-pfizer-abbvie-gsk-eli-lilly-among-drugmakers-to-raise-prices?utm_source=businessinsider&utm_medium=referral
1468.0,1/17/2023 4:01:25 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-17-2023-1032022889
1469.0,1/17/2023 6:36:59 PM,Bristol-Myers earns bullish views at Cantor on breakout potential,Seeking Alpha,https://seekingalpha.com/news/3925135-bmy-stock-earns-bullish-views-cantor-breakout-potential?utm_source=businessinsider&utm_medium=referral
1470.0,1/18/2023 4:10:10 PM,"Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen",Benzinga,/news/stocks/neurodegenerative-diseases-focused-company-goes-public-via-wilbur-ross-backed-spac-joins-alzheimer-s-race-to-compete-biogen-1032025916
1471.0,1/21/2023 9:40:00 PM,"AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs",Seeking Alpha,https://seekingalpha.com/news/3926479-astrazeneca-biogen-bristol-and-eli-lilly-among-companies-with-blockbuster-potential-drugs?utm_source=businessinsider&utm_medium=referral
1472.0,1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral
1473.0,1/26/2023 12:22:33 PM,Bristol Myers says trial for CAR T therapy met main goal in leukemia,Seeking Alpha,https://seekingalpha.com/news/3928300-bristol-myers-says-trial-car-t-therapy-met-main-goal-leukemia?utm_source=businessinsider&utm_medium=referral
1474.0,1/26/2023 4:40:17 PM,"iVexSol closes $23.8M series A-3 financing by Bristol Myers Squibb, Charles River, Asahi Kasei",Seeking Alpha,https://seekingalpha.com/news/3928506-ivexsol-closes-238m-series-a-3-financing-by-bristol-myers-squibb-charles-river-asahi-kasei?utm_source=businessinsider&utm_medium=referral
1475.0,1/27/2023 11:52:56 AM,Bristol Myers psoriasis drug Sotyktu an inch away from EU approval with EMA panel nod,Seeking Alpha,https://seekingalpha.com/news/3928867-bristol-myers-psoriasis-drug-sotyktu-an-inch-away-from-eu-approval-with-ema-panel-nod?utm_source=businessinsider&utm_medium=referral
1476.0,1/27/2023 12:19:52 PM,Bristol Myers wins EU backing to expand label for anemia therapy,Seeking Alpha,https://seekingalpha.com/news/3928887-bristol-myers-wins-eu-backing-to-expand-label-for-anemia-therapy?utm_source=businessinsider&utm_medium=referral
1477.0,1/27/2023 5:55:12 PM,"Earnings week ahead: Amazon, Apple, Meta, Alphabet, ExxonMobil, GM, AMD and more",Seeking Alpha,https://seekingalpha.com/news/3929027-earnings-week-ahead-amazon-apple-meta-alphabet-exxonmobil-gm-amd-and-more?utm_source=businessinsider&utm_medium=referral
1478.0,1/28/2023 6:00:40 PM,The use of artificial intelligence in medical devices and drug development,Seeking Alpha,https://seekingalpha.com/news/3929184-the-growing-use-of-artificial-intelligence-in-medical-devices-diagnostics-drug-development?utm_source=businessinsider&utm_medium=referral
1479.0,1/29/2023 11:25:33 PM,"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",Benzinga,/news/stocks/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among-key-quarterly-reports-to-watch-1032048678
1480.0,1/31/2023 9:56:29 PM,Prothena says Alzheimer’s candidate was safe in early-stage trial,Seeking Alpha,https://seekingalpha.com/news/3930173-prothena-says-alzheimers-candidate-was-safe-early-stage-trial?utm_source=businessinsider&utm_medium=referral
1481.0,2/1/2023 3:01:13 PM,Bristol-Myers Squibb earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-quarter-earnings-preview-q4-1032058995
1482.0,2/1/2023 3:55:38 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3930495-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral
1483.0,2/1/2023 5:10:02 PM,Will Bristol Myers Q4 revenues see boost from potential blockbuster Sotyktu?,Seeking Alpha,https://seekingalpha.com/news/3930535-will-bristol-myers-q4-revenues-see-boost-from-potential-blockbuster-sotyktu?utm_source=businessinsider&utm_medium=referral
1484.0,2/2/2023 12:00:23 PM,"Bristol-Myers Squibb Company  Non-GAAP EPS of $1.82 beats by $0.09, revenue of $11.4B beats by $200M",Seeking Alpha,https://seekingalpha.com/news/3931120-bristol-myers-squibb-company-and-nbsp-non-gaap-eps-of-1_82-beats-0_09-revenue-of-11_4b-beats?utm_source=businessinsider&utm_medium=referral
1485.0,2/2/2023 12:34:23 PM,"Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?",Benzinga,/news/stocks/nasdaq-futures-fly-as-meta-keeps-tech-earnings-buoyancy-intact-will-apple-amazon-alphabet-toe-in-line-1032062305
1486.0,2/2/2023 1:08:58 PM,Bristol Myers Q4 revenue falls as Revlimid continues to take hit from generics; FY23 outlook in higher range,Seeking Alpha,https://seekingalpha.com/news/3931196-bristol-myers-q4-revenue-falls-as-revlimid-continues-to-take-hit-from-generics-fy23-outlook-in-higher-range?utm_source=businessinsider&utm_medium=referral
1487.0,2/2/2023 1:29:07 PM,Bristol-Myers Squibb Guides FY23 Adj. EPS In Line; Q4 Results Top Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-guides-fy23-adj-eps-in-line-q4-results-top-estimates-1032062561
1488.0,2/2/2023 6:12:11 PM,"Merck, GM among BofA's latest Alpha Surprise picks",Seeking Alpha,https://seekingalpha.com/news/3931429-merck-gm-among-bofas-latest-alpha-surprise-picks?utm_source=businessinsider&utm_medium=referral
1489.0,2/2/2023 7:11:33 PM,U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates,Seeking Alpha,https://seekingalpha.com/news/3931486-uk-pharma-lobby-urges-govt-to-halt-plans-to-raise-revenue-recovery-rates?utm_source=businessinsider&utm_medium=referral
1490.0,2/3/2023 11:05:16 AM,Bank of America Securities Sticks to Their Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-their-buy-rating-for-bristol-myers-bmy-1032065673
1491.0,2/3/2023 12:15:47 PM,Bristol Myers (BMY) Gets a Hold from Barclays,TipRanks,/news/stocks/bristol-myers-bmy-gets-a-hold-from-barclays-1032065948
1492.0,2/3/2023 12:26:02 PM,Bristol Myers (BMY) Receives a Buy from BMO Capital,TipRanks,/news/stocks/bristol-myers-bmy-receives-a-buy-from-bmo-capital-1032065909
1493.0,2/3/2023 12:26:06 PM,Atlantic Equities Sticks to Its Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/atlantic-equities-sticks-to-its-buy-rating-for-bristol-myers-bmy-1032065906
1494.0,2/3/2023 1:01:15 PM,What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-5-analyst-ratings-have-to-say-about-bristol-myers-squibb-1032065811
1495.0,2/3/2023 4:25:34 PM,Morgan Stanley Reaffirms Their Sell Rating on Bristol Myers (BMY),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-sell-rating-on-bristol-myers-bmy-1032066590
1496.0,2/3/2023 7:30:12 PM,"Catalyst watch: Google talks AI, Nordstrom drama and Canada Goose event",Seeking Alpha,https://seekingalpha.com/news/3931946-catalyst-watch-google-talks-ai-nordstrom-drama-and-canada-goose-event?utm_source=businessinsider&utm_medium=referral
1497.0,2/6/2023 4:05:11 PM,Truist Financial Remains a Buy on Bristol Myers (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-bmy-1032070846
1498.0,2/6/2023 5:56:09 PM,Teva follows AbbVie to leave top pharma industry group,Seeking Alpha,https://seekingalpha.com/news/3932426-teva-follows-abbvie-to-leave-top-pharma-industry-group?utm_source=businessinsider&utm_medium=referral
1499.0,2/10/2023 12:18:08 PM,Medicare mulls rebates in 2025 for drug prices rising faster than inflation,Seeking Alpha,https://seekingalpha.com/news/3934728-medicare-mulls-rebates-in-2025-for-drug-prices-rising-faster-than-inflation?utm_source=businessinsider&utm_medium=referral
1500.0,2/10/2023 4:46:18 PM,"Bristol-Myers, 2seventy post late-stage data for CAR-T therapy in multiple myeloma",Seeking Alpha,https://seekingalpha.com/news/3934866-bristol-myers-2seventy-late-stage-data-car-t-therapy-multiple-myeloma?utm_source=businessinsider&utm_medium=referral
1501.0,2/10/2023 6:28:27 PM,"Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients",Benzinga,/news/stocks/bristol-myers-2seventy-partnered-abecma-cuts-risk-of-disease-progression-death-by-51-in-pretreated-myeloma-patients-1032087011
1502.0,2/11/2023 9:00:00 PM,"Super Bowl ads boost sales of drugs, yet only handful of companies advertising this year",Seeking Alpha,https://seekingalpha.com/news/3934902-super-bowl-ads-boost-sales-of-drugs-yet-only-two-companies-advertising-this-year?utm_source=businessinsider&utm_medium=referral
1503.0,2/13/2023 3:57:12 PM,"Wainwright initiates Arcellx with a buy on CAR-T pipeline, partnership with Gilead's Kite",Seeking Alpha,https://seekingalpha.com/news/3935243-wainwright-initiates-arcellx-with-a-buy-on-car-t-pipeline-partnership-with-gilead-kite?utm_source=businessinsider&utm_medium=referral
1504.0,2/14/2023 10:59:48 AM,"Bristol Myers Opdivo, Exelixis/Ipsen's Cabometyx combo shows survival benefit in kidney cancer in 3 year data",Seeking Alpha,https://seekingalpha.com/news/3935573-bristol-myers-opdivo-exelixisipsens-cabometyx-combo-shows-survival-benefit-in-kidney-cancer-in-3-year-data?utm_source=businessinsider&utm_medium=referral
1505.0,2/14/2023 3:05:50 PM,"Keros Therapeutics a buy at Cowen on candidates for PAH, myelofibrosis",Seeking Alpha,https://seekingalpha.com/news/3935749-keros-therapeutics-a-buy-at-cowen-on-candidates-for-pah-myelofibrosis?utm_source=businessinsider&utm_medium=referral
1506.0,2/15/2023 6:14:32 PM,Medicare mulls limiting per month costs for generic drugs at $2,Seeking Alpha,https://seekingalpha.com/news/3936542-medicare-mulls-limiting-per-month-costs-for-generic-drugs-at-2?utm_source=businessinsider&utm_medium=referral
1507.0,2/15/2023 7:09:07 PM,3 ETFs Investors Can Buy to Weather a Recession,TipRanks,/news/stocks/3-etfs-investors-can-buy-to-weather-a-recession-1032100105
1508.0,2/17/2023 4:01:46 PM,Bristol's Opdivo improves disease-free survival in urothelial carcinoma over long term,Seeking Alpha,https://seekingalpha.com/news/3937750-bristol-opdivo-improves-disease-free-survival-in-urothelial-carcinoma-over-long-term?utm_source=businessinsider&utm_medium=referral
1509.0,2/17/2023 6:35:08 PM,I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said.,InvestorPlace,/news/stocks/i-tricked-chatgpt-into-picking-stocks-to-buy-heres-what-it-said-1032106844
1510.0,2/19/2023 5:00:10 PM,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise – report,Seeking Alpha,https://seekingalpha.com/news/3937885-next-big-wave-of-patent-cliffs-ahead-biopharma-m-and-a-to-rise?utm_source=businessinsider&utm_medium=referral
1511.0,2/24/2023 2:23:12 PM,Why Nektar Therapeutics Stock Is Plunging Today,Benzinga,/news/stocks/why-nektar-therapeutics-stock-is-plunging-today-1032123579
1512.0,2/25/2023 9:00:00 PM,"Pharmas, medtechs dominate list of innovation leaders thanks to patents",Seeking Alpha,https://seekingalpha.com/news/3940793-pharmas-medtechs-dominate-list-of-innovation-leaders-thanks-to-patents?utm_source=businessinsider&utm_medium=referral
1513.0,2/27/2023 1:57:14 PM,7 Dividend Stocks to Buy During a Market Downturn,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-during-a-market-downturn-1032127983
1514.0,2/28/2023 1:08:21 PM,"Bristol Myers Opdivo for skin cancer gets review in US, EU",Seeking Alpha,https://seekingalpha.com/news/3941763-bristol-myers-opdivo-for-skin-cancer-gets-review-in-us-eu?utm_source=businessinsider&utm_medium=referral
1515.0,3/2/2023 11:07:41 AM,Bristol Myers wins $6.4B lawsuit over cancer drug delay,Seeking Alpha,https://seekingalpha.com/news/3943111-bristol-myers-wins-64b-lawsuit-over-cancer-drug-delay?utm_source=businessinsider&utm_medium=referral
1516.0,3/2/2023 1:01:02 PM,"Bristol-Myers, Janssen launch late-stage Librexia program evaluating milvexian",Seeking Alpha,https://seekingalpha.com/news/3943202-bristol-myers-janssen-launch-late-stage-librexia-program-evaluating-milvexian?utm_source=businessinsider&utm_medium=referral
1517.0,3/3/2023 12:35:32 PM,EC approves Bristol Myers' Reblozyl for anemia due to beta thalassemia,Seeking Alpha,https://seekingalpha.com/news/3943800-ec-approves-bristol-myers-reblozyl-for-anemia-due-to-beta-thalassemia?utm_source=businessinsider&utm_medium=referral
1518.0,3/3/2023 1:19:21 PM,"Bristol Myers, Viz.ai team up to deploy AI tool to detect heart disease",Seeking Alpha,https://seekingalpha.com/news/3943827-bristol-myers-vizai-team-up-to-deploy-ai-tool-to-detect-heart-disease?utm_source=businessinsider&utm_medium=referral
1519.0,3/3/2023 9:18:56 PM,Bristol-Myers Squibb Company  declares $0.57 dividend,Seeking Alpha,https://seekingalpha.com/news/3944131-bristol-myers-squibb-company-declares-0_57-dividend?utm_source=businessinsider&utm_medium=referral
1520.0,3/4/2023 6:45:00 PM,Pharma R&D funding soared to a new record in 2022 as oncology candidates dominate pipelines,Seeking Alpha,https://seekingalpha.com/news/3944195-pharma-research-developmeny-funding-soared-to-a-new-record-in-2022-as-oncology-candidates-dominate-pipelines?utm_source=businessinsider&utm_medium=referral
1521.0,3/6/2023 1:42:34 PM,Ikena gains on FDA’s fast track status for bladder cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3944409-ikna-stock-gains-fdas-fast-track-status-bladder-cancer-candidate?utm_source=businessinsider&utm_medium=referral
1522.0,3/6/2023 2:00:56 PM,Where Bristol-Myers Squibb Stands With Analysts,Benzinga,/news/stocks/where-bristol-myers-squibb-stands-with-analysts-1032147149
1523.0,3/6/2023 4:00:36 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-6-2023-1032147650
1524.0,3/7/2023 10:45:06 AM,Bank of America Securities Sticks to Their Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-their-buy-rating-for-bristol-myers-bmy-1032149733
1525.0,3/7/2023 12:33:25 PM,Biden to announce plan to keep Medicare solvent beyond 2050,Seeking Alpha,https://seekingalpha.com/news/3944823-biden-to-announce-plan-to-keep-medicare-solvent-beyond-2050?utm_source=businessinsider&utm_medium=referral
1526.0,3/7/2023 9:30:42 PM,Quant Ratings Updated on 157 Stocks,InvestorPlace,/news/stocks/20230307-quant-ratings-1032151646
1527.0,3/8/2023 1:34:07 AM,Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason,Benzinga,/news/stocks/health-care-etfs-have-lost-in-the-last-month---these-top-pharma-stocks-are-the-reason-1032151775
1528.0,3/8/2023 11:41:29 AM,Sleep-at-night stocks for those hedging or risk averse,Seeking Alpha,https://seekingalpha.com/news/3945026-sleep-at-night-stocks-for-those-hedging-or-risk-averse?utm_source=businessinsider&utm_medium=referral
1529.0,3/9/2023 2:30:05 PM,Teva Pharmaceutical launches additional dosage strengths of generic Revlimid,Seeking Alpha,https://seekingalpha.com/news/3945980-teva-pharmaceutical-launches-additional-dosage-strengths-of-generic-revlimid?utm_source=businessinsider&utm_medium=referral
1530.0,3/9/2023 6:55:10 PM,Biden budget to save $160B by allowing Medicare to negotiate prices for more drugs,Seeking Alpha,https://seekingalpha.com/news/3946094-biden-budget-to-save-160b-by-allowing-medicare-to-negotiate-prices-for-more-drugs?utm_source=businessinsider&utm_medium=referral
1531.0,3/13/2023 12:07:25 PM,"Pfizer, AbbVie, BMS among firms at risk of U.S. drug price negotiations - report",Seeking Alpha,https://seekingalpha.com/news/3946793-pfizer-abbvie-bristol-myers-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1532.0,3/16/2023 7:51:21 AM,Evotec Announces Progress In Protein Degradation Partnership With Bristol Myers ,RTTNews,/news/stocks/evotec-announces-progress-in-protein-degradation-partnership-with-bristol-myers-1032171647
1533.0,3/16/2023 6:15:32 PM,Medicare publishes initial guidance on drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3948265-medicare-publishes-initial-guidance-on-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1534.0,3/20/2023 11:10:18 AM,Analysts Offer Insights on Healthcare Companies: Kinnate Biopharma (KNTE) and Bristol Myers (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-kinnate-biopharma-knte-and-bristol-myers-bmy-1032178490
1535.0,3/20/2023 3:21:16 PM,"Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says",Benzinga,/news/stocks/takeda-s-highest-dose-psoriasis-candidate-can-potentially-beat-bristol-myers-approved-drug-analyst-says-1032179263
1536.0,3/23/2023 12:29:24 PM,"BridgeBio starts dosing in phase 1/2 trial of BBP-398, Opdivo combo for solid tumors",Seeking Alpha,https://seekingalpha.com/news/3950325-bridgebio-starts-dosing-in-phase-12-trial-of-bbp-398-opdivo-combo-for-solid-tumors?utm_source=businessinsider&utm_medium=referral
1537.0,3/23/2023 6:33:09 PM,White House seeking alternative supply chains for pharmaceutical ingredients,Seeking Alpha,https://seekingalpha.com/news/3950575-white-house-alternative-supply-chains-pharmaceutical-ingredients-drug-shortages?utm_source=businessinsider&utm_medium=referral
1538.0,3/23/2023 7:56:20 PM,Aurinia Pharmaceuticals gains amid renewed takeover speculation,Seeking Alpha,https://seekingalpha.com/news/3950664-aurinia-pharmaceuticals-gains-amid-renewed-takeover-speculation?utm_source=businessinsider&utm_medium=referral
1539.0,3/24/2023 5:01:00 PM,FDA draft guidance impacts companies using accelerated approval for oncology drugs,Seeking Alpha,https://seekingalpha.com/news/3951000-fda-draft-guidance-impacts-companies-accelerated-approval-oncology-drugs?utm_source=businessinsider&utm_medium=referral
1540.0,3/24/2023 9:06:23 PM,BridgeBio Pharma jumps on report of takeover interest,Seeking Alpha,https://seekingalpha.com/news/3951153-bridgebio-jumps-on-report-of-takeover-interest?utm_source=businessinsider&utm_medium=referral
1541.0,3/28/2023 10:24:03 AM,Evotec gets $50M upfront from Bristol Myers in pact to develop neuro disease drugs,Seeking Alpha,https://seekingalpha.com/news/3951755-evotec-gets-50m-upfront-bristol-myers-neuro-disease-drug-pact?utm_source=businessinsider&utm_medium=referral
1542.0,3/28/2023 10:26:13 AM,Bristol Myers (BMY) Gets a Hold from Barclays,TipRanks,/news/stocks/bristol-myers-bmy-gets-a-hold-from-barclays-1032196474
1543.0,3/28/2023 12:18:24 PM,Evotec Stock Up As It Extends Neurodegeneration Partnership With Bristol Myers Squibb ,RTTNews,/news/stocks/evotec-stock-up-as-it-extends-neurodegeneration-partnership-with-bristol-myers-squibb-1032196425
1544.0,3/28/2023 12:32:05 PM,Bristol Myers' psoriasis drug Sotyktu gets approval in EU,Seeking Alpha,https://seekingalpha.com/news/3951828-bristol-myers-psoriasis-drug-sotyktu--approval-in-eu?utm_source=businessinsider&utm_medium=referral
1545.0,3/31/2023 1:00:59 PM,Bristol Myers' blood cancer drug Breyanzi gets EMA greenlight for earlier use,Seeking Alpha,https://seekingalpha.com/news/3953140-bristol-myers-blood-cancer-drug-breyanzi-gets-ema-greenlight-for-earlier-use?utm_source=businessinsider&utm_medium=referral
1546.0,4/6/2023 1:19:05 AM,MRK vs. BMY: Which Pharmaceutical Stock is Better?,TipRanks,/news/stocks/mrk-vs-bmy-which-pharmaceutical-stock-is-better-1032217882
1547.0,4/6/2023 4:35:54 PM,FDA forces pre-term birth drug off the market after 12 years,Seeking Alpha,https://seekingalpha.com/news/3955084-fda-pulls-pre-term-birth-drug-makena-off-market?utm_source=businessinsider&utm_medium=referral
1548.0,4/7/2023 6:15:29 PM,"Catalyst Watch: Eyes on inflation data, big bank earnings",Seeking Alpha,https://seekingalpha.com/news/3955188-catalyst-watch-eyes-on-inflation-data-big-bank-earnings?utm_source=businessinsider&utm_medium=referral
1549.0,4/11/2023 12:56:42 PM,US DOJ asks appeals court to block Texas judge abortion pill ruling,Seeking Alpha,https://seekingalpha.com/news/3955611-us-doj-asks-appeals-court-block-texas-judge-abortion-pill-ruling?utm_source=businessinsider&utm_medium=referral
1550.0,4/11/2023 3:21:35 PM,Foundation Medicine to develop companion diagnostic for Bristol Myers' cancer drug repotrectinib,Seeking Alpha,https://seekingalpha.com/news/3955679-foundation-medicine-bristol-myers-to-develop-companion-diagnostic-for-repotrectinib?utm_source=businessinsider&utm_medium=referral
1551.0,4/13/2023 9:02:47 AM,"Appeals court permits limited access to abortion pill, blocks part of Texas ruling",Seeking Alpha,https://seekingalpha.com/news/3956187-appeals-court-partially-allows-access-abortion-pill?utm_source=businessinsider&utm_medium=referral
1552.0,4/14/2023 9:32:00 AM,Ghana 1st in world to approve new malaria vaccine by Oxford,Seeking Alpha,https://seekingalpha.com/news/3956507-ghana-1st-in-world-approve-new-malaria-vaccine-oxford?utm_source=businessinsider&utm_medium=referral
1553.0,4/16/2023 10:30:42 AM,7 Sorry Pharma Stocks to Sell in April Before It’s Too Late,InvestorPlace,/news/stocks/7-sorry-pharma-stocks-to-sell-in-april-before-its-too-late-1032234376
1554.0,4/18/2023 9:08:17 AM,"Bristol Myers, 2seventy bio blood cancer drug Abecma gets review in US, EU, Japan for expanded use",Seeking Alpha,https://seekingalpha.com/news/3957205-bristol-myers-2seventy-cancer-drug-abecma-gets-review-us-eu-japan?utm_source=businessinsider&utm_medium=referral
1555.0,4/18/2023 12:59:59 PM,Guardant Health cancer immunotherapy response test covered by Medicare,Seeking Alpha,https://seekingalpha.com/news/3957308-guardant-health-cancer-immunotherapy-response-test-covered-medicare?utm_source=businessinsider&utm_medium=referral
1556.0,4/19/2023 1:24:40 AM,COWZ ETF: A Cash Cow for Your Portfolio,TipRanks,/news/stocks/cowz-etf-a-cash-cow-for-your-portfolio-1032241273
1557.0,4/19/2023 11:48:49 AM,Legend Biotech adds 18% after leaked report on JNJ-partnered CAR-T therapy,Seeking Alpha,https://seekingalpha.com/news/3957646-jnj-stock-legend-biotech-stock-gain-on-leaked-carvykti-data?utm_source=businessinsider&utm_medium=referral
1558.0,4/19/2023 6:00:09 PM,"Geron, CTI rally after leaked data for Legend Biotech’s blood cancer drug",Seeking Alpha,https://seekingalpha.com/news/3957879-geron-stock-cti-stock-rally-after-leaked-carvykti-data?utm_source=businessinsider&utm_medium=referral
1559.0,4/19/2023 8:16:05 PM,Amgen wins appeals court ruling in patent dispute over psoriasis drug Otezla,Seeking Alpha,https://seekingalpha.com/news/3957938-amgen-stock-wins-appeals-court-ruling-otezla-patent-dispute?utm_source=businessinsider&utm_medium=referral
1560.0,4/20/2023 9:57:40 AM,Bristol Myers inks up to $1B license deal with Tubulis to develop cancer drugs,Seeking Alpha,https://seekingalpha.com/news/3958092-bristol-myers-inks-up-to-1b-cancer-drug-license-deal-tubulis?utm_source=businessinsider&utm_medium=referral
1561.0,4/21/2023 1:09:00 PM,"Bristol Myers, LianBio's heart drug Camzyos gets priority review in China",Seeking Alpha,https://seekingalpha.com/news/3958657-bristol-myers-lianbios-heart-drug-camzyos-gets-priority-review-china?utm_source=businessinsider&utm_medium=referral
1562.0,4/21/2023 5:01:07 PM,Where Bristol-Myers Squibb Stands With Analysts,Benzinga,/news/stocks/where-bristol-myers-squibb-stands-with-analysts-1032250262
1563.0,4/21/2023 5:09:23 PM,Legend Biotech up 10% on confirming Carvykti multiple myeloma data,Seeking Alpha,https://seekingalpha.com/news/3958762-legend-biotech-up-10-confirming-carvykti-multiple-myeloma-data?utm_source=businessinsider&utm_medium=referral
1564.0,4/21/2023 5:30:41 PM,"Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more",Seeking Alpha,https://seekingalpha.com/news/3958718-earnings-week-ahead-amazon-meta-platforms-alphabet-coca-cola-boeing-and-more?utm_source=businessinsider&utm_medium=referral
1565.0,4/23/2023 4:00:00 PM,What is behind biotech M&A resurgence?,Seeking Alpha,https://seekingalpha.com/news/3958874-reasons-for-biotech-buyout-resurgence?utm_source=businessinsider&utm_medium=referral
1566.0,4/24/2023 9:10:58 PM,Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday,Benzinga,/news/stocks/is-aurinia-pharmaceuticals-up-for-grabs-shareholder-suggests-a-quick-sale-for-a-bigger-payday-1032255367
1567.0,4/25/2023 3:38:42 PM,Bipartisan agreement reached in Senate prescription drug price legislation,Seeking Alpha,https://seekingalpha.com/news/3959793-bipartisan-agreement-reached-senate-prescription-drug-price-legislation?utm_source=businessinsider&utm_medium=referral
1568.0,4/26/2023 11:54:22 AM,Bristol Myers to acquire viral vector manufacturing site in Illinois from Novartis,Seeking Alpha,https://seekingalpha.com/news/3960367-bristol-myers-to-acquire-viral-vector-manufacturing-site-in-illinois-from-novartis?utm_source=businessinsider&utm_medium=referral
1569.0,4/26/2023 12:53:02 PM,"Bristol Myers, LianBio's heart drug Camzyos meets main goal in Chinese patients study",Seeking Alpha,https://seekingalpha.com/news/3960417-bristol-myers-lianbio-heart-drug-meets-main-goal-in-chinese-patients?utm_source=businessinsider&utm_medium=referral
1570.0,4/26/2023 2:58:15 PM,Will Bristol-Myers Squibb Q4 positive trend continue in Q1?,Seeking Alpha,https://seekingalpha.com/news/3960510-will-bristol-myers-squibb-q4-positive-trend-continue-in-q1?utm_source=businessinsider&utm_medium=referral
1571.0,4/26/2023 3:01:13 PM,Bristol-Myers Squibb earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q1-quarterly-earnings-preview-1032263676
1572.0,4/26/2023 3:07:35 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3960517-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral
1573.0,4/26/2023 5:21:35 PM,Democratic senators introduce bill to enhance CMS drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3960629-democratic-senators-introduce-bill-enhance-cms-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1574.0,4/27/2023 11:33:03 AM,"Bristol-Myers Squibb Company  Non-GAAP EPS of $2.05 beats by $0.05, revenue of $11.3B misses by $290M",Seeking Alpha,https://seekingalpha.com/news/3961249-bristol-myers-squibb-company-and-nbsp-non-gaap-eps-of-2_05-beats-0_05-revenue-of-11_3b-misses?utm_source=businessinsider&utm_medium=referral
1575.0,4/27/2023 12:17:08 PM,Bristol Myers stock dips as Q1 revenue falls amid generic impact on Revlimid,Seeking Alpha,https://seekingalpha.com/news/3961290-bristol-myers-stock-dips-revenue-falls-amid-generic-impact-on-revlimid?utm_source=businessinsider&utm_medium=referral
1576.0,4/27/2023 1:04:48 PM,"Stocks Rise On Strong Earnings, Expectation Of Fed Rate Hikes Ending: Analyst Says 'No Earnings Recession In Cards Yet'",Benzinga,/news/stocks/us-stocks-eye-higher-open-as-meta-q1-uplifts-tech-sector-analyst-says-no-earnings-recession-in-cards-yet-1032268050
1577.0,4/27/2023 1:27:59 PM,Bristol-Myers Squibb Affirms FY23 Outlook; Q1 Adj. EPS Tops Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-affirms-fy23-outlook-q1-adj-eps-tops-estimates-1032268243
1578.0,4/27/2023 5:01:56 PM,"Hot Stocks: TDOC, LLY, ROKU and CMCSA rises on earnings; DBX falls on layoffs; LUV, CAT and BMY slides",Seeking Alpha,https://seekingalpha.com/news/3961499-hot-stocks-tdoc-lly-roku-and-cmcsa-rises-on-earnings-dbx-fallss-on-layoffs-luv-cat-and-bmy-slides?utm_source=businessinsider&utm_medium=referral
1579.0,4/28/2023 6:05:34 AM,Goldman Sachs Keeps Their Buy Rating on Bristol Myers (BMY),TipRanks,/news/stocks/goldman-sachs-keeps-their-buy-rating-on-bristol-myers-bmy-1032272324
1580.0,4/28/2023 8:25:46 AM,Barclays Sticks to Their Hold Rating for Bristol Myers (BMY),TipRanks,/news/stocks/barclays-sticks-to-their-hold-rating-for-bristol-myers-bmy-1032272676
1581.0,4/28/2023 8:45:36 AM,"Bristol Myers, LianBio's heart therapy Camzyos gets EMA panel nod",Seeking Alpha,https://seekingalpha.com/news/3961897-bristol-myers-lianbios-heart-therapy-camzyos-gets-ema-panel-nod?utm_source=businessinsider&utm_medium=referral
1582.0,4/28/2023 9:25:08 AM,Morgan Stanley Sticks to Their Sell Rating for Bristol Myers (BMY),TipRanks,/news/stocks/morgan-stanley-sticks-to-their-sell-rating-for-bristol-myers-bmy-1032272873
1583.0,4/28/2023 10:21:23 AM,"Bristol Myers Opdivo, Yervoy get EMA panel backing for skin cancer in adolescents",Seeking Alpha,https://seekingalpha.com/news/3961918-bristol-myers-opdivo-yervoy-get-ema-panel-backing-for-skin-cancer-in-adolescents?utm_source=businessinsider&utm_medium=referral
1584.0,5/1/2023 9:25:25 AM,Bristol Myers (BMY) Gets a Hold from Barclays,TipRanks,/news/stocks/bristol-myers-bmy-gets-a-hold-from-barclays-1032277519
1585.0,5/1/2023 11:51:02 AM,"Bristol Myers, Merck anemia therapy undergoes U.S. and EU review for label expansion",Seeking Alpha,https://seekingalpha.com/news/3962527-bristol-myers-merck-anemia-drug-us-eu-reviews-label-expansion?utm_source=businessinsider&utm_medium=referral
1586.0,5/1/2023 5:29:00 PM,"Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report",Seeking Alpha,https://seekingalpha.com/news/3962788-abbvie-bristol-myers-competed-with-merck-in-sale-of-prometheus-report?utm_source=businessinsider&utm_medium=referral
1587.0,5/1/2023 5:57:18 PM,"Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration",Benzinga,/news/stocks/bristol-myers-squibb-s-breyanzi-aces-two-lymphoma-studies-on-overall-response-rate-endpoint-plus-new-collaboration-1032278774
1588.0,5/5/2023 12:10:21 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol Myers (BMY), Chimerix (CMRX) and Moderna (MRNA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bristol-myers-bmy-chimerix-cmrx-and-moderna-mrna-1032297263
1589.0,5/6/2023 3:00:34 AM,XLV: 5 Reasons to Put This Healthcare ETF on Your Radar,TipRanks,/news/stocks/xlv-5-reasons-to-put-this-healthcare-etf-on-your-radar-1032298857
1590.0,5/9/2023 12:56:49 PM,Big pharma maps legal strategy against U.S. drug pricing regulation – Reuters,Seeking Alpha,https://seekingalpha.com/news/3967966-big-pharma-maps-legal-strategy-against-drug-pricing-regulation?utm_source=businessinsider&utm_medium=referral
1591.0,5/10/2023 7:17:12 PM,Vanda to consider options after appeals court ruling on Hetlioz generics,Seeking Alpha,https://seekingalpha.com/news/3969409-vanda-stock-slips-appeals-court-reaffirms-hetlioz-generics?utm_source=businessinsider&utm_medium=referral
1592.0,5/13/2023 8:00:00 PM,Cancer therapies spending set to surge through end of decade,Seeking Alpha,https://seekingalpha.com/news/3971001-cancer-therapies-spending-set-surge-through-end-decade?utm_source=businessinsider&utm_medium=referral
1593.0,5/16/2023 12:52:10 PM,AstraZeneca to exit leading U.S. drug industry group PhRMA,Seeking Alpha,https://seekingalpha.com/news/3972045-astrazeneca-stock-exits-leading-us-drug-lobby-phrma?utm_source=businessinsider&utm_medium=referral
1594.0,5/17/2023 4:13:55 PM,Prothena adds former FDA neuro chief Billy Dunn to director board,Seeking Alpha,https://seekingalpha.com/news/3972658-prothena-stock-adds-ex-fda-neuro-chief-billy-dunn-board?utm_source=businessinsider&utm_medium=referral
1595.0,5/18/2023 12:50:29 PM,Zai Lab gets priority review for lung cancer dug repotrectinib in China,Seeking Alpha,https://seekingalpha.com/news/3972983-zai-lab-gets-priority-review-for-lung-cancer-dug-repotrectinib-in-china?utm_source=businessinsider&utm_medium=referral
1596.0,5/18/2023 3:23:30 PM,Arcellx a buy at Truist on unique cancer cell therapies,Seeking Alpha,https://seekingalpha.com/news/3973091-arcellx-buy-at-truist-unique-cancer-cell-therapies?utm_source=businessinsider&utm_medium=referral
1597.0,5/18/2023 4:13:46 PM,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,Seeking Alpha,https://seekingalpha.com/news/3973082-supreme-court-rules-against-amgen-rapatha-patent-dispute?utm_source=businessinsider&utm_medium=referral
1598.0,5/19/2023 10:59:40 PM,Intensity Therapeutics upsizes proposed IPO to $15M from $8M,Seeking Alpha,https://seekingalpha.com/news/3973606-intensity-therapeutics-upsizes-proposed-ipo-to-15m-from-8m?utm_source=businessinsider&utm_medium=referral
1599.0,5/21/2023 4:00:17 PM,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,Seeking Alpha,https://seekingalpha.com/news/3973623-billions-fda-shortcut-allows-half-proven-drugs?utm_source=businessinsider&utm_medium=referral
1600.0,5/22/2023 4:13:22 PM,Bristol-Myers pulmonary fibrosis candidate reduces lung decline rate,Seeking Alpha,https://seekingalpha.com/news/3973845-bristol-myers-pulmonary-fibrosis-candidate-reduces-lung-function-decline-rate?utm_source=businessinsider&utm_medium=referral
1601.0,5/23/2023 2:55:05 AM,Goldman Sachs Sticks to Their Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/goldman-sachs-sticks-to-their-buy-rating-for-bristol-myers-bmy-1032343893
1602.0,5/23/2023 3:15:12 AM,Bank of America Securities Sticks to Its Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-its-buy-rating-for-bristol-myers-bmy-1032343918
1603.0,5/23/2023 10:55:09 AM,BMO Capital Keeps Their Buy Rating on Bristol Myers (BMY),TipRanks,/news/stocks/bmo-capital-keeps-their-buy-rating-on-bristol-myers-bmy-1032344865
1604.0,5/23/2023 8:30:34 PM,Quant Ratings Updated on 119 Stocks,InvestorPlace,/news/stocks/20230523-quant-ratings-1032346659
1605.0,5/25/2023 1:22:09 PM,"Bristol Myers, J&J's blood clot therapy milvexian gets FDA fast track status",Seeking Alpha,https://seekingalpha.com/news/3975069-bristol-myers-jjs-blood-clot-drug-milvexian-gets-fda-fast-track-tag?utm_source=businessinsider&utm_medium=referral
1606.0,5/25/2023 7:23:24 PM,Mirati tumbles after study failure for cancer drug; Oppenheimer upgrades,Seeking Alpha,https://seekingalpha.com/news/3975194-mirati-stock-falls-study-failure-oppenheimer-upgrades?utm_source=businessinsider&utm_medium=referral
1607.0,5/26/2023 12:51:14 PM,Bristol Myers Opdivo gets EMA panel backing for expanded use in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3975409-bristol-myers-opdivo-gets-ema-panel-backing-for-expanded-use?utm_source=businessinsider&utm_medium=referral
1608.0,5/30/2023 11:42:47 AM,Bristol Myers granted FDA priority review for lung cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3975738-bristol-myers-stock-wins-fda-review-lung-cancer-drug?utm_source=businessinsider&utm_medium=referral
1609.0,6/1/2023 11:20:14 AM,Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Bristol Myers (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-bristol-myers-bmy-1032363937
1610.0,6/5/2023 8:55:16 AM,Barclays Remains a Hold on Bristol Myers (BMY),TipRanks,/news/stocks/barclays-remains-a-hold-on-bristol-myers-bmy-1032369660
1611.0,6/5/2023 9:10:18 AM,"Analysts Conflicted on These Healthcare Names: Amicus (FOLD), Teladoc (TDOC) and Bristol Myers (BMY)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amicus-fold-teladoc-tdoc-and-bristol-myers-bmy-1032369703
1612.0,6/7/2023 8:50:29 AM,"Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Sanofi (OtherSNYNF) and Bristol Myers (BMY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-thermo-fisher-tmo-sanofi-othersnynf-and-bristol-myers-bmy-1032375151
1613.0,6/7/2023 9:01:18 AM,"Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY), Edwards Lifesciences (EW) and Amedisys (AMED)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-bmy-edwards-lifesciences-ew-and-amedisys-amed-1032375205
1614.0,6/8/2023 10:15:54 PM,Bristol-Myers gets FDA approval for Devens cell therapy manufacturing facility,Seeking Alpha,https://seekingalpha.com/news/3978826-bristol-myers-gets-fda-approval-for-devens-cell-therapy-manufacturing-facility?utm_source=businessinsider&utm_medium=referral
1615.0,6/9/2023 11:11:57 AM,AstraZeneca in pact with Quell Therapeutics for Treg cell therapies,Seeking Alpha,https://seekingalpha.com/news/3978896-astrazeneca-stock-co-develop-treg-cell-therapies?utm_source=businessinsider&utm_medium=referral
1616.0,6/9/2023 1:26:24 PM,"AbbVie, Amgen among firms targeted for Medicare inflation penalties",Seeking Alpha,https://seekingalpha.com/news/3978943-abbvie-among-firms-targeted-for-medicare-inflation-penalties?utm_source=businessinsider&utm_medium=referral
1617.0,6/9/2023 6:15:10 PM,Don’t Forget About Cyclical Value. 3 Stocks to Consider,TipRanks,/news/stocks/don-t-forget-about-cyclical-value-3-stocks-to-consider-1032381469
1618.0,6/13/2023 11:03:59 AM,Seagen posts 93% complete remission for lymphoma therapy in Phase 2 trial,Seeking Alpha,https://seekingalpha.com/news/3979459-seagen-lymphoma-drug-adcetris-sets-93-complete-remission?utm_source=businessinsider&utm_medium=referral
1619.0,6/14/2023 8:20:46 PM,Bristol-Myers Squibb Company  declares $0.57 dividend,Seeking Alpha,https://seekingalpha.com/news/3979948-bristol-myers-squibb-company-declares-0_57-dividend?utm_source=businessinsider&utm_medium=referral
1620.0,6/16/2023 11:10:50 AM,"Dividend Roundup: Southwest Airlines, Philip Morris, Microsoft, Target, and more",Seeking Alpha,https://seekingalpha.com/news/3980282-dividend-roundup-southwest-airlines-phillip-morris-microsoft-target-and-more?utm_source=businessinsider&utm_medium=referral
1621.0,6/16/2023 10:11:45 PM,Bristol Meyers reportedly sues over new Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/3980604-bristol-meyers-reportedly-sues-over-new-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral
1622.0,6/20/2023 10:50:07 AM,"Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Axonics Modulation Technologies (AXNX)",TipRanks,/news/stocks/analysts-top-healthcare-picks-rhythm-pharmaceuticals-rytm-axonics-modulation-technologies-axnx-1032398478
1623.0,6/20/2023 12:12:53 PM,Bristol Myers reportedly sues over new Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/3980604-bristol-myers-reportedly-sues-over-new-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral
1624.0,6/20/2023 12:18:59 PM,3 AI Stocks That Could Skyrocket Your Wealth,InvestorPlace,/news/stocks/3-ai-stocks-that-could-skyrocket-your-wealth-1032398783
1625.0,6/20/2023 4:36:03 PM,"Alexandria Research completes sale of five facilities, reiterates 2023 guidance",Seeking Alpha,https://seekingalpha.com/news/3981077-alexandria-research-completes-sale-of-five-facilities-reiterates-2023-guidance?utm_source=businessinsider&utm_medium=referral
1626.0,6/21/2023 3:44:52 PM,Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3981469-top-pharma-lobby-sues-us-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral
1627.0,6/22/2023 12:41:24 AM,7 Healthcare Stocks to Make You the Millionaire Next Door,InvestorPlace,/news/stocks/7-healthcare-stocks-to-make-you-the-millionaire-next-door-1032403201
1628.0,6/25/2023 4:00:43 PM,What is behind big pharma's underperformance?,Seeking Alpha,https://seekingalpha.com/news/3982575-pharma-underperforms-amid-regulatory-woes?utm_source=businessinsider&utm_medium=referral
1629.0,6/26/2023 9:11:43 PM,Bristol-Myers Squibb wins EC approval of Camzyos for cardiomyopathy,Seeking Alpha,https://seekingalpha.com/news/3982986-bristol-myers-squibb-wins-ec-approval-camzyos-cardiomyopathy?utm_source=businessinsider&utm_medium=referral
1630.0,6/26/2023 10:22:00 PM,Bristol Myers Camzyos Gets European Commission Approval ,RTTNews,/news/stocks/bristol-myers-camzyos-gets-european-commission-approval-1032410780
1631.0,6/28/2023 11:00:45 AM,Fresh Blood: 3 Stocks Ready to Rally Under New CEOs,InvestorPlace,/news/stocks/3-stocks-ready-to-rally-under-new-ceos-1032414676
1632.0,6/28/2023 5:00:34 PM,Analyst Expectations for Bristol-Myers Squibb's Future,Benzinga,/news/stocks/analyst-expectations-for-bristol-myers-squibb-s-future-1032415602
1633.0,6/30/2023 11:48:19 AM,"Dividend Roundup: General Mills, Mastercard, JPMorgan, Verizon, and more",Seeking Alpha,https://seekingalpha.com/news/3984403-dividend-roundup-general-mills-mastercard-jpmorgan-verizon-and-more?utm_source=businessinsider&utm_medium=referral
1634.0,6/30/2023 4:41:16 PM,Medicare revises guidance on drug price negotiations amid lawsuits,Seeking Alpha,https://seekingalpha.com/news/3984642-medicare-revises-guidance-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1635.0,7/5/2023 6:12:16 PM,Why Is Allarity Therapeutics (ALLR) Stock Up 30% Today?,InvestorPlace,/news/stocks/why-is-allarity-therapeutics-allr-stock-up-30-today-1032428359
1636.0,7/9/2023 4:00:00 PM,Goldman Sachs sees rays of hope in underperforming health sector,Seeking Alpha,https://seekingalpha.com/news/3986286-goldman-sachs-sees-hope-underperforming-health-sector?utm_source=businessinsider&utm_medium=referral
1637.0,7/10/2023 10:45:33 AM,Bristol Myers (BMY) Has a New Rating from SVB Securities,TipRanks,/news/stocks/bristol-myers-bmy-has-a-new-rating-from-svb-securities-1032434511
1638.0,7/10/2023 3:43:53 PM,ImmunityBio phase 1 data finds combo may induce tumor regression,Seeking Alpha,https://seekingalpha.com/news/3986506-immunitybio-phase-1-data-finds-combo-may-induce-tumor-regression?utm_source=businessinsider&utm_medium=referral
1639.0,7/10/2023 5:02:11 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 10, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-10-2023-1032435238
1640.0,7/10/2023 9:26:45 PM,Bristol gains worldwide license to Prothena Alzheimer's candidate,Seeking Alpha,https://seekingalpha.com/news/3986600-bristol-gains-worldwide-license-prothena-alzheimers-candidate?utm_source=businessinsider&utm_medium=referral
1641.0,7/11/2023 7:50:42 AM,Evotec Get $40 Mln Payment As Bristol Myers Enters Global Licence Agreement ,RTTNews,/news/stocks/evotec-get-40-mln-payment-as-bristol-myers-enters-global-licence-agreement-1032436681
1642.0,7/11/2023 9:35:11 AM,Bristol Myers (BMY) Gets a Hold from Barclays,TipRanks,/news/stocks/bristol-myers-bmy-gets-a-hold-from-barclays-1032437138
1643.0,7/11/2023 10:49:40 AM,Bristol Myers inks licensing pact under Evotec neuroscience deal,Seeking Alpha,https://seekingalpha.com/news/3986680-bristol-myers-licenses-evotech-neuroscience-deal?utm_source=businessinsider&utm_medium=referral
1644.0,7/11/2023 11:43:48 AM,Bristol Myers succeeds in Phase 3 trial for Opdivo in bladder cancer,Seeking Alpha,https://seekingalpha.com/news/3986700-bristol-myers-hits-phase-3-win-opdivo-bladder-cancer?utm_source=businessinsider&utm_medium=referral
1645.0,7/11/2023 7:02:45 PM,Israel's Purple reports encouraging early data for pancreatic cancer drug,Seeking Alpha,https://seekingalpha.com/news/3986877-israels-purple-reports-encouraging-early-data-for-pancreatic-cancer-drug?utm_source=businessinsider&utm_medium=referral
1646.0,7/12/2023 6:05:31 PM,Merck intensifies legal fight to halt Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3987148-merck-files-motion-in-suit-halt-medicare-drug-pricing-law?utm_source=businessinsider&utm_medium=referral
1647.0,7/14/2023 5:02:15 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-14-2023-1032447974
1648.0,7/15/2023 6:00:00 PM,Atrial fibrillation drug market expected to decline as brand therapies go generic,Seeking Alpha,https://seekingalpha.com/news/3987824-atrial-fibrillation-drug-market-expected-decline-brand-therapies-generic?utm_source=businessinsider&utm_medium=referral
1649.0,7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral
1650.0,7/17/2023 12:14:12 AM,"HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna",Seeking Alpha,https://seekingalpha.com/news/3987876-hsbc-bullish-on-roche-lonza-bearish-on-bristol-myers-gsk-moderna?utm_source=businessinsider&utm_medium=referral
1651.0,7/18/2023 5:33:04 PM,J&J becomes latest Big Pharma to sue over Medicare drug pricing,Seeking Alpha,https://seekingalpha.com/news/3988476-jj-becomes-latest-big-pharma-to-sue-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral
1652.0,7/19/2023 8:00:22 PM,Analyst Expectations for Bristol-Myers Squibb's Future,Benzinga,/news/stocks/analyst-expectations-for-bristol-myers-squibb-s-future-1032460076
1653.0,7/21/2023 11:35:06 AM,Bristol Myers nabs EU endorsement for Opdivo in melanoma,Seeking Alpha,https://seekingalpha.com/news/3989567-bristol-myers-nabs-eu-backing-for-opdivo-melanoma?utm_source=businessinsider&utm_medium=referral
1654.0,7/21/2023 2:22:22 PM,CHMP Recommends Approval Of Bristol Myers' Opdivo For Adjuvant Treatment For Melanoma ,RTTNews,/news/stocks/chmp-recommends-approval-of-bristol-myers-opdivo-for-adjuvant-treatment-for-melanoma-1032465750
1655.0,7/21/2023 7:00:10 PM,"Catalyst Watch: Earnings blitz, central bank meetings, UPS strike jitters and Barbenheimer",Seeking Alpha,https://seekingalpha.com/news/3989741-catalyst-watch-earnings-blitz-central-bank-meetings-ups-strike-jitters-and-barbenheimer?utm_source=businessinsider&utm_medium=referral
1656.0,7/21/2023 7:31:28 PM,The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-now-july-2023-1032466871
1657.0,7/24/2023 11:34:11 AM,Immatics climbs 8% on $35M investment by Bristol Myers Squibb,Seeking Alpha,https://seekingalpha.com/news/3989979-immatics-climbs-8-on-35m-investment-by-bristol-myers-squibb?utm_source=businessinsider&utm_medium=referral
1658.0,7/24/2023 4:05:16 PM,Why Immatics Shares Are Rising Today,Benzinga,/news/stocks/why-immatics-shares-are-rising-today-1032470698
1659.0,7/26/2023 3:01:13 PM,Here's what to expect from Bristol-Myers Squibb's earnings report,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q2-earnings-preview-stock-1032479770
1660.0,7/26/2023 5:20:41 PM,Bristol-Myers Squibb set to continue streak of EPS beats with Q2 results,Seeking Alpha,https://seekingalpha.com/news/3991373-bristol-myers-squibb-set-continue-streak-eps-beats-q2-results?utm_source=businessinsider&utm_medium=referral
1661.0,7/27/2023 9:05:39 AM,Bank of America Securities Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-its-buy-rating-for-bristol-myers-squibb-bmy-1032483491
1662.0,7/27/2023 11:00:44 AM,"Bristol-Myers Squibb Company Non-GAAP EPS of $1.75 misses by $0.24, revenue of $11.2B misses by $610M",Seeking Alpha,https://seekingalpha.com/news/3991942-bristol-myers-squibb-company-non-gaap-eps-of-175-misses-by-024-revenue-of-112b-misses-by-610m?utm_source=businessinsider&utm_medium=referral
1663.0,7/27/2023 12:17:16 PM,Bristol-Myers sets below-consensus guidance amid generic competition,Seeking Alpha,https://seekingalpha.com/news/3992051-bristol-myers-squibb-stock-falls-amid-q2-mis?utm_source=businessinsider&utm_medium=referral
1664.0,7/27/2023 1:27:00 PM,"6 stocks to watch on Thursday: Netflix, Mastercard, AbbVie, McDonald's and more",Seeking Alpha,https://seekingalpha.com/news/3992133-6-stocks-to-watch-on-thursday-netflix-mastercard-abbvie-mcdonalds-and-more?utm_source=businessinsider&utm_medium=referral
1665.0,7/27/2023 1:30:32 PM,Bristol-Myers Squibb Slashes FY23 Outlook As Q2 Results Miss Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-slashes-fy23-outlook-as-q2-results-miss-estimates-1032484112
1666.0,7/27/2023 7:37:23 PM,"Bristol slumps to 52-week low on earnings, guidance disappointments",Seeking Alpha,https://seekingalpha.com/news/3992324-bristol-slumps-52-week-low-earnings-guidance-disappointments?utm_source=businessinsider&utm_medium=referral
1667.0,7/28/2023 9:16:00 AM,Barclays Keeps Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-keeps-their-hold-rating-on-bristol-myers-squibb-bmy-1032489191
1668.0,7/28/2023 11:45:32 AM,BMO Capital Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/bmo-capital-sticks-to-their-buy-rating-for-bristol-myers-squibb-bmy-1032489794
1669.0,7/28/2023 1:40:20 PM,"Analysts Offer Insights on Healthcare Companies: Anixa Biosciences (ANIX), Roche Holding AG (OtherRHHVF) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-anixa-biosciences-anix-roche-holding-ag-otherrhhvf-and-bristol-myers-squibb-bmy-1032490223
1670.0,7/28/2023 1:47:07 PM,2seventy bio downgraded at Morgan Stanley after Abecma sales,Seeking Alpha,https://seekingalpha.com/news/3992869-2seventy-bio-stock-downgraded-at-morgan-stanley-abecma?utm_source=businessinsider&utm_medium=referral
1671.0,7/28/2023 1:48:11 PM,Roku To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Friday,Benzinga,/news/stocks/roku-to-rally-around-25-here-are-10-other-analyst-forecasts-for-friday-1032489755
1672.0,7/30/2023 7:00:57 PM,3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes,InvestorPlace,/news/stocks/3-millionaire-maker-biotech-stocks-to-buy-before-the-window-closes-1032492374
1673.0,8/1/2023 2:25:30 AM,Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-squibb-bmy-1032497502
1674.0,8/1/2023 11:10:35 AM,Looking for a Bargain? 7 Blue-Chip Stocks to Buy That Are Down 5% in 2023,InvestorPlace,/news/stocks/looking-for-a-bargain-7-blue-chip-stocks-to-buy-that-are-down-5-in-2023-1032500151
1675.0,8/10/2023 11:36:21 AM,Bristol Myers announces $4B accelerated share buybacks,Seeking Alpha,https://seekingalpha.com/news/4000815-bristol-myers-stock-gains-on-share-buybacks?utm_source=businessinsider&utm_medium=referral
1676.0,8/10/2023 1:57:38 PM,Bristol-Myers Squibb To Buyback $4 Bln Of Shares Under Accelerated Share Repurchase ,RTTNews,/news/stocks/bristol-myers-squibb-to-buyback-4-bln-of-shares-under-accelerated-share-repurchase-1032540131
1677.0,8/10/2023 3:00:00 PM,Medicare Part D drug price increases far exceed inflation - AARP,Seeking Alpha,https://seekingalpha.com/news/4000101-medicare-part-d-drug-price-increases-far-exceed-inflation?utm_source=businessinsider&utm_medium=referral
1678.0,8/10/2023 8:04:28 PM,Dr. Reddy's launches generic version of Kombiglyze XR in US,Seeking Alpha,https://seekingalpha.com/news/4001262-dr-reddys-launches-generic-version-of-kombiglyze-xr-in-us?utm_source=businessinsider&utm_medium=referral
1679.0,8/13/2023 6:00:00 PM,Pharma under threat from bill to expand drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4002034-pharma-under-threat-bill-expand-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1680.0,8/16/2023 4:50:11 PM,Bristol touts updated data on lung cancer candidate repotrectinib,Seeking Alpha,https://seekingalpha.com/news/4003550-bristol-touts-updated-data-lung-cancer-candidate-repotrectinib?utm_source=businessinsider&utm_medium=referral
1681.0,8/17/2023 11:15:18 AM,Bristol-Myers Squibb (BMY) Gets a Buy from BMO Capital,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-buy-from-bmo-capital-1032562888
1682.0,8/18/2023 5:10:25 PM,"AARP, Public Citizen file briefs in Medicare drug price negotiations case",Seeking Alpha,https://seekingalpha.com/news/4004411-aarp-public-citizen-file-briefs-medicare-drug-price-negotiations-case?utm_source=businessinsider&utm_medium=referral
1683.0,8/21/2023 7:26:37 PM,Lawsuits unlikely to hinder Medicare drug price negotiations – UBS,Seeking Alpha,https://seekingalpha.com/news/4004908-lawsuits-wont-hurt-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1684.0,8/22/2023 8:38:01 PM,3 Sorry Pharma Stocks to Sell in August Before It’s Too Late,InvestorPlace,/news/stocks/3-sorry-pharma-stocks-to-sell-in-august-before-its-too-late-1032574450
1685.0,8/22/2023 9:03:43 PM,Bristol wins European approval of Opdivo as adjuvant for melanoma,Seeking Alpha,https://seekingalpha.com/news/4005323-bristol-wins-european-approval-opdivo-adjuvant-melanoma?utm_source=businessinsider&utm_medium=referral
1686.0,8/23/2023 2:27:22 PM,Roche sends anti-TIGIT developers higher after cancer drug data (update),Seeking Alpha,https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?utm_source=businessinsider&utm_medium=referral
1687.0,8/23/2023 11:42:25 PM,Biotech Breakthroughs: 3 Companies on the Cusp of Major Discoveries,InvestorPlace,/news/stocks/biotech-breakthroughs-3-companies-on-the-cusp-of-major-discoveries-1032578042
1688.0,8/24/2023 1:44:18 PM,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,Seeking Alpha,https://seekingalpha.com/news/4005992-drug-list-picked-medicare-price-negotiations-due-tuesday?utm_source=businessinsider&utm_medium=referral
1689.0,8/25/2023 3:54:51 PM,AstraZeneca latest drugmaker to challenge Medicare drug price negotiation,Seeking Alpha,https://seekingalpha.com/news/4006445-astrazeneca-latest-drugmaker-challenge-medicare-drug-price-negotiation?utm_source=businessinsider&utm_medium=referral
1690.0,8/25/2023 7:00:25 PM,"Catalyst Watch: Spotlight on Lululemon, drug pricing and the August jobs report",Seeking Alpha,https://seekingalpha.com/news/4006432-catalyst-watch-spotlight-on-lululemon-drug-pricing-and-the-august-jobs-report?utm_source=businessinsider&utm_medium=referral
1691.0,8/26/2023 6:00:00 PM,Crohn's disease drugmakers set to benefit from expected rise in cases,Seeking Alpha,https://seekingalpha.com/news/4006563-crohns-disease-drugmakers-benefit-expected-rise-cases?utm_source=businessinsider&utm_medium=referral
1692.0,8/27/2023 4:00:00 PM,Wall Street lists potential targets for Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4006581-wall-street-lists-targets-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1693.0,8/28/2023 2:00:00 PM,Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform,PR Newswire,/news/stocks/cellares-announces-bristol-myers-squibb-has-joined-technology-adoption-partnership-program-to-evaluate-automated-manufacturing-of-car-t-cell-therapy-on-the-cell-shuttle-platform-1032585677
1694.0,8/28/2023 6:05:07 PM,Bristol's Camzyos shows long-term benefit for heart condition,Seeking Alpha,https://seekingalpha.com/news/4006799-bristol-camzyos-long-term-benefit-heart-condition?utm_source=businessinsider&utm_medium=referral
1695.0,8/29/2023 10:53:40 AM,"Bristol Myers, Merck win U.S. label expansion for Reblozyl",Seeking Alpha,https://seekingalpha.com/news/4006945-bristol-myers-merck-win-us-label-expansion-reblozyl?utm_source=businessinsider&utm_medium=referral
1696.0,8/29/2023 11:45:20 AM,Medicare lists first ten drugs selected for pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4006764-medicare-lists-first-ten-drugs-picked-pricing-talks?utm_source=businessinsider&utm_medium=referral
1697.0,8/29/2023 2:33:29 PM,"Coinbase Global, Bristol-Myers Squibb And 2 Other Stocks Insiders Are Selling",Benzinga,/news/stocks/coinbase-global-bristol-myers-squibb-and-2-other-stocks-insiders-are-selling-1032588879
1698.0,8/29/2023 7:29:57 PM,Republicans say Medicare drug negotiations will mean fewer new meds,Seeking Alpha,https://seekingalpha.com/news/4007245-republicans-say-medicare-drug-negotiations-fewer-new-meds?utm_source=businessinsider&utm_medium=referral
1699.0,8/29/2023 7:40:54 PM,"Bristol Myers' Expanded Approval For Anemia Drug, Shows Superior Efficacy Over Concurrent Blood Transfusion",Benzinga,/news/stocks/bristol-myers-expanded-approval-for-anemia-drug-shows-superior-efficacy-over-concurrent-blood-transfusion-1032590291
1700.0,9/3/2023 4:00:00 PM,Why is big pharma unmoved despite Medicare pricing threat?,Seeking Alpha,https://seekingalpha.com/news/4008703-why-big-pharma-unmoved-despite-medicare-pricing-threat?utm_source=businessinsider&utm_medium=referral
1701.0,9/5/2023 11:37:27 AM,Bristol Myers in pact for autoimmune disease therapy,Seeking Alpha,https://seekingalpha.com/news/4008980-bristol-myers-zenas-biopharma-pact-autoimmune-disease-therapy?utm_source=businessinsider&utm_medium=referral
1702.0,9/7/2023 12:37:27 AM,How To Earn $500 From Pfizer Stock With Shares Trading At 52-Week Low,Benzinga,/news/stocks/how-to-earn-500-from-pfizer-stock-with-shares-trading-at-52-week-low-1032610884
1703.0,9/7/2023 4:55:40 AM,Bristol-Myers Squibb (BMY) Gets a Buy from Goldman Sachs,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-buy-from-goldman-sachs-1032611252
1704.0,9/7/2023 7:39:56 PM,Astellas withdraws federal lawsuit over Medicare drug pricing,Seeking Alpha,https://seekingalpha.com/news/4010044-astellas-withdraws-federal-lawsuit-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1705.0,9/8/2023 1:14:42 PM,The 3 Best Pharma Stocks to Buy Now: September 2023,InvestorPlace,/news/stocks/the-3-best-pharma-stocks-to-buy-now-september-2023-1032616131
1706.0,9/8/2023 7:00:57 PM,"Catalyst Watch: Arm IPO, Apple event, and Senate AI Forum with Musk, Zuckerberg, and Gates",Seeking Alpha,https://seekingalpha.com/news/4010342-catalyst-watch-arm-ipo-apple-event-and-senate-ai-forum-with-musk-zuckerberg-and-gates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1707.0,9/11/2023 12:20:32 PM,Marker gains as lymphoma therapy leads to complete remission,Seeking Alpha,https://seekingalpha.com/news/4010535-marker-stock-gains-complete-remission-lymphoma-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1708.0,9/12/2023 1:38:17 PM,Geron rises as Goldman Sachs upgrades citing FDA nod for imetelstat,Seeking Alpha,https://seekingalpha.com/news/4010966-geron-stock-rises-goldman-sachs-upgrades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1709.0,9/12/2023 8:43:53 PM,Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs,Benzinga,/news/stocks/recent-pullback-buying-opportunity-for-blood-cancer-firm-geron-goldman-sachs-1032624669
1710.0,9/13/2023 8:18:14 PM,The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.,InvestorPlace,/news/stocks/the-next-walgreens-ceo-my-top-3-picks-to-replace-roz-brewer-1032628468
1711.0,9/14/2023 8:30:37 PM,The 3 Most Undervalued Pharma Stocks to Buy in September 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-in-september-2023-1032631934
1712.0,9/15/2023 8:55:47 AM,Bristol-Myers Squibb (BMY) Gets a Buy from Bank of America Securities,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-buy-from-bank-of-america-securities-1032632911
1713.0,9/15/2023 10:15:29 AM,Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/morgan-stanley-keeps-their-sell-rating-on-bristol-myers-squibb-bmy-1032633149
1714.0,9/15/2023 10:46:50 AM,Three stocks strategies heading into Q4 from Goldman,Seeking Alpha,https://seekingalpha.com/news/4010492-three-stocks-strategies-going-heading-into-q4-from-goldman?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1715.0,9/15/2023 12:10:16 PM,Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-and-bristol-myers-squibb-bmy-1032633453
1716.0,9/15/2023 1:35:53 PM,Goldman Sachs Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/goldman-sachs-sticks-to-its-buy-rating-for-bristol-myers-squibb-bmy-1032633849
1717.0,9/18/2023 1:57:00 AM,Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance,PR Newswire,/news/stocks/samsung-biologics-announces-expanded-strategic-agreement-with-bristol-myers-squibb-to-manufacture-an-antibody-cancer-drug-substance-1032635242
1718.0,9/18/2023 7:59:46 PM,Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison,Benzinga,/news/stocks/anemia-advantage-for-gsk-s-blood-cancer-therapy-could-influence-market-share-despite-incyte-s-jakafi-comparison-1032638040
1719.0,9/19/2023 2:25:22 AM,Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-squibb-bmy-1032638379
1720.0,9/19/2023 8:33:26 PM,Quant Ratings Updated on 98 Stocks,InvestorPlace,/news/stocks/091923-quant-ratings-1032641584
1721.0,9/24/2023 8:00:35 PM,Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.,InvestorPlace,/news/stocks/beware-3-healthcare-stocks-waving-massive-red-flags-right-now-1032651288
1722.0,10/2/2023 3:32:07 PM,Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024,InvestorPlace,/news/stocks/q4-stock-predictions-3-pharma-stocks-ready-to-roar-into-2024-1032671152
1723.0,10/2/2023 11:09:29 PM,Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs,InvestorPlace,/news/stocks/cancer-drug-approval-3-biotech-stocks-on-the-brink-of-breakthroughs-1032671847
1724.0,10/6/2023 12:30:00 PM,Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials,PR Newswire,/news/stocks/paradigm-and-bristol-myers-squibb-collaborate-to-build-a-new-model-for-clinical-trials-1032684128
1725.0,10/9/2023 3:11:42 AM,Bristol Myers To Acquire Mirati Therapeutics In Deal Worth Up To $5.8 Bln ,RTTNews,/news/stocks/bristol-myers-to-acquire-mirati-therapeutics-in-deal-worth-up-to-5-8-bln-1032686840
1726.0,10/9/2023 9:20:32 AM,"Analysts’ Top Healthcare Picks: Resmed (RMD), Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-resmed-rmd-bristol-myers-squibb-bmy-1032688055
1727.0,10/9/2023 9:55:48 AM,Goldman Sachs Recommends Buy Rating for BMY: Acquisition of MRTX Bolsters Revenue Growth and Long-Term Prospects,TipRanks,/news/stocks/goldman-sachs-recommends-buy-rating-for-bmy-acquisition-of-mrtx-bolsters-revenue-growth-and-long-term-prospects-1032688099
1728.0,10/9/2023 11:57:25 AM,"Tesla, Mirati Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session",Benzinga,/news/stocks/tesla-mirati-therapeutics-and-other-big-stocks-moving-lower-in-monday-s-pre-market-session-1032688124
1729.0,10/9/2023 7:11:36 PM,"Stocks Halt Gains, Oil, Treasuries Rally As Investors React to Israel-Hamas Conflict: What's Driving Markets Monday?",Benzinga,/news/etf/stocks-halt-gains-oil-treasuries-rally-as-investors-react-to-israel-hamas-conflict-what-s-driving-markets-monday-1032689801
1730.0,10/9/2023 7:30:06 PM,Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/why-parazero-technologies-shares-are-trading-higher-by-over-100-here-are-other-stocks-moving-in-monday-s-mid-day-session-1032689828
1731.0,10/10/2023 4:20:34 AM,"Analysts Are Bullish on Top Healthcare Stocks: Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-bristol-myers-squibb-bmy-johnson-johnson-jnj-1032690640
1732.0,10/10/2023 8:20:10 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-bristol-myers-squibb-bmy-1032691280
1733.0,10/10/2023 10:46:47 PM,7 Innovator Stocks Primed for Exceptional Growth,InvestorPlace,/news/stocks/7-innovator-stocks-primed-for-exceptional-growth-1032694094
1734.0,10/12/2023 3:19:24 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields-1032700617
1735.0,10/13/2023 12:00:35 PM,3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition,InvestorPlace,/news/stocks/3-healthcare-stocks-to-make-you-the-millionaire-next-door-october-edition-1032704000
1736.0,10/19/2023 8:11:36 PM,7 Healthcare Stocks That Can Cure a Lackluster Portfolio,InvestorPlace,/news/stocks/healthcare-stocks-to-buy-4-1032722294
1737.0,10/20/2023 8:40:07 AM,"Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Bristol-Myers Squibb (BMY) and Edwards Lifesciences (EW)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-royalty-pharma-rprx-bristol-myers-squibb-bmy-and-edwards-lifesciences-ew-1032723592
1738.0,10/20/2023 3:00:16 PM,What 12 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-12-analyst-ratings-have-to-say-about-bristol-myers-squibb-1032724304
1739.0,10/20/2023 10:08:03 PM,"Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets",Benzinga,/news/etf/investor-risk-sentiment-wavers-amid-war-interest-rate-concerns-tesla-earnings-disappoint-the-week-in-the-markets-1032725210
1740.0,10/24/2023 2:47:19 PM,'Never Buy A Drug Stock Just For The Yield': Jim Cramer On This Big Pharma Company,Benzinga,/news/stocks/never-buy-a-drug-stock-just-for-the-yield-jim-cramer-on-this-big-pharma-company-1032733252
1741.0,10/24/2023 3:21:37 PM,LianBio Reaches Agreement With Bristol Myers Squibb For Mavacamten; Stock Up ,RTTNews,/news/stocks/lianbio-reaches-agreement-with-bristol-myers-squibb-for-mavacamten-stock-up-1032733684
1742.0,10/24/2023 5:48:58 PM,Why Is LianBio (LIAN) Stock Up 130% Today?,InvestorPlace,/news/stocks/why-lianbio-lian-stock-up-130-percent-today-1032734783
1743.0,10/25/2023 3:01:13 PM,Bristol-Myers Squibb earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-q3-earnings-preview-1032738729
1744.0,10/26/2023 9:31:17 AM,"Geoff Meacham’s Optimistic Buy Rating for Bristol-Myers Squibb: Assessing Upcoming Results, Strategic Acquisitions and ‘Big 9’ Product Performance",TipRanks,/news/stocks/geoff-meacham-s-optimistic-buy-rating-for-bristol-myers-squibb-assessing-upcoming-results-strategic-acquisitions-and-big-9-product-performance-1032745759
1745.0,10/26/2023 1:43:13 PM,Bristol-Myers Squibb Boosts FY23 Adj. EPS Outlook As Q3 Adj. EPS Tops Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-boosts-fy23-adj-eps-outlook-as-q3-adj-eps-tops-estimates-1032743473
1746.0,10/26/2023 7:23:50 PM,"US Stocks Sink, VIX Soars As Overheated Economy, Mixed Earnings Complicate Fed's Path: What's Driving Markets Thursday?",Benzinga,/news/stocks/us-stocks-sink-vix-soars-as-overheated-economy-mixed-earnings-complicate-fed-s-action-what-s-driving-markets-thursday-1032745198
1747.0,10/27/2023 7:40:17 AM,"Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Immutep (IMMP) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amgen-amgn-immutep-immp-and-bristol-myers-squibb-bmy-1032749776
1748.0,10/27/2023 11:36:51 AM,Hold Rating on Bristol-Myers Squibb: An Analysis of Future Challenges and Investment Strategies,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-an-analysis-of-future-challenges-and-investment-strategies-1032750156
1749.0,10/27/2023 7:47:57 PM,Bristol Myers Squibb Analysts Slash Their Forecasts Following Q3 Results,Benzinga,/news/stocks/bristol-myers-squibb-analysts-slash-their-forecasts-following-q3-results-1032749611
1750.0,10/27/2023 8:13:44 PM,Pharma Giant Bristol-Myers Stock At 52-Week Low: Analyst Sees Uncertainty In Near-Term Outlook,Benzinga,/news/stocks/pharma-giant-bristol-myers-stock-at-52-week-low-analyst-sees-uncertainty-in-near-term-outlook-1032749657
1751.0,10/28/2023 5:15:33 PM,Biotech Stocks Facing FDA Decision In November 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-2023-1032750454
1752.0,10/30/2023 3:01:03 PM,"Karyopharm Enters Clinical Trial Collaboration, Supply Agreement With Bristol-Myers Squibb ",RTTNews,/news/stocks/karyopharm-enters-clinical-trial-collaboration-supply-agreement-with-bristol-myers-squibb-1032754488
1753.0,10/31/2023 6:50:16 AM,"Analysts Offer Insights on Healthcare Companies: NovoCure (NVCR), Insmed (INSM) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-novocure-nvcr-insmed-insm-and-bristol-myers-squibb-bmy-1032760985
1754.0,10/31/2023 12:10:43 PM,"Analysts Are Bullish on These Healthcare Stocks: Conmed (CNMD), Resmed (RMD)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-conmed-cnmd-resmed-rmd-1032761561
1755.0,11/1/2023 1:08:03 AM,Bristol Myers Squibb Elects Christopher Boerner To Serve As Chair Of Board ,RTTNews,/news/stocks/bristol-myers-squibb-elects-christopher-boerner-to-serve-as-chair-of-board-1032761556
1756.0,11/2/2023 9:10:58 AM,Bristol-Myers Squibb: A Hold Rating Amid Concerns over Sales Growth and Competitive Pressure – An Analysis by Berenberg Bank’s Luisa Hector,TipRanks,/news/stocks/bristol-myers-squibb-a-hold-rating-amid-concerns-over-sales-growth-and-competitive-pressure-–-an-analysis-by-berenberg-bank-s-luisa-hector-1032772397
1757.0,11/7/2023 1:55:28 AM,Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/berenberg-bank-remains-a-hold-on-bristol-myers-squibb-bmy-1032787543
1758.0,11/13/2023 4:36:30 PM,Debt-Fueled Buybacks: 3 Stocks Undeterred by Rising Rates,InvestorPlace,/news/stocks/debt-fueled-buybacks-3-stocks-undeterred-by-rising-rates-1032814009
1759.0,11/15/2023 6:00:55 PM,The Latest Analyst Ratings for Bristol-Myers Squibb,Benzinga,/news/stocks/the-latest-analyst-ratings-for-bristol-myers-squibb-1032824134
1760.0,11/20/2023 1:49:25 PM,"Bristol Myers Squibb, 2seventy Bio Issue Update On FDA Review For Abecma ",RTTNews,/news/stocks/bristol-myers-squibb-2seventy-bio-issue-update-on-fda-review-for-abecma-1032835270
1761.0,11/20/2023 3:08:46 PM,Why Is Bristol-Myers Squibb (BMY) Stock Down Today?,InvestorPlace,/news/stocks/why-is-bristol-myers-squibb-bmy-stock-down-today-1032836230
1762.0,11/20/2023 3:47:36 PM,Uber Stock Falls After Announcement of $1.2 Billion Convertible Notes Offering,InvestorPlace,/news/stocks/uber-stock-falls-after-announcement-of-1-2-billion-convertible-notes-offering-1032836306
1763.0,11/20/2023 4:00:27 PM,Dutch Bros (BROS) Stock Gains on JPMorgan Upgrade,InvestorPlace,/news/stocks/dutch-bros-bros-stock-gains-on-jpmorgan-upgrade-1032836349
1764.0,11/20/2023 8:58:21 PM,Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence,Benzinga,/news/stocks/analyst-assess-implications-of-bristol-myers-investigational-blood-thinner-post-bayer-trial-setback-amid-shaken-investor-confidence-1032836877
1765.0,11/21/2023 1:56:19 AM,Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters,InvestorPlace,/news/stocks/soothing-stocks-7-reliable-picks-to-ease-your-market-jitters-1032837327
1766.0,11/21/2023 10:31:10 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-bristol-myers-squibb-bmy-and-abbvie-abbv-1032840916
1767.0,11/26/2023 9:43:24 PM,3 Resilient Stocks with Massive Potential to Boost Your Wealth,InvestorPlace,/news/stocks/3-resilient-stocks-with-massive-potential-to-boost-your-wealth-1032849635
1768.0,11/27/2023 2:37:27 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields-1032851232
1769.0,11/28/2023 12:30:00 PM,Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology,PR Newswire,/news/stocks/avidity-biosciences-announces-expansion-of-cardiovascular-collaboration-with-bristol-myers-squibb-for-up-to-five-targets-utilizing-avidity-s-proprietary-aoc-platform-technology-1032854231
1770.0,11/28/2023 12:53:28 PM,Avidity Biosciences Inks Global Licensing And Research Collaboration Deal With Bristol Myers Squibb ,RTTNews,/news/stocks/avidity-biosciences-inks-global-licensing-and-research-collaboration-deal-with-bristol-myers-squibb-1032854290
1771.0,11/28/2023 3:09:27 PM,Why Is Avidity Biosciences (RNA) Stock Up 15% Today?,InvestorPlace,/news/stocks/why-is-avidity-biosciences-rna-stock-up-15-today-1032855547
1772.0,11/28/2023 3:17:30 PM,Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?,Benzinga,/news/stocks/why-is-rna-therapeutics-focused-avidity-biosciences-stock-trading-higher-today-1032855069
1773.0,11/30/2023 2:25:51 AM,Truist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-sticks-to-its-buy-rating-for-bristol-myers-squibb-bmy-1032862770
1774.0,12/5/2023 2:12:51 PM,Bristol Myers: FDA Accepts SBLA For Opdivo Combination For Priority Review ,RTTNews,/news/stocks/bristol-myers-fda-accepts-sbla-for-opdivo-combination-for-priority-review-1032874084
1775.0,12/6/2023 3:26:56 PM,2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains,Benzinga,/news/stocks/2024-s-potential-stock-surprises-goldman-sachs-unveils-s-p-500-laggards-for-major-gains-1032878413
1776.0,12/7/2023 12:50:32 PM,Bristol Myers Squibb To Repurchase Additional $3 Bln Of Shares ,RTTNews,/news/stocks/bristol-myers-squibb-to-repurchase-additional-3-bln-of-shares-1032881459
1777.0,12/8/2023 1:04:58 PM,Insiders Buying Bristol-Myers Squibb And 3 Other Stocks,Benzinga,/news/stocks/insiders-buying-bristol-myers-squibb-and-3-other-stocks-1032885253
1778.0,12/11/2023 12:17:08 PM,Bristol-Myers Squibb: Hold Rating Affirmed Amid Progress and Considerations in Drug Development,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-affirmed-amid-progress-and-considerations-in-drug-development-1032891210
1779.0,12/12/2023 3:00:06 PM,Bristol Myers Squibb's Mega $8.4B Oncology Bet - Secures Exclusive License With SystImmune,Benzinga,/news/stocks/bristol-myers-squibb-further-diversifies-oncology-portfolio-with-mega-8-4b-deal-1032893319
1780.0,12/13/2023 6:18:24 AM,Bristol-Myers Squibb Hold Rating: Balancing CAR-T Therapy Prospects with Manufacturing and Market Constraints,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-balancing-car-t-therapy-prospects-with-manufacturing-and-market-constraints-1032898378
1781.0,12/14/2023 1:00:00 PM,Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb,PR Newswire,/news/stocks/terray-therapeutics-announces-multi-target-collaboration-with-bristol-myers-squibb-1032900567
1782.0,12/14/2023 1:13:08 PM,"Terray, Bristol Myers Squibb Join To Identify Small Molecule Therapeutics Using TNova Platform ",RTTNews,/news/stocks/terray-bristol-myers-squibb-join-to-identify-small-molecule-therapeutics-using-tnova-platform-1032900655
1783.0,12/17/2023 5:35:39 PM,7 Stocks with Strong Insider Buying: December 2023,InvestorPlace,/news/stocks/7-stocks-with-strong-insider-buying-december-2023-1032907072
1784.0,12/20/2023 5:39:46 PM,3 Potential Turnaround Stocks to Buy for Big Rewards in 2024,InvestorPlace,/news/stocks/3-potential-turnaround-stocks-to-buy-for-big-rewards-in-2024-1032917080
1785.0,12/22/2023 1:20:59 PM,Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash ,RTTNews,/news/stocks/bristol-myers-squibb-to-acquire-karuna-therapeutics-for-330-share-cash-1032922004
1786.0,12/22/2023 5:20:07 PM,"Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday",Benzinga,/news/stocks/karuna-therapeutics-jumps-following-takeover-by-bristol-myers-joins-rocket-lab-usa-altair-engineering-and-other-big-stocks-moving-higher-on-friday-1032922858
1787.0,12/22/2023 6:07:59 PM,"With Karuna Therapeutics $14B Deal, Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio: Analyst",Benzinga,/news/stocks/with-karuna-therapeutics-14b-deal-bristol-myers-is-serious-for-re-establishing-its-neurology-portfolio-analyst-1032923010
1788.0,12/22/2023 6:18:34 PM,Gold Moves Higher; US Consumer Sentiment Improves In December,Benzinga,/news/stocks/gold-moves-higher-us-consumer-sentiment-improves-in-december-1032923027
1789.0,12/22/2023 7:04:25 PM,"S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?",Benzinga,/news/stocks/s-p-500-nasdaq-100-aim-for-8th-week-of-gains-as-fed-s-inflation-gauge-cools-what-s-driving-markets-friday-1032923094
1790.0,12/22/2023 7:28:37 PM,Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session,Benzinga,/news/stocks/why-aar-shares-are-trading-lower-by-7-here-are-other-stocks-moving-in-friday-s-mid-day-session-1032923121
1791.0,12/22/2023 8:47:48 PM,Dow Edges Lower; Nike Sales Miss Estimates,Benzinga,/news/stocks/dow-edges-lower-nike-sales-miss-estimates-1032923197
1792.0,12/26/2023 11:05:33 AM,Hold Rating on Bristol-Myers Squibb Amid Strategic Karuna Acquisition and Long-Term Growth Prospects,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-strategic-karuna-acquisition-and-long-term-growth-prospects-1032926503
1793.0,12/26/2023 11:41:12 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), AlloVir (ALVR) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-sarepta-therapeutics-srpt-allovir-alvr-and-bristol-myers-squibb-bmy-1032926491
1794.0,12/26/2023 1:18:41 PM,Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal ,RTTNews,/news/stocks/bristol-myers-squibb-to-acquire-rayzebio-for-62-50-share-in-all-cash-deal-1032925528
1795.0,12/26/2023 3:10:15 PM,Why Is RayzeBio (RYZB) Stock Up 100% Today?,InvestorPlace,/news/stocks/why-is-rayzebio-ryzb-stock-up-100-today-1032926088
1796.0,12/26/2023 8:02:49 PM,Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst,Benzinga,/news/stocks/bristol-myers-acquisition-of-karuna-therapeutics-paves-way-for-aggressive-global-marketing-of-karxt-analyst-1032926298
1797.0,12/27/2023 6:25:58 AM,Bristol-Myers Squibb’s Strategic Expansion: Buy Rating Affirmed Following RayzeBio Acquisition,TipRanks,/news/stocks/bristol-myers-squibb-s-strategic-expansion-buy-rating-affirmed-following-rayzebio-acquisition-1032928641
1798.0,12/27/2023 10:26:23 AM,Buy Rating on Bristol-Myers Squibb: Strategic Acquisitions Bolster Oncology Portfolio Despite Near-Term Earnings Dilution,TipRanks,/news/stocks/buy-rating-on-bristol-myers-squibb-strategic-acquisitions-bolster-oncology-portfolio-despite-near-term-earnings-dilution-1032928858
1799.0,12/27/2023 12:16:05 PM,Bristol-Myers Squibb (BMY) Gets a Hold from Cantor Fitzgerald,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-hold-from-cantor-fitzgerald-1032928898
1800.0,12/27/2023 1:00:13 PM,Analyst Expectations For Bristol-Myers Squibb's Future,Benzinga,/news/stocks/analyst-expectations-for-bristol-myers-squibb-s-future-1032927723
1801.0,12/27/2023 3:06:32 PM,Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday,Benzinga,/news/stocks/meta-to-rally-over-18-here-are-10-top-analyst-forecasts-for-wednesday-1032927940
1802.0,12/27/2023 6:42:14 PM,"Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned",Benzinga,/news/stocks/recent-m-a-bodes-well-for-targeted-cancer-therapy-player-fusion-pharmaceuticals-analyst-say-astrazeneca-is-favorably-positioned-1032928584
1803.0,12/27/2023 6:59:59 PM,Why Is Cytokinetics (CYTK) Stock Up 70% Today?,InvestorPlace,/news/stocks/why-is-cytokinetics-cytk-stock-up-70-today-1032928698
1804.0,12/28/2023 6:19:47 PM,Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch,Benzinga,/news/stocks/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-potential-launch-1032930741
1805.0,12/29/2023 2:30:13 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032932343
1806.0,1/3/2024 6:29:31 PM,"This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns",Benzinga,/news/stocks/this-analyst-downgrades-bristol-myers-squibb-cautions-amid-product-launch-and-revenue-concerns-1032940889
1807.0,1/3/2024 11:17:42 PM,7 Stocks Primed for a Spectacular Comeback in 2024,InvestorPlace,/news/stocks/7-stocks-primed-for-a-spectacular-comeback-in-2024-1032941382
1808.0,1/4/2024 8:27:35 PM,3 Dividend Stocks for Strong Returns in 2024 and Beyond,InvestorPlace,/news/stocks/3-dividend-stocks-for-strong-returns-in-2024-and-beyond-1032944373
1809.0,1/5/2024 10:35:26 AM,Buy Rating Justified: Bristol-Myers Squibb’s Growth Prospects Bolstered by Strong Pipeline and Strategic Acquisitions,TipRanks,/news/stocks/buy-rating-justified-bristol-myers-squibb-s-growth-prospects-bolstered-by-strong-pipeline-and-strategic-acquisitions-1032947167
1810.0,1/9/2024 10:12:21 AM,Bristol-Myers Squibb: A Cautious Hold Amid Long-Term Growth Prospects,TipRanks,/news/stocks/bristol-myers-squibb-a-cautious-hold-amid-long-term-growth-prospects-1032955143
1811.0,1/19/2024 1:05:15 PM,Senate panel to consider subpoenas for J&J and Merck CEOs,Seeking Alpha,https://seekingalpha.com/news/4056351-sen-bernie-sanders-weighs-subpoenas-jj-merck-ceos?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1812.0,1/19/2024 6:24:22 PM,Mirati Therapeutics ticks higher amid Nasdaq delisting for sale to Bristol-Myers,Seeking Alpha,https://seekingalpha.com/news/4056557-mirati-therapeutics-ticks-higher-amid-nasdaq-delisting-for-sale-to-bristol-myers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1813.0,1/19/2024 8:55:45 PM,Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes,Benzinga,/news/stocks/ikena-oncology-refocuses-on-key-programs-analysts-maintain-outperform-ratings-amid-strategic-organizational-changes-1032980970
1814.0,1/20/2024 4:25:35 PM,Bristol Opdivo/Yervoy combo for colorectal cancer boosted by new data,Seeking Alpha,https://seekingalpha.com/news/4056644-bristol-opdivo-yervoy-combo-colorectal-cancer-boosted-new-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1815.0,1/22/2024 7:37:43 PM,Bristol-Myers almost lost Karuna buyout to third party,Seeking Alpha,https://seekingalpha.com/news/4057026-bristol-myers-almost-lost-karuna-buyout-third-party?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1816.0,1/22/2024 8:40:18 PM,"Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Bristol-Myers Squibb (BMY) and Immunocore Holdings (IMCR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-evolus-eols-bristol-myers-squibb-bmy-and-immunocore-holdings-imcr-1032987232
1817.0,1/22/2024 10:49:49 PM,Bristol's Opdivo + Yervoy combo excels over long term in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/4057161-bristol-opdivo-yervoy-combo-excels-long-term-kidney-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1818.0,1/23/2024 4:09:28 AM,CAR-T therapies to get boxed warning on blood cancer risk,Seeking Alpha,https://seekingalpha.com/news/4057175-car-t-therapies-get-boxed-warning-blood-cancer-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1819.0,1/23/2024 8:25:50 AM,Barclays Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1032987155
1820.0,1/23/2024 1:51:17 PM,Bristol Myers sees $0.35 per share impact as Mirati acquisition completes,Seeking Alpha,https://seekingalpha.com/news/4057339-bristol-myers-squibb-mirati-acquisition?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1821.0,1/23/2024 3:11:34 PM,Bristol Myers Squibb Completes Acquisition Of Mirati For Upto $5.8 Bln ,RTTNews,/news/stocks/bristol-myers-squibb-completes-acquisition-of-mirati-for-upto-5-8-bln-1032988040
1822.0,1/23/2024 10:06:38 PM,7 Beaten-Down Value Stocks Poised for an Epic Turnaround,InvestorPlace,/news/stocks/7-beaten-down-value-stocks-poised-for-an-epic-turnaround-1032989561
1823.0,1/26/2024 12:16:34 PM,PBMs ramp up lobbying efforts amid growing public scrutiny,Seeking Alpha,https://seekingalpha.com/news/4058952-pbms-ramp-up-lobbying-amid-growing-public-scrutiny?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1824.0,1/26/2024 1:09:58 PM,Bristol-Myers Squibb wins EU nod for expanded Abecma indication,Seeking Alpha,https://seekingalpha.com/news/4059013-bristol-myers-squibb-abecma-expanded-eu-nod?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1825.0,1/26/2024 3:46:58 PM,Bristol-Myers's Abecma Receives CHMP Recommendation For Market Authorization ,RTTNews,/news/stocks/bristol-myers-s-abecma-receives-chmp-recommendation-for-market-authorization-1033001136
1826.0,1/26/2024 5:01:25 PM,3 Healthcare Stocks at 52-Week Lows: Buy or Bye?,InvestorPlace,/news/stocks/3-healthcare-stocks-at-52-week-lows-buy-or-bye-1033001939
1827.0,1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1828.0,1/29/2024 5:14:01 PM,"Marathon Petroleum, Exxon among BofA picks for options opportunity on earnings surprise",Seeking Alpha,https://seekingalpha.com/news/4059539-marathon-petroleum-exxon-among-bofa-picks-for-options-opportunity-on-earnings-surprise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1829.0,1/29/2024 8:13:38 PM,Karuna’s KarXT tops Evaluate’s most anticipated drug list,Seeking Alpha,https://seekingalpha.com/news/4059673-karuna-karxt-tops-evaluate-most-anticipated-drug-list?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1830.0,1/30/2024 12:25:14 PM,Regulatory applications accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi,Seeking Alpha,https://seekingalpha.com/news/4059943-regulatory-applications-accepted-in-the-us-and-japan-for-bristol-myers-squibbs-breyanzi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1831.0,1/30/2024 12:50:11 PM,Pfizer beats with COVID franchise despite Q4 revenue miss,Seeking Alpha,https://seekingalpha.com/news/4059957-pfizer-beats-covid-franchise-despite-q4-revenue-miss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1832.0,1/30/2024 1:49:38 PM,Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?,Benzinga,/news/stocks/did-you-miss-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-street-s-most-accurate-analysts-1033009690
1833.0,1/30/2024 3:00:42 PM,"Bristol-Myers Says Regulatory Applications For Breyanzi Accepted By FDA, Japan's MHLW ",RTTNews,/news/stocks/bristol-myers-says-regulatory-applications-for-breyanzi-accepted-by-fda-japan-s-mhlw-1033010243
1834.0,2/1/2024 3:00:02 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/4061340-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1835.0,2/1/2024 3:01:13 PM,Bristol-Myers Squibb earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q4-earnings-preview-1033020715
1836.0,2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-opening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1837.0,2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-ppening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1838.0,2/1/2024 9:30:02 PM,Earnings preview: Bristol Myers seen reporting lower Q4 earnings Friday,Seeking Alpha,https://seekingalpha.com/news/4061685-earnings-preview-bristol-myers-seen-reporting-lower-q4-earnings-friday?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1839.0,2/2/2024 1:17:57 AM,Bristol-Myers Squibb: A Cautious Hold Amidst Financial Uncertainties and Product Launches,TipRanks,/news/stocks/bristol-myers-squibb-a-cautious-hold-amidst-financial-uncertainties-and-product-launches-1033022906
1840.0,2/2/2024 12:01:52 PM,Bristol-Myers Squibb beats top-line and bottom-line estimates; initiates FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4061943-bristol-myers-squibbbeats-top-line-and-bottom-line-estimates-initiates-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1841.0,2/2/2024 12:49:26 PM,Bristol-Myers Squibb beats in Q4 as Eliquis and Opdivo outperform,Seeking Alpha,https://seekingalpha.com/news/4061968-bristol-myers-squibb-q4-beats-driven-eliquis-and-opdivo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1842.0,2/2/2024 1:07:20 PM,"Bristol-Myers Squibb Co. Q4 Profit Decreases, but beats estimates",RTTNews,/news/stocks/bristol-myers-squibb-co-q4-profit-decreases-but-beats-estimates-1033024635
1843.0,2/2/2024 1:26:08 PM,Bristol-Myers Squibb Guides FY24 Adj. EPS Above Estimates As Q4 Results Top Estimates - Update ,RTTNews,/news/stocks/bristol-myers-squibb-guides-fy24-adj-eps-above-estimates-as-q4-results-top-estimates-update-1033024683
1844.0,2/4/2024 8:26:49 PM,Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/wells-fargo-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1033027473
1845.0,2/5/2024 7:55:59 AM,Barclays Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1033029365
1846.0,2/5/2024 12:28:26 PM,"Bristol Myers, 2seventy bio to face FDA panel in March for Abecma decision",Seeking Alpha,https://seekingalpha.com/news/4062480-bristol-myers-faces-fda-panel-abecma-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1847.0,2/5/2024 12:58:08 PM,Hold Rating on Bristol-Myers Squibb Amid Balanced Growth and Execution Challenges,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-balanced-growth-and-execution-challenges-1033031057
1848.0,2/5/2024 1:41:00 PM,Undervalued Gems: 7 Stocks Set for a Major Rebound,InvestorPlace,/news/stocks/undervalued-gems-7-stocks-set-for-a-major-rebound-1033030315
1849.0,2/6/2024 1:19:58 PM,Bristol Myers cut at Redburn as looming headwinds offset buyouts,Seeking Alpha,https://seekingalpha.com/news/4063080-bristol-myers-stock-cut-redburn-atlantic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1850.0,2/6/2024 1:54:09 PM,Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday,Benzinga,/news/stocks/uber-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday-1033034665
1851.0,2/6/2024 8:19:40 PM,"UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst",Benzinga,/news/stocks/ubs-bullish-on-this-depression-drug-maker-says-alzheimer-s-agitation-data-is-attractive-catalyst-1033036588
1852.0,2/7/2024 1:30:24 PM,"Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Waters (WAT) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-arrowhead-pharmaceuticals-arwr-waters-wat-and-bristol-myers-squibb-bmy-1033042129
1853.0,2/7/2024 1:35:55 PM,"Bristol Myers granted FDA, EU reviews for Opdivo label expansion",Seeking Alpha,https://seekingalpha.com/news/4063806-bristol-myers-granted-fda-eu-reviews-for-opdivo-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1854.0,2/7/2024 6:40:44 PM,3 Blue-Chip Stocks to Buy at a 52-Week Low in February,InvestorPlace,/news/stocks/want-blue-chip-stocks-at-a-low-price-here-are-3-solid-options-1033042564
1855.0,2/8/2024 9:10:42 PM,7 Biotech Stocks Fighting America’s Deadliest Diseases,InvestorPlace,/news/stocks/7-biotech-stocks-fighting-americas-deadliest-diseases-1033048253
1856.0,2/9/2024 12:24:06 PM,Pharma CEOs defend high drug prices; blame PBMs at Senate hearing,Seeking Alpha,https://seekingalpha.com/news/4065061-pharma-ceos-defend-high-drug-prices-blame-pbms-senate-hearing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1857.0,2/9/2024 1:57:00 PM,"7 stocks to watch on Friday: Major drugmakers on Senate hearing, PepsiCo and more",Seeking Alpha,https://seekingalpha.com/news/4065116-7-stocks-to-watch-on-friday-major-drugmakers-on-senate-hearing-pepsico-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1858.0,2/12/2024 1:21:45 PM,"Bristol Myers Squibb, RayzeBio Report Expiration Of HSR Act Waiting Period ",RTTNews,/news/stocks/bristol-myers-squibb-rayzebio-report-expiration-of-hsr-act-waiting-period-1033056612
1859.0,2/12/2024 1:57:56 PM,7 Dividend Stocks to Buy at a 52-Week Low ,InvestorPlace,/news/stocks/7-dividend-stocks-that-are-ready-for-a-bounce-back-year-1033057146
1860.0,2/12/2024 4:36:24 PM,RayzeBio ticks higher after HSR waiting period for Bristol Myers deal expires,Seeking Alpha,https://seekingalpha.com/news/4065612-rayzebio-ticks-higher-after-hsr-waiting-period-for-bristol-myers-deal-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1861.0,2/13/2024 2:01:27 AM,Federal judge dismisses PhRMA challenge to Medicare price negotiations,Seeking Alpha,https://seekingalpha.com/news/4065840-federal-judge-tosses-phrma-lawsuit-medicare-price-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1862.0,2/14/2024 12:28:54 PM,Bristol Myers wins FDA review for label expansion of lung cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4066637-bristol-myers-wins-fda-review-cancer-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1863.0,2/14/2024 12:54:01 PM,Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields-1033066002
1864.0,2/14/2024 5:03:40 PM,Bristol-Myers' Augtyro Receives Priority Review Status From FDA ,RTTNews,/news/stocks/bristol-myers-augtyro-receives-priority-review-status-from-fda-1033067503
1865.0,2/14/2024 9:45:18 PM,Bristol Myers urges investors to reject mini-tender offer,Seeking Alpha,https://seekingalpha.com/news/4067189-bristol-myers-urges-investors-to-reject-mini-tender-offer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1866.0,2/14/2024 11:50:22 PM,"Tudor Investment exits Airbnb, Adobe; boosts Nvidia, Splunk",Seeking Alpha,https://seekingalpha.com/news/4067303-tudor-investment-exits-airbnb-adobe-boosts-nvidia-splunk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1867.0,2/15/2024 7:51:12 AM,Bristol Myers Squibb prices $13B senior notes at varying maturities,Seeking Alpha,https://seekingalpha.com/news/4067330-bristol-myers-squibb-prices-13b-senior-notes-at-varying-maturities?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1868.0,2/15/2024 9:13:52 PM,7 Contrarian Biotech Stocks to Consider Amid Sector Weakness,InvestorPlace,/news/stocks/7-contrarian-biotech-stocks-to-consider-amid-sector-weakness-1033073521
1869.0,2/21/2024 1:04:09 PM,The 3 Best Stocks Beginning Investors Can Buy: February 2024,InvestorPlace,/news/stocks/the-3-best-stocks-beginning-investors-can-buy-february-2024-1033087518
1870.0,2/21/2024 4:03:58 PM,"UBS cuts BioXcel to neutral; cites regulatory issues, financing",Seeking Alpha,https://seekingalpha.com/news/4069650-ubs-cuts-bioxcel-to-neutral-cites-regulatory-issues-financing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1871.0,2/21/2024 8:06:10 PM,Mental Health Mavericks: 3 Stocks Changing the Game,InvestorPlace,/news/stocks/mental-health-mavericks-3-stocks-changing-the-game-1033089514
1872.0,2/22/2024 2:24:03 PM,Immunocore to work with Bristol on combination melanoma therapy trial,Seeking Alpha,https://seekingalpha.com/news/4070346-immunocore-work-bristol-combination-melanoma-therapy-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1873.0,2/23/2024 12:30:21 PM,Bristol Myers blood disorder therapy endorsed in EU for label expansion,Seeking Alpha,https://seekingalpha.com/news/4070991-bristol-myers-wins-eu-backing-expand-label-reblozyl?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1874.0,2/23/2024 1:19:34 PM,Bristol Myers Squibb: Approx. 86% Of RayzeBio Common Stock Validly Tendered As Of Expiration Time ,RTTNews,/news/stocks/bristol-myers-squibb-approx-86-of-rayzebio-common-stock-validly-tendered-as-of-expiration-time-1033097084
1875.0,2/25/2024 5:00:00 PM,Radiopharmaceutical market expected to reach ~$14B by 2032,Seeking Alpha,https://seekingalpha.com/news/4071376-radiopharmaceutical-market-reach-14b-by-2032?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1876.0,2/26/2024 11:55:00 AM,3 Highly Rated Biotech Stocks to Buy for 300% Gains,InvestorPlace,/news/stocks/3-highly-rated-biotech-stocks-to-buy-for-300-gains-1033102093
1877.0,2/26/2024 4:59:38 PM,Karuna Therapeutics drops on no apparent news amid deal with Bristol-Myers Squibb,Seeking Alpha,https://seekingalpha.com/news/4071718-karuna-therapeutics-drops-on-no-apparent-news-amid-deal-with-bristol-myers-squibb?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1878.0,2/27/2024 10:58:02 AM,Bristol-Myers Squibb: Balancing Growth Prospects Against Market Challenges and Uncertainties,TipRanks,/news/stocks/bristol-myers-squibb-balancing-growth-prospects-against-market-challenges-and-uncertainties-1033107719
1879.0,2/27/2024 11:02:30 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Krystal Biotech (KRYS) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-staar-surgical-staa-krystal-biotech-krys-and-bristol-myers-squibb-bmy-1033107687
1880.0,2/27/2024 1:37:09 PM,Minerva falls as FDA rejects schizophrenia therapy,Seeking Alpha,https://seekingalpha.com/news/4072211-minerva-stock-falls-fda-rejects-schizophrenia-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1881.0,2/28/2024 9:52:49 AM,Biotech Stocks Facing FDA Decision In March 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2024-1033111344
1882.0,2/28/2024 11:31:34 PM,Schrodinger down 15% after hours on soft 2024 guidance,Seeking Alpha,https://seekingalpha.com/news/4073589-schrodinger-down-15-after-hours-soft-2024-guidance?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1883.0,3/1/2024 12:30:00 PM,The Hot List: 3 AI Stocks Worth Buying on Weakness,InvestorPlace,/news/stocks/the-hot-list-3-ai-stocks-worth-buying-on-weakness-1033123124
1884.0,3/1/2024 6:10:27 PM,Medicare price negotiations survive another legal challenge,Seeking Alpha,https://seekingalpha.com/news/4074801-medicare-price-negotiations-survive-legal-challenge?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1885.0,3/1/2024 9:21:07 PM,Bristol-Myers Squibb Company  declares $0.60 dividend,Seeking Alpha,https://seekingalpha.com/news/4074882-bristol-myers-squibb-company-declares-0_60-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1886.0,3/4/2024 7:08:25 PM,Biden says drugmakers to continue to engage in Medicare drug price negoiations,Seeking Alpha,https://seekingalpha.com/news/4075531-biden-says-drugmakers-continue-engage-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1887.0,3/4/2024 7:56:37 PM,Biden to launch task force to target health care costs - report,Seeking Alpha,https://seekingalpha.com/news/4075586-biden-launch-task-force-target-health-care-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1888.0,3/6/2024 1:40:00 PM,Millionaire’s Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town,InvestorPlace,/news/stocks/millionaires-blueprint-7-must-have-stocks-for-your-road-to-wealthy-town-1033137473
1889.0,3/6/2024 10:40:54 PM,Biden to push for expanding Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/4076912-biden-to-push-for-expanding-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1890.0,3/7/2024 5:45:31 PM,Bristol-Myers wins FDA nod for Opdivo combo as first line bladder cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4077300-bristol-myers-wins-fda-nod-expand-opdivo-label?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1891.0,3/7/2024 8:52:40 PM,"Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley",Benzinga,/news/stocks/arcellx-s-lead-asset-can-potentially-outperform-bristol-myers-squibb-johnson-johnson-s-multiple-myeloma-cell-therapies-morgan-stanley-1033143791
1892.0,3/8/2024 8:00:00 PM,"Catalyst Watch: Oracle earnings, Arm IPO lockup, and triple-witching day",Seeking Alpha,https://seekingalpha.com/news/4076911-catalyst-watch-oracle-earnings-arm-ipo-lockup-and-triple-witching-day?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1893.0,3/10/2024 5:08:00 PM,Cantor sees strong year ahead for oncology M&A,Seeking Alpha,https://seekingalpha.com/news/4077812-patent-cliffs-could-fuel-increased-ma-in-oncology-this-year-cantor-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1894.0,3/11/2024 5:15:19 PM,"Societe Generale cuts Bristol Myers to hold, cites patent expiries",Seeking Alpha,https://seekingalpha.com/news/4078102-societe-generale-cuts-bristol-myers-to-hold-cites-patent-expiries?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1895.0,3/12/2024 12:37:30 PM,Truist Financial Keeps Their Buy Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-bristol-myers-squibb-bmy-1033155954
1896.0,3/12/2024 5:26:43 PM,CytomX falls as Bristol Myers ends deal for cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4078539-cytomx-stock-falls-bristol-myers-cancer-therapy-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1897.0,3/13/2024 1:44:45 PM,"J&J, Bristol Myers slip as FDA comments on CAR-T drugs ahead of AdCom",Seeking Alpha,https://seekingalpha.com/news/4078882-jj-bristol-myers-slip-fda-comments-car-t-drugs-adcom?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1898.0,3/14/2024 11:16:08 AM,Hold Rating on Bristol-Myers Squibb Amid Concerns Over Abecma’s Efficacy and Safety,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-concerns-over-abecma-s-efficacy-and-safety-1033164389
1899.0,3/14/2024 6:10:57 PM,Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires (update),Seeking Alpha,https://seekingalpha.com/news/4079400-karuna-therapeutics-gains-as-hsr-waiting-period-for-bristol-myers-deal-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1900.0,3/14/2024 6:54:38 PM,Biotech bankruptcies hit a record despite sector’s recovery,Seeking Alpha,https://seekingalpha.com/news/4079630-biotech-bankruptcies-hit-record-despite-sectors-recovery?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1901.0,3/15/2024 10:17:01 AM,FDA approves expanded use of Bristol Myers CAR T-cell therapy,Seeking Alpha,https://seekingalpha.com/news/4079828-fda-approves-expanded-use-of-bristol-myers-car-t-cell-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1902.0,3/15/2024 2:06:29 PM,Geron surges after FDA AdCom backing for lead drug,Seeking Alpha,https://seekingalpha.com/news/4079976-geron-stock-surges-fda-adcom-backs-imetelstat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1903.0,3/15/2024 5:25:53 PM,Johnson & Johnson wins FDA AdCom backing for Carvykti label expansion,Seeking Alpha,https://seekingalpha.com/news/4080088-jj-wins-fda-adcom-carvykti-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1904.0,3/16/2024 11:58:13 AM,Bristol Myers wins FDA AdCom backing for Abecma label expansion,Seeking Alpha,https://seekingalpha.com/news/4080229-bristol-myers-wins-fda-adcom-backing-abecma-labeling?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1905.0,3/18/2024 9:15:27 AM,Hold Rating on Bristol-Myers Squibb Amid Mixed Clinical Outcomes and Market Competition,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-mixed-clinical-outcomes-and-market-competition-1033172153
1906.0,3/18/2024 1:08:03 PM,Perspective Therapeutics partners with Bristol Myers for its metastatic melanoma treatment study,Seeking Alpha,https://seekingalpha.com/news/4080434-perspective-therapeutics-partners-with-bristol-myers-for-its-metastatic-melanoma-treatment-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1907.0,3/18/2024 2:01:49 PM,Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-completes-acquisition-of-karuna-therapeutics-quick-facts-1033172279
1908.0,3/19/2024 5:37:25 AM,Hold Rating on Bristol-Myers Squibb Amidst NSCLC Trial Uncertainties and Pending KarXT Results,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amidst-nsclc-trial-uncertainties-and-pending-karxt-results-1033175058
1909.0,3/19/2024 12:19:47 PM,AstraZeneca-Fusion deal reignites radiopharma space,Seeking Alpha,https://seekingalpha.com/news/4080965-fusion-pharma-stock-jumps-astrazeneca-hunts-radiopharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1910.0,3/19/2024 1:08:39 PM,Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers ,RTTNews,/news/stocks/perspective-therapeutics-inks-clinical-trial-collaboration-agreement-with-bristol-myers-1033176103
1911.0,3/20/2024 11:28:13 AM,Bristol Myers hits late-stage win for liver cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4081496-bristol-myers-stock-gains-trial-win-liver-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1912.0,3/20/2024 1:00:32 PM,Labcorp expands Alzheimer's testing portfolio with new diagnostic,Seeking Alpha,https://seekingalpha.com/news/4081545-labcorp-expands-alzheimers-test-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1913.0,3/20/2024 9:53:04 PM,Bristol Myers gets EU approval for Abecma for multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/4081853-bristol-myers-gets-eu-approval-for-abecma-for-multiple-myeloma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1914.0,3/21/2024 5:21:53 PM,China's Xi Jinping plans to meet with U.S. CEOs in China next week - report,Seeking Alpha,https://seekingalpha.com/news/4082269-chinas-xi-jinping-plans-to-meet-with-us-ceos-in-china-next-week-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1915.0,3/26/2024 5:37:15 PM,"BTIG upgrades Nuvation to buy, cites AnHeart acquisition",Seeking Alpha,https://seekingalpha.com/news/4083900-btig-upgrades-nuvation-to-buy-cites-anheart-acquisition?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1916.0,3/27/2024 5:57:50 PM,The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio,InvestorPlace,/news/stocks/the-healthcare-bargain-blitz-7-undervalued-stocks-to-inject-into-your-portfolio-1033202581
1917.0,3/28/2024 8:39:29 PM,Bristol Myers drug Zeposia fails Phase 3 study for Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/4085190-bristol-myers-drug-zeposia-fails-phase-3-study-for-crohns-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1918.0,3/29/2024 10:40:00 AM,The 3 Best Biotech Stocks to Buy in Q2 2024,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-in-q2-2024-1033208071
1919.0,4/1/2024 1:56:39 PM,Zai Lab: Bristol Myers' KRYSTAL-12 Confirmatory Trial With Adagrasib Meets Meets Primary Endpoint ,RTTNews,/news/stocks/zai-lab-bristol-myers-krystal-12-confirmatory-trial-with-adagrasib-meets-meets-primary-endpoint-1033210730
1920.0,4/1/2024 2:57:29 PM,Zai Lab reports Krazati lung cancer study meets primary endpoint,Seeking Alpha,https://seekingalpha.com/news/4085685-zai-lab-reports-krazati-lung-cancer-study-meets-primary-endpoint?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1921.0,4/1/2024 6:16:16 PM,The Bargain Hunter’s Dream: 3 Underpriced Stocks Poised for Massive Gains,InvestorPlace,/news/stocks/the-bargain-hunters-dream-3-underpriced-stocks-poised-for-massive-gains-1033212301
1922.0,4/2/2024 4:13:19 PM,Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts,InvestorPlace,/news/stocks/merger-mania-3-potential-takeover-targets-to-watch-for-lucrative-buyouts-1033216143
1923.0,4/3/2024 9:16:52 AM,Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/wells-fargo-sticks-to-its-hold-rating-for-bristol-myers-squibb-bmy-1033218697
1924.0,4/3/2024 5:07:34 PM,Bristol Myers wins label expansion for anemia therapy in EU,Seeking Alpha,https://seekingalpha.com/news/4086933-bristol-myers-wins-eu-label-expansion-anemia-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1925.0,4/4/2024 3:12:55 PM,Top buy-rated stocks and sell-rated stocks within Health Care - Citi,Seeking Alpha,https://seekingalpha.com/news/4087312-top-buy-rated-stocks-and-sell-rated-stocks-within-health-care-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1926.0,4/4/2024 10:43:54 PM,"Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More",Benzinga,/news/stocks/biotech-stock-roundup-iron-verv-down-on-study-updates-bmys-drug-news-more-1033223986
1927.0,4/5/2024 1:33:47 PM,"Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma",Seeking Alpha,https://seekingalpha.com/news/4087581-bristol-myers-2seventy-bio-receive-fda-approval-for-abecma-to-treat-multiple-myeloma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1928.0,4/5/2024 2:16:16 PM,"Biggest stock mover today: GCTS, TSVT, GRIN, ANGO, ATUS, and more",Seeking Alpha,https://seekingalpha.com/news/4087498-biggest-stock-mover-today-grindrod-shipping-holdings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1929.0,4/5/2024 4:04:14 PM,"Bristol Myers, 2seventy Bio Get FDA Nod For Abecma For Relapsed Multiple Myeloma Patients ",RTTNews,/news/stocks/bristol-myers-2seventy-bio-get-fda-nod-for-abecma-for-relapsed-multiple-myeloma-patients-1033226250
1930.0,4/5/2024 5:54:07 PM,The 3 Most Undervalued Biotech Stocks to Buy in April 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-in-april-2024-1033226729
1931.0,4/6/2024 12:38:09 PM,Johnson & Johnson wins FDA nod for Carvykti label expansion,Seeking Alpha,https://seekingalpha.com/news/4087716-jj-wins-fda-nod-carvykti-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1932.0,4/6/2024 7:21:29 PM,Bristol-Myers highlights safety of KarXT schizophrenia therapy,Seeking Alpha,https://seekingalpha.com/news/4087724-bristol-myers-schizophrenia-therapy-safe-late-stage-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1933.0,4/7/2024 12:00:00 PM,"Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst",Seeking Alpha,https://seekingalpha.com/news/4087726-phathom-pharma-rhythm-vaxcyte-most-likely-takeover-targets-in-pharma-analyst?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1934.0,4/7/2024 5:31:00 PM,Morgan Stanley sees Fed rate cut fueling biotech stocks,Seeking Alpha,https://seekingalpha.com/news/4087727-fed-rate-cut-should-fuel-biotech-outperformance-morgan-stanley-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1935.0,4/8/2024 9:47:43 AM,Bristol-Myers Squibb’s Hold Rating: Balancing KarXT’s Efficacy and Safety with Financial Uncertainties,TipRanks,/news/stocks/bristol-myers-squibb-s-hold-rating-balancing-karxt-s-efficacy-and-safety-with-financial-uncertainties-1033229670
1936.0,4/8/2024 3:38:08 PM,Bristol Myers reports positive Phase 3 data for schizophrenia drug,Seeking Alpha,https://seekingalpha.com/news/4087959-bristol-myers-reports-positive-phase-3-data-for-schizophrenia-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1937.0,4/8/2024 4:00:46 PM,Bristol Myers releases encouraging data for Krazati in colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/4087973-bristol-myers-releases-encouraging-data-for-krazati-in-colorectal-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1938.0,4/9/2024 8:19:09 PM,Bristol Myers Squibb snaps a six day losing spell,Seeking Alpha,https://seekingalpha.com/news/4088370-bristol-myers-squibb-snaps-a-six-day-losing-spell?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1939.0,4/10/2024 6:18:46 AM,Hold Rating on Bristol-Myers Squibb Amid Promising Yet Incomplete KarXT Schizophrenia Trial Data,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-promising-yet-incomplete-karxt-schizophrenia-trial-data-1033236280
1940.0,4/11/2024 1:47:56 PM,The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today,InvestorPlace,/news/stocks/the-5-billion-reason-alpine-immune-sciences-alpn-stock-is-up-30-today-1033241236
1941.0,4/11/2024 5:49:13 PM,"If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names",InvestorPlace,/news/stocks/if-you-can-only-buy-one-biotech-stock-in-april-it-better-be-one-of-these-3-names-1033242242
1942.0,4/12/2024 9:25:45 AM,Bristol-Myers Squibb: A Buy Rating on Undervaluation and Promising Product Portfolio,TipRanks,/news/stocks/bristol-myers-squibb-a-buy-rating-on-undervaluation-and-promising-product-portfolio-1033244086
1943.0,4/12/2024 10:00:36 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bristol-myers-squibb-bmy-and-roche-holding-ag-otherrhhvf-1033244262
1944.0,4/12/2024 11:00:00 AM,Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-warren-buffett-stocks-with-strong-buy-ratings-for-april-2024-1033243869
1945.0,4/12/2024 8:18:42 PM,"Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom",Benzinga,/news/stocks/small-cap-cancer-drug-developer-agenus-highlights-encouraging-data-from-colorectal-cancer-but-funding-concerns-loom-1033245379
1946.0,4/15/2024 9:51:31 PM,3 Pharma Stocks That Are Money-Printing Machines in 2024,InvestorPlace,/news/stocks/3-pharma-stocks-that-are-money-printing-machines-in-2024-1033250995
1947.0,4/16/2024 4:22:50 PM,"As more rare disease therapies launch, their prices are rising",Seeking Alpha,https://seekingalpha.com/news/4089415-more-rare-disease-therapies-launch-their-prices-rising?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1948.0,4/17/2024 7:20:39 PM,3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500,InvestorPlace,/news/stocks/3-undervalued-dividend-stocks-to-buy-now-to-beat-the-sp-500-1033259364
1949.0,4/18/2024 10:10:26 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-accolade-accd-ultragenyx-pharmaceutical-rare-and-bristol-myers-squibb-bmy-1033262170
1950.0,4/18/2024 11:00:23 AM,AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug,Seeking Alpha,https://seekingalpha.com/news/4090847-abbvie-buyout-cerevel-marks-trial-win-parkinsons-disease-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1951.0,4/19/2024 10:13:03 AM,FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk,Seeking Alpha,https://seekingalpha.com/news/4091378-fda-requires-changes-car-t-cell-therapy-boxed-warning?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1952.0,4/19/2024 6:30:20 PM,These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?,InvestorPlace,/news/stocks/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher-1033267239
1953.0,4/21/2024 12:00:00 PM,"Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more",Seeking Alpha,https://seekingalpha.com/news/4091495-earnings-week-ahead-tesla-meta-platforms-google-microsoft-intel-exxon-mobil-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1954.0,4/21/2024 6:42:04 PM,Goldman picks top capex and R&D stocks,Seeking Alpha,https://seekingalpha.com/news/4091724-goldman-picks-top-capex-and-rd-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1955.0,4/22/2024 12:00:00 PM,5 Crash-Proof Stocks to Buy Immediately,InvestorPlace,/news/stocks/5-crash-proof-stocks-to-buy-immediately-1033270786
1956.0,4/22/2024 1:51:41 PM,"Bristol-Myers, Cellares ink $380M CAR-T therapies supply deal",Seeking Alpha,https://seekingalpha.com/news/4091926-bristol-myers-cellares-ink-380m-car-t-therapies-supply-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1957.0,4/23/2024 4:33:52 PM,S&P 500 stocks with biggest estimated EPS declines for Q1,Seeking Alpha,https://seekingalpha.com/news/4092482-sp-500-stocks-with-biggest-estimated-eps-decrease-this-season?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1958.0,4/24/2024 3:01:13 PM,Bristol-Myers Squibb earnings preview: what to expect,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-q1-earnings-preview-1033281945
1959.0,4/25/2024 9:35:46 AM,Bristol-Myers Squibb: A Hold Rating Amid Mixed Financial Outlook and Upcoming Strategic Updates,TipRanks,/news/stocks/bristol-myers-squibb-a-hold-rating-amid-mixed-financial-outlook-and-upcoming-strategic-updates-1033287828
1960.0,4/25/2024 11:01:03 AM,"Bristol-Myers Squibb Company  Non-GAAP EPS of -$4.40 beats by $0.02, revenue of $11.78B beats by $330M",Seeking Alpha,https://seekingalpha.com/news/4093952-bristol-myers-squibb-company-and-nbsp-non-gaap-eps-of-4_40-beats-0_02-revenue-of-11_78b-beats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1961.0,4/25/2024 11:44:29 AM,"Bristol-Myers in charts: Revenue from Eliquis rises, while Opdivo drops in Q1",Seeking Alpha,https://seekingalpha.com/news/4093975-bristol-myers-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1962.0,4/25/2024 11:56:55 AM,Bristol-Myers posts Q1 beat despite growth headwinds,Seeking Alpha,https://seekingalpha.com/news/4094029-bristol-myers-stock-falls-despite-q1-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1963.0,4/25/2024 1:18:56 PM,Bristol-Myers Squibb Co. Q1 Earnings Summary,RTTNews,/news/stocks/bristol-myers-squibb-co-q1-earnings-summary-1033287334
1964.0,4/25/2024 1:41:36 PM,Bristol Myers Squibb Posts Loss In Q1; Updates 2024 Non-GAAP EPS Guidance ,RTTNews,/news/stocks/bristol-myers-squibb-posts-loss-in-q1-updates-2024-non-gaap-eps-guidance-1033287464
1965.0,4/25/2024 2:02:44 PM,"Biggest stock movers today: LUV, META, IBM, F, and more",Seeking Alpha,https://seekingalpha.com/news/4093836-biggest-stock-movers-today-meta-ibm-f-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1966.0,4/25/2024 2:08:18 PM,"Bristol-Myers to cut 2,200 jobs as part of $1.5B cost savings plan",Seeking Alpha,https://seekingalpha.com/news/4094160-bristol-myers-stock-drops-amid-plans-cut-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1967.0,4/25/2024 3:50:29 PM,Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts,InvestorPlace,/news/stocks/bristol-myers-squibb-layoffs-2024-what-to-know-about-the-latest-bmy-job-cuts-1033289272
1968.0,4/25/2024 3:55:40 PM,"BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q1 2024",InvestorPlace,/news/stocks/bmy-stock-earnings-bristol-myers-squibb-for-q1-of-2024-1033289509
1969.0,4/25/2024 4:05:19 PM,PLTR Stock: Palantir Beefs Up Healthcare AI Work Through Parexel Deal,InvestorPlace,/news/stocks/pltr-stock-palantir-beefs-up-healthcare-ai-work-through-parexel-deal-1033289489
1970.0,4/26/2024 4:16:21 AM,"Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat",Benzinga,/news/stocks/bristol-myers-q1-loss-narrower-than-expected-sales-beat-1033290926
1971.0,4/26/2024 8:47:50 AM,Barclays Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-sticks-to-their-hold-rating-for-bristol-myers-squibb-bmy-1033293617
1972.0,4/26/2024 9:19:06 AM,Bristol-Myers Squibb: Hold Rating Amid Mixed Performance and Future Revenue Concerns,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-amid-mixed-performance-and-future-revenue-concerns-1033293814
1973.0,4/26/2024 9:25:46 AM,"Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-universal-health-uhs-laboratory-lh-and-bristol-myers-squibb-bmy-1033293790
1974.0,4/26/2024 11:40:35 AM,Analysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-viking-therapeutics-vktx-and-bristol-myers-squibb-bmy-1033294775
1975.0,4/26/2024 3:38:32 PM,Bristol Myers: CHMP Recommends Approval Of Opdivo In Combination With Cisplatin And Gemcitabine ,RTTNews,/news/stocks/bristol-myers-chmp-recommends-approval-of-opdivo-in-combination-with-cisplatin-and-gemcitabine-1033294190
1976.0,4/26/2024 4:56:53 PM,19 out 20 S&P 500 healthcare companies beat profit estimates - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095057-19-out-20-sp-500-healthcare-companies-beat-profit-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1977.0,4/26/2024 6:32:03 PM,"Bristol, Sanofi, Takeda gain positive CHMP recommendations",Seeking Alpha,https://seekingalpha.com/news/4095088-bristol-sanofi-takeda-gain-positive-chmp-recommendations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1978.0,4/26/2024 7:00:25 PM,Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights,Benzinga,/news/stocks/peeling-back-the-layers-exploring-bristol-myers-squibb-through-analyst-insights-1033295400
1979.0,4/27/2024 7:39:17 PM,Amgen’s Blincyto data send Cullinan higher,Seeking Alpha,https://seekingalpha.com/news/4095218-cullinan-stock-rises-amgens-blincyto-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1980.0,4/29/2024 10:56:23 AM,"Bristol Myers, Repertoire to develop tolerizing vaccines in multi-year pact",Seeking Alpha,https://seekingalpha.com/news/4095339-bristol-myers-repertoire-to-develop-tolerizing-vaccines-in-multi-year-pact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1981.0,4/29/2024 11:18:18 AM,"Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-atricure-atrc-alkermes-alks-1033301050
1982.0,4/29/2024 12:26:06 PM,Repertoire Immune Medicines In Strategic Partnership With Bristol Myers Squibb ,RTTNews,/news/stocks/repertoire-immune-medicines-in-strategic-partnership-with-bristol-myers-squibb-1033299445
1983.0,4/30/2024 7:20:50 AM,"Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Bristol-Myers Squibb (BMY) and Laboratory (LH)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-edwards-lifesciences-ew-bristol-myers-squibb-bmy-and-laboratory-lh-1033305216
1984.0,4/30/2024 1:49:06 PM,"J&J, Bristol Myers latest to lose bids to halt Medicare price negotiations",Seeking Alpha,https://seekingalpha.com/news/4096283-jj-bristol-myers-lose-bid-halt-medicare-price-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1985.0,4/30/2024 5:10:58 PM,"Stifel, Morgan Stanley bullish on newly public Contineum",Seeking Alpha,https://seekingalpha.com/news/4096594-stifel-morgan-stanley-bullish-on-newly-public-contineum?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1986.0,4/30/2024 7:47:54 PM,Biotech Stocks Facing FDA Decision In May 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-2024-1033308434
1987.0,5/1/2024 10:37:36 AM,Hold Rating on Bristol-Myers Squibb Amid Earnings Uncertainty and Strategic Investments,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-earnings-uncertainty-and-strategic-investments-1033313614
1988.0,5/1/2024 12:37:31 PM,Pfizer raises guidance amid cost savings,Seeking Alpha,https://seekingalpha.com/news/4097227-pfizer-stock-gains-guidance-raise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1989.0,5/1/2024 4:12:21 PM,"Editas, Bristol Myers extend T cell therapy collaboration",Seeking Alpha,https://seekingalpha.com/news/4097559-editas-bristol-myers-extend-t-cell-therapy-collaboration?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1990.0,5/2/2024 7:04:30 PM,Schrodinger gets rights to cancer drug candidate back from Bristol,Seeking Alpha,https://seekingalpha.com/news/4099038-schrodinger-gets-rights-cancer-drug-candidate-back-bristol?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1991.0,5/4/2024 7:30:00 PM,Pharma R&D productivity seen improving for the first time in years - Deloitte,Seeking Alpha,https://seekingalpha.com/news/4099974-pharma-research-development-productivity-improving-first-time-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1992.0,5/6/2024 10:00:00 AM,Uncover the Potential: 3 Discounted Stocks Ready for a Comeback,InvestorPlace,/news/stocks/uncover-the-potential-3-discounted-stocks-ready-for-a-comeback-1033332169
1993.0,5/6/2024 2:09:54 PM,Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation ,RTTNews,/news/stocks/bristol-myers-says-type-ii-variation-application-for-opdivo-yervoy-granted-ema-validation-1033332657
1994.0,5/6/2024 4:11:46 PM,FDA accepts Bristol Myers application for injected Opdivo,Seeking Alpha,https://seekingalpha.com/news/4100501-fda-accepts-bristol-myers-application-for-injected-opdivo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1995.0,5/6/2024 6:22:51 PM,Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields,InvestorPlace,/news/stocks/maximize-your-dividends-7-stocks-trading-under-50-with-5-yields-1033334935
1996.0,5/7/2024 9:22:54 AM,"Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-lyra-therapeutics-lyra-bristol-myers-squibb-bmy-and-axsome-therapeutics-axsm-1033338974
1997.0,5/9/2024 4:41:08 PM,A Look at Pharma ETFs Post Q1 Earnings,Benzinga,/news/etf/a-look-at-pharma-etfs-post-q1-earnings-1033357001
1998.0,5/10/2024 6:13:46 PM,AI-discovered drugs have an 80%–90% success rate: study,Seeking Alpha,https://seekingalpha.com/news/4104786-ai-discovered-drugs-have-an-8090-success-rate-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1999.0,5/10/2024 9:13:16 PM,Bristol Myers' Opdivo fails in Phase 3 lung cancer study,Seeking Alpha,https://seekingalpha.com/news/4104879-bristol-myers-opdivo-fails-in-phase-3-lung-cancer-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2000.0,5/13/2024 11:58:54 AM,Merck discontinues testing of experimental skin cancer combo therapy,Seeking Alpha,https://seekingalpha.com/news/4105055-merck-discontinues-testing-of-experimental-skin-cancer-combo-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2001.0,5/13/2024 10:47:36 PM,Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/wells-fargo-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1033373030
2002.0,5/14/2024 10:46:00 AM,Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders,InvestorPlace,/news/stocks/dividend-capture-captains-the-3-best-blue-chip-stocks-for-tactical-traders-1033375424
2003.0,5/15/2024 9:36:48 PM,Bristol Myers' Breyanzi gains additional indication for follicular lymphoma,Seeking Alpha,https://seekingalpha.com/news/4107041-bristol-myers-squibb-breyanzi-gains-additional-indication-follicular-lymphoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2004.0,5/15/2024 9:47:35 PM,Tudor Investment's top buys and sells in Q1,Seeking Alpha,https://seekingalpha.com/news/4107057-tudor-investments-top-buys-and-sells-in-q1?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2005.0,5/16/2024 11:15:00 AM,7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs,InvestorPlace,/news/stocks/7-pharma-stocks-harnessing-ai-brainpower-for-big-breakthroughs-1033392344
2006.0,5/16/2024 3:35:19 PM,Hold Rating on Bristol-Myers Squibb Amid Mounting Competition and Flat Growth Projections,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-mounting-competition-and-flat-growth-projections-1033394845
2007.0,5/17/2024 7:47:17 PM,AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion':  Analyst,Benzinga,/news/stocks/abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion-analyst-1033400477
2008.0,5/18/2024 6:52:07 PM,"Novo Nordisk, J&J lead R&D rankings in big pharma: report",Seeking Alpha,https://seekingalpha.com/news/4108110-novo-nordisk-j-j-lead-rd-big-pharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2009.0,5/19/2024 7:05:03 PM,SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued?,Seeking Alpha,https://seekingalpha.com/news/4108152-sa-roundtable-are-eli-lilly-and-novo-nordisk-overvalued?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2010.0,5/21/2024 11:29:59 AM,Bristol-Myers says FDA has revised decision date on injected Opdivo,Seeking Alpha,https://seekingalpha.com/news/4108688-bristol-myers-injected-opdivo-new-fda-decision-date?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2011.0,5/21/2024 11:45:00 AM,3 Bargain Stocks to Buy Now: May 2024,InvestorPlace,/news/stocks/3-bargain-stocks-to-buy-now-may-2024-1033406804
2012.0,5/22/2024 9:45:41 AM,Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-hold-from-wells-fargo-1033411491
2013.0,5/22/2024 7:38:02 PM,"Bristol-Myers, Sanofi liability in Hawaii Plavix litigation tops $900M",Seeking Alpha,https://seekingalpha.com/news/4109535-bristol-myers-sanofi-ordered-pay-916m-in-hawaii-plavix-case?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2014.0,5/22/2024 8:22:24 PM,"Bristol-Myers Squibb snaps six days of losses, trades in the green",Seeking Alpha,https://seekingalpha.com/news/4109575-bristol-myers-squibb-snaps-six-days-of-losses-trades-in-the-green?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2015.0,5/23/2024 6:49:06 PM,Bristol Myers Updates Action Date for Subcutaneous Opdivo,Benzinga,/news/stocks/bristol-myers-updates-action-date-for-subcutaneous-opdivo-1033416965
2016.0,5/24/2024 7:00:53 PM,"Catalyst Watch: Costco earnings, M&A drama, Viking ratings, and a key inflation read",Seeking Alpha,https://seekingalpha.com/news/4110251-catalyst-watch-costco-earnings-ma-drama-viking-ratings-and-a-key-inflation-read?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2017.0,5/25/2024 2:24:03 PM,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/4110471-viking-crispr-cytokinetics-m-a-targets-wells-fargo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2018.0,5/27/2024 10:13:00 AM,3 Blue-Chip Stocks to Buy at 52-Week Lows in May,InvestorPlace,/news/stocks/3-blue-chip-stocks-to-buy-at-52-week-lows-in-may-1033423869
2019.0,5/28/2024 8:23:34 PM,Bristol Myers licenses second compound from Prothena,Seeking Alpha,https://seekingalpha.com/news/4110917-bristol-myers-licenses-second-compound-from-prothena?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2020.0,5/29/2024 11:56:10 AM,Truist Financial Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-sticks-to-their-buy-rating-for-bristol-myers-squibb-bmy-1033432461
2021.0,5/29/2024 2:04:43 PM,Bristol-Myers gets EU approval for Opdivo for bladder cancer,Seeking Alpha,https://seekingalpha.com/news/4111155-bristol-myers-gets-eu-approval-for-opdivo-for-bladder-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2022.0,5/30/2024 10:10:00 AM,7 Underappreciated Stocks With 25% Return Potential in 2024,InvestorPlace,/news/stocks/7-underappreciated-stocks-with-25-return-potential-in-2024-1033435401
2023.0,5/30/2024 4:22:21 PM,Bristol Myers' Breyanzi gains additional indication for mantle cell lymphoma,Seeking Alpha,https://seekingalpha.com/news/4111641-bristol-myers-squibb-breyanzi-gains-additional-indication-mantle-cell-lymphoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2024.0,5/31/2024 4:19:46 PM,Novartis boasts Scemblix beats tyrosine kinase inhibitors for chronic myeloid leukemia,Seeking Alpha,https://seekingalpha.com/news/4111998-novartis-boasts-scemblix-beats-tyrosine-kinase-inhibitors-chronic-myeloid-leukemia?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2025.0,5/31/2024 8:31:58 PM,Immunocore touts updated phase 1 results for melanoma asset brenetafusp,Seeking Alpha,https://seekingalpha.com/news/4112056-immunocore-touts-updated-phase-1-results-melanoma-asset-brenetafusp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2026.0,6/1/2024 12:53:44 PM,Bristol Myers lung cancer drug Krazati succeeds in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/4112126-bristol-myers-wins-late-stage-trial-krazati?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2027.0,6/2/2024 6:00:00 PM,Emerging and Chinese pharmas playing greater role in oncology drug development,Seeking Alpha,https://seekingalpha.com/news/4112099-emerging-chinese-pharmas-playing-greater-role-oncology-drug-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2028.0,6/3/2024 3:10:17 PM,Bristol's Breyanzi demonstrates efficacy across a range of B-cell malignancies,Seeking Alpha,https://seekingalpha.com/news/4112361-bristols-breyanzi-demonstrates-efficacy-across-range-b-cell-malignancies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2029.0,6/3/2024 4:03:10 PM,"GSK says Blenrep combo cuts disease progression, death in multiple myeloma",Seeking Alpha,https://seekingalpha.com/news/4112369-gsk-says-belnrep-combo-cuts-disease-progression-death-multiple-myeloma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2030.0,6/3/2024 6:25:56 PM,Bristol Myers' 3 Breyanzi Trials Show Consistent Benefit Across B-Cell Malignancies ,RTTNews,/news/stocks/bristol-myers-3-breyanzi-trials-show-consistent-benefit-across-b-cell-malignancies-1033446790
2031.0,6/4/2024 8:30:15 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Xeris Pharmaceuticals (XERS) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ultragenyx-pharmaceutical-rare-xeris-pharmaceuticals-xers-and-bristol-myers-squibb-bmy-1033449003
2032.0,6/4/2024 2:26:59 PM,"Bristol's Opdivo + Yervoy bests Lenvima, Nexavar in first-line liver cancer",Seeking Alpha,https://seekingalpha.com/news/4112739-bristol-opdivo-yervoy-bests-lenvima-nexavar-first-line-liver-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2033.0,6/5/2024 1:15:55 PM,Bristol Myers Squibb inks clinical trial pact with I-Mab,Seeking Alpha,https://seekingalpha.com/news/4113128-i-mab-stock-gains-study-pact-bristol-myers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2034.0,6/5/2024 1:42:49 PM,I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study ,RTTNews,/news/stocks/i-mab-inks-partnership-with-bristol-myers-squibb-to-evaluate-givastomig-in-combination-study-1033453070
2035.0,6/6/2024 11:40:22 AM,Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-ionis-pharmaceuticals-ions-1033458252
2036.0,6/6/2024 2:47:18 PM,"Goldman cuts 2seventy bio to neutral, cites competition concerns",Seeking Alpha,https://seekingalpha.com/news/4113699-goldman-cuts-2seventy-bio-to-neutral-cites-competition-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2037.0,6/6/2024 4:05:40 PM,Replimune up 30% on results for RP1 combo in melanoma,Seeking Alpha,https://seekingalpha.com/news/4113744-replimune-up-30-results-rp1-combo-melanoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2038.0,6/6/2024 9:36:29 PM,Halozyme's ENHANZE Product Gets New Patent Grant in EU,Benzinga,/news/stocks/halozyme-s-enhanze-product-gets-new-patent-grant-in-eu-1033459113
2039.0,6/7/2024 10:39:00 AM,Geron jumps as FDA approves lead asset for blood cancer,Seeking Alpha,https://seekingalpha.com/news/4113925-geron-stock-gains-rytelo-approval?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2040.0,6/7/2024 7:00:58 PM,"Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility",Seeking Alpha,https://seekingalpha.com/news/4114173-catalyst-watch-apples-wwdc-teslas-shareholder-meeting-fomc-meeting-and-gamestop-volatility?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2041.0,6/8/2024 1:00:00 PM,The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024,InvestorPlace,/news/stocks/the-7-most-undervalued-under-50-stocks-to-buy-in-june-2024-1033462733
2042.0,6/8/2024 2:19:36 PM,"AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes",Seeking Alpha,https://seekingalpha.com/news/4114301-astrazeneca-dominates-merck-beaten-asco-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2043.0,6/8/2024 2:19:47 PM,Bristol Myers Squibb wins antitrust case against insurers regarding generics,Seeking Alpha,https://seekingalpha.com/news/4114300-bristol-myers-squibb-wins-antitrust-case-against-insurers-regarding-generics?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2044.0,6/10/2024 4:00:00 PM,7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too),InvestorPlace,/news/stocks/7-stocks-warren-buffett-has-sold-in-the-past-year-and-you-should-too-1033466529
2045.0,6/11/2024 2:00:00 PM,3 Penny Stocks to Buy if You Want to Spend Less and Earn More,InvestorPlace,/news/stocks/3-penny-stocks-to-buy-if-you-want-to-spend-less-and-earn-more-1033469513
2046.0,6/12/2024 12:11:43 PM,"Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (SAGE), Bristol-Myers Squibb (BMY) and Cellectis SA (CLLS)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-sage-therapeutics-sage-bristol-myers-squibb-bmy-and-cellectis-sa-clls-1033473470
2047.0,6/13/2024 9:28:51 PM,Bristol Myers gets FDA approval for Autyro for NTRK-positive cancers,Seeking Alpha,https://seekingalpha.com/news/4115993-bristol-myers-gets-fda-approval-for-autyro-for-ntrk-positive-cancers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2048.0,6/14/2024 7:55:36 PM,EU to require additional cancer risk labeling on CAR T therapies,Seeking Alpha,https://seekingalpha.com/news/4116402-eu-to-require-additional-cancer-risk-labeling-on-car-t-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2049.0,6/17/2024 7:27:56 PM,7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline,InvestorPlace,/news/stocks/7-breakthrough-biotech-stocks-for-a-shot-of-portfolio-adrenaline-1033485033
2050.0,6/18/2024 11:04:41 AM,Bristol-Myers Squibb Company declares $0.60 dividend,Seeking Alpha,https://seekingalpha.com/news/4116876-bristol-myers-squibb-company-declares-0_60-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2051.0,6/19/2024 6:17:23 PM,3 Warren Buffett Stocks to Buy Now: June 2024,InvestorPlace,/news/stocks/3-warren-buffett-stocks-to-buy-now-june-2024-1033491003
2052.0,6/21/2024 11:25:03 AM,Bristol Myers Opdivo injectable accepted for EU review,Seeking Alpha,https://seekingalpha.com/news/4117867-bristol-myers-opdivo-injectable-accepted-eu-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2053.0,6/21/2024 6:06:48 PM,Bristol-Myers wins FDA nod to expand label for cancer therapy Krazati,Seeking Alpha,https://seekingalpha.com/news/4118016-bristol-myers-stock-gains-krazati-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2054.0,6/23/2024 5:38:49 PM,7 Dividend Stocks to Buy Now: June 2024 ,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-now-june-2024-1033498164
2055.0,6/27/2024 10:56:19 AM,Novo Nordisk buys 2seventy bio’s Hemophilia A program,Seeking Alpha,https://seekingalpha.com/news/4119932-2seventy-bio-stock-gains-novo-buys-assets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2056.0,6/27/2024 5:14:55 PM,You’ve Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.,InvestorPlace,/news/stocks/youve-been-warned-3-pharma-stocks-to-buy-now-or-regret-forever-1033512708
2057.0,6/29/2024 7:44:55 PM,Rising drug costs force a third of Americans to leave prescriptions unfilled: report,Seeking Alpha,https://seekingalpha.com/news/4120808-many-prescriptions-remain-unfilled-amid-soaring-drug-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2058.0,6/30/2024 2:13:35 PM,Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet,InvestorPlace,/news/stocks/treasure-hunt-3-small-cap-stocks-wall-street-hasnt-discovered-yet-1033517243
2059.0,7/1/2024 12:30:56 AM,"Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2",Seeking Alpha,https://seekingalpha.com/news/4120874-alnylam-lilly-astrzeneca-best-performing-pharmas-biotechs-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2060.0,7/1/2024 7:03:10 PM,Eisai receives rights to antibody drug conjugate after Bristol ends collaboration,Seeking Alpha,https://seekingalpha.com/news/4121337-eisai-receives-rights-antibody-drug-conjugate-after-bristol-ends-collaboration?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2061.0,7/2/2024 12:23:40 PM,J&J says Carvykti beat standard drugs in late-stage blood cancer trial,Seeking Alpha,https://seekingalpha.com/news/4121567-jj-carvykti-beat-standard-drugs-blood-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2062.0,7/5/2024 10:45:00 AM,3 Hidden Stock Gems That Wall Street Is Overlooking,InvestorPlace,/news/stocks/3-hidden-stock-gems-that-wall-street-is-overlooking-1033531639
2063.0,7/8/2024 10:43:00 AM,3 Defensive Stocks to Buy During the Market Dip,InvestorPlace,/news/stocks/3-defensive-stocks-to-buy-during-the-market-dip-1033535387
2064.0,7/9/2024 11:40:00 AM,The 7 Best Warren Buffett Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-best-warren-buffett-stocks-7-names-to-buy-in-july-1033539110
2065.0,7/10/2024 8:48:55 AM,Barclays Remains a Hold on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-remains-a-hold-on-bristol-myers-squibb-bmy-1033542872
2066.0,7/10/2024 4:00:00 PM,3 Undervalued Stocks Ready for a Breakout This Summer,InvestorPlace,/news/stocks/3-undervalued-stocks-ready-for-a-breakout-this-summer-1033544286
2067.0,7/11/2024 12:46:20 PM,Morgan Stanley Sticks to Its Sell Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/morgan-stanley-sticks-to-its-sell-rating-for-bristol-myers-squibb-bmy-1033548019
2068.0,7/11/2024 6:23:24 PM,3 Under-$10 Biotech Stocks That Could Make You Rich,InvestorPlace,/news/stocks/3-under-10-biotech-stocks-that-could-make-you-rich-1033548360
2069.0,7/12/2024 5:27:22 PM,Bristol Myers Squibb Suffers a Larger Drop Than the General Market: Key Insights,Benzinga,/news/stocks/bristol-myers-squibb-suffers-a-larger-drop-than-the-general-market-key-insights-1033551112
2070.0,7/12/2024 6:50:39 PM,Legend Biotech surges amid takeover speculation (update),Seeking Alpha,https://seekingalpha.com/news/4124018-legend-biotech-surges-amid-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2071.0,7/12/2024 7:00:29 PM,"Catalyst Watch: Netflix, Taiwan Semi, Amazon, and HashiCorp are in the spotlight",Seeking Alpha,https://seekingalpha.com/news/4123992-catalyst-watch-netflix-taiwan-semi-amazon-and-hashicorp-are-in-the-spotlight?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2072.0,7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2073.0,7/15/2024 12:45:43 PM,Hold Rating on Bristol-Myers Squibb Amid Balanced Strengths and Long-Term Revenue Concerns,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-balanced-strengths-and-long-term-revenue-concerns-1033556220
2074.0,7/16/2024 4:15:22 AM,Bristol-Myers Squibb: Hold Rating Maintained Amid Growth Challenges and Uncertain Long-Term Prospects,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-maintained-amid-growth-challenges-and-uncertain-long-term-prospects-1033557977
2075.0,7/17/2024 6:09:20 PM,Big pharma rally after J&J earnings,Seeking Alpha,https://seekingalpha.com/news/4125149-big-pharma-rally-after-jj-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2076.0,7/19/2024 12:01:22 PM,Bristol Myers’ immunotherapy combo undergoes EU review for liver cancer,Seeking Alpha,https://seekingalpha.com/news/4125791-bristol-myers-immunotherapy-combo-gets-eu-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2077.0,7/19/2024 1:53:12 PM,Bristol Myers Squibb Receives EMA Validation For Opdivo Plus Yervoy For Treatment Of HCC ,RTTNews,/news/stocks/bristol-myers-squibb-receives-ema-validation-for-opdivo-plus-yervoy-for-treatment-of-hcc-1033572039
2078.0,7/19/2024 7:00:00 PM,"Catalyst watch: Earnings deluge, Farnborough Airshow, Paris Olympics, and Trump talks crypto",Seeking Alpha,https://seekingalpha.com/news/4125573-catalyst-watch-earnings-deluge-farnborough-airshow-paris-olympics-and-trump-talks-crypto?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2079.0,7/19/2024 7:25:48 PM,7 Value Stocks to Buy at a 52-Week Low in July,InvestorPlace,/news/stocks/7-value-stocks-to-buy-at-a-52-week-low-in-july-1033573491
2080.0,7/20/2024 11:55:00 AM,3 Defensive Stocks to Shield Your Portfolio in July,InvestorPlace,/news/stocks/3-defensive-stocks-to-shield-your-portfolio-in-july-1033573764
2081.0,7/20/2024 7:58:00 PM,Financials dominate in Q2 as Wall Street slides amidst concerns on tech - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4125975-financials-dominate-in-q2-as-wall-street-slides-amidst-concerns-on-tech-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2082.0,7/21/2024 11:00:00 AM,Here are Big Pharma’s leading blockbuster makers,Seeking Alpha,https://seekingalpha.com/news/4126044-eli-lilly-astrazeneca-top-blockbuster-makers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2083.0,7/21/2024 12:01:00 PM,"Earnings week ahead: TSLA, GOOG, IBM, AAL, GM, F, VZ, T, and more",Seeking Alpha,https://seekingalpha.com/news/4125930-earnings-week-ahead-tsla-goog-ibm-aal-gm-f-vz-t-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2084.0,7/22/2024 1:02:13 AM,Kamala Harris' potential impact on health care stocks,Seeking Alpha,https://seekingalpha.com/news/4126065-kamala-harris-potential-impact-health-care-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2085.0,7/22/2024 8:00:42 PM,A Glimpse Into The Expert Outlook On Bristol-Myers Squibb Through 4 Analysts,Benzinga,/news/stocks/a-glimpse-into-the-expert-outlook-on-bristol-myers-squibb-through-4-analysts-1033579081
2086.0,7/23/2024 11:25:49 AM,Hold Rating on Bristol-Myers Squibb Amid Mixed Performance and Evolving Pipeline,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-mixed-performance-and-evolving-pipeline-1033583237
2087.0,7/23/2024 3:59:38 PM,Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday,Benzinga,/news/stocks/microsoft-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday-1033583172
2088.0,7/24/2024 9:25:04 PM,Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation,Benzinga,/news/stocks/newly-listed-psoriasis-focused-alumis-attracts-analysts-attention-with-promising-lead-program-and-modest-valuation-1033590627
2089.0,7/25/2024 1:47:02 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/4128372-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2090.0,7/25/2024 3:01:13 PM,Bristol-Myers Squibb earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-quarter-earnings-preview-q2-1033594625
2091.0,7/25/2024 3:13:10 PM,Bristol-Myers Squibb Q2 Earnings Preview: Strong results on the back of legacy portfolio,Seeking Alpha,https://seekingalpha.com/news/4128438-bristol-myers-squibb-q2-earnings-preview-strong-results-on-the-back-of-legacy-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2092.0,7/26/2024 11:00:49 AM,"Bristol-Myers Squibb Company Non-GAAP EPS of $2.07 beats by $0.44, revenue of $12.2B beats by $680M",Seeking Alpha,https://seekingalpha.com/news/4128861-bristol-myers-squibb-company-and-nbsp-non-gaap-eps-of-2_07-beats-0_44-revenue-of-12_2b-beats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2093.0,7/26/2024 11:16:19 AM,"Earnings summary: Bristol-Myers Squibb Q2 results top estimates, raises adj. EPS outlook",Seeking Alpha,https://seekingalpha.com/news/4128849-earnings-summary-bristol-myers-squibb-q2-results-top-estimates-raises-adj-eps-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2094.0,7/26/2024 11:34:37 AM,"Bristol-Myers Squibb in charts: Q2 revenue from Eliquis, Opdivo climb, while Sprycel falls",Seeking Alpha,https://seekingalpha.com/news/4128858-bristol-myers-squibb-in-charts-q2-revenue-from-eliquis-opdivo-climb?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2095.0,7/26/2024 1:08:02 PM,"Bristol-Myers Squibb Co. Q2 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/bristol-myers-squibb-co-q2-profit-decreases-but-beats-estimates-1033599642
2096.0,7/26/2024 1:25:00 PM,"4 stocks to watch on Friday: BMY, MMM and more",Seeking Alpha,https://seekingalpha.com/news/4128974-4-stocks-to-watch-on-friday-bmy-mmm-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2097.0,7/26/2024 1:34:53 PM,Bristol Myers Squibb Raises 2024 Non-GAAP Guidance ,RTTNews,/news/stocks/bristol-myers-squibb-raises-2024-non-gaap-guidance-1033599730
2098.0,7/26/2024 2:26:22 PM,"Biggest stock movers today:WW, MMM, DXCM, COUR, and more",Seeking Alpha,https://seekingalpha.com/news/4128818-biggest-stock-movers-today-dxcm-cour-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2099.0,7/26/2024 2:45:00 PM,Bristol Myers Squibb hosts conference call for investors,Markets Insider Automation,/news/stocks/bristol-myers_squibb_conference-1030194896
2100.0,7/26/2024 3:53:36 PM,"BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q2 2024",InvestorPlace,/news/stocks/bmy-stock-earnings-bristol-myers-squibb-for-q2-of-2024-1033601286
2101.0,7/26/2024 5:00:03 PM,Bristol-Myers hits three-month high on Q2 beat and trial win (update),Seeking Alpha,https://seekingalpha.com/news/4128916-bristol-myers-stock-gains-q2-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2102.0,7/29/2024 10:39:58 AM,Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Uncertainties,TipRanks,/news/stocks/bristol-myers-squibb-a-hold-rating-amidst-short-term-gains-and-long-term-uncertainties-1033606431
2103.0,7/29/2024 12:25:45 PM,Morgan Stanley Reaffirms Their Sell Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-sell-rating-on-bristol-myers-squibb-bmy-1033607123
2104.0,7/29/2024 8:11:14 PM,Bristol-Myers stock snaps six days of gains,Seeking Alpha,https://seekingalpha.com/news/4129728-bristol-myers-stock-snaps-six-days-of-gains?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2105.0,7/29/2024 8:19:03 PM,"Barclays cuts Bristol Myers to underweight, cites recent run up",Seeking Alpha,https://seekingalpha.com/news/4129744-barclays-cuts-bristol-myers-to-underweight-cites-recent-run-up?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2106.0,7/30/2024 5:55:32 AM,Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Pricing Concerns,TipRanks,/news/stocks/bristol-myers-squibb-a-hold-rating-amidst-short-term-gains-and-long-term-pricing-concerns-1033610608
2107.0,7/30/2024 6:36:31 AM,Bristol-Myers Squibb: A Cautious Hold Amidst Uneven Growth Prospects,TipRanks,/news/stocks/bristol-myers-squibb-a-cautious-hold-amidst-uneven-growth-prospects-1033610772
2108.0,7/30/2024 11:13:18 AM,Pfizer stock gains after raising annual earnings outlook,Seeking Alpha,https://seekingalpha.com/news/4129993-pfizer-stock-gains-after-raising-annual-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2109.0,7/31/2024 11:00:00 AM,Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?,InvestorPlace,/news/stocks/kazia-therapeutics-stock-is-kzia-a-buyout-candidate-in-the-making-1033617326
2110.0,7/31/2024 11:00:00 AM,The Top 3 Healthcare Stocks to Buy Now: Summer 2024,InvestorPlace,/news/stocks/the-top-3-healthcare-stocks-to-buy-now-summer-2024-1033617324
2111.0,7/31/2024 3:16:25 PM,Argus Research Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/argus-research-sticks-to-its-hold-rating-for-bristol-myers-squibb-bmy-1033620407
2112.0,8/1/2024 2:00:00 PM,Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore,InvestorPlace,/news/stocks/bargain-hunters-paradise-7-value-stocks-that-are-too-cheap-to-ignore-1033627397
2113.0,8/1/2024 8:40:33 PM,"The 3 Biggest Earnings Beats for Q2 as of August 1, 2024",InvestorPlace,/news/stocks/the-3-biggest-earnings-beats-for-q2-as-of-august-1-2024-1033629095
2114.0,8/2/2024 8:43:25 PM,Bristol ends licensing agreement with Agenus on TIGIT bispecific antibody,Seeking Alpha,https://seekingalpha.com/news/4133613-bristol-ends-licensing-agreement-agenus-tigit-bispecific-antibody?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2115.0,8/7/2024 5:53:29 PM,Bristol Myers cited by FDA for misleading claims on Krazati website,Seeking Alpha,https://seekingalpha.com/news/4136316-bristol-myers-cited-fda-misleading-claims-krazati-website?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2116.0,8/8/2024 10:40:00 AM,3 Biotech Stocks With Promising Drug Pipelines: August 2024,InvestorPlace,/news/stocks/3-biotech-stocks-with-promising-drug-pipelines-august-2024-1033659855
2117.0,8/9/2024 3:13:05 PM,74 S&P 500 stocks that can beat the cash yield - BofA,Seeking Alpha,https://seekingalpha.com/news/4138195-74-sp-500-stocks-that-can-beat-the-cash-yield-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2118.0,8/11/2024 5:20:50 PM,"Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray ",RTTNews,/news/stocks/weekly-review-antx-downsizes-aldx-aces-dry-eye-disease-trial-fda-oks-1st-epinephrine-nasal-spray-1033672016
2119.0,8/12/2024 12:21:11 AM,"Analysts’ Top Healthcare Picks: Generation Bio (GBIO), Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-generation-bio-gbio-bristol-myers-squibb-bmy-1033672147
2120.0,8/12/2024 11:00:00 AM,The 3 Best Healthcare Stocks to Buy in August 2024,InvestorPlace,/news/stocks/the-3-best-healthcare-stocks-to-buy-in-august-2024-1033676547
2121.0,8/13/2024 7:52:37 AM,Evotec Secures $75 Mln In Milestone Payments From Bristol Myers Amid Pipeline Advancements ,RTTNews,/news/stocks/evotec-secures-75-mln-in-milestone-payments-from-bristol-myers-amid-pipeline-advancements-1033680319
2122.0,8/14/2024 7:28:06 PM,"Tudor Investment buys/sells in Q2 feature Bristol Myers, PepsiCo, AMD, others",Seeking Alpha,https://seekingalpha.com/news/4139985-tudor-investment-buyssells-in-q2-feature-bristol-myers-pepsico-amd-others?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2123.0,8/15/2024 11:27:19 AM,U.S. government targets $6B in savings from first Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4140341-us-government-targets-6b-in-saving-from-first-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2124.0,8/15/2024 11:44:07 AM,U.S. announces final drug prices after Medicare negotiations,Seeking Alpha,https://seekingalpha.com/news/4140356-us-posts-final-drug-prices-medicare-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2125.0,8/15/2024 2:17:57 PM,"Bristol Myers, Novartis react as Medicare prices for key drugs announced",Seeking Alpha,https://seekingalpha.com/news/4140530-bristol-myers-novartis-slam-medicare-prices-key-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2126.0,8/17/2024 2:09:07 PM,Trending stocks this week as U.S. equities notch their best week of 2024,Seeking Alpha,https://seekingalpha.com/news/4141247-trending-stocks-this-week-as-us-equities-notch-their-best-week-of-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2127.0,8/19/2024 4:03:45 PM,EMA Validates Bristol Myers Squibb's Application For CAR T Cell Therapy Breyanzi ,RTTNews,/news/stocks/ema-validates-bristol-myers-squibb-s-application-for-car-t-cell-therapy-breyanzi-1033704477
2128.0,8/19/2024 5:33:38 PM,Bristol Myers says EMA to review label expansion for Breyanzi in follicular lymphoma,Seeking Alpha,https://seekingalpha.com/news/4141548-bristol-myers-says-ema-review-label-expansion-breyanzi-follicular-lymphoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2129.0,8/20/2024 6:07:51 PM,"FTC says FDA biosimilar guidance would increase competition, lead to lower prices",Seeking Alpha,https://seekingalpha.com/news/4142026-ftc-says-fda-biosimilar-guidance-would-increase-competition-lead-lower-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2130.0,8/21/2024 11:53:20 AM,Bristol Myers bid to expand label for liver cancer drug under FDA review,Seeking Alpha,https://seekingalpha.com/news/4142249-bristol-myers-liver-cancer-drug-labeling-wins-fda-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2131.0,8/21/2024 12:06:57 PM,Jefferies Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/jefferies-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1033711699
2132.0,8/21/2024 1:56:50 PM,Bristol Myers : FDA Accepts SBLA For First-Line Treatment Of Unresectable Hepatocellular Carcinoma ,RTTNews,/news/stocks/bristol-myers-fda-accepts-sbla-for-first-line-treatment-of-unresectable-hepatocellular-carcinoma-1033710617
2133.0,8/22/2024 9:16:49 AM,Barclays Reaffirms Their Sell Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-reaffirms-their-sell-rating-on-bristol-myers-squibb-bmy-1033714422
2134.0,8/23/2024 3:25:50 PM,"Merck, Bristol Myers cancer drugs included in September FDA advisory panel meeting",Seeking Alpha,https://seekingalpha.com/news/4143379-merck-bristol-myers-cancer-drugs-included-september-fda-advisory-panel-meeting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2135.0,8/28/2024 12:05:22 PM,Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-patent-expirations-and-speculative-prospects-of-milvexian-1033729593
2136.0,8/28/2024 12:05:51 PM,Neurocrine stock dips even as schizophrenia drug meets main goal in study,Seeking Alpha,https://seekingalpha.com/news/4144517-neurocrine-stock-dips-even-as-schizophrenia-drug-meets-main-goal-in-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2137.0,8/29/2024 10:26:46 AM,"New Medicare drug price caps could help seniors save over $1,000 a year - AARP",Seeking Alpha,https://seekingalpha.com/news/4144962-new-medicare-drug-price-caps-could-help-seniors-save-over-1000-a-year-aarp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2138.0,8/29/2024 2:30:37 PM,"Neurocrine upped to overweight by Piper, sees '568 as still viable",Seeking Alpha,https://seekingalpha.com/news/4145099-piper-ups-neurocrine-to-overweight-says-568-still-in-the-game?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2139.0,9/1/2024 7:26:06 PM,"Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies ",RTTNews,/news/stocks/weekly-biotech-buzz-bmrn-cuts-jobs-fda-approves-new-mpox-vaccine-mrk-halts-2-keytruda-studies-1033738673
2140.0,9/2/2024 4:35:44 AM,Biotech Stocks Facing FDA Decision In September 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-2024-1033738787
2141.0,9/3/2024 6:05:30 AM,Barclays Keeps Their Sell Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-keeps-their-sell-rating-on-bristol-myers-squibb-bmy-1033742670
2142.0,9/3/2024 12:25:39 PM,Hold Rating on Bristol-Myers Squibb Amid Asundexian Trial Uncertainties and Milvexian Prospects,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-asundexian-trial-uncertainties-and-milvexian-prospects-1033744436
2143.0,9/5/2024 2:59:46 AM,Merck's Winrevair Approved For Pulmonary Arterial Hypertension In Canada ,RTTNews,/news/stocks/merck-s-winrevair-approved-for-pulmonary-arterial-hypertension-in-canada-1033748977
2144.0,9/9/2024 5:45:21 AM,Bristol-Myers Squibb (BMY): Hold Rating Justified by Mixed Growth Prospects and Pipeline Catalysts,TipRanks,/news/stocks/bristol-myers-squibb-bmy-hold-rating-justified-by-mixed-growth-prospects-and-pipeline-catalysts-1033756491
2145.0,9/11/2024 5:14:26 AM,Bristol-Myers Squibb declares $0.60 dividend,Seeking Alpha,https://seekingalpha.com/news/4148533-bristol-myers-squibb-declares-060-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2146.0,9/11/2024 5:16:40 AM,Bristol-Myers Squibb Company PFD CONV 2 declares $0.50 dividend,Seeking Alpha,https://seekingalpha.com/news/4148534-bristol-myers-squibb-company-pfd-conv-2-declares-050-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2147.0,9/13/2024 6:22:24 PM,"Bicara, MBX Bio lead gainers as biotech trio makes trading debut",Seeking Alpha,https://seekingalpha.com/news/4149681-bicara-mbx-bio-lead-gainers-among-biotech-ipos?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2148.0,9/14/2024 12:46:29 PM,Bristol-Myers Squibb’s KarXT Faces FDA Approval Hurdles: Analyst Issues Sell Rating Amid Labeling Concerns,TipRanks,/news/stocks/bristol-myers-squibb-s-karxt-faces-fda-approval-hurdles-analyst-issues-sell-rating-amid-labeling-concerns-1033771672
2149.0,9/16/2024 9:36:11 AM,Evaluating Bristol-Myers Squibb: A Balanced View Amidst NSCLC Treatment Prospects and Market Uncertainties,TipRanks,/news/stocks/evaluating-bristol-myers-squibb-a-balanced-view-amidst-nsclc-treatment-prospects-and-market-uncertainties-1033774045
2150.0,9/16/2024 11:16:05 AM,Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-squibb-bmy-1033774764
2151.0,9/16/2024 4:15:17 PM,Bristol unveils 10-year Opdivo + Yervoy follow-up data in melanoma,Seeking Alpha,https://seekingalpha.com/news/4150032-bristol-unveils-10-year-opdivo-yervoy-follow-up-data-melanoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2152.0,9/18/2024 7:48:22 PM,Bristol Myers Squibb Zeposia shows long-term efficacy,Seeking Alpha,https://seekingalpha.com/news/4150893-bristol-myers-squibb-zeposia-shows-long-term-efficacy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2153.0,9/19/2024 6:43:06 PM,Centessa Pharmaceuticals a new buy at B Riley on sleep disorders pipeline,Seeking Alpha,https://seekingalpha.com/news/4151333-centessa-pharmaceuticals-new-buy-b-riley-sleep-disorders-pipeline?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2154.0,9/20/2024 7:00:55 PM,"Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers",Seeking Alpha,https://seekingalpha.com/news/4151613-catalyst-watch-spotlight-on-micron-southwest-airlines-and-fomc-speakers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2155.0,9/20/2024 8:43:49 PM,Sanofi Sarclisa combo gains approval as first-line multiple myeloma treatment,Seeking Alpha,https://seekingalpha.com/news/4151719-sanofi-sarclisa-combo-gains-approval-first-line-multiple-myeloma-treatment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2156.0,9/23/2024 11:15:53 AM,Bristol-Myers Squibb: Hold Rating Justified by Market-Reflected Approval of KarXT Despite Promising Clinical Data,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-justified-by-market-reflected-approval-of-karxt-despite-promising-clinical-data-1033790889
2157.0,9/23/2024 7:17:40 PM,UCB gets expanded FDA approval for psoriasis drug Bimzelx,Seeking Alpha,https://seekingalpha.com/news/4152277-ucb-gets-expanded-fda-approval-for-psoriasis-drug-bimzelx?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2158.0,9/24/2024 9:45:22 PM,"Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting",Seeking Alpha,https://seekingalpha.com/news/4152864-bristol-merck-checkpoint-inhibitors-focus-fda-advisory-committee-meeting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2159.0,9/25/2024 10:49:50 AM,"Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial",Seeking Alpha,https://seekingalpha.com/news/4153004-bristol-myers-2seventy-bio-halt-abecma-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2160.0,9/25/2024 1:46:53 PM,"2seventy, Bristol Myers Discontinue Enrollment In Phase 3 KarMMa-9 Study - Quick Facts ",RTTNews,/news/stocks/2seventy-bristol-myers-discontinue-enrollment-in-phase-3-karmma-9-study-quick-facts-1033796466
2161.0,9/26/2024 5:49:21 PM,"Merck, Bristol-Myers fail to convince FDA AdCom on wider Opdivo, Keytruda use",Seeking Alpha,https://seekingalpha.com/news/4153858-merck-bristol-myers-face-setback-wider-opdivo-keytruda-use?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2162.0,9/27/2024 2:15:55 AM,Sell Rating on Bristol-Myers Squibb Amid Competitive Pressures and Pricing Concerns,TipRanks,/news/stocks/sell-rating-on-bristol-myers-squibb-amid-competitive-pressures-and-pricing-concerns-1033802561
2163.0,9/27/2024 2:25:37 AM,Bristol-Myers Squibb’s Cobenfy: A Balanced Hold Rating Amidst FDA Approval and Market Uncertainties,TipRanks,/news/stocks/bristol-myers-squibb-s-cobenfy-a-balanced-hold-rating-amidst-fda-approval-and-market-uncertainties-1033802550
2164.0,9/27/2024 3:31:39 AM,Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult Schizophrenia Treatment ,RTTNews,/news/stocks/bristol-myers-squibb-s-cobenfy-gains-fda-approval-for-adult-schizophrenia-treatment-1033802204
2165.0,9/27/2024 4:16:00 AM,Bristol-Myers Squibb’s Cobenfy Launch Spurs ‘Buy’ Rating Amid Favorable Market Dynamics,TipRanks,/news/stocks/bristol-myers-squibb-s-cobenfy-launch-spurs-buy-rating-amid-favorable-market-dynamics-1033802729
2166.0,9/27/2024 10:15:50 AM,Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns,TipRanks,/news/stocks/bristol-myers-squibb-sell-rating-justified-by-market-challenges-and-drug-uptake-concerns-1033803772
2167.0,9/27/2024 10:52:00 AM,Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic (update),Seeking Alpha,https://seekingalpha.com/news/4153957-bristol-myers-wins-fda-nod-for-first-of-its-kind-antipsychotic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2168.0,9/27/2024 11:16:40 AM,Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-amid-new-schizophrenia-drug-launch-and-patent-expiries-1033804211
2169.0,9/27/2024 11:26:33 AM,Truist Financial Gives a Buy Rating to Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-gives-a-buy-rating-to-bristol-myers-squibb-bmy-1033804200
2170.0,9/27/2024 2:00:29 PM,"Biggest stock movers Friday: HPQ, BB, BMY, and more",Seeking Alpha,https://seekingalpha.com/news/4153990-biggest-stock-movers-friday-bb-bmy-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2171.0,9/27/2024 5:59:43 PM,"Bristol Cobenfy approval draws optimism from Street, though with caveats",Seeking Alpha,https://seekingalpha.com/news/4154179-bristol-cobenfy-approval-draws-optimism-from-street-though-with-caveats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2172.0,9/27/2024 8:42:26 PM,J&J releases encouraging data on Talvey combination therapies,Seeking Alpha,https://seekingalpha.com/news/4154260-jj-releases-encouraging-data-on-talvey-combination-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2173.0,9/28/2024 4:09:05 PM,Trending stocks this week as market reactions to Fed rate cut continue,Seeking Alpha,https://seekingalpha.com/news/4154316-trending-stocks-this-week-as-market-reactions-to-fed-rate-cut-continue?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2174.0,9/28/2024 5:06:10 PM,Here are the Medicare Part D drugs expected to face 2025 price negotiations,Seeking Alpha,https://seekingalpha.com/news/4154318-these-medicare-drugs-set-to-face-2025-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2175.0,9/30/2024 12:59:37 PM,Biotech Stocks Facing FDA Decision In October 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2024-1033806960
2176.0,9/30/2024 2:02:03 PM,Prime Medicine Inks Strategic Research Collaboration And License Agreement With Bristol Myers Squibb ,RTTNews,/news/stocks/prime-medicine-inks-strategic-research-collaboration-and-license-agreement-with-bristol-myers-squibb-1033807165
2177.0,9/30/2024 3:55:48 PM,"Bristol, Prime Medicine in deal to develop T-cell therapies",Seeking Alpha,https://seekingalpha.com/news/4154520-bristol-prime-medicine-deal-develop-t-cell-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2178.0,9/30/2024 8:16:49 PM,Bristol Myers gets $6.4B Celgene CVR case dismissed: report,Seeking Alpha,https://seekingalpha.com/news/4154744-bristol-myers-gets-64b-celgene-cvr-case-dismissed-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2179.0,10/1/2024 5:25:40 AM,Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-market-challenges-and-strategic-execution-risks-1033810156
2180.0,10/1/2024 7:35:29 PM,U.S. port strike expected to have limited impact on healthcare supply chain: HHS,Seeking Alpha,https://seekingalpha.com/news/4155196-us-port-strike-have-limited-impact-medical-supplies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2181.0,10/2/2024 2:07:00 PM,Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3,Seeking Alpha,https://seekingalpha.com/news/4155316-bristol-myers-tops-growth-chart-among-sp-500-healthcare-stocks-in-q3?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2182.0,10/3/2024 12:02:11 PM,U.S. tweaks 2025 Medicare price negotiation process,Seeking Alpha,https://seekingalpha.com/news/4155891-us-tweaks-2025-medicare-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2183.0,10/3/2024 3:32:03 PM,Bristol-Myers wins FDA nod for Opdivo lung cancer indication,Seeking Alpha,https://seekingalpha.com/news/4156093-bristol-myers-stock-up-fda-expands-opdivo-label?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2184.0,10/4/2024 5:00:23 PM,UMB to refile $6.4B lawsuit against Bristol-Myers by end of next week - report,Seeking Alpha,https://seekingalpha.com/news/4156523-umb-to-refile-64b-lawsuit-against-bristol-myers-by-end-of-next-week-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2185.0,10/4/2024 6:02:06 PM,Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August,Seeking Alpha,https://seekingalpha.com/news/4156522-q3-pharma-biotech-layoffs-charts-more-than-1000-each-july-august?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2186.0,10/4/2024 8:34:51 PM,Bristol-Myers trades in the green for seventh straight session,Seeking Alpha,https://seekingalpha.com/news/4156562-bristol-myers-trades-in-the-green-for-seventh-straight-session?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2187.0,10/7/2024 2:15:22 AM,Barclays Sticks to Their Sell Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-sticks-to-their-sell-rating-for-bristol-myers-squibb-bmy-1033823283
2188.0,10/8/2024 6:03:33 PM,Harris home health care benefit likely funded through Medicare drug negotiations savings,Seeking Alpha,https://seekingalpha.com/news/4157079-harris-home-health-care-benefit-could-funded-through-medicare-drug-negotiations-savings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2189.0,10/10/2024 6:04:23 PM,"Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential",Seeking Alpha,https://seekingalpha.com/news/4157672-kyverna-cabaletta-started-at-buys-by-ubs-on-car-t-therapy-potential?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2190.0,10/11/2024 12:35:59 PM,Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/morgan-stanley-keeps-their-sell-rating-on-bristol-myers-squibb-bmy-1033839281
2191.0,10/11/2024 2:10:42 PM,Perspective falls after data for radiopharmaceutical in skin cancer,Seeking Alpha,https://seekingalpha.com/news/4157904-perspective-stock-plunges-after-trial-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2192.0,10/14/2024 10:55:30 AM,Bristol-Myers Squibb: Hold Rating with Anticipated Revenue Outperformance Offset by Generic Competition Concerns,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-with-anticipated-revenue-outperformance-offset-by-generic-competition-concerns-1033843092
2193.0,10/16/2024 9:05:09 PM,"Lilly, Gilead, Amgen started at outperform by Bernstein",Seeking Alpha,https://seekingalpha.com/news/4167588-lilly-gilead-amgen-started-at-outperform-by-bernstein?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2194.0,10/23/2024 6:45:27 AM,Bristol-Myers Squibb: Navigating Financial Adjustments and Competitive Pressures Amidst a Hold Rating,TipRanks,/news/stocks/bristol-myers-squibb-navigating-financial-adjustments-and-competitive-pressures-amidst-a-hold-rating-1033877222
2195.0,10/23/2024 9:20:17 AM,"Evotec and Bristol Myers expand proteomics pact, triggers $50M payment",TipRanks,/news/stocks/evotec-and-bristol-myers-expand-proteomics-pact-triggers-50m-payment-1033877993
2196.0,10/23/2024 11:45:20 AM,Redwire launches investigation to ISS with BMS to study drugs with PIL-BOX,TipRanks,/news/stocks/redwire-launches-investigation-to-iss-with-bms-to-study-drugs-with-pil-box-1033879611
2197.0,10/23/2024 4:40:19 PM,Evotec gains following $50M payment from Bristol for molecular glue degraders,Seeking Alpha,https://seekingalpha.com/news/4196308-evotec-gains-following-50-m-payment-bristol-molecular-glue-degraders?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2198.0,10/25/2024 10:12:15 AM,Bristol Myers downgraded to Neutral from Buy at Citi,TipRanks,/news/stocks/bristol-myers-downgraded-to-neutral-from-buy-at-citi-1033892615
2199.0,10/25/2024 1:46:37 PM,"Apple downgraded, Tesla upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/apple-downgraded-tesla-upgraded-wall-street-s-top-analyst-calls-1033894593
2200.0,10/28/2024 4:23:31 AM,"Earnings week ahead: MSFT, AMZN, AAPL, META, GOOG, AMD, PFE, F, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4205996-earnings-week-ahead-msft-amzn-aapl-meta-goog-amd-pfe-f-mcd-sbux-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2201.0,10/29/2024 12:21:04 PM,Biogen appoints Quirk as Chief Medical Officer,TipRanks,/news/stocks/biogen-appoints-quirk-as-chief-medical-officer-1033910411
2202.0,10/29/2024 12:33:15 PM,Biogen names former Bristol-Myers executive as medical chief,Seeking Alpha,https://seekingalpha.com/news/4217750-biogen-names-medical-chief-from-bristol-myers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2203.0,10/29/2024 4:36:07 PM,Zai Lab reports positive Chinese study data for KarXT for schizophrenia,Seeking Alpha,https://seekingalpha.com/news/4219420-zai-lab-reports-positive-chinese-study-data-for-karxt-for-schizophrenia?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2204.0,10/30/2024 6:00:59 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1033921038
2205.0,10/30/2024 7:07:33 PM,Bristol Myers Squibb Q3 2024 Earnings Preview: Profit decline anticipated,Seeking Alpha,https://seekingalpha.com/news/4225478-bristol-myers-squibb-q3-2024-earnings-preview-profit-decline-anticipated?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2206.0,10/31/2024 11:00:02 AM,"Bristol-Myers Squibb Company  Non-GAAP EPS of $1.80 beats by $0.30, revenue of $11.89B beats by $640M",Seeking Alpha,https://seekingalpha.com/news/4227809-bristol-myers-squibb-company-and-nbsp-non-gaap-eps-of-1_80-beats-0_30-revenue-of-11_89b-beats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2207.0,10/31/2024 11:05:37 AM,"Bristol Myers reports Q3 EPS $1.80, consensus $1.49",TipRanks,/news/stocks/bristol-myers-reports-q3-eps-1-80-consensus-1-49-1033928687
2208.0,10/31/2024 11:45:01 AM,Bristol-Myers raises outlook ahead of consensus after Q3 beat,Seeking Alpha,https://seekingalpha.com/news/4228044-bristol-myers-stock-gains-guidance-raise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2209.0,10/31/2024 12:24:33 PM,"Bristol-Myers Squibb Co. Q3 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/bristol-myers-squibb-co-q3-profit-decreases-but-beats-estimates-1033927047
2210.0,10/31/2024 12:43:52 PM,"Bristol-Myers Squibb in charts: Q3 revenue from Eliquis, Opdivo, Yervoy rises, Sprycel falls",Seeking Alpha,https://seekingalpha.com/news/4228391-bristol-myers-squibb-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2211.0,10/31/2024 12:56:50 PM,Bristol Myers Squibb Lifts FY24 Earnings View Above Market; Stock Up In Pre-market - Update ,RTTNews,/news/stocks/bristol-myers-squibb-lifts-fy24-earnings-view-above-market-stock-up-in-pre-market-update-1033927432
2212.0,10/31/2024 1:01:20 PM,Morning Movers: Roblox surges and Estee Lauder sinks following earnings,TipRanks,/news/stocks/morning-movers-roblox-surges-and-estee-lauder-sinks-following-earnings-1033930078
2213.0,10/31/2024 4:01:23 PM,"Microsoft reports Q1 beat, Comcast weighs cable networks spinoff: Morning Buzz",TipRanks,/news/stocks/microsoft-reports-q1-beat-comcast-weighs-cable-networks-spinoff-morning-buzz-1033931015
2214.0,10/31/2024 8:30:29 PM,Bristol Myers presents new long-term data from EMERGENT study of COBENFY,TipRanks,/news/stocks/bristol-myers-presents-new-long-term-data-from-emergent-study-of-cobenfy-1033931793
2215.0,11/1/2024 4:33:27 AM,Bristol Myers Squibb Posts Robust Q3 2024 Growth,TipRanks,/news/stocks/bristol-myers-squibb-posts-robust-q3-2024-growth-1033934554
2216.0,11/1/2024 7:30:13 AM,"Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), 10x Genomics (TXG) and Bicycle Therapeutics (BCYC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-10x-genomics-txg-and-bicycle-therapeutics-bcyc-1033935639
2217.0,11/1/2024 9:12:26 AM,Cautious Optimism: Bristol-Myers Squibb’s Hold Rating Amid Growth Prospects and Uncertainties,TipRanks,/news/stocks/cautious-optimism-bristol-myers-squibb-s-hold-rating-amid-growth-prospects-and-uncertainties-1033936174
2218.0,11/1/2024 9:20:18 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-bristol-myers-squibb-bmy-abbott-laboratories-abt-and-merck-company-mrk-1033936132
2219.0,11/1/2024 11:16:12 AM,Bristol Myers price target raised to $60 from $55 at BofA,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-60-from-55-at-bofa-1033937020
2220.0,11/1/2024 11:39:33 AM,Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-squibb-bmy-1033937087
2221.0,11/1/2024 11:55:43 AM,Silexion Therapeutics initiated with a Buy at Maxim,TipRanks,/news/stocks/silexion-therapeutics-initiated-with-a-buy-at-maxim-1033937192
2222.0,11/1/2024 12:01:40 PM,Analysts Offer Insights on Healthcare Companies: Select Medical (SEM) and Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-select-medical-sem-and-bristol-myers-squibb-bmy-1033937671
2223.0,11/1/2024 12:09:34 PM,Bristol-Myers Squibb: Sell Rating Due to Mixed Financial Outlook and Long-Term Challenges,TipRanks,/news/stocks/bristol-myers-squibb-sell-rating-due-to-mixed-financial-outlook-and-long-term-challenges-1033937622
2224.0,11/1/2024 12:15:38 PM,Bristol-Myers Squibb: Hold Rating Reflects Gradual Improvement and Strategic Caution,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-reflects-gradual-improvement-and-strategic-caution-1033937753
2225.0,11/1/2024 12:36:39 PM,Jefferies Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/jefferies-sticks-to-their-hold-rating-for-bristol-myers-squibb-bmy-1033937861
2226.0,11/5/2024 6:35:23 AM,Bristol-Myers Squibb: Hold Rating Maintained Amid Positive Clinical Trials and Long-term EPS Concerns,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-maintained-amid-positive-clinical-trials-and-long-term-eps-concerns-1033950375
2227.0,11/5/2024 6:40:47 AM,"Analysts’ Top Healthcare Picks: Bristol-Myers Squibb (BMY), Agios Pharma (AGIO)",TipRanks,/news/stocks/analysts-top-healthcare-picks-bristol-myers-squibb-bmy-agios-pharma-agio-1033950367
2228.0,11/5/2024 12:50:21 PM,Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (BMY) and Envista Holdings (NVST),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-bristol-myers-squibb-bmy-and-envista-holdings-nvst-1033953136
2229.0,11/11/2024 2:32:24 PM,AbbVie declines after missing main goal in schizophrenia treatment trials,Seeking Alpha,https://seekingalpha.com/news/4274511-abbvie-declines-after-missing-main-goal-in-schizophrenia-treatment-trials?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2230.0,11/11/2024 2:45:15 PM,"Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets",TipRanks,/news/stocks/bristol-myers-rises-abbvie-sinks-after-schizophrenia-trials-miss-targets-1033993919
2231.0,11/11/2024 2:50:11 PM,Bristol Myers rises 11.6%,TipRanks,/news/stocks/bristol-myers-rises-11-6-1033993911
2232.0,11/11/2024 2:50:30 PM,"Biggest stock movers Monday: Crypto stocks, TSLA, ABBV, and more",Seeking Alpha,https://seekingalpha.com/news/4272963-biggest-stock-movers-monday?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2233.0,11/11/2024 2:55:08 PM,Early notable gainers among liquid option names on November 11th,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-november-11th-1033993901
2234.0,11/11/2024 3:05:25 PM,"AbbVie ‘pain’ is Bristol Myers ‘gain’ after emraclidine fails, says Truist",TipRanks,/news/stocks/abbvie-pain-is-bristol-myers-gain-after-emraclidine-fails-says-truist-1033993966
2235.0,11/11/2024 3:15:16 PM,"JPMorgan sees AbbVie off about 10%, Bristol up 10%-15% on emraclidine news",TipRanks,/news/stocks/jpmorgan-sees-abbvie-off-about-10-bristol-up-10--15-on-emraclidine-news-1033994006
2236.0,11/11/2024 3:35:15 PM,Leerink sees AbbVie’s trial results as ‘clear positive’ for Bristol Myers,TipRanks,/news/stocks/leerink-sees-abbvie-s-trial-results-as-clear-positive-for-bristol-myers-1033994048
2237.0,11/11/2024 4:10:06 PM,AbbVie under pressure as schizophrenia drug fails two trials,TipRanks,/news/stocks/abbvie-under-pressure-as-schizophrenia-drug-fails-two-trials-1033994121
2238.0,11/11/2024 4:35:39 PM,Evercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positive,TipRanks,/news/stocks/evercore-says-failure-of-emraclidine-may-be-substantial-neurocrine-positive-1033994161
2239.0,11/11/2024 5:38:20 PM,How AbbVie can still benefit from Cerevel acquisition despite emraclidine setback,Seeking Alpha,https://seekingalpha.com/news/4275200-how-abbvie-can-still-benefit-cerevel-acquisition-despite-emraclidine-setback?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2240.0,11/12/2024 11:05:09 AM,Bristol Myers upgraded to Outperform from Market Perform at Leerink,TipRanks,/news/stocks/bristol-myers-upgraded-to-outperform-from-market-perform-at-leerink-1033999318
2241.0,11/12/2024 11:05:58 AM,Bristol Myers price target raised to $60 from $55 at Citi,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-60-from-55-at-citi-1033999308
2242.0,11/12/2024 11:20:30 AM,Leerink upgrades Bristol to Outperform after AbbVie schizophrenia failure,TipRanks,/news/stocks/leerink-upgrades-bristol-to-outperform-after-abbvie-schizophrenia-failure-1033999384
2243.0,11/12/2024 12:31:40 PM,AbbVie price target lowered to $224 from $231 at Morgan Stanley,TipRanks,/news/stocks/abbvie-price-target-lowered-to-224-from-231-at-morgan-stanley-1034000363
2244.0,11/12/2024 12:31:53 PM,Bristol Myers price target raised to $39 from $36 at Morgan Stanley,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-39-from-36-at-morgan-stanley-1034000362
2245.0,11/12/2024 1:22:50 PM,Bristol-Myers upgraded at Leerink after AbbVie setback,Seeking Alpha,https://seekingalpha.com/news/4279606-bristol-myers-stock-upgraded-leerink?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2246.0,11/12/2024 2:45:47 PM,"Nvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/nvidia-initiated-airbnb-downgraded-wall-street-s-top-analyst-calls-1034001381
2247.0,11/12/2024 2:45:59 PM,Bristol Myers price target raised to $61 from $57 at BMO Capital,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-61-from-57-at-bmo-capital-1034001380
2248.0,11/12/2024 5:05:59 PM,"Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz",TipRanks,/news/stocks/elliott-confirms-big-honeywell-stake-home-deport-reports-q3-beat-morning-buzz-1034001929
2249.0,11/13/2024 5:15:13 PM,Bristol Myers Squibb put volume heavy and directionally bearish,TipRanks,/news/stocks/bristol-myers-squibb-put-volume-heavy-and-directionally-bearish-1034011073
2250.0,11/14/2024 9:16:17 PM,Bristol Myers initiated with a Peer Perform at Wolfe Research,TipRanks,/news/stocks/bristol-myers-initiated-with-a-peer-perform-at-wolfe-research-1034021183
2251.0,11/14/2024 9:38:21 PM,"Tudor Investment adds Infinera, Trane, exits Disney, UnitedHealth, among top Q3 trades",Seeking Alpha,https://seekingalpha.com/news/4292366-tudor-investmentadds-infinera-traneexits-disney-united-healthamongtop-q-3-trades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2252.0,11/14/2024 11:50:27 PM,"Wolfe starts Bristol Myers at Peer Perform, sees potential comeback story",TipRanks,/news/stocks/wolfe-starts-bristol-myers-at-peer-perform-sees-potential-comeback-story-1034021599
2253.0,11/15/2024 12:06:58 PM,Bristol Myers receives positive CHMP opinion for repotrectinib,TipRanks,/news/stocks/bristol-myers-receives-positive-chmp-opinion-for-repotrectinib-1034025093
2254.0,11/15/2024 1:30:21 PM,Bristol Myers announces CHMP opinion recommending approval of Opdivo plus Yervoy,TipRanks,/news/stocks/bristol-myers-announces-chmp-opinion-recommending-approval-of-opdivo-plus-yervoy-1034025634
2255.0,11/15/2024 2:59:25 PM,Bristol Myers gets positive EMA opinion for repotrectinib,Seeking Alpha,https://seekingalpha.com/news/4295034-bristol-myers-gets-positive-ema-opinion-for-repotrectinib?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2256.0,11/15/2024 7:29:29 PM,U.S. Pharma is largely immune from 'MAHA' impact: Wolfe,Seeking Alpha,https://seekingalpha.com/news/4296178-us-pharma-largely-immune-from-maha-impact-wolfe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2257.0,11/15/2024 7:30:36 PM,"Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS",Seeking Alpha,https://seekingalpha.com/news/4296140-large-pharmas-biotechs-down-industries-grapple-with-rfk-jr-hhs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2258.0,11/15/2024 7:40:19 PM,Buy/Sell: Wall Street’s top 10 stock calls this week,TipRanks,/news/stocks/buy-sell-wall-street-s-top-10-stock-calls-this-week-1034026593
2259.0,11/17/2024 2:40:56 PM,Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-mimedx-group-mdxg-1034027530
2260.0,11/17/2024 2:50:40 PM,Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-mimedx-group-mdxg-1034027551
2261.0,11/18/2024 2:05:48 PM,Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/wells-fargo-sticks-to-its-hold-rating-for-bristol-myers-squibb-bmy-1034032161
2262.0,11/19/2024 12:19:17 PM,Truist Financial Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-bristol-myers-squibb-bmy-1034037419
2263.0,11/21/2024 6:45:46 PM,Optimism over global healthcare sector rises: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4318258-optimism-over-global-healthcare-sector-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2264.0,11/22/2024 1:31:12 PM,Replimune climbs after updates on lead drug,Seeking Alpha,https://seekingalpha.com/news/4320954-replimune-stock-climbs-after-updates-on-rp-1?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2265.0,11/22/2024 3:40:08 PM,Health care sector had the most stocks with 4-week low and RSI below 30 since spring,Seeking Alpha,https://seekingalpha.com/news/4321978-health-care-sector-had-the-most-stocks-with-4-week-low-and-rsi-below-30-since-spring?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2266.0,11/23/2024 2:25:05 AM,"Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC",Seeking Alpha,https://seekingalpha.com/news/4323803-trump-picks-surgeon-makary-to-head-fda-rep-dave-weldon-to-lead-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2267.0,11/25/2024 5:45:57 AM,Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Cobenfy Projections and Competitive Advantages,TipRanks,/news/stocks/optimistic-buy-rating-for-bristol-myers-squibb-driven-by-promising-cobenfy-projections-and-competitive-advantages-1034058910
2268.0,11/25/2024 3:27:55 PM,Merck Phase 3 study of Winrevair in PAH meets primary endpoint,Seeking Alpha,https://seekingalpha.com/news/4330240-merck-phase-3-study-of-winrevair-in-pah-meets-primary-endpoint?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2269.0,11/27/2024 11:23:42 AM,Trump taps Jay Bhattacharya to lead National Institutes of Health,Seeking Alpha,https://seekingalpha.com/news/4338432-trump-taps-jay-bhattacharya-to-lead-national-institutes-of-health?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2270.0,11/28/2024 3:33:22 PM,AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe,Seeking Alpha,https://seekingalpha.com/news/4344692-astrazeneca-enhertu-added-for-china-reimbursement?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2271.0,11/29/2024 5:00:00 PM,"Catalyst Watch: November jobs, OPEC+ meeting, Marvell, Salesforce earnings",Seeking Alpha,https://seekingalpha.com/news/4340728-catalyst-watch-november-jobs-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2272.0,12/2/2024 2:05:36 PM,"Bausch Health appoints Jonathan Sadeh as CMO, head of R&D",TipRanks,/news/stocks/bausch-health-appoints-jonathan-sadeh-as-cmo-head-of-r-d-1034087648
2273.0,12/2/2024 5:38:36 PM,Biotech Stocks Facing FDA Decision In December 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2024-1034087402
2274.0,12/3/2024 3:28:47 PM,Bristol in research agreement with AI Proteins on miniprotein-based therapies,Seeking Alpha,https://seekingalpha.com/news/4359654-bristol-in-research-agreement-ai-proteins-on-miniprotein-based-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/10/2024 12:26:18 PM,Bristol-Myers Squibb: Balancing Stability and Competition with Cautious Optimism,TipRanks,/news/stocks/bristol-myers-squibb-balancing-stability-and-competition-with-cautious-optimism-1034119754
,12/10/2024 2:45:24 PM,"eBay downgraded, GM upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/ebay-downgraded-gm-upgraded-wall-street-s-top-analyst-calls-1034120783
,12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/11/2024 6:35:17 AM,Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/berenberg-bank-remains-a-hold-on-bristol-myers-squibb-bmy-1034123133
,12/11/2024 9:20:31 PM,Bristol Myers raises quarterly dividend 3.3% to 62c per share,TipRanks,/news/stocks/bristol-myers-raises-quarterly-dividend-3-3-to-62c-per-share-1034127010
,12/11/2024 9:20:47 PM,Bristol-Myers Squibb Company  raises quarterly dividend by 3.3% to  $0.62/share,Seeking Alpha,https://seekingalpha.com/news/4385725-bristol-myers-squibb-company-raises-quarterly-dividend-by-33-to-062share?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/13/2024 9:20:11 PM,Bristol Myers files automatic mixed securities shelf,TipRanks,/news/stocks/bristol-myers-files-automatic-mixed-securities-shelf-1034137117
,12/16/2024 11:26:02 AM,Bristol Myers upgraded to Buy from Hold at Jefferies,TipRanks,/news/stocks/bristol-myers-upgraded-to-buy-from-hold-at-jefferies-1034140565
,12/16/2024 11:30:54 AM,"Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline",TipRanks,/news/stocks/bristol-myers-upgraded-to-buy-at-jefferies-on-new-launch-momentum-pipeline-1034140712
,12/16/2024 2:35:49 PM,"Netflix, MongoDB downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/netflix-mongodb-downgraded-wall-street-s-top-analyst-calls-1034142189
,12/16/2024 5:01:01 PM,"Honeywell still exploring alternatives, Capri weighs Versace sale: Morning Buzz",TipRanks,/news/stocks/honeywell-still-exploring-alternatives-capri-weighs-versace-sale-morning-buzz-1034142630
,12/16/2024 5:06:51 PM,Bristol-Myers upgraded to buy by Jefferies,Seeking Alpha,https://seekingalpha.com/news/4386765-bristol-myers-upgraded-to-buy-by-jefferies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/18/2024 2:30:47 PM,Cytokinetics price target raised to $82 from $80 at RBC Capital,TipRanks,/news/stocks/cytokinetics-price-target-raised-to-82-from-80-at-rbc-capital-1034152597
,12/19/2024 12:05:39 PM,Bristol Myers added to Analyst Focus List at JPMorgan,TipRanks,/news/stocks/bristol-myers-added-to-analyst-focus-list-at-jpmorgan-1034156817
,12/19/2024 12:12:25 PM,Bristol Myers enters $100M PyroGlu-Ass license agreement with BioArctic,TipRanks,/news/stocks/bristol-myers-enters-100m-pyroglu-ass-license-agreement-with-bioarctic-1034156781
,12/19/2024 6:16:03 PM,Regeneron reports positive results for two anti-coagulant drugs,Seeking Alpha,https://seekingalpha.com/news/4388091-regeneron-reports-positive-results-for-two-anti-coagulant-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/19/2024 8:16:45 PM,Bristol in license agreement with BioArctic for two Alzheimer's antibody programs,Seeking Alpha,https://seekingalpha.com/news/4388608-bristol-license-agreement-bioarctic-two-alzheimers-antibody-programs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/20/2024 8:20:32 PM,Buy/Sell: Wall Street’s top 10 stock calls this week,TipRanks,/news/stocks/buy-sell-wall-street-s-top-10-stock-calls-this-week-1034164300
,12/22/2024 9:12:14 PM,SA Asks: Which Big Pharmas are likely to announce big M&A deals?,Seeking Alpha,https://seekingalpha.com/news/4389614-sa-asks-which-big-pharmas-are-likely-to-announce-big-m-deals?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/23/2024 11:50:14 AM,Bristol Myers receives EC approval for Opdivo plus Yervoy,TipRanks,/news/stocks/bristol-myers-receives-ec-approval-for-opdivo-plus-yervoy-1034167773
,12/23/2024 12:05:43 PM,Bristol Myers announces ‘positive’ results from Phase 3 Sotyktu trials,TipRanks,/news/stocks/bristol-myers-announces-positive-results-from-phase-3-sotyktu-trials-1034168154
,12/23/2024 2:03:51 PM,Bristol-Myers Squibb meets main goal in late-stage trials of its psoriatic arthritis treatment,Seeking Alpha,https://seekingalpha.com/news/4389970-bristol-myers-squibb-meets-main-goal-in-late-stage-trials-of-its-psoriatic-arthritis-treatment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/23/2024 2:15:01 PM,Bristol Myers: Sotyktu Phase 3 Trials In Psoriatic Arthritis Meet Primary Goals ,RTTNews,/news/stocks/bristol-myers-sotyktu-phase-3-trials-in-psoriatic-arthritis-meet-primary-goals-1034167316
,12/23/2024 5:46:35 PM,Bristol-Myers gets EU okay for Opdivo/Yervoy combo,Seeking Alpha,https://seekingalpha.com/news/4390176-bristol-myers-gets-eu-okay-for-opdivoyervoy-combo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/27/2024 4:35:14 PM,FDA approves Bristol Myers’ Opdivo Qvantig,TipRanks,/news/stocks/fda-approves-bristol-myers-opdivo-qvantig-1034177070
,12/27/2024 7:43:23 PM,Bristol-Myers gets FDA okay for injectable Opdivo,Seeking Alpha,https://seekingalpha.com/news/4391265-bristol-myers-gets-fda-okay-for-injectable-opdivo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/27/2024 10:40:09 PM,Bristol Myers announces FDA approval of Opdivo Qvantig injection,TipRanks,/news/stocks/bristol-myers-announces-fda-approval-of-opdivo-qvantig-injection-1034177307
,12/28/2024 4:33:24 AM,Bristol-Myers Squibb : FDA Approves Opdivo Qvantig For Subcutaneous Use In Adult Solid Tumors ,RTTNews,/news/stocks/bristol-myers-squibb-fda-approves-opdivo-qvantig-for-subcutaneous-use-in-adult-solid-tumors-1034177342
,12/29/2024 5:15:05 PM,Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/bernstein-sticks-to-its-hold-rating-for-bristol-myers-squibb-bmy-1034177878
,12/30/2024 11:25:14 AM,Century Therapeutics price target lowered to $4 from $12 at Piper Sandler,TipRanks,/news/stocks/century-therapeutics-price-target-lowered-to-4-from-12-at-piper-sandler-1034179566
,12/30/2024 11:45:06 AM,Halozyme reports FDA approval for Opdivo co-formulated with Enhanze,TipRanks,/news/stocks/halozyme-reports-fda-approval-for-opdivo-co-formulated-with-enhanze-1034179699
,12/30/2024 1:03:09 PM,Halozyme Says FDA Approved Bristol Myers's Opdivo Qvantig With ENHANZE For Subcutaneous Use ,RTTNews,/news/stocks/halozyme-says-fda-approved-bristol-myers-s-opdivo-qvantig-with-enhanze-for-subcutaneous-use-1034179055
,1/1/2025 2:00:28 PM,Brand prescription drugs to rise an average 4.5% in 2025,Seeking Alpha,https://seekingalpha.com/news/4391754-brand-prescription-drugs-rise-average-4_5-percent-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/2/2025 3:15:09 PM,Jefferies Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/jefferies-reaffirms-their-buy-rating-on-bristol-myers-squibb-bmy-1034187935
,1/2/2025 8:25:08 PM,Bristol Myers Squibb call volume above normal and directionally bullish,TipRanks,/news/stocks/bristol-myers-squibb-call-volume-above-normal-and-directionally-bullish-1034188424
,1/6/2025 5:52:14 PM,"FDA issues first draft guidance on use of AI in drug, medical device development",Seeking Alpha,https://seekingalpha.com/news/4392790-fda-issues-first-draft-guidance-use-ai-drug-medical-device-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/6/2025 11:38:05 PM,Bristol Myers to report Q4 IPRD/licensing expense of $18M,Seeking Alpha,https://seekingalpha.com/news/4392878-bristol-myers-to-report-q4-iprdlicensing-expense-of-18m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/7/2025 1:43:21 PM,Bristol late-stage trial of Opdivo for head and neck cancer meets endpoint,Seeking Alpha,https://seekingalpha.com/news/4392996-bristol-late-stage-trial-opdivo-head-and-neck-cancer-meets-endpoint?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/8/2025 1:10:34 AM,Bristol Myers price target raised to $65 from $62 at Truist,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-65-from-62-at-truist-1034202827
,1/8/2025 1:16:01 AM,Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-squibb-bmy-1034202849
,1/9/2025 1:56:22 PM,"Novo, Eli Lilly to dominate global pharma sales in 2025: report",Seeking Alpha,https://seekingalpha.com/news/4393716-novo-eli-lilly-lead-2025-global-pharma-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/9/2025 8:36:08 PM,Pharma companies welcome new year with 583 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/4393873-2025-start-583-drug-price-hikes?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/11/2025 3:40:31 PM,Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/bernstein-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1034217248
,1/13/2025 12:46:00 PM,"Bristol Myers, ArsenalBio achieve milestone for AB-4000 series",TipRanks,/news/stocks/bristol-myers-arsenalbio-achieve-milestone-for-ab-4000-series-1034221570
,1/13/2025 1:40:37 PM,ArsenalBios Says Bristol Myers Squibb Exercises Exclusive License Option For AB-4000 Series Programs ,RTTNews,/news/stocks/arsenalbios-says-bristol-myers-squibb-exercises-exclusive-license-option-for-ab-4000-series-programs-1034219914
,1/13/2025 2:40:15 PM,Unusually active option classes on open January 13th,TipRanks,/news/stocks/unusually-active-option-classes-on-open-january-13th-1034222275
,1/13/2025 5:53:38 PM,Bristol sees annual $1.5B in cost savings by end of 2025,Seeking Alpha,https://seekingalpha.com/news/4394642-bristol-sees-annual-1_5b-cost-savings-end-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/14/2025 2:40:39 PM,"Drugmakers to push Trump to pause price negotiations, Bloomberg reports",TipRanks,/news/stocks/drugmakers-to-push-trump-to-pause-price-negotiations-bloomberg-reports-1034226968
,1/14/2025 10:55:17 PM,"Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports",TipRanks,/news/stocks/bristol-myers-ceo-says-new-drug-cobenfy-effective-in-schizophrenia-cnbc-reports-1034227742
,1/15/2025 6:56:23 AM,Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy,TipRanks,/news/stocks/positive-outlook-for-bristol-myers-squibb-with-promising-market-access-and-societal-benefits-of-cobenfy-1034229484
,1/17/2025 1:19:18 PM,Wegovy included as Medicare lists 15 drugs selected for next pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4396094-wegovy-latest-medicare-pricing-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/17/2025 1:20:48 PM,"Ozempic, Xtandi among next 15 drugs selected for U.S. price talks",TipRanks,/news/stocks/ozempic-xtandi-among-next-15-drugs-selected-for-u-s-price-talks-1034240882
,1/17/2025 2:39:38 PM,Chinese regulators accept Zai Lab application for KarXT,Seeking Alpha,https://seekingalpha.com/news/4396130-chinese-regulators-accept-zai-lab-application-for-karxt?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/17/2025 4:58:51 PM,"Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting",Seeking Alpha,https://seekingalpha.com/news/4396192-pharma-lobby-slams-ira-pbms-as-medicare-lists-15-more-drugs-for-price-setting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/17/2025 8:35:26 PM,Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations,TipRanks,/news/stocks/sector-spotlight-big-pharma-will-push-to-pause-medicare-drug-price-negotiations-1034241772
,1/24/2025 2:40:19 PM,Unusually active option classes on open January 24th,TipRanks,/news/stocks/unusually-active-option-classes-on-open-january-24th-1034267361
,1/25/2025 6:11:15 PM,Bristol Myers says Opdivo + Yervoy cut risk of relapse by 38% in colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/4398675-bristol-myers-colorectal-cancer-drug-cuts-relapse-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/28/2025 7:26:44 AM,Buy Rating for Bristol-Myers Squibb Driven by Cobenfy’s Strong Sales Momentum and Growth Potential,TipRanks,/news/stocks/buy-rating-for-bristol-myers-squibb-driven-by-cobenfy-s-strong-sales-momentum-and-growth-potential-1034275977
,1/28/2025 11:10:42 AM,"Drugmakers modestly raise price on drugs at start of year, WSJ reports",TipRanks,/news/stocks/drugmakers-modestly-raise-price-on-drugs-at-start-of-year-wsj-reports-1034276940
,1/28/2025 11:18:29 AM,Cautious Outlook on Bristol-Myers Squibb: Sell Rating Maintained Amid Revenue Declines and Financial Challenges,TipRanks,/news/stocks/cautious-outlook-on-bristol-myers-squibb-sell-rating-maintained-amid-revenue-declines-and-financial-challenges-1034277072
,1/28/2025 11:36:40 AM,Bristol Myers price target raised to $65 from $60 at Citi,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-65-from-60-at-citi-1034277155
,1/28/2025 5:10:31 PM,"GM, Boeing report quarterly results: Morning Buzz",TipRanks,/news/stocks/gm-boeing-report-quarterly-results-morning-buzz-1034278980
,1/29/2025 7:30:50 PM,CMS aiming for more transparency in drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4400241-cms-aiming-for-more-transparency-in-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/30/2025 1:52:59 PM,Merck to stop late-stage HYPERION trial evaluating WINREVAIR,Seeking Alpha,https://seekingalpha.com/news/4400749-merck-to-stop-late-stage-hyperion-trial-evaluating-winrevair?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/31/2025 11:55:16 AM,Bristol Myers’ Breyanzi receives positive CHMP opinion in follicular lymphoma,TipRanks,/news/stocks/bristol-myers-breyanzi-receives-positive-chmp-opinion-in-follicular-lymphoma-1034294927
,1/31/2025 12:07:26 PM,Bristol Myers gets positive CHMP opinion for Opdivo plus Yervoy,TipRanks,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-opdivo-plus-yervoy-1034295061
,1/31/2025 2:05:25 PM,Bristol Myers Squibb receives positive CHMP opinion for hepatocellular carcinoma treatment,Seeking Alpha,https://seekingalpha.com/news/4401412-bristol-myers-squibb-receives-positive-chmp-opinion-for-hepatocellular-carcinoma-treatment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/31/2025 8:00:55 PM,"Catalyst Watch: Tariff drama, OPEC+, Alphabet and Amazon earnings, Lennar spinoff",Seeking Alpha,https://seekingalpha.com/news/4401505-catalyst-watch-tariff-drama-opec-alphabet-and-amazon-earnings-lennar-spinoff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/2/2025 1:00:00 PM,"Earnings week ahead: PLTR, AMZN, GOOG, AMD, LLY, PEP, F, PFE, MRK, PYPL and more",Seeking Alpha,https://seekingalpha.com/news/4401431-earnings-week-ahead-pltr-amzn-goog-amd-lly-pep-f-pfe-mrk-pypl-qcom-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 1:27:30 PM,Pfizer's 2025 guidance falls short of expectations,Seeking Alpha,https://seekingalpha.com/news/4402612-pfizer-2025-guidance-falls-short-expectations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/5/2025 1:35:33 PM,Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/jefferies-keeps-their-buy-rating-on-bristol-myers-squibb-bmy-1034315683
,2/5/2025 5:30:13 PM,Bristol Myers Squibb call volume above normal and directionally bullish,TipRanks,/news/stocks/bristol-myers-squibb-call-volume-above-normal-and-directionally-bullish-1034317214
,2/5/2025 6:40:19 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1034317367
,2/5/2025 6:42:25 PM,Bristol-Myers Squibb Q4 2024 Earnings Preview: Strong product sales to continue into 2025,Seeking Alpha,https://seekingalpha.com/news/4403814-bristol-myers-squibb-q4-2024-earnings-preview-strong-product-sales-to-continue-into-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/6/2025 12:04:16 PM,Bristol-Myers Squibb beats Q4 estimates,Seeking Alpha,https://seekingalpha.com/news/4404314-bristol-myers-squibb-beats-q4-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/6/2025 12:05:36 PM,"Options Volatility and Implied Earnings Moves Today, February 06, 2025",TipRanks,/news/stocks/options-volatility-and-implied-earnings-moves-today-february-06-2025-1034322024
,2/6/2025 12:07:06 PM,"Bristol Myers sees FY25 adjusted EPS $6.55-$6.85, consensus $6.92",TipRanks,/news/stocks/bristol-myers-sees-fy25-adjusted-eps-6-55--6-85-consensus-6-92-1034322009
,2/6/2025 12:10:39 PM,Bristol Myers expects to deliver additional ~$2B in cost savings by 2027-end,TipRanks,/news/stocks/bristol-myers-expects-to-deliver-additional-~-2b-in-cost-savings-by-2027-end-1034321965
,2/6/2025 12:41:04 PM,"Bristol Myers Squibb in charts: Q4 revenue from Eliquis, Opdivo, Yervoy rises; Sprycel falls",Seeking Alpha,https://seekingalpha.com/news/4404353-bristol-myers-squibb-in-charts-q4-revenue-from-eliquis-opdivo-yervoy-rises-sprycel-falls?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/6/2025 12:47:26 PM,Bristol-Myers Squibb slips as 2025 outlook disappoints,Seeking Alpha,https://seekingalpha.com/news/4404333-bristol-myers-stock-slips-amid-outlook-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/6/2025 1:06:14 PM,"Bristol-Myers Squibb Co. Q4 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/bristol-myers-squibb-co-q4-profit-decreases-but-beats-estimates-1034321923
,2/6/2025 1:26:52 PM,Bristol-Myers Squibb Guides FY25 Below Estimates - Update ,RTTNews,/news/stocks/bristol-myers-squibb-guides-fy25-below-estimates-update-1034322212
,2/6/2025 1:57:03 PM,Morning Movers: Roblox sinks following fourth quarter results and guidance,TipRanks,/news/stocks/morning-movers-roblox-sinks-following-fourth-quarter-results-and-guidance-1034322920
,2/6/2025 3:50:07 PM,"Cytokinetics share weakness on updated Camzyos REMS overdone, says Truist",TipRanks,/news/stocks/cytokinetics-share-weakness-on-updated-camzyos-rems-overdone-says-truist-1034323842
,2/6/2025 5:06:03 PM,"Qualcomm, Eli Lilly report quarterly earnings beats: Morning Buzz",TipRanks,/news/stocks/qualcomm-eli-lilly-report-quarterly-earnings-beats-morning-buzz-1034324189
,2/6/2025 5:55:07 PM,"Camzyos news has negative readthroughs for Cytokinetics, says BofA",TipRanks,/news/stocks/camzyos-news-has-negative-readthroughs-for-cytokinetics-says-bofa-1034324349
,2/6/2025 6:35:50 PM,"White House readying order to fire thousands of federal health workers, WSJ says",TipRanks,/news/stocks/white-house-readying-order-to-fire-thousands-of-federal-health-workers-wsj-says-1034324421
,2/7/2025 11:38:22 AM,Bristol-Myers Squibb (BMY) Gets a Hold from Citi,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-hold-from-citi-1034326736
,2/7/2025 12:01:15 PM,Cytokinetics initiated with a Buy at Citi,TipRanks,/news/stocks/cytokinetics-initiated-with-a-buy-at-citi-1034327003
,2/7/2025 12:55:35 PM,Bristol Myers price target raised to $62 from $60 at Wells Fargo,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-62-from-60-at-wells-fargo-1034327270
,2/7/2025 12:58:20 PM,Truist Financial Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-bristol-myers-squibb-bmy-1034327241
,2/7/2025 3:21:13 PM,Trump Trade: President advocates to close carried interest tax loophole,TipRanks,/news/stocks/trump-trade-president-advocates-to-close-carried-interest-tax-loophole-1034328479
,2/7/2025 3:41:01 PM,Cytokinetics draws new Buy from Citi on aficamten potential,Seeking Alpha,https://seekingalpha.com/news/4405175-cytokinetics-stock-draws-new-buy-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/8/2025 9:04:00 PM,18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard,Seeking Alpha,https://seekingalpha.com/news/4405247-18-out-of-21-healthcare-companies-beat-profit-estimates-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
